

UNITED STATES BANKRUPTCY COURT
WESTERN DISTRICT OF NORTH CAROLINA
CHARLOTTE DIVISION

<p>In re</p> <p>ALDRICH PUMP LLC, <i>et al.</i>,¹</p> <p style="text-align: center;">Debtors.</p>	<p>Chapter 11</p> <p>Case No. 20-30608</p> <p>(Jointly Administered)</p>
<p>ARMSTRONG WORLD INDUSTRIES, INC. ASBESTOS PERSONAL INJURY SETTLEMENT TRUST, <i>et al.</i></p> <p style="text-align: center;">Plaintiffs,</p> <p style="text-align: center;">v.</p> <p>ALDRICH PUMP LLC, <i>et al.</i></p> <p style="text-align: center;">Defendants.</p>	<p>Miscellaneous Proceeding</p> <p>No. 22-00303 (JCW)</p> <p>(Transferred from District of Delaware)</p>
<p>AC&S ASBESTOS SETTLEMENT TRUST, COMBUSTION ENGINEERING 524(G) ASBESTOS PI TRUST, GI HOLDINGS INC. ASBESTOS PERSONAL INJURY SETTLEMENT TRUST, GST SETTLEMENT FACILITY, KAISER ALUMINUM & CHEMICAL CORPORATION ASBESTOS PERSONAL INJURY TRUST, QUIGLEY COMPANY, INC. ASBESTOS PI TRUST, T H AGRICULTURE & NUTRITION, L.L.C. ASBESTOS PERSONAL INJURY TRUST, and YARWAY ASBESTOS PERSONAL INJURY TRUST,</p> <p style="text-align: center;">Petitioners,</p> <p style="text-align: center;">v.</p> <p>ALDRICH PUMP LLC, <i>et al.</i></p>	<p>Miscellaneous Proceeding</p> <p>No. 23-00300 (JCW)</p> <p>(Transferred from District of New Jersey)</p>

¹ The Debtors are the following entities (the last four digits of their respective taxpayer identification numbers follow in parentheses): Aldrich Pump LLC (2290) and Murray Boiler LLC (0679). The Debtors' address is 800-E Beaty Street, Davidson, North Carolina 28036.



Respondents,
VERUS CLAIM SERVICES, LLC,
Interested Party,
NON-PARTY CERTAIN MATCHING CLAIMANTS,
Interested Party.

DECLARATION OF MORGAN R. HIRST

I, Morgan R. Hirst, hereby declare under penalty of perjury:

1. I am a partner of the law firm of Jones Day; my office is located at 110 North Wacker Drive, Suite 4800, Chicago, Illinois 60606. I am a member in good standing of the Bar of the State of Illinois. There are no disciplinary proceedings pending against me.

2. I submit this declaration in connection with *Debtors' Consolidated Reply Brief in Support of Their Motion for Rehearing*, filed contemporaneously herewith. I have personal knowledge of the matters set forth herein.

3. Attached hereto as **Exhibit A** is a true and correct copy of the transcript from the May 17, 2023 deposition of Dr. Abraham Wyner.

4. Attached hereto as **Exhibit B** is a true and correct copy of the transcript from the May 8, 2023 deposition of Dr. Charles Mullin.

5. Attached hereto as **Exhibit C** is a true and correct copy of excerpts of the transcript of the April 13, 2023 hearing in In re DBMP LLC, No. 20-30080 (JCW) (Bankr. W.D.N.C.).

6. Attached hereto as **Exhibit D** is a true and correct copy of the Declaration of Jorge Gallardo-Garcia, Ph.D., In re Bestwall LLC, No. 17-31795 [Dkt. 2183, Ex. B] (W.D.N.C. Oct. 28, 2021).

7. Attached hereto as **Exhibit E** is a true and correct copy of excerpts of the transcript

of the February 9, 2023 hearing in In re DBMP LLC, No. 20-30080 (JCW) (Bankr. W.D.N.C.).

8. Attached hereto as **Exhibit F** is a true and correct copy of the transcript from the May 16, 2023 deposition of Mark T. Eveland.

9. Attached hereto as **Exhibit G** is a true and correct copy of the transcript from the May 16, 2023 deposition of Richard Winner.

10. Attached hereto as **Exhibit H** is a true and correct copy of excerpts of the transcript of the January 6, 2023 hearing in In re Paddock Enterprises LLC, No. 20-10028 (LSS) (Bankr. D. Del.).

Pursuant to 28 U.S.C. § 1746, I declare under penalty of perjury that the foregoing is true and correct to the best of my knowledge and belief.

Dated: May 26, 2023
Chicago, IL

Respectfully submitted,

/s/ Morgan R Hirst
Morgan R. Hirst

EXHIBIT A

ABRAHAM J. WYNER, PH.D.
ARMSTRONG WORLD INDUSTRIES vs ALDRICH PUMP

May 17, 2023

1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

UNITED STATES BANKRUPTCY COURT
WESTERN DISTRICT OF NORTH CAROLINA
CHARLOTTE DIVISION

ARMSTRONG WORLD) Miscellaneous Proceeding
INDUSTRIES, INC.) NO. 22-303 (JCW)
ASBESTOS PERSONAL) (Transferred from the
INJURY SETTLEMENT) District of Delaware)
TRUST, et al)
- vs -)
ALDRICH PUMP, LLC,)
et al)
- - - - -)

IN RE:) Chapter 11
ALDRICH PUMP, LLC,) No. 20-30608 (JCW)
et al)

Oral Deposition of ABRAHAM J. WYNER,
Ph.D., held on May 17, 2023, at 1:01 p.m., before
Dolores M. Horne, Professional Reporter and Notary
Public, in and for the Commonwealth of
Pennsylvania.

ESQUIRE DEPOSITION SOLUTIONS
1835 Market Street, Suite 555
Philadelphia, Pennsylvania 19103
215-988-9191

1 APPEARANCES :

2 ROBINSON & COLE

3 BY: AMANDA PHILLIPS, ESQUIRE

4 LAURIE KREPTO, ESQUIRE

5 One Boston Place, 26th Floor

6 Boston Massachusetts, 02108

7 aphillisp@rc.com

8 lkrepto@rc.com

9 Representing ACC

10

11

12 BALLARD SPAHR

13 BY: BETH MOSKOW-SCHNOLL, ESQUIRE

14 BRIAN N. KEARNEY, ESQUIRE

15 919 North Market Street

16 Eleventh Floor

17 Wilmington, Delaware 19801

18 moscowb@ballardsphar.com

19 kearneyb@ballardsphar.com

20 Representing DCPF Trusts

21

22

23

24

1 APPEARANCES: (Continued)

2

3

4 YOUNG CONWAY STARGATT & TAYLOR

5 BY: KEVIN A. GUERKE, ESQUIRE

6 Rodney Square

7 1000 North King Street

8 Wilmington, Delaware 19801

9 kguerke@cst.com

10 Representing DCFP

11

12

13 HOGAN & MCDANIEL

14 BY: DANIEL K. HOGAN, ESQUIRE

15 1311 Delaware Avenue

16 Wilmington, Delaware 19806

17 dkhogan@dkhogan.com

18 Representing Certain Matching

19 Claims

20

21

22

23

24

1 APPEARANCES: (Continued)

2

3

4 ANSELMI & CARVELLI

5 BY: ANDREW E. ANSELMI, ESQUIRE

6 56 Headquarters Plaza

7 West Tower, 5th Floor

8 Morristown, New Jersey 07960

9 aanselmi@acllp.com

10 Representing Verus, LLC

11

12

13

14 EVERT WEATHERSBY HOUFF

15 BY: C. MICHAEL EVERT, JR.

16 CLARE M. MAISANO, ESQUIRE

17 3455 Peachtree Road, NE

18 Suite 1550

19 Atlanta, Georgia 30326

20 cmevert@ewhlaw.com

21 cmmaisano@ewhlaw.com

22

23

24

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

I N D E X .

WITNESS EXAMINATION PAGE

ABRAHAM J. WYNER, Ph.D.

By: Mr. Evert 8

E X H I B I T S

NO. DESCRIPTION PAGE

(NONE)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

DEPOSITION SUPPORT INDEX

Direction to Witness Not to Answer

Page Line Page Line Page Line

Request for Production of Documents

Page Line Page Line Page Line

Stipulations

Page Line Page Line Page Line

Question Marked

Page Line Page Line Page Line

1 MR. EVERT: Andrew Wyner --

2 MS. MOSCOW-SCHNOLL: Abraham

3 Wyner.

4 MR. EVERT: Abraham. I'm sorry.

5 It won't be the deposition of Dr. Andrew Wyner.

6 It will be the deposition of Dr. Abraham Wyner

7 taken pursuant to notice. And in agreement of

8 counsel all objections except those as to form of

9 the question or responsive to answers will be

10 preserved until the time of trial or in the use of

11 the deposition. And the witness would like to

12 reserve or waive signature?

13 MS. MOSKOW-SCHNOLL: We want to

14 sign.

15 MR. EVERT: Witness would like to

16 read and sign. Any other stips from anybody?

17 MS. PHILLIPS: Yes. The ACC

18 would like to join in any and all objections by

19 Verus or the Trusts.

20 MR. EVERT: So stipulated.

21 ABRAHAM J. WYNER, Ph.D., after

22 having been first duly sworn, was examined and

23 testified as follows:

24 * * *

1 EXAMINATION

2 * * *

3 BY MR. EVERT:

4 Q. Dr. Wyner, I should start by apologizing
5 for mispronouncing or misstating your name in the
6 stipulation. I apologize for that. Hopefully the
7 court reporter will cure it and no one will ever
8 know but us. Could you state your full name for
9 the record, please?

10 A. Abraham Wyner.

11 Q. And you are at Wharton; is that right?

12 A. Yes.

13 Q. In Philadelphia?

14 A. Yes.

15 Q. How long have you been there?

16 A. Twenty-four years.

17 Q. And your current title?

18 A. Professor of statistics and data
19 science.

20 Q. Your educational background is?

21 A. Ph.D. from Stanford, bachelor's from
22 Yale.

23 Q. I was looking at some of the syllabi for
24 some of your courses in statistics and I saw some

1 of the texts that you use. They would include
2 Keller on statistics for management in economics;
3 is that right?

4 A. I don't use that.

5 Q. Do you use Cochran on sampling
6 techniques?

7 A. I don't.

8 Q. Stein and Foster, statistics for
9 business?

10 A. Yes.

11 Q. So, if the Keller text and the Cochran
12 text were on one of your syllabuses or syllabi,
13 I'm not sure which is right, then that would be --
14 that would have been inaccurate?

15 A. I'm not sure. It could have been a long
16 time ago.

17 Q. Would you consider those texts to be
18 ones that are reliable in your field?

19 A. Yes.

20 Q. Did you come to Wilmington this
21 morning?

22 A. I did.

23 Q. Did you meet with anybody to present for
24 your deposition?

1 A. I talked with lawyers.

2 Q. Everybody here or just some of them?

3 A. Just some of them.

4 Q. Which ones?

5 A. Raise your hand.

6 Q. Fair enough. How long were you here.

7 A. I got here around 9 o'clock.

8 Q. Was that your first preparation for this
9 deposition?

10 A. No.

11 Q. What was your first preparation for this
12 deposition?

13 A. We talked by phone on Monday
14 afternoon.

15 Q. For about how long?

16 A. Hour, hour and one-half.

17 Q. So, your preparation in total for the
18 deposition has been this morning from 9:00 to now
19 and another hour and one-half on the telephone, at
20 least with counsel; is that right?

21 A. Yes.

22 Q. Have you done other preparation for the
23 deposition?

24 A. I read my own report. I read

1 Dr. Mullen's report. I read Dr. Mullen's
2 deposition.

3 Q. Great. How do you bill for your time?

4 A. Hourly.

5 Q. So, on a day like today you drove down
6 from Philadelphia, I presume?

7 A. (The witness indicates.)

8 Q. Is that a yes?

9 A. I drove from Wynnewood. It's separate.

10 Q. Of Philadelphia?

11 A. Yes.

12 Q. Close enough?

13 A. Yes.

14 Q. Do you bill \$1000 an hour for travel
15 time as well?

16 A. Yes.

17 Q. And that is still your current rate,
18 \$1000?

19 A. Yes.

20 Q. Have you sent a bill for your work yet
21 in this particular case?

22 A. No.

23 Q. Can you tell me approximately how much
24 time you have spent thus far in total on this

1 particular case?

2 A. Somewhere between 25 and 40 hours I
3 would guess.

4 Q. So, your current fees up to this moment
5 will be somewhere in the range of twenty-five to
6 \$40,000; is that fair?

7 A. Approximately.

8 Q. Okay. It's not a memory test.
9 When were you originally contacted for your expert
10 report generally? I'm not looking for a date and
11 time. A week before you did it, two weeks before
12 you did it?

13 A. Two weeks, a week and one-half.

14 Q. And who contacted you; do you recall?

15 A. No.

16 Q. Some lawyer?

17 A. I don't want to make you feel bad but
18 yes.

19 Q. Pejorative is fine, some lawyer, that's
20 fine.

21 A. I mean, I've worked with asbestos
22 trusts, so I was recommended.

23 Q. Had you worked with this particular
24 lawyer before?

1 A. No.

2 Q. You mentioned your work with asbestos
3 trusts. I know you have done work with the NARCO
4 Trust; is that correct?

5 A. Yes.

6 Q. Are there other asbestos trusts you have
7 done work with?

8 A. Yes.

9 Q. What would those be?

10 A. I've worked with the DII and then I
11 worked on some legal cases that involved
12 consortiums and trusts.

13 Q. I'll come back to that in just a minute.
14 So, I think, if I have got this right, when the
15 lawyers raised their hands for who you met with,
16 there were counsel for the Asbestos Claims
17 Committee, Counsel for Verus and counsel for
18 DCPF --

19 A. Yes.

20 Q. -- do I have that right?

21 A. Yes.

22 Q. And that's who you have worked with over
23 the course of preparation for this testimony; is
24 that right?

1 A. Approximately, right.

2 Q. Fair enough.

3 MS. PHILLIPS: I want to state
4 for the record, we were in the room this morning
5 for five minutes and we did not work with Dr.
6 Wyner.

7 MS. MOSKOW-SCHNOLL: That was it,
8 yes.

9 MR. EVERT: So, the ACC showed up
10 but they didn't contribute; is that basically what
11 the statement is?

12 MS. PHILLIPS: Yes, just to make
13 sure that was clear for the record.

14 MR. EVERT: Thank you.

15 BY MR. EVERT:

16 Q. So, I saw in your -- in both your
17 declaration and your CV that you've published
18 across a number of methods like applied
19 probability, right?

20 A. Yes.

21 Q. Information theory, correct?

22 A. Yes.

23 Q. Mathematics analysis of algorithms?

24 A. Yes.

1 Q. Machine learning?

2 A. Yes.

3 Q. Applied statistical analysis?

4 A. Yes.

5 Q. All right. And I presume you consider
6 yourself an expert in each of those fields?

7 A. Yes.

8 Q. Do you have any specialized training or
9 knowledge in the field of data privacy?

10 A. No.

11 Q. Your fees that you make for litigation
12 consulting, do they go to you or to the
13 university?

14 A. Me.

15 Q. This is not part of your role at work;
16 is that correct?

17 A. Yes.

18 Q. So, like today, for example, you would
19 take a vacation day, for lack of a better term; is
20 that right?

21 A. I don't have to take a vacation day but
22 yes.

23 Q. How much would you say you work on
24 non-academic -- let me rephrase that. How much

1 litigation consulting do you do on an annual
2 basis?

3 A. A couple of days a month.

4 Q. So, approximately what would be your
5 litigation consulting income on an average annual
6 basis over the last two or three years?

7 A. Litigation consulting.

8 Q. Litigation consulting.

9 A. Fifty to \$75,000, \$75,000 to \$100,000,
10 somewhere in that range.

11 Q. And then do you do other non-litigation
12 consulting outside of your university work?

13 A. Sometimes.

14 Q. You included a list of publications and
15 testimony in exhibits to your report. Are they up
16 to date and accurate?

17 A. To the best of my knowledge.

18 Q. Your --

19 A. We got a paper accepted this morning.

20 Q. Congratulations.

21 A. Thank you.

22 Q. To what journal?

23 A. Journal of Quantitative Analysis in
24 Sports, just proud of my students.

1 Q. You should be. That's always a big
2 deal. I presume this is a peer reviewed journal
3 that is well respected in the field?

4 A. It is, tops.

5 Q. Your list of publications in your
6 exhibit, not all of them were scholarly journals;
7 is that right?

8 A. No.

9 Q. What I said was correct?

10 A. Yes.

11 Q. Have you -- and your list in Exhibit B
12 of litigations you've been involved, it included
13 Grayson versus GE. Do you remember that case?

14 A. A while ago but yes.

15 Q. US Ex Rel. Scott versus Arizona
16 Hematology?

17 A. Yes.

18 Q. R. Wood versus Broadtree Partners?

19 A. Yes.

20 Q. Mann versus National Review?

21 A. Yes.

22 Q. And Honeywell versus NARCO?

23 A. Yes.

24 Q. Are those the only four pieces of

1 litigation that you have been involved in in the
2 past?

3 A. Litigation -- those are depositions.

4 Q. Those are the only depositions you've
5 given in the past?

6 A. Yes.

7 Q. Is it depositions for trial testimony?

8 A. For trial testimony.

9 Q. And you have been involved in other
10 pieces of litigation in your consulting work?

11 A. Recently just maybe one or two.

12 Q. What would those have been?

13 A. There's one with the asbestos trusts
14 where I produced an expert report but there was no
15 deposition and it was thrown out, so.

16 Q. That's the consortium of trusts that you
17 were speaking of?

18 A. Yes.

19 Q. Can you tell me a little bit about that?
20 What was that about?

21 A. It was a sampling case. There was a
22 doctor whose expertise was essentially
23 disqualified by the consortium of trusts, and he
24 sued them for wrongful termination or for -- for

1 some legal problem. And the evidence against him
2 was based on a sample. And I was evaluating the
3 quality of the evidence.

4 Q. As I recall it arose out of Mississippi.
5 Does that ring a bell?

6 A. It does.

7 Q. Do you remember the doctor's name?

8 A. (The witness indicates.)

9 Q. I don't, either, right.

10 A. No.

11 Q. But it will come to me. And that case
12 has been dismissed; is that your understanding?

13 A. It's my understanding, yes.

14 Q. You were never deposed in that case?

15 A. Never.

16 Q. Likewise, in your declaration you
17 attached an Exhibit A, which listed the materials
18 that you have reviewed for your work in this case.
19 Do you remember that?

20 A. I do.

21 Q. And I presume it was complete at the
22 time?

23 A. Yes.

24 Q. That has now been supplemented, I take

1 it, by your testimony of just now of Dr. -- by
2 your testimony just now of the deposition of Dr.
3 Mullen?

4 A. Yes.

5 Q. Is there anything else that should be
6 added to that list?

7 A. Not that I'm aware of.

8 Q. You make a statement in paragraph seven
9 of your declaration, which I'm glad to show you if
10 you want to see a copy, that says, if called to
11 testify, I may also explain principles and
12 terminology referred and alluded to in this
13 report. Can you tell me what that means?

14 A. If extra elucidation of some of the
15 terms I used are required, I would be happy to
16 explain.

17 Q. So, would it be fair to say in short
18 what you're saying is if you have to use different
19 words that are in your words to explain what is in
20 your report, you don't want me to hold it against
21 you; is that --

22 A. Yes.

23 Q. Is that a simpleton's way of saying it?
24 I'm from Georgia, Dr. Wyner, so things come slow

1 to me?

2 A. I don't believe that.

3 Q. But what I said is correct, my summary
4 is essentially right?

5 A. Approximately, yes.

6 Q. Okay. Fair enough. Let me go back for
7 a second to the litigation that you've been
8 involved in. I presume some or all of them
9 involved, they certainly involved statistics; is
10 that right?

11 A. All of them.

12 Q. Did they all involve sampling?

13 A. No.

14 Q. Which ones of them involved sampling, if
15 you can remember? If you want me to go through
16 the list again I'm glad to do that because, again,
17 it's not a blind memory test.

18 A. Certainly R. Wood, certainly the
19 hematology one, that was where sampling was
20 fundamental, certainly the non-deposition we
21 talked about with the doctor. That was all about
22 sampling. Grayson maybe, I don't remember. That
23 was the GE case. And the one that certainly did
24 not was NARCO and neither did Mann versus National

1 Review, et cetera, et cetera.

2 Q. In the claims that involved sampling,
3 was there litigation over the reliability of the
4 sample?

5 A. Yes.

6 Q. So, I presume that that was typically a
7 part of your testimony, a sampling case, is your
8 opinions regarding the reliability of the sample;
9 is that a fair statement?

10 A. Yes.

11 Q. Did that litigation involve a Daubert
12 motions, if you know what those are?

13 A. Almost every litigation is a Daubert
14 motion. So, yes, I'm sure they do.

15 Q. Yes, probably --

16 A. Yes.

17 Q. -- is that a fair recitation?

18 A. Yes.

19 Q. What else -- hearings, court hearings
20 over the quality of the sample or the reliability
21 of the sample?

22 A. Generally not.

23 Q. Any testimony at trial over the quality
24 of the sample or in depositions, in these

1 depositions that you have?

2 A. Certainly not at trial. The ones that
3 have gone to trial were not about the sampling.
4 Well, maybe. I'm not sure.

5 Q. But I take it from your comments just
6 now that the litigation over sampling in those
7 cases that involved sampling from your perspective
8 was extensive?

9 A. Oh, yes, yes.

10 Q. Your raised eyebrows tell me you were
11 deluged with lawyers who litigated endlessly over
12 the reliability of the sample; is that a fair
13 statement?

14 A. Yes. None of those that were listed
15 were particularly complicated. I've done years
16 back other ones which were much more complex for
17 which there can be a big fight over the value of
18 the sample.

19 Q. But notwithstanding the simplicity, of
20 what appears to you to be the simplicity of the
21 sampling issues in the case, they were heavily
22 litigated; is that fair to say?

23 A. They were heavily litigated, yes.

24 Q. So, coming back to your experience in

1 litigation. I think I have it right that you have
2 done two -- you have been involved in two pieces
3 of litigation that involve asbestos; is that
4 correct?

5 A. Actual litigation, yes.

6 Q. So, the NARCO Trust litigation, correct,
7 and the litigation in Mississippi over the
8 doctor?

9 A. Yes.

10 Q. Did you perform any work -- strike that.
11 In the consortium of trust cases
12 involving the Mississippi doctor, was your
13 testimony related to the quality of the sample
14 that the trust had taken in regard to the doctor's
15 submitted diagnoses?

16 A. I'm sorry. Can you repeat that?

17 Q. Probably not but I'll try.
18 Was your testimony in that case, that is the
19 consortium of trust involving the doctor in
20 Mississippi, was your testimony related to the
21 quality or the reliability of the sample of the
22 diagnoses that had been reviewed by the trust from
23 this particular doctor?

24 MR. ANSELM: Objection to form.

1 BY MR. EVERT:

2 Q. Let me rephrase the question.

3 When you worked in the consortium of trust case in
4 Mississippi, what did your testimony entail?

5 A. Well, my expert report. I didn't give
6 testimony.

7 Q. You only gave a report. Thank you very
8 much. What was the crux of your expert report?

9 A. That the conclusion that the trust had
10 come to regarding the doctor's work was
11 substantially supported by the samples that they
12 had generated and checked and evaluated.

13 Q. Would it be fair to say that you
14 concluded that the trust sample was reliable?

15 A. Yes.

16 Q. In the NARCO case, did you do any work
17 other than developing the individual review
18 model?

19 A. Yes.

20 Q. What else did you do?

21 A. I tracked the individual review model
22 results over time. I discussed with them many,
23 many issues that would come up that they would
24 consider of a statistical nature and they would

1 just like my opinion.

2 Q. So, probably a poorly phrased question

3 on my part. Let me give it another shot.

4 Did you do any work in the NARCO litigation that

5 was not associated with the individual review of

6 cases.

7 A. Nothing -- I didn't do any work that

8 ended up in a report or in testimony.

9 Q. I see. So, as I understand it, you are

10 saying that you did some other work with the NARCO

11 Trust when they sought your opinion on various

12 sampling issues; is that a fair statement?

13 A. Not only sampling but any issue they

14 conceived that was statistical in nature,

15 mathematical --

16 Q. Got it.

17 A. -- they often asked for my opinion.

18 Q. Would it be fair to say the primary work

19 that you did with the NARCO Trust was associated

20 with the individual review model?

21 A. Yes.

22 Q. Are you still doing work with the NARCO

23 Trust?

24 A. Yes.

1 Q. And this -- the work you're still doing
2 for the NARCO Trust is not about the individual
3 review model but is instead related to these other
4 issues that you're describing; is that fair?

5 A. It's fair to describe it that way.

6 Q. As I understand it, the goal of the
7 individual review model was to arrive at a value
8 of each individual review claim; is that right?

9 A. Well, the goal of the IR model is to
10 come up with a valuation that approximated what
11 would be the liquidated value of the -- the full
12 liquidated value of the claim under the trust
13 distribution procedures.

14 Q. So, the goal of the individual review
15 model was to value the claim pursuant to the NARCO
16 Trust distribution procedures?

17 A. Yes.

18 Q. As I understand it, you based that model
19 on various factors that affect the severity of
20 damages in valuing a claim; is that right?

21 A. Yes.

22 Q. So, in building that model you, for
23 example, had inputs for an injured party's
24 industry; is that right?

1 A. Yes.

2 Q. And you had inputs for an injured
3 party's occupation; is that right?

4 A. Yes.

5 Q. You also had inputs for an injured
6 party's age; is that correct?

7 A. Yes.

8 Q. You also had inputs for an injured
9 party's law firm; is that correct?

10 A. Yes.

11 Q. And I believe you also had inputs for an
12 injured party's gender; is that right?

13 A. It's hard to say because it's not in the
14 model.

15 Q. It's not in the model?

16 A. Not that I recall at any level.

17 Q. Did I miss anything in particular --

18 A. Sure.

19 Q. -- factor?

20 A. You missed a lot of factors.

21 Q. Let me hear some more?

22 A. Well, these are things in the TDP, so I
23 guess anybody can read them, economic loss,
24 dependency, whether the claimant is alive. These

1 are just a couple of examples.

2 Q. Sure. Okay.

3 A. Smoking, that's a big one.

4 Q. In your work in the NARCO matter and in
5 building the individual review model, did you have
6 access to the entire claims database for the NARCO
7 Trust?

8 A. At some point, yes.

9 Q. So, in that particular instance, you did
10 not constrain your analysis to a sample; is that
11 fair?

12 A. I mean, we used -- I used the data that
13 was provided. So I didn't need the sample. They
14 gave me the data.

15 Q. They gave you the entire population; is
16 that correct?

17 A. They gave me what they had. I'm -- I
18 can't elaborate where that came from because I
19 don't know.

20 Q. As far as you know, they gave you
21 everything they had?

22 A. Yes.

23 Q. And you did not design a sample for your
24 purpose in that particular --

1 A. In this particular exercise for the
2 building of an IR model, no. But for other things
3 you do samples.

4 Q. When you do work like that, when you're
5 working with a large database, where do you
6 perform the work physically?

7 A. On my computer.

8 Q. That's a fair answer. At your office?

9 A. No. Usually in my home.

10 Q. And how would that data be transferred
11 to your home computer?

12 A. Oh, generally it comes in a file.

13 Q. So, in this instance, let's just talk
14 specifically about the Honeywell and NARCO claims
15 database that you worked with to build the
16 individual review model. Did they share with you
17 the database in a secure link; is that how you got
18 it?

19 A. Well, I got the data. Some of the data
20 came over the years, at least ten years ago now.
21 So I can't remember. Sometimes I get big
22 envelopes. Sometimes it would be -- here's a word
23 from the past, disk.

24 Q. Wow.

1 A. Sometimes it just gets mailed, emailed.
2 Things have gotten much better recently.

3 Q. So, it's been long enough ago that it
4 may have been a hard drive of some type; is that
5 right?

6 A. Yes.

7 Q. And it's -- some of it has been recent
8 enough that it may have been sent via the
9 internet; is that right?

10 A. Yes.

11 Q. You would maintain this data on a
12 personal computer?

13 A. Yes.

14 Q. A laptop probably?

15 A. Yes.

16 Q. And that laptop I presume is routinely
17 connected to the internet?

18 A. Yes.

19 Q. I'm going to illustrate my ignorance
20 with statistics and ask you some basic questions.
21 Would you agree with me that sampling error refers
22 to differences between the sample and the
23 population that exists only because of the
24 observations that happened to be selected for the

1 sample?

2 A. Can you repeat the first part of that?

3 Q. I can. Sampling error refers to
4 differences between the sampling and the
5 population that exists only because of the
6 observations that happened to be selected from the
7 sample?

8 A. Yes, that sounds about right. I even
9 said something similar in my report.

10 Q. Would you agree with me that sampling
11 error is an error that we expect to occur when we
12 make a statement about population that is based
13 only on the observations contained in a sample
14 taken from the population?

15 A. Sounds about right.

16 Q. Would you agree with me that even when
17 the statistics practitioner performs experiments
18 properly, a certain proportion of the experiments
19 will produce incorrect estimates by random
20 chance?

21 A. That's very ill defined.

22 Q. I'm sorry. I didn't understand.

23 A. That's not a very well defined question
24 because when you use the word incorrect, that has

1 to be defined. What does it mean to be incorrect?

2 Q. Okay. Let me try again. Even when the
3 statistics practitioner performs experiments
4 properly, a certain proportion of the experiments
5 will produce estimates inconsistent with the total
6 population by random chance.

7 A. Now I'll ask you what does it mean to be
8 inconsistent?

9 Q. All right. I'll give up. Would you
10 agree that the difference between the true value
11 of the parameter you're measuring in the
12 population and its estimate is the sampling error?

13 A. Yes.

14 Q. Would you agree that the size of the
15 deviation, that is the sampling error, may be
16 large simply because of bad luck, bad luck that a
17 particularly unrepresented sample happened to be
18 selected?

19 A. Well, it would have to be -- what do you
20 mean by large? So that has to be defined.

21 Q. All right. You used the word, I
22 believe, large in your expert report and I can
23 find it for you, I think, or I could ask you how
24 would you define large?

1 MR. ANSELM: Objection to form.

2 BY MR. EVERT:

3 Q. You may answer.

4 A. I'd have to know what problem I'm
5 solving.

6 Q. Fair enough. Would you agree with the
7 statement that the only way we can reduce the
8 expected size of the sampling error is to take a
9 larger sample?

10 A. I would disagree with that.

11 Q. Would you agree with the statement that
12 if we are willing to accept less than 100 percent
13 accuracy we can use statistical inference to
14 obtain an estimate?

15 A. It's very hard to answer a question that
16 is vaguely phrased. So if you want to try a
17 different question.

18 Q. Well, I'm reading from statistical
19 textbooks. So, you know, I get it.

20 A. They have a paragraph that preceeded the
21 question.

22 Q. Fair enough. So, you're unable to tell
23 me whether you're able to agree that if we are
24 willing to accept less than 100 percent accuracy

1 we can use statistical inference to obtain an
2 estimate?

3 A. Yes.

4 Q. Would you agree that the use of a sample
5 in place of the whole introduces sampling
6 variation, that is the results from one sample
7 will differ from those provided by another sample?

8 A. Yes.

9 Q. Would you agree that the presence of
10 sampling variation means that sample statistics
11 differ from sample to sample --

12 A. Yes.

13 Q. -- and that is the price we pay for
14 working with a sample rather than the population?

15 MR. ANSELMI Objection to form.

16 BY MR. EVERT:

17 Q. I'll ask it again. Would you agree that
18 the presence of sampling variation means that
19 sample statistics differ from sample to sample and
20 sampling variation is the price we pay for working
21 with a sample rather than the population?

22 MR. ANSELMI: Same objection.

23 BY MR. EVERT:

24 Q. You may answer.

1 A. There is sample to sample variation and
2 it is inherent in the idea of sampling. And the
3 consequence of the sampling is something you have
4 to attempt when you're dealing with sampling.

5 Q. Would you agree that the results of
6 sample surveys are always subject to some
7 uncertainty because only part of the population
8 has been measured?

9 A. Yes.

10 Q. Would you agree that if you analyze the
11 entire data set rather than a sample, by
12 definition there is no sampling error?

13 A. Yes.

14 Q. Would you agree that the chief motive
15 for examining a sample rather than a population is
16 cost?

17 MR. ANSELM: Objection to form.

18 BY MR. EVERT:

19 Q. You may answer.

20 A. It's complicated because usually
21 examination of the complete population is
22 impossible. So even when it's cost, cost can be
23 infinite, you still can't get the full
24 population.

1 Q. Well, let's -- I want you to assume for
2 me that we have a circumstance where you can get
3 the full population. Would you agree with me that
4 the chief motive for examining a sample rather
5 than population is cost?

6 A. Yes.

7 Q. As a result, would you agree that one
8 should undertake a cost benefit analysis as to
9 whether to use the sample or the entire
10 population?

11 A. Yes.

12 Q. I think in your expert report you
13 identify some of the costs associated with
14 sampling and some of the benefits; is that
15 right?

16 A. I'm not sure exactly what you're
17 referring to, but.

18 Q. All right. So, I think in your expert
19 report you say that one cost of sampling -- I'm
20 going to say cost is a very economic term to me,
21 so I'm going to say one -- one negative of
22 sampling is it's potential loss of accuracy; is
23 that fair?

24 A. Yes. So sampling is -- does lead to

1 loss of accuracy.

2 Q. And one potential negative of a sample
3 is the dollar cost of preparing the sample; is
4 that fair?

5 A. Well, that's hard to quantify. The
6 dollar cost to preparing the sample depends on who
7 is doing it and how much they charge.

8 Q. Will you agree with me that as your
9 experience in your litigation has borne out that
10 one of the negatives of sampling is the litigation
11 that ensues over the reliability of the sample; is
12 that a fair statement?

13 A. I'm not sure it's the reliability of the
14 sample that is the issue in the litigation. I
15 think it more has to do with what the sample means
16 that people seem to fight about.

17 Q. That's fair. So, you would agree with
18 me that one of the negatives of sampling is the
19 litigation that ensues over the meaning of the
20 sample; is that fair?

21 A. Yes, because in most cases everyone
22 accepts that data is hard to get. And you have
23 the data but you have to understand what it's
24 telling you, right.

1 Q. Okay.

2 A. So it's often someone has done some work
3 to -- to contribute something to each observation
4 in the sample and they argue about what it means.
5 So there's so many things that people argue about
6 in litigation, you know.

7 MR. ANSELM: Agreed.

8 BY MR. EVERT:

9 Q. Would you agree with me that one of the
10 benefits of sampling is lowering the
11 administrative costs to the provider of the
12 sample?

13 A. That's common.

14 Q. And are you aware that in this
15 particular instance the debtor has agreed to pay
16 those administrative costs?

17 A. No, I wasn't aware of that.

18 Q. So, if I were to tell that you in this
19 case the debtor has been ordered by the court to
20 pay those administrative costs, would you agree
21 with me that at least from the proprietor's
22 perspective, that's no longer a negative?

23 A. That's complicated to know because from
24 the proprietor's perspective, it may not be easy

1 for them to articulate what their costs are. I've
2 been in that situation before where people offer
3 you to pay for something. And you're like, well,
4 that doesn't capture really what I'm going to do
5 here. So I can't put a dollar value on it because
6 what -- what it's requiring me is much more
7 complicated than that. I just have no opinion on
8 what that means.

9 Q. Are you aware that a full population of
10 similar data has been produced by the DCPF in
11 another case?

12 A. I'm vaguely aware that there's been
13 other data produced. I don't know exactly what it
14 is or what it's similar to. So I don't really
15 know how to answer that question precisely. I do
16 know that other data has been produced.

17 Q. You know generally that other data has
18 been produced?

19 A. Yes.

20 Q. Are you aware that as a result of the
21 production of that data pursuant to the court's
22 order, that the debtor pay the cost for that, that
23 DCPF submitted a bill for their cost. Has that
24 been made apparent to you at all?

1 A. There was some discussion about how much
2 it costs, but I don't know details or what that
3 represents or what the full costs are or anything
4 of that nature.

5 Q. So, that's just not been part of what
6 you have been educated about in your work in this
7 case?

8 A. Yes. I don't know much about it, and I
9 certainly wasn't asked to offer an opinion on
10 that.

11 Q. I presume that likewise you were not
12 informed about the process that DCPF had to go
13 through or did go through in order to produce the
14 data that they produced?

15 MS. MOSKOW-SCHNOLL: Objection to
16 form.

17 THE WITNESS: What I'm aware of
18 is -- I've read lots of stuff in the list.
19 There's a lot of discussion about what it takes to
20 produce the sample.

21 BY MR. EVERT:

22 Q. My question is more current. That is,
23 have you had discussions at all with your clients,
24 DCPF or Verus, about productions of similar data

1 that have been made recently?

2 A. No.

3 Q. So, if I were to tell you that in a case
4 called DB&P, the Delaware claims processing
5 facility responded to a very similar subpoena and
6 produced the entire population of data, you have
7 no knowledge about that?

8 MS. MOSKOW-SCHNOLL: Objection.

9 THE WITNESS: No.

10 BY MR. EVERT:

11 Q. Okay. In your expert report one of the
12 other benefits of sampling that you talk about is
13 a reduction in privacy risk; is that right?

14 A. Yes.

15 Q. So, the benefits that we just talked
16 about that I saw listed in your expert report --
17 strike that.

18 The benefits of sampling that we just
19 talked about, that at least I saw listed in your
20 expert report, were reduction of privacy risk and
21 the reduction of administrative costs to the
22 provider of the sample. Were there any more in
23 your report or do you have any more benefits of
24 sampling in this instance in your opinion?

1 A. So, my expert report was not about
2 the -- what I consider the cost side of the
3 equation. So, the trusts have to put or has to
4 provide the data. They have costs associated with
5 that. And I did talk in my report about two of
6 them. If there are other costs that are out
7 there, I'm not -- I don't have an opinion about
8 whether they're more. There may be and there may
9 be many more. That was not the scope of my
10 opinion. My opinion was much more on the other
11 side of the equation, what would be the benefit to
12 having the full population compared to the
13 sample.

14 Q. That was not what you were asked to do
15 is what you're saying?

16 A. I'm not on what I would call the cost
17 side of the equation.

18 Q. So, in your declaration I think you say
19 that your ultimate opinion is that a random 10
20 percent sample of 1200 claimants would fulfill all
21 of the debtors reasonable needs or reasonable
22 purposes. Do I have that right?

23 A. Yes.

24 Q. How do you define reasonable needs or

1 reasonable purpose?

2 A. So, basically where I looked was in Dr.
3 Mullen's report where he explains what he wants to
4 do with the data. It was just very, very limited.
5 But he did indicate a couple places where he wants
6 to look at the data. I evaluated those
7 specifically. And then I also have substantial
8 knowledge about what gets done in these asbestos
9 cases, and I also know how big a sample of 1200 is
10 and I know the things at issue here. And what I
11 could imagine the reasonable things you would want
12 to do, I couldn't come up with something that
13 requires -- would require more than 1200 data --
14 1200 observations at a cost that was
15 significant.

16 Q. Let me ask a little more granularly.
17 Are reasonable purpose and reasonable need the
18 same thing as used in your expert report?

19 A. I'm not sure what you're asking. Is
20 there something --

21 Q. Yes. So, in your expert report, which
22 here is a copy if you would like to look at it
23 while your -- we don't need to mark it. There's
24 plenty in this case. You in a number of

1 paragraphs use the words, quote, reasonable
2 purpose, unquote and, quote, reasonable need,
3 unquote.

4 A. I'm probably using them
5 interchangeably.

6 Q. That's what I figured. I'm just trying
7 to clarify. Those are not statistical terms. I
8 mean, I couldn't look them up -- I tried to look
9 them up, and I couldn't look them up in a
10 statistics textbook; is that fair?

11 A. That's fair.

12 Q. So, there's no authoritative text I
13 could go to to define what a reasonable purpose or
14 a reasonable need is; is that right?

15 A. No. A reasonable need depends on the
16 problem that you're solving specifically.

17 Q. So, help me understand what you mean by
18 reasonable need or reasonable purpose?
19 Can you explain it for me any better?

20 A. Well, yeah. There's a couple of
21 examples where I gave and -- but, so, one example,
22 reasonable need would be to estimate the
23 proportion of the settled claims in the
24 population, which you just called the 12,000

1 mesothelioma, what fraction of them have a
2 disclosure of their exposure that is different in
3 the trust data than was in the data that Bates and
4 White already has. A discrepancy in the exposure
5 record to figure that number out, that seems to be
6 a very important and very reasonable need. In
7 fact, it seems to be the driving purpose of this.
8 And then a few other things that were discussed in
9 Dr. Mullen's report that explains why he wants
10 this data and what -- what it will be used for.
11 So, reasonable things are things -- are what I
12 call reasonable are attributes of the population
13 and the sample, which would be used to estimate,
14 it would have an impact on something that is
15 currently at issue.

16 Q. So, by employing the term reasonable,
17 are you effectively doing the cost benefit
18 analysis that we talked about a minute ago?

19 MR. ANSEMI: Objection to form.

20 THE WITNESS: No. I'm only on
21 the benefit side of the equation.

22 BY MR. EVERT:

23 Q. I see. So, in this particular instance
24 employing the word reasonable would mean that in

1 your opinion for the parameters you identified in
2 your expert report, a 10 percent sample is as good
3 as the entire population; is that --

4 A. I'm going to have to -- maybe you want
5 to rephrase it because when you say as good, you
6 have to -- what are you talking about? Again, I'm
7 doing this again. What does it mean to be as
8 good. So do you want to re-ask or --

9 Q. We have already agreed, correct, that by
10 definition when we sample, you bring in sampling
11 error, correct?

12 A. That's right.

13 Q. I think we're in agreement -- strike
14 that.

15 As you use the term in your expert
16 report, are the reasonable needs of the debtors
17 the two parameters of study that you identified in
18 your expert report that were from Dr. Mullen's
19 declaration?

20 MR. ANSEMI: Objection to form.

21 THE WITNESS: Dr. Mullen indicated
22 two. From there you can kind of understand what
23 the purpose of this data is. What you clearly
24 quickly understand is that this has -- the data

1 has a particular role to play in a much, much
2 larger problem. And the much larger problem has
3 to do with -- which isn't articulated in Dr.
4 Mullen's report at all, but it is talked about in
5 his deposition testimony, has to do with much
6 bigger questions that are hugely uncertain and
7 very difficult to answer accurately. And there's
8 no expectation that it does get answered
9 particularly accurate. You just try to do as best
10 as you can. This particular data set is there to
11 provide a gloss, a little bit of depth and perhaps
12 some changes into those estimates. But you could
13 do it with all the data, all 12,000 or you can do
14 it with a sample of 1200. And my basic opinion is
15 that if you had 1200, you're going to get --
16 you're going to use it in a way that will be
17 almost exactly the same way in terms of the
18 overall result at the end of the line, which is
19 doing things like forecasting what the total of
20 the trust liability would be.

21 BY MR. EVERT:

22 Q. You have not reviewed the debtor's
23 claims database; is that correct?

24 A. No.

1 Q. You have not spoken with the debtor or
2 their counsel about the estimation proceedings; is
3 that correct?

4 A. No.

5 Q. You have not read the order in this case
6 ordering that an estimation proceeding be held
7 before the court; is that right?

8 A. I'm not sure. I read a lot.

9 Q. It's not on your Exhibit A.

10 A. Okay.

11 Q. So does that mean I'm correct, you have
12 not read it; is that right?

13 A. Right.

14 Q. Have you ever rendered an expert opinion
15 on the value of current and future asbestos claims
16 pending against a company?

17 A. So, I have never written an expert
18 report but I have certainly discussed this with
19 trusts at length.

20 Q. Well, do you purport to be an expert on
21 the estimation of current future asbestos
22 claims?

23 A. If I were asked to be an expert and
24 comment on how this has been done, I would

1 absolutely do so.

2 Q. You would accept the obligation; is that
3 what you're saying? You would accept the task?

4 A. Yes, because I'm an expert in statistics
5 and most of these tasks are fundamentally
6 statistical tasks.

7 Q. You've never done it before?

8 A. No. They usually are done by consulting
9 firms.

10 Q. Have you ever rendered an opinion on the
11 forecasting of the number of future asbestos
12 claims?

13 A. Not for a court.

14 Q. And for whom have you rendered that
15 opinion?

16 A. For trusts.

17 Q. For the NARCO Trust?

18 A. And the DII Trust.

19 Q. But it's never been published in any
20 form?

21 A. No.

22 Q. Have you ever wrote an opinion on the
23 likely incidence of mesothelioma in the future?

24 A. I've never written an opinion on it but

1 I've looked at this data enormously.

2 Q. You have a view is your point?

3 A. I know what goes into this.

4 Q. You say you know what goes into it. How
5 do you know?

6 A. Because I've read lots and lots of
7 reports on how it's done.

8 Q. And those reports have surrounded your
9 work for the trusts?

10 A. Yes.

11 Q. How much of that work has surrounded
12 tort litigation?

13 A. The only one that was litigated was
14 NARCO.

15 Q. I think my question was poorly phrased.
16 When you looked at this information in regard to
17 future claiming practices, they're all in relation
18 to trust claiming; are they not?

19 A. I'm sorry. Can you repeat --

20 MS. MOSKOW-SCHNOLL: Objection.

21 BY MR. EVERT:

22 Q. When you have looked at these issues of
23 future asbestos claiming, they're all in relation
24 to claims made against a trust; is that correct?

1 A. Yes.

2 Q. And a defined TDP; is that correct?

3 A. Yes.

4 Q. Have you ever looked at the issue for a
5 company involved in the tort litigation, not in a
6 trust?

7 A. No.

8 MR. ANSELM: Can we take a
9 break?

10 MR. EVERT: Anybody can take a
11 break at any time.

12 THE WITNESS: Can we go on for
13 five more minutes? Round it out to 2:00.

14 MR. EVERT: Absolutely. I should
15 have said it at the beginning. All you have to do
16 is say, hey, I need a break. I apologize for not
17 laying that out.

18 BY MR. EVERT:

19 Q. In ordering that the debtors could
20 pursue this subpoena, pursue the information that
21 the debtors were seeking, the court found that the
22 information was relevant and necessary to the
23 negotiation of a plan of reorganization. Do you
24 have any expertise in that area?

1 MR. ANSELM: Objection to form.

2 MS. MOSKOW-SCHNOLL: Objection.

3 THE WITNESS: I mean, I certainly
4 know what has happened in other trusts and what
5 they use. So I do have some expertise. I have no
6 reason to doubt the judge -- the court's opinion.

7 BY MR. EVERT:

8 Q. When you say you know what other trusts
9 use, you're talking about trust distribution
10 procedures?

11 A. Yes.

12 Q. So, you've never been involved in any
13 form in the negotiations of a plan of
14 reorganization?

15 A. No.

16 Q. Even as an expert, not as a lawyer?

17 A. I've never been at that level.

18 Q. The court also found that this trust
19 data was relevant and necessary to the
20 confirmation of a plan of reorganization. I
21 presume you've never been involved in the process
22 of confirming a plan for reorganization as an
23 expert; is that fair?

24 MS. MOSKOW-SCHNOLL: Objection.

1 THE WITNESS: I'm still -- I
2 still haven't worked with a company at the level
3 of reorganization, not in the time period that
4 you're asking me this question.

5 BY MR. EVERT:

6 Q. Have you ever been involved in the
7 negotiation and formulation of trust distribution
8 procedures?

9 A. I probably have to say yes to that
10 because the NARCO ones have just been redone, and
11 I was certainly involved in that.

12 Q. So, you were involved in the negotiation
13 of those trust distribution procedures or you were
14 involved in their revisions by the trust?

15 A. The revision, not the original one but
16 they were revised, so.

17 Q. The latter, you were involved in the
18 revisions that were done by the NARCO Trust; is
19 that right?

20 A. Yes.

21 Q. In ordering the subpoenas that are at
22 issue here today, the court found that this trust
23 data was relevant and necessary to the estimation
24 of the debtor's asbestos liability. Do you have

1 any reason to disagree with that?

2 MR. ANSELM: Objection to form.

3 THE WITNESS: I don't have any
4 reason to disagree, but I have no reason to
5 affirm, either.

6 MR. EVERT: Let's go ahead and
7 break because the next line is going to take a
8 little while.

9 (Whereupon a break was taken.)

10 MR. EVERT: Counsel for DCPF
11 wants to know if Dr. Mullen is on the phone.
12 Dr. Mullen, if you're on the phone, would you say
13 present.

14 MR. GUERKE: Thank you.

15 MR. EVERT: No response was
16 given.

17 BY MR. EVERT:

18 Q. Dr. Wyner, before we broke, you had said
19 that you had rendered some opinions in your
20 consulting practice for the trusts in regard to
21 the future incidences of mesothelioma. Did I
22 understand you correctly?

23 A. Yes.

24 Q. What do you base those opinions on?

1 A. Data that consulting firms have
2 provided.

3 Q. I see. So, what incidence model do you
4 use?

5 A. Well, I haven't built the models. I
6 just read the models that others have used.

7 Q. And --

8 A. I'm happy to build them.

9 Q. I'm sorry. I didn't mean to interrupt
10 you.

11 A. I haven't actually been asked to build a
12 model. I'm more asked to sort of opine on the
13 results and what they mean and how accurate they
14 might be and things of that nature.

15 Q. What models in that opinion have you
16 relied upon?

17 A. Just general statistical knowledge.
18 I've done lots of things. There's nothing
19 specific as an issue. I won't be able to be
20 specific about what I did.

21 Q. So, specifically when you have rendered
22 an opinion about the expected future incidence of
23 mesothelioma, what incidence model have you relied
24 on to render that opinion?

1 A. I've just reviewed the ones that are
2 there and I've just discussed them. And I don't
3 have a memory of exactly the ones that were
4 used.

5 Q. So, let me make sure because I want to
6 make sure I understand your expertise in this
7 area. You have reviewed more than one, I don't
8 know how many actuarial or other consulting
9 reports that have made estimates as to the future
10 incidence of mesothelioma; do I understand that
11 correctly?

12 A. Yes.

13 Q. Those same or similar reports have made
14 estimates about the future claiming rates against
15 the trust for which you are consulting; is that
16 fair?

17 A. Yes.

18 Q. And what I think I hear you saying is
19 that you have provided to your clients, the trust
20 in that instance, your critique of those estimates
21 based on your expertise in statistics; is that
22 fair?

23 A. Yes.

24 Q. So, I want to make the distinction

1 between you having expertise in actually making
2 those estimate versus you having expertise in
3 being able to analyze statistical assumptions or
4 inferences made in those types of reports.

5 MS. MOSKOW-SCHNOLL: Objection.

6 MR. EVERT: I haven't gotten to
7 the question yet.

8 MS. MOSKOW-SCHNOLL: That was my
9 objection.

10 BY MR. EVERT:

11 Q. So, your expertise is used in this
12 instance to evaluate forecasts made by others; is
13 that fair?

14 A. One of the things. A statistician is
15 different from the actuary or an economist or an
16 accountant in the sense that those experts rely on
17 statistical tools and they apply them. A
18 statistician, particularly an academic one, we
19 make them. I build the tools, and I typically
20 know what they're good for and where they are
21 inappropriate. But you don't build a tool unless
22 you are asked to fundamentally work on the problem
23 from scratch. So I have not actually built one of
24 those and had a trust rely on my actual

1 construction or my estimate. I've only reviewed
2 the ones that have been given to me and I've
3 examined them. Sometimes the review is very
4 simple because they made the forecasts in the past
5 and the question is, well, how did you do. And
6 that's often very straight forward. And that's a
7 fundamental statistical question I'm asked, things
8 like, well, were we within the margin of error in
9 what we've predicted or were we not. Some things
10 are more general. Here is what they're
11 forecasting. What do you think about that. And
12 generally one of the things I look at, questions
13 like what are the assumptions that are here and
14 are they valid. You can't really build a model
15 without assumptions but you really have to
16 understand what assumptions mean and how they
17 ramify and what they do to your forecasts. And
18 that's what kind of like a fundamental builder of
19 methodology does. That's what I do for a living.
20 I build methods.

21 Q. When you build those statistical
22 methods, I presume the process is iterative; is
23 that fair?

24 A. Well, it depends on the -- that's

1 probably usually more in the application, when you
2 actually apply it then it becomes iterative. But
3 usually when you build a method it starts with an
4 idea. And I don't think anyone wants me to go on
5 and talk about how research in statistics takes
6 place.

7 Q. What I'm trying to get to is that you've
8 not built such a model for forecasting future
9 claims, correct?

10 A. I haven't done it from scratch.

11 Q. And if you were to do it from scratch, I
12 presume that process would have certain stress
13 tests, certain changes through the course of
14 building the model so that you would improve its
15 reliability; is that accurate?

16 A. I would say that things like that are
17 done, of course, to get a sense of what the --
18 what we call sensitivity to assumptions are and
19 estimate parameters and what -- what causes things
20 to be uncertain.

21 Q. So, if you started from scratch, that
22 would be part of your learning process to build
23 your model; is that correct?

24 A. It would be but it's also part of the

1 review process. It's actually one of the most
2 important things, what stresses have been used,
3 what are the assumptions that were made, how did
4 they -- how -- if you used different values, what
5 did that do to the criteria. A lot of things --
6 you know, there's what we call -- in statistics we
7 often are concerned with what we call known
8 unknowns. But the bigger question is the unknown
9 unknowns. And that's where you have to be open
10 to, you know, real, real poor forecasts. That's
11 one of the things that generally comes up that is
12 ignored, this idea, well, things can go really
13 badly wrong in the ways you aren't anticipating.

14 Q. And none of your clients has asked you
15 to build that model from ground up, correct?

16 A. No. I don't think I'm in a position to
17 do that. That's a full-time job.

18 Q. Okay. Are you aware that the 1200
19 claims sample that is being discussed in your
20 expert report in this case is less than .3 percent
21 of the debtor's total historical asbestos claims?

22 A. That wasn't in the expert report of Dr.
23 Mullen. I saw that he raised that in the
24 beginning and I don't know why that -- what is the

1 point. So I'm aware of that but I don't know how
2 that is relevant.

3 Q. You're now aware but it's not relevant
4 to you; is that right?

5 A. No. Because we're talking about the
6 difference between getting 12,000 versus getting
7 1200. The fact that the 12,000 came from 400,000
8 in some mysterious process is not something that I
9 opined on.

10 Q. So, would you agree with me that the
11 1200 is an extremely small sample of the debtor's
12 overall historical asbestos claims regardless of
13 its import to you?

14 A. I categorically disagree. The sample
15 size is dependent on the -- the utility of the
16 sample is dependent on the size, not the size of
17 the population it's drawn from. I'm now lecturing
18 you, I know. That's my job as a professor and you
19 just earned a failing grade, sir.

20 Q. I've clearly asked my question poorly to
21 gain my failing grade. Let me try it again.
22 Would you agree with me that the 1200 claims
23 samples being discussed in this case is a very
24 small percentage of the debtor's overall

1 historical asbestos claims?

2 MR. ANSEMI: Objection to form.

3 THE WITNESS: Again, it's going
4 to sound like a broken record. What does it mean
5 to be very small. If you want to say that it is
6 less than 1 percent, the answer is it is.

7 BY MR. EVERT:

8 Q. In your opinion, would a 600 claim
9 sample be enough for the debtor's purposes?

10 A. Again, it depends on what the purpose is
11 and what the additional uncertainty would mean. I
12 would probably guess that 600 would offer a lot of
13 value and probably solve most of their questions
14 at issue. But I would have to know what those
15 questions are and I'd have to do a calculation.
16 And, so, ultimately my answer would be it depends.
17 But my intuition would suggest that it would
18 probably be sufficient.

19 Q. Well, now, I don't mean to sound like
20 I'm lecturing you --

21 A. Please don't.

22 Q. -- but in your expert declaration you
23 opine that 1200 claims was enough for the debtor's
24 needs?

1 A. Yes.

2 Q. I'm asking you, would 600 claims be
3 enough for the debtor's needs, in your opinion?

4 A. I didn't do a calculation. I did some
5 calculations of the 1200. I haven't done any with
6 600.

7 Q. So, you would have to study that is your
8 answer?

9 A. Yes.

10 Q. Now that you've read Dr. Mullen's
11 deposition, is there anything in there that
12 changed your view about the debtor's needs?

13 A. Dr. Mullen brought up a whole new set of
14 things that he's -- I don't know -- interested in
15 is probably the best word, that he cares about.
16 But, unfortunately, I wasn't really able to
17 understand the connection between those interests
18 and the 1200 versus 12,000. That wasn't done in a
19 way that was easily for me to understand.

20 MR. EVERT: Can you read that
21 back to me.

22 (The court reporter read back the
23 record as requested.)

24 BY MR. EVERT:

1 Q. Dr. Wyner, not on your Exhibit A list of
2 documents you reviewed for this case was the
3 actual subpoena that was issued to the trust. Do
4 you recall if you ever reviewed the subpoena
5 issued to the trust?

6 A. I'm curious. I thought I've asked for
7 that. You have to forgive my lack of knowledge of
8 the difference between the subpoena and a response
9 and things like that. I mean, I think that was
10 something I wanted but I don't recall what it
11 was.

12 Q. I'm not trying to catch you in something
13 that is not fair. Will you agree with me it's not
14 listed in your Exhibit A? And you're welcome to
15 look at it if you want.

16 A. I'm not sure I would even be able to
17 know how a subpoena would be described in this
18 list.

19 Q. Okay.

20 A. So, I just have to take your word for
21 it.

22 Q. So, the subpoena says, among other
23 things, the following. The subpoena seeks
24 evidence that is relevant and necessary to

1 specific purposes in connection with the
2 estimation of the debtor's liability for current
3 and future asbestos related claims. Were you
4 aware of that at the time you did your expert
5 report?

6 A. I mean, I understand what this data is
7 for in a broad sense. But it's not -- I don't
8 believe that it's -- this data is here to answer
9 all of those questions. My understanding was that
10 it was really only a very small sub set of the way
11 that this data is supposed to interact with those
12 big questions.

13 Q. Where did you get that understanding?

14 A. From my conversations with the lawyers,
15 from reading the various different things that
16 I've read, from the introduction and discussion of
17 Garlock which kept coming up and the idea that a
18 particular issue here -- and, also, you look at
19 the fields that they provided. And there's a lot
20 of discussion about the alternative exposures and
21 exposures that don't match to what was presented
22 and then what -- in the cases against Aldrich and
23 Murray. The debtors have some understanding of
24 what the claimants claimed and that the same

1 claimants went to trusts and may have said
2 something different. So the -- my understanding
3 is that what is at issue is the difference between
4 these alternate exposure records and how those
5 might have an impact on these bigger questions.

6 Q. So, is it fair to say, Dr. Wyner, that
7 your opinion in regard to the 1200 claims sample
8 and its reliability is limited to the question of
9 evident suppression?

10 MR. ANSEMI: Objection to form.

11 THE WITNESS: So, my understanding
12 comes from Dr. Mullen. Dr. Mullen, who I was
13 asked to respond to, indicated this is what he's
14 interested in. I pulled it out in my own report,
15 if I don't mind. Specifically, the data -- and
16 I'm quoting, specifically the data would allow us
17 to compare exposure allegations to the products of
18 the reorganized entities for which the trusts were
19 established with the exposures the same claimants
20 disclosed in their tort litigation against the
21 debtors. This would enable us to quantify the
22 proportion of alternative exposures disclosed to
23 the debtor at the time of the settlement. So,
24 first thing he talked about.

1 BY MR. EVERT:

2 Q. If I could read to you the sentence
3 before what you just quoted out of Dr. Mullen's
4 report, which is in paragraph 16 of his report.
5 It says, the trust data are also needed to assess
6 whether the debtors entered into settlements aware
7 of the totality of alternative exposures. And
8 then it continues, specifically, which is the data
9 -- which is the quote which you have in your
10 report. Did it occur to you that Dr. Mullen's use
11 of the word also meant that there were other uses
12 for the data as well?

13 A. I think the word was still about
14 exposures and the impact on his calculations. So,
15 I mean, the question is what is this about. And
16 from everything I could tell, it's all about
17 exposure allegations.

18 Q. I guess what I'm trying to get to,
19 Dr. Wyner is, what Dr. Mullen said, Dr. Mullen
20 said. Your report, am I correct, is focused on
21 the two parameters that you identified; is that
22 correct?

23 A. Well, let me step back. Dr. Mullen
24 writes extensively that there's a benefit. I

1 don't think he uses the word benefit but that's
2 really what it is. There's a benefit to the
3 debtors to get 12,000 as opposed to 1200. But he
4 never explains what that benefit is or how he
5 calculated it. So, I was in a position to try to
6 respond and say, well, if there is a benefit, it's
7 very, very small. So I have to focus on the
8 things that were actually described. This is what
9 I'm going to do with this data. And those were
10 the ones I did. Then I, of course, I can't know
11 everything that someone is going to do but I have
12 to sort of use my imagination, my experience, my
13 history, my understanding of the way things work
14 to -- to sort of think about what you might be
15 doing. And I thought about that. And I sort of
16 tried to generalize that. But I concentrated on
17 the two that he gave me because those were the two
18 he gave me.

19 Q. Now that you have reviewed his
20 deposition, you now understand that he is
21 interested in more parameters; is that a fair
22 statement?

23 A. It's not -- when you say he's interested
24 in more parameters, I'm going to have to followup

1 by saying more parameters for what and what is its
2 connection to this data set.

3 Q. So, in his declaration, Dr. Mullen said,
4 the relationship of exposures alleged to the
5 various occupations and trades of the debtor's
6 historical claimants and the extent to which the
7 full range of alleged exposures is changing over
8 time are important to estimating the defendant's
9 legal liability share. Does that assist you in
10 telling you the kinds of things Dr. Mullen is
11 interested in from this data?

12 A. Do you mind, could I read that?

13 Q. Sure.

14 A. Just tell me where it was.

15 Q. Paragraph 15.

16 MR. ANSELM: This is from Dr.
17 Mullen's declaration.

18 BY MR. EVERT:

19 Q. The pending question is does that
20 language from Dr. Mullen assist you in
21 understanding the additional parameters in which
22 he is interested besides the ones identified in
23 your report?

24 A. So, what they don't do is connect to the

1 data that he already has, which you indicate it
2 was vast, 400,000 observations and how that will
3 be used in the major -- the big questions that
4 he's faced with. He also doesn't address how 1200
5 won't be sufficient to do those.

6 Q. We talked about earlier how in your
7 construction of the individual review model in
8 NARCO you relied on a number of factors that
9 affect the valuation of an asbestos claim; is that
10 right?

11 A. Yes.

12 Q. And you'll agree with me that what
13 Dr. Mullen is trying to estimate here is the
14 overall value of the asbestos claims against the
15 debtors; is that fair?

16 A. That seems to be what is going on. Some
17 of the questions he answered in his deposition
18 indicated that that is a major issue, the overall
19 liability. That is certainly front and center, a
20 big problem.

21 Q. The overall liability is merely
22 amalgamation of all the individual liabilities; is
23 that fair?

24 A. It is.

1 Q. And, so, for example, if Dr. Mullen
2 wanted to analyze some of the parameters that you
3 used in your individual review model in NARCO like
4 law firm or jurisdiction, then right now we don't
5 know the sample size of the claims that would fit
6 within -- strike that.

7 If we do a 1200 claims sample, we don't
8 know how many law firms that 1200 claims sample
9 will encompass; is that correct?

10 A. Well, it depends on how you design it.
11 If you design it stratified, you can stratify on
12 the law firm and you know exactly how many are in
13 the sample.

14 Q. And then the same answer would be true
15 for jurisdiction; is that right?

16 A. It is if you deem that important to
17 sample over.

18 Q. And all of the other factors that we
19 talked about earlier, age; is that right?

20 A. Yeah. There are lots of factors that
21 matter to the IR model. But this has to do with
22 exposure allegations. And I don't think that the
23 debtors are unaware of their industries and
24 occupations and they're not unaware of their ages.

1 I think they know all of that already.

2 Q. You base that on what?

3 A. Well that's based on my -- the
4 information that I've gotten from the lawyers who
5 discussed this. Of course, they have the claims.
6 They know -- see, none of the data -- we're not
7 talking about -- we're talking they're going to
8 make their model based on what the claims were and
9 the settled claims and paid claims to the debtors.
10 And they have that information. That's what my
11 understanding is. They already have that.
12 They're not -- in fact, he talks about how we have
13 all of their information, the personal information
14 you might call it. That is all known. The only
15 field that we're missing here is the alternative
16 exposure allegations. They know everything about
17 these claimants, all 400,000 presumably, although
18 I don't know that for sure. I'm under the
19 assumption that they do know that for all 12,000
20 as well. The purpose of this is to figure out if
21 you built, say, an IR model, right, based on
22 those, say, 12,000, you might use -- you probably
23 would do much more than that, you might ask, well,
24 how would -- how would any individual claim value

1 change if you had a different exposure allegation.
2 That would be an interesting question that you
3 could answer with the data you have. That's --
4 you wouldn't use the 12,000 for that. You would
5 use the data you already have to answer that, how
6 exposure allegations and the extent of exposure
7 allegations would change the amount. That would
8 be the data. You wouldn't need this data for
9 that. You would work on that. What you would use
10 this data for, and this is my understanding why
11 it's here, is to figure out, well, if a certain
12 fraction of my 400,000 that I've already settled
13 and understand deeply have alternative exposures
14 that are -- don't match what actually happened in
15 the litigation or the settlement or whatever it
16 is, what is the impact of that on the overall
17 dollar amount. And that's the purpose. And you
18 could do that very well with 1200. You don't need
19 all 12,000 for that. I guess the point I'm making
20 is if we took Dr. Mullen and we made a
21 doppleganger and put him in the same room, a copy
22 of him, it's not really feasible. I don't have
23 that technology. And said here, Dr. Mullen, here
24 is 12,000, go do your work. Here, Dr. Mullen,

1 here is 1200, go do your work. The big question
2 is like how much liability and what the models
3 are. They won't be materially different.

4 Q. Let me try to unpack a lot of that and
5 see if I have got it right. I think I understand
6 your opinion to be that for these two issues that
7 you identified in your expert report you believe
8 in a sample of 1200 is not materially different
9 than an analysis of the entire population; is that
10 fair?

11 A. Where 12,000 is the population.

12 Q. Where 12,000 is the population; is that
13 fair?

14 A. Yes, that's fair.

15 Q. In giving that opinion, you are assuming
16 that those are the purposes, that is those two
17 issues identified in your report, are the purposes
18 for which the debtor wants the data?

19 MR. ANSELM: Objection to form.

20 THE WITNESS: I'm not assuming
21 that's the only purpose. I began with those two
22 because those are the ones that are explained.
23 And there's just a general feeling that the most
24 important ones come first. And, again, I'm

1 familiar with this exercise. I know what this is
2 about. And I've thought about it. And I don't --
3 it hasn't occurred to me that there's anything
4 that can't be done with the 1200 that -- that
5 would require the 12,000, that would have a
6 material impact on these big questions, which
7 weren't really discussed fully in Dr. Mullen's
8 report but did come out in his deposition.

9 BY MR. EVERT:

10 Q. So, the additional questions that
11 Dr. Mullen talked about in his deposition that are
12 in addition to the two identified in your expert
13 report, I'm trying to understand, is your view
14 different about those particular questions or you
15 don't have enough information?

16 A. No. Dr. Mullen talked about his -- he
17 made this big task what -- what he's here to do in
18 a broad sense in the deposition he doesn't talk
19 about in his report. That's really what I'm
20 describing. He talks about building test -- test
21 distribution procedures or at least he responds to
22 a question about that. He talks about estimating
23 liabilities, things that have big whopping, 100
24 million dollar price tags. I mean it's

1 uncertainty zone. That's what gets talked about
2 in his deposition that isn't described in his
3 report. But that was implicit. I understood what
4 was going on because I've done this. But he
5 didn't make it explicit. But he also talked about
6 how somehow getting 12,000 would make that task --
7 sorry -- getting 1200 would make that task sort of
8 monumentally more uncertain. He used words like
9 three times more uncertain and he kind of imagined
10 applying that to the -- to this big huge 100
11 million dollar uncertainty bar that you get on
12 estimating total liability. That wasn't done with
13 any justification.

14 Q. You've made the point that a -- for a
15 proportion with a known sample size you can
16 calculate the standard error, right?

17 A. You can upper bound the standard error.

18 Q. There's a formula for that, right?

19 A. Yes.

20 Q. And that's what you've used the 1200
21 claim sample in your assumption, you've calculated
22 what the standard error would be?

23 A. I did three things. I calculated the
24 upper bound on the standard error and then I gave

1 two more specific values for the standard error
2 under assumptions that are just -- just to show
3 that it could be a lot lower than the upper
4 bound.

5 Q. If Dr. Mullen wanted to analyze within
6 that 1200 claim sample whether the actions of
7 individual law firms varied, we don't know the
8 number of law firms that would be within that 1200
9 claim sample; do we?

10 A. Well, we could if we did a stratified
11 sample. I mean, if you did a random sample,
12 you'll get -- you get a lot of coverage of the law
13 firms that have a lot of observations. You may
14 not get coverage of the ones that are smaller.
15 But that's why you would do a stratification if
16 that was important.

17 Q. So, assume for me that there are eight
18 different factors and parameters that Dr. Mullen
19 would like to analyze. Is it your position that
20 you could design a stratified random sample that
21 would provide a reasonable sample of all of those
22 eight different factors?

23 A. Well, you can do it. You certainly can
24 stratify by eight different samples. The question

1 is what you're going to do with the result when it
2 comes out -- I'm sorry -- by doing different
3 attributes you can certainly stratify. That's
4 perfectly possible. When you build a model you
5 probably will have to start making assumptions
6 about interactions. But that's 100 percent going
7 to have to happen anyway, whether you have all
8 12,000 or just 1200. You're going to -- even with
9 12,000, once you drill down to claimants that have
10 more than two attributes, you're going to find
11 yourself in very rare territory. So all modeling
12 has to do what we call borrowed strength in
13 statistics. We have to assume that all the data
14 points have something to tell us about every other
15 data point That's what we mean by borrowing
16 strength. That's how statistical modeling works.
17 And when you overdo that, that's when you get
18 yourself into unknown unknowns. It's kind of how
19 the activity of sampling and building a model
20 works. But I don't think there's any talk about
21 sampling by law firm because ultimately we're here
22 really probably drive by dollar value. I've read
23 a couple of samples that have been proposed,
24 particularly for this one, as well as the Bestwall

1 case. All the sampling is done by size of
2 settlement. And that's generally the most
3 important. It may be a misdirection. But when it
4 comes to total impact, that's the thing that is
5 really at issue here. Sampling by size of
6 settlement tends to be the right thing to do.

7 Q. But, again, in making that statement
8 you're assuming you know what the needs are?

9 A. Well, I'm not making an assumption that
10 I know what the needs are. I'm assuming that the
11 needs that are described here are, at least two of
12 the needs, and I'm assuming that the ones that
13 were described in the deposition testimony are
14 also ones and those are also related to dollar
15 amounts. They're never talking about building an
16 individual review model and making sure that it
17 works for every person who does it. That does not
18 seem to be at issue here, at least not yet. It
19 certainly wouldn't be with this data. So, there's
20 of course lots and lots of things to do. But I
21 haven't -- you know, the task at hand is a very,
22 very big one. But what this data is here to
23 illuminate is just a small piece of a very
24 complicated problem that is loaded with

1 uncertainty, loaded, very, very hard problem to
2 predict what future numbers of mesos a year are
3 going to be, let alone their attributes of the
4 individuals who have them, how old they are, where
5 they're coming from. We have a pretty good idea
6 of where they'll come from because they'll come
7 from the same places they've been coming from.
8 But things will change over time. We'll have a
9 hard time predicting that and known certainties
10 are just going to be enormous. No one is deluded
11 about that point. People really understand that
12 this is a very hard task.

13 Q. And if we took a 1200 claim sample here
14 instead of the entire population of 12,000, we
15 would be adding one more uncertainty to those
16 large group of uncertainties that you've
17 described; is that not correct?

18 A. But it would be irrelevant. This is one
19 of the classic misunderstandings of statistics.
20 It's like a chain linked fence, if I have a chain
21 that has, say, eight links in them, I don't really
22 care. The one that you need to strengthen is the
23 one that is weakest. Strengthening the others is
24 just not relevant. It certainly doesn't add and

1 it certainly doesn't multiply. The big ones drive
2 everything. That's a fundamental statistical fact
3 that I'm sure Dr. Mullen is aware of. Although in
4 his deposition, it didn't seem like he wanted to
5 fess up to that.

6 Q. Without having any experience in the
7 negotiation formulation and confirmation of a plan
8 of reorganization in cases like this, it's your
9 view that adding additional error is irrelevant,
10 notwithstanding the fact you really don't know
11 what we're trying to measure?

12 MR. ANSELM: Objection to form.

13 THE WITNESS: Okay. This is a
14 little bit of sampling error, 1200 versus 12,000
15 to an extremely complicated problem, which I'm
16 very familiar with certainly in general. So, I
17 would argue that the -- I would be prepared to
18 listen to Dr. Mullen if he were to explain why he
19 thinks this little bit of uncertainty is going to
20 have an impact. He didn't describe his
21 calculations. It doesn't appear anywhere in his
22 expert report. In his depositions he talked about
23 it. But, frankly, the things he said just were
24 either too vague to get a grip on or just flat out

1 just seemingly not right.

2 BY MR. EVERT:

3 Q. What if Dr. Mullen wanted to do
4 regression analysis of some of these parameters,
5 can you tell me what the standard error would
6 be?

7 A. Well, you would have to tell me what the
8 parameter was and then what the source of
9 uncertainty is and you could figure out the
10 standard error. Standard errors also have --
11 typically follow the square root law like they did
12 in the ones I defined in my report.

13 Q. If Dr. Mullen wanted to do regression
14 analysis that included explanatory variables like
15 law firm and jurisdiction and the proportion of
16 non-disclosure of exposure information you've
17 described, can you tell me now what the standard
18 error would be?

19 A. Typically in a regression analysis
20 there's two parameters that we're interested in.
21 There's what we call the standard error on the
22 parameters of the regression and then there's what
23 we call the standard error of the predictions. In
24 other words, if I'm going to use a regression

1 model for something, I want to know how accurate
2 it is. Let me give you an example. If I were to
3 try to predict how many wins a baseball team will
4 have next year, I can very accurately figure out
5 what the importance of starting pitching is and I
6 can get that very accurately. But damned if I can
7 predict you how many wins they're going to get you
8 next year. That's extremely uncertain. In other
9 words, I can use with regression analysis, I can
10 figure out how age affects torts, settlements,
11 sort of an average. But damn if I can figure out
12 what is going to happen in an individual case.
13 That is going to be incredibly, incredibly random.
14 That's what makes this problem so hard, is that
15 individual cases -- even if I were to tell you
16 that this person had a different exposure level
17 than they claimed, it would still be very hard to
18 predict what the jury would have done, and you
19 know that. So that's why -- that's why standard
20 error is not always the thing that you're
21 interested in, it's the purpose of the model, why
22 is it here. What is it here to tell us. And it's
23 here to give us a value. And uncertainty in that
24 value is the thing that generally matters, not the

1 uncertainty in the parameter that went into it.

2 It's the overall, what we call the residual
3 uncertainty. I know that was long winded, but.

4 Q. If Dr. Mullen wanted to perform
5 regression analysis that included explanatory
6 variables of law firm, the jurisdiction and the
7 proportion of non-disclosure, can you tell me now
8 what would be the standard error?

9 A. If you -- with a few more observations,
10 I could probably bound it pretty nicely,
11 particularly if you're familiar with the values
12 and you can pretty -- you can get a pretty nice
13 bound.

14 Q. But we don't know the values until we
15 have the data?

16 A. Well, they have the data from the --
17 they know the payment values. That's what we call
18 the regressor. They know what they are.
19 They're -- they want to know -- see, what they're
20 looking to do here, see, if you -- if he tries to
21 build a model to predict the value of a claim in,
22 say, the tort system and you want to manipulate
23 the value of exposure, he's going to need to know
24 what the payments were in the tort system. And he

1 has those. So you can easily figure out what --
2 what you're -- you're not trying to run a
3 regression on that. What you're really trying to
4 do is understand how the changes in the -- the
5 uncertainty in the percentage of people that have
6 alternate exposures, how that is going to change
7 your forecast at the end. It's not really the
8 regression parameters that are at issue here.
9 It's going to be the regression inputs that are
10 going to be at issue.

11 Q. Is it fair to say that when you began --
12 that when you began your answer with what they are
13 looking to do here means you are giving an opinion
14 about how the data will be used?

15 A. Well, I'm certainly giving an opinion on
16 how having only 1200 observations would be
17 different from having 12,000 on what I seem to
18 understand are the possible ways that they're
19 going to use this data. So, yes, I have a general
20 sense of what they're trying to do.

21 Q. Your opinions are based on your general
22 sense of what they're trying to do; is that
23 fair?

24 A. Well, my opinions are based on Dr.

1 Mullen's report.

2 Q. And his deposition?

3 A. Well, my opinion in my expert report is
4 only on his expert --

5 Q. Your opinion today includes your review
6 of his deposition; is that correct?

7 A. Yes.

8 Q. Let's assume that Dr. Mullen wants to
9 use the exposure data in the trust information to
10 predict how many pipe fitters might file claims in
11 the future, and he wanted to use regression
12 analysis in order to do that, can you tell me what
13 the standard error would be?

14 A. He would want to use regression analysis
15 to predict how many pipe fitters will file claims
16 in the future. Well, I mean, if he built the
17 model and specified his assumptions and showed me
18 the data he was using, we could calculate the
19 regression parameter estimates. But I think we're
20 not interested in the regression parameters.
21 We're interested in knowing what the standard
22 error is or what we call the residual error on
23 that estimate. So if I try to predict how many
24 pipe fitters is going to be in a given year who

1 have mesothelioma, you're going to find that
2 uncertainty to be absolutely massive. So we could
3 bound it. We can roughly approximate that,
4 sure.

5 Q. In order to bound it or approximate it,
6 would you not need to know the sample size?

7 A. Yeah, except the fact that you certainly
8 would need to have some data, absolutely. But
9 it's -- it will be what we call the law of
10 diminishing returns. The first few observations
11 will give you so much. They'll tell you an
12 enormous amount. Once you get to have a certain
13 understanding, once you've seen a few pipe
14 fitters, you don't have to see very many, you're
15 going to have a pretty good sense of what is going
16 on. You won't need that many to do it. That's --
17 because what is fundamentally uncertain is this
18 number. You brought it up, the number of pipe
19 fitters in a given year, that's really hard to get
20 with any accuracy at all. And the uncertainty on
21 that would be massive and it will dwarf any
22 uncertainty that would be -- that would come from
23 any extra data that you would get from going from
24 having observed, say, 50 pipe fitters to 100 pipe

1 fitters in this data set. That big thing at the
2 end wouldn't be very much more accurate.

3 Q. So, you criticized me for using the term
4 large. I'm going to ask you about few. How many
5 is a few, you said you need just a few. How many
6 is a few? You said you need just a few.

7 A. It depends on the value. So if the
8 value -- it could be -- if it's very, very rare,
9 so, for example pipe fitters with mesothelioma
10 come along very, very rarely. I won't need very
11 many at all because I just need to look at a bunch
12 a mesos and get a sense of whether it's 1 percent,
13 zero percent, 2 percent and 25 will be wonderful.
14 If I want to know -- say if it's a much bigger
15 value, say 25 percent in a particular profession,
16 say boiler makers, I don't know if that's at issue
17 here, then you can get that pretty accurately with
18 about 30, 50 or 100 as well. You really don't
19 need that much data to get pretty good estimates
20 of what is going on in the universe that you're
21 looking at.

22 Q. Until we see the data, we don't know the
23 size of that population?

24 A. Well, we know we're getting 1200

1 observations and we know what it's for. So you
2 have to show me -- I haven't been able to imagine
3 an application that I would be required -- that
4 there's something in here that would make a very
5 big impact on the overall -- on any big question
6 at all that won't be fully answered by having
7 1200. I mean, if there is something, if there's
8 something that Dr. Mullen has in mind, he should
9 be able to show it to me. In his deposition he
10 says I can't know until I look at the data. That
11 strikes me as a statistician to be very odd.
12 Because we statisticians, our job is to estimate
13 uncertainty before we actually have data because
14 it helps us figure out how much data to get. So
15 when we design an experiment, when we go on an
16 exposition to acquire new data, whether it's in
17 medical or business or advertising or sociology,
18 you have to be able to estimate what we call the
19 size of the affect before we start. And that's
20 what we often call power calculation. And
21 generally that proceeds by just sort of going
22 through all the things you're going to want to do
23 with this data. And then you make power
24 calculations, you go and you estimate, you

1 determine if you have enough data. This always
2 can be done by looking at the data.

3 Q. Can you do all of those estimates
4 without knowing the size of the sample?

5 A. No. You estimate them -- you know what
6 the size of the sample is, 1200.

7 Q. In our example that we're just using
8 it's not 1200 pipe fitters.

9 A. Well, the question is is that -- so what
10 you do is you talk about, well the number of pipe
11 fitters that come in at all kinds of different
12 levels, right. So the way it works is that if
13 you -- you'll just make an assumption and you'll
14 calculate your uncertainty. If there's only this
15 number of pipe fitters, this will be the
16 implication. If there's only this number of pipe
17 fitters, then this will be the implication.
18 There's very few pipe fitters in the data set,
19 which may mean that it would be very hard for me
20 to figure out what is going on with pipe fitters.
21 It also won't matter in the overall liability
22 because there's very few of them. So the big
23 questions about trust distribution procedures and
24 overall liabilities won't really be affected by

1 things that are very infrequent in this data set.
2 So, the big questions will be the ones that happen
3 a lot in this data set and they'll happen a lot in
4 1200 as well.

5 Q. So, am I understanding you to say that
6 the sampling error that would by definition result
7 from taking a sample of 1200 in this case in your
8 view would be immaterial in light of the overall
9 estimate of liabilities?

10 A. Yes, that's very much -- and that very
11 much contradicts what Mullen was saying in his
12 deposition. He seemed to be just disagreeing with
13 that. He seemed to indicate that this bound of
14 sampling error will vastly increase the
15 liabilities. He specifically talked about that.

16 Q. And your opinion that the sampling error
17 that will be driven by this 1200 claim sample is
18 immaterial, is based on your understanding of what
19 would need to be done in order to make an
20 estimation of current -- of the value of current
21 and future asbestos claims?

22 A. My experience, my opinion about how hard
23 it is to do those tasks and how uncertain they are
24 is in some meta level very important here because

1 we're talking about a very specific task that
2 we're trying to get here, what is the effective
3 alternative exposure histories on the amounts. My
4 general -- my claim, my opinion, my essential
5 opinion is that 1200 is a lot and will do -- we'll
6 be able to make a lot -- get a lot of information
7 out of that. And the difference between 1200 and
8 12,000 would just be little wrinkles along the
9 edges. They won't have major impacts on anything,
10 anything certainly at the big scale. And if it
11 did, well, I can't conceive of it. So I would
12 leave that to Dr. Mullen to show me that that is
13 possible. So I don't claim to have all the
14 answers by any measure, but my opinion is that I
15 don't see that.

16 Q. And do you know the level of uncertainty
17 that is expected by the court?

18 A. I mean, I know what the level of
19 uncertainty that is what we call irreducible, that
20 no amount of sampling, no amount of statistical
21 modeling, there's nothing -- this is fundamental
22 to the problem and it's a lot.

23 Q. You're unaware of what level of
24 uncertainty is acceptable to the court?

1 A. No.

2 Q. The word I said is correct?

3 A. Yes.

4 Q. Thank you. Let's change gears for a
5 minute and talk about where you have opined about
6 a risk of inadvertent dissemination of highly
7 confidential data. What are the facts on which
8 you base that opinion?

9 A. Well, I was involved in -- nothing that
10 went to litigation, nothing -- I was involved in a
11 case involving inadvertent data leak of hundreds
12 of millions of records that no one intended to
13 ever let out and it was hacked. So these things
14 happen and they're a problem. And you read about
15 them in the papers. This is the kind of thing
16 that happens hopefully rarely but it does occur.

17 Q. I want to talk about the incremental
18 risk that is presented here in this particular
19 instance. Do you understand what data has been
20 requested from the trust?

21 A. Yes.

22 Q. And will you agree with me that the data
23 that has been requested does not include personal
24 identifying information?

1 A. Well, I guess that's definitely what,
2 you know, the debtors are claiming. I don't have
3 any -- I mean, there is -- I read lots of reports
4 saying that it has to be -- in order to make sure
5 that it doesn't have personal identification, it
6 does have to be cleaned.

7 Q. I'm going to walk through with you the
8 information requested, and I just want to make
9 sure we're talking about the same thing. The
10 subpoena requests the claimants' law firm. Would
11 you consider that personal identifying
12 information?

13 A. Well, I mean, I don't have an opinion on
14 what is or isn't personal identifying information.
15 My guess is which law firm you're working for, I
16 don't know, is that personal.

17 Q. If you don't have an opinion about what
18 PII and confidential information is, then how do
19 you have an opinion that there may be the
20 inadvertent disclosure of confidential information
21 that is requested by the subpoenas?

22 A. My understanding from reading all of
23 these reports and submissions is that personal
24 identifying information may be in this data.

1 Q. All right. And have you come to
2 understand that the place in which the personal
3 identifying information that may be in this data
4 is included is in the exposure fields?

5 A. Yes, that's been my understanding, the
6 exposure fields and in particular narratives that
7 go on and on about potentially other family
8 members and other people who are not at issue and
9 that my -- my more or less understanding is that a
10 lot of that has to do with cost, the cost to
11 prepare that data to excise this and things
12 related to that.

13 Q. I just want to make sure we're talking
14 about the same thing.

15 A. Yes.

16 Q. So, your understanding is that the risk
17 of inadvertent disclosure of personal identifying
18 information involves the exposure fields of
19 information that have been requested in the
20 subpoenas; is that right?

21 MR. ANSEMI: Objection to form.

22 THE WITNESS: My understanding is
23 that. There may be other things as well but
24 certainly that.

1 BY MR. EVERT:

2 Q. I'm in a little bit of a box here, Dr.
3 Wyner because you tell me you can't tell me what
4 is personal identifying information but you also
5 are unclear on where the fields are. So let me
6 try again. Let me try this a different way.

7 Do you believe a claimant's law firm is
8 personal identifying information or do you not
9 know?

10 A. I don't have an opinion.

11 Q. Do you have an opinion on whether or not
12 the date claim was filed is personal identifying
13 information?

14 A. Again, I don't have an opinion.

15 Q. Is it fair to say you have no opinion
16 about what is and what is not personal identifying
17 information?

18 A. It is fair to say that.

19 Q. If I were to tell you that the trusts
20 have maintained that they're concerned with
21 production of this data has to do with the
22 inadvertent disclosure of personal identifying
23 information that is in the requested exposure
24 fields, would that be consistent with your

1 understanding?

2 A. It is.

3 Q. So, I want to walk through, as I
4 understand it, what would have to happen for that
5 inadvertent disclosure to occur. Are you aware
6 that the order requires the trusts to scrub those
7 exposure fields for any personal identifying
8 information?

9 A. I am aware.

10 Q. Are you aware the order from the court
11 requires for any personal identifying information
12 that is missed by the trusts, that Bates White is
13 required to scrub that data?

14 A. I am aware.

15 Q. Are you aware that Bates White already
16 has personal identifying information on all 12,000
17 claimants?

18 A. I read that in Dr. Mullen's report, so,
19 yes.

20 Q. Are you also aware, of course, that
21 Verus has the personal identifying information on
22 those 12,000 claimants?

23 A. Yes.

24 Q. And the DCPF has that information,

1 correct?

2 A. That's right.

3 Q. And you would assume that the law firms
4 that represent those claimants have the personal
5 identifying information, correct?

6 A. Yeah.

7 Q. And the debtors have it in their claims
8 database; is that correct?

9 A. Yes. But there must be something that
10 is going -- they must be transmitting something,
11 right.

12 Q. And the ACC in this case, the Asbestos
13 Claims Committee because they now have the
14 database, they have the personal identifying
15 information on the 12,000 claimants, would you
16 agree with that?

17 A. I suppose so.

18 Q. But that's on the claimants. What we
19 are talking about is the inadvertent disclosure in
20 the exposure fields, correct?

21 A. Certainly.

22 Q. So, you're in the business of estimates.
23 For an inadvertent disclosure to occur, the first
24 thing that would have to happen would be for a

1 claimant to put in personal identifying
2 information in the exposure field for a
3 non-claimant; is that correct?

4 A. That certainly is one thing that has
5 been described. But there can be other ways. I'm
6 not an expert on this.

7 Q. We're talking about exposure fields,
8 that's what we're talking about defining, right,
9 so it would have to be in the field in order for
10 it to be disclosed, right?

11 A. This is you you're talking about and I'm
12 agreeing that would be personal information. I'm
13 not saying it's the only way.

14 Q. Bad question. In order for there to be
15 inadvertent disclosure of personal identifying
16 information that is in an exposure field, it has
17 to be placed in the exposure field?

18 MR. ANSEMI: Objection to form.

19 THE WITNESS: It seems to me
20 that's absolutely right, logical.

21 BY MR. EVERT:

22 Q. Thank you. And then that personal
23 identifying information would have to be missed by
24 the trusts in their scrub of the data, correct?

1 A. Yes, I would guess, right.

2 Q. Then that personal identifying
3 information would have to be missed in Bates
4 White's scrub of the data; is that correct?

5 A. Well, there's lots of ways for this to
6 happen here. Can I tell you a story?

7 Q. I understand we're not talking about in
8 possibilities but that would be the next step that
9 would have to occur, correct?

10 MR. ANSEMI: Objection to the
11 form.

12 THE WITNESS: Well, what actually
13 would also have to is that in the process of
14 transmitting it, for Bates White to clean it, it
15 would have to not been accidentally copied or sent
16 to the wrong place or put in the wrong -- human
17 beings are involved. Human beings make mistakes.
18 And I've seen it up close and personal with some
19 of the most unbelievable personal information that
20 was sworn up and down no one should ever, ever
21 see, yet it went out.

22 BY MR. EVERT:

23 Q. I understand. So, in some form or
24 fashion it would have to be an inadvertent

1 disclosure that occurs, and your point is that
2 could occur after only Verus has done their scrub
3 or only the DCPF has done their scrub; is that
4 your point?

5 MR. ANSELM: Objection to form.

6 THE WITNESS: I mean, we're
7 talking about inadvertent -- if Verus lets it out,
8 that's on them. Let's separate that. We're in
9 the process -- where things get dangerous is when
10 things get moved from one entity to another.
11 That's really the issue and how that happens and
12 who does the transfer. In my experience, that's
13 been the weakest link in exposure of private
14 information is in the transferral. So, Verus will
15 do what it does and we assume they do it right.
16 And then that's when things could happen. That's
17 just my experience and my opinion. But the real
18 question is my statement very much is that there's
19 some risk here. I don't even know how likely it
20 is. I don't know that. I have no opinion on how
21 likely these things are.

22 BY MR. EVERT:

23 Q. I'd like to try to focus on the
24 incrementality of the risk. The risk of

1 inadvertent disclosure of PII already exists for
2 all 12,000 claimants, correct?

3 A. Well, the risk of PII disclosure will
4 only happen if it is disseminated from the trusts
5 that already have them to Bates White.

6 Q. Remember, PII for the 12,000 claimants
7 does reside at Verus, agreed?

8 A. Yes, that's right.

9 Q. It also resides at DCPF, agreed?

10 A. As far as I know, yes.

11 Q. It also resides in the debtor's database
12 at Bates White, agreed?

13 A. I assume. That's what I've been told.

14 Q. It also resides in the debtor's database
15 at the debtors?

16 A. Yes. But there's other people's
17 personal information that I think may only reside
18 with Verus and the trusts. That can get
19 communicated.

20 Q. It's where I'm trying to get. The risk
21 of inadvertent disclosure of the PII from the
22 12,000 claimants already exists in multiple
23 places, correct?

24 MR. ANSELM: Objection to form.

1 THE WITNESS: Yeah. But those
2 aren't moving, right. So movement is the real
3 question.

4 BY MR. EVERT:

5 Q. Inadvertent is what we're talking about
6 here. It already exists at those places, correct?

7 A. Again, this is the level of existence.
8 It generally isn't at risk until it's in the
9 process of being transferred.

10 Q. So, in this case, the debtors were
11 required to produce their database to different
12 parties, the ACC, the FCR, so it had to move. So
13 that risk existed at that time; is that correct?

14 A. Presumably.

15 Q. What I'm trying to get to, Dr. Wyner, is
16 the 12,000 claimants, their PII is already at
17 risk; can we agree on that?

18 A. Well, it already was at risk. And I
19 think it managed to go through okay.

20 Q. So, there is no risk of a hack of any of
21 these entities, in your view?

22 MR. ANSELM: Object to form.

23 THE WITNESS: I guess that's
24 possible but I don't know.

1 BY MR. EVERT:

2 Q. So, how many more claimants do you think
3 or -- I'm sorry. Strike that.

4 How many non claimants do you think
5 would be missed by Verus in their scrub?

6 MR. ANSELM: Objection to form.

7 THE WITNESS: I have no idea.

8 BY MR. EVERT:

9 Q. Did you ask DCPF what their rate was
10 when they scrubbed the data in the DB&P matter?

11 A. My opinion had nothing to do with that.

12 MR. EVERT: It's a good time for
13 a break.

14 (Whereupon a break was taken.)

15 BY MR. EVERT:

16 Q. Dr. Wyner, I want to pick back up with
17 the discussion about the inadvertent data breach
18 that might occur. I think I understood you to say
19 that the real risk is in the transfer; is that
20 right?

21 A. In my experience that's been the risk.

22 Q. Are you aware of the way that the
23 information on the claimants will be transferred
24 in response to this subpoena?

1 A. I don't, no.

2 Q. So, if I were to tell you that there are
3 actually claimant pseudonyms used in the transfer
4 and not the names of either the 1200 or the 12,000
5 claimants such that one cannot identify whose
6 information it is, would you agree with me that
7 there's not much risk of disclosure of PII in the
8 transfer?

9 MR. ANSEMI: Objection to form.

10 THE WITNESS: I can't say what
11 the amounts of the risk are. I don't have an
12 opinion on the amounts of the risk, either. But I
13 can tell you that in my personal experience that
14 it was promised it wasn't supposed to happen
15 through my cases and somehow it did.

16 BY MR. EVERT:

17 Q. So, is it fair to say that at the end of
18 the day your opinion on this is that inadvertent
19 disclosures occur?

20 A. Yes.

21 Q. And this particular case, you don't
22 really know the mechanics of what the transfer is
23 going to be or how the data is going to be kept
24 or transferred or any of those things, your

1 opinion is not really based on any of those
2 things; am I correct?

3 A. That's correct.

4 Q. Your opinion is merely based on the fact
5 that you know that inadvertent disclosures, in
6 fact, occur?

7 A. Yes.

8 Q. Now, you do make a statement in your
9 report that says if only 10 percent of the target
10 population is produced, the damage and the
11 resulting data breach to the individual claimants
12 can be expected to be ten times smaller because it
13 would involve ten times fewer claimants. Did I
14 read that correctly?

15 A. You did.

16 Q. And that falls under the sort of common
17 sense rules of statistics; is that fair?

18 A. Yes, it's very fair and very common
19 sense. It's not any deeper than that.

20 Q. In fact, in this case it's not exactly
21 right because we're not talking about the
22 claimants' PII, we're talking about non claimants
23 in the exposure fields, so it won't match up
24 exactly, fair?

1 A. Yeah, it's splitting hairs but yes.

2 Q. So, it would still be in the ball park,
3 in your opinion, but it's not exactly right in
4 this instance, fair enough?

5 A. Yeah, I'm making, as you say, the common
6 sense observation that the scale of the damages --
7 the size of the damage would scale the number of
8 the size of the data sets, expected size. It's a
9 random variable.

10 Q. I think I understand your testimony
11 earlier about the over arching effort here to
12 estimate the value of current and future asbestos
13 claims. Did I understand you to say that there's
14 going to be uncertainty in the final estimate,
15 it's just a question of how much uncertainty?

16 A. Well, I mean, both questions, you want
17 to make an estimate and then you would want to
18 give an estimate of the uncertainty. Those are
19 the two most important tasks. They're both --
20 obviously you need to know the estimate. You also
21 need to know the size of the uncertainty in the
22 estimate. The first thing people communicate is
23 the estimate. The second thing they communicate
24 is the uncertainty of the estimate.

1 Q. Let me try to say it a different way.
2 Your testimony is that the effort to try to
3 estimate the current and future asbestos claims
4 against these debtors is one that will be fraught
5 with uncertainty; is that your testimony?

6 A. Yes.

7 Q. And I think I understand you to say that
8 there's going to be uncertainty no matter what we
9 do, whether we sample 1200 claimants in this
10 instance or whether we get the entire population
11 of 12,000 claimants, there will still be
12 uncertainty in the final answer; is that what
13 you're saying?

14 A. I'm saying more than that, but that is
15 certainly the first thing that I am saying.

16 Q. What else are you saying?

17 A. I'm also saying that the uncertainty in
18 the final estimates that you're talking about are
19 going to be much, much larger than the uncertainty
20 caused by only sampling 1200.

21 Q. That was my next question. Although you
22 would see the uncertainty that is created by the
23 sampling of 1200 versus a review of the entire
24 population of 12,000 as immaterial in the face of

1 the remaining uncertainties; is that right?

2 A. Yes.

3 Q. And that's based on your assumptions
4 about the purposes for which this data will be
5 used to reach the final estimate?

6 A. Well, it's based on the purposes that
7 are outlined in Mullen's report and it's based on
8 my other knowledge and it's also based on the
9 assumption that if there was something that would
10 depend on having more data, Dr. Mullen would have
11 told me. It's right there, right.

12 Q. Are you surprised that Dr. Mullen wants
13 to study and analyze many of same factors that you
14 used in your Honeywell NARCO individual review
15 model?

16 A. Not at all.

17 Q. I want to ask you about your discussion
18 in your report about the declaration signed by Dr.
19 Mullen's colleague from Bates White in the
20 Bestwall. Do you remember that?

21 A. Yes.

22 Q. So, that was a declaration signed by
23 Dr. Gallardo-Garcia; is that correct?

24 A. I think so, yes. I'm pretty sure I read

1 it, but I may only be referring to the
2 descriptions of it in some of the other places.

3 Do we have it on our list?

4 Q. When you say it, you're referring --

5 A. Gallardo-Garcia.

6 Q. -- Gallardo-Garcia's declaration?

7 A. Yes.

8 MS. MOSKOW-SCHNOLL: It was
9 attached as an exhibit, too --

10 THE WITNESS: It was an exhibit to
11 one of these. Okay.

12 BY MR. EVERT:

13 Q. Is it your understanding from your
14 review of Dr. Mullen's testimony is that his
15 opinion is that he will still be able to provide
16 opinions regarding estimation of the debtor's
17 liability, negotiation of a plan, formulation of a
18 plan and the other items he outlines even if the
19 court orders a 1200 claim sample of the trust
20 data?

21 A. I think I've parsed that correctly but
22 can you say it again?

23 Q. Sure. Is it your understanding from Dr.
24 Mullen's testimony his opinion is is that he will

1 still be able to provide opinions in regard to
2 estimations of the debtors asbestos liability and
3 negotiation of a plan to reorganization,
4 formulation of a plan of reorganization and
5 confirmation of a plan of reorganization in these
6 cases even if the court orders only a 1200 claim
7 sample of the trust data rather than the entire
8 population?

9 MR. ANSEMI: Did you say Mullen
10 or Gallardo-Garcia?

11 MR. EVERT: I said Mullen.

12 THE WITNESS: I don't think -- I
13 think he doesn't talk about that directly in his
14 expert report. I do think in the -- if I recall
15 that in the deposition he said something to the
16 affect that I'll still be able -- I'll do my job
17 as best as I can if you give me whatever you give
18 me. I don't think he's making any opinion that
19 goes beyond that.

20 BY MR. EVERT:

21 Q. I think we're in the same place. I just
22 want to make sure. Dr. Mullen's testimony is he
23 can still give an estimate if the court orders
24 only a 1200 claim sample, it's just the level of

1 uncertainty that will be associated with that
2 estimate, is that --

3 A. I think so, yes.

4 Q. -- your understanding?

5 A. Yes.

6 Q. Do you recall that that is essentially
7 the point that was being made in Dr.
8 Gallardo-Garcia's declaration or do you not recall
9 it one way or the other?

10 MR. ANSEMI: Objection to form.

11 THE WITNESS: I mean, my
12 understanding was that, yes, he was going to say
13 this is what I'm given and we're going to do the
14 best that we can. But he -- he had opportunities
15 to talk about like what the deficiencies would be
16 and how things would -- are really -- where they
17 might be weaker and things of that nature and none
18 of that happened.

19 BY MR. EVERT:

20 Q. When you say he had opportunities to
21 talk about that, are you aware that the court in
22 that case had already ordered a 10 percent sample
23 only be provided?

24 A. Yeah, I'm aware of that.

1 Q. So, what would be the point of
2 Dr. Gallardo-Garcia discussing the loss of
3 accuracy associated with a sample if the court has
4 already ordered it?

5 MS. MOSKOW-SCHNOLL: Objection.

6 MR. ANSELM: Objection.

7 THE WITNESS: Because he's at
8 liberty to design the sample any way he wants. So
9 when you're designing a sample, the fundamental
10 discussion has to be about loss of uncertainty and
11 the most efficient use of the data you have. He
12 didn't talk about that at all.

13 BY MR. EVERT:

14 Q. Let me rephrase the question. What
15 would be the point of Dr. Gallardo-Garcia in an
16 instance where the court has already ordered a 10
17 percent sample in talking about the problems
18 associated with having to use a sample as opposed
19 to analyzing the entire population?

20 MR. ANSELM: Objection to form.

21 THE WITNESS: Because if I were
22 told to order -- I can only use 1200 and I was
23 concerned about uncertainty that resulted from
24 that, I would opine at length about the way and

1 the design of my stratification and what goes into
2 it because I'd have to argue this is how I want to
3 do it and the purpose for why I would do that. I
4 wouldn't just drop something down that seems
5 rather generic unless you were comfortable that
6 you had a lot of data and this generic thing would
7 work well.

8 BY MR. EVERT:

9 Q. As I understand your testimony, you're
10 saying that had you been in Dr. Gallardo-Garcia's
11 position, you would have provided more information
12 about the deficiencies in the sampling; is that
13 correct?

14 MR. ANSEMI: Objection to form.

15 THE WITNESS: Not exactly. If I
16 had been in Dr. Gallard's position and I was
17 concerned that 1200 -- a random sample of 1200 or
18 1200 somehow leaving me in a hole, I would talk at
19 great length about how I would use my 1200 and I'd
20 have to work really hard to provide that
21 stratified or weighted or any design I would wish
22 to apply to this data because 1200 is leaving me
23 in a hole and I want to explain how I'm going to
24 do the best I can. But if on the other hand 1200

1 was just fine, then I would just throw, you know,
2 anything right out of the audit book right at it.

3 BY MR. EVERT:

4 Q. And you say that because that is what
5 you would have done even if the judge had already
6 ordered you that you're only getting a 10 percent
7 sample?

8 A. Listen, Dr. Gallardo went to a terrific
9 school, the University of Pennsylvania. I don't
10 want to criticize how he designs his sample. But
11 I'm just saying that my -- the way I would have
12 done it if I were concerned that 1200 were not
13 enough, I would have spent a lot of time talking
14 about why I wouldn't want to design a particular
15 sample in the way I did and I probably would not
16 make it generic. I would make one that is very
17 specific for this specific purpose.

18 Q. And are you aware of whether or not
19 those positions had already been taken in the
20 Bestwall case before the court ruled on the 10
21 percent sample?

22 A. I'm not aware.

23 Q. To your knowledge, that litigation had
24 already occurred or not, you don't know?

1 A. I don't know. But I do know what, you
2 know, what a standard sample looks like and this
3 was it. In fact, I saw some emails discussing a
4 variety of samples that would be used in this case
5 that looked just like that.

6 Q. Would you agree that Dr. Gallardo-Garcia
7 in his declaration said that sampling relative to
8 a full data set analysis increases the analytical
9 cost and reduces the precision of the results?

10 MR. ANSEMI: Objection to form.

11 THE WITNESS: Well, those are
12 again on some levels basic common sense. Of
13 course it's going to take more work, arguably not
14 any substantively more work and it will reduce the
15 precision, again, arguably but not any materially
16 relevant amount.

17 BY MR. EVERT:

18 Q. So, you don't remember whether that was
19 in the declaration or not?

20 A. No, I don't remember.

21 Q. But those statements are ones that you
22 would agree with?

23 A. In a very general way they are true but
24 they're not -- it doesn't mean that they're -- it

1 decreases by a precision amount that has a
2 material or practical application.

3 Q. I understand. But the statement is true
4 as stated?

5 A. As stated.

6 Q. Can you stratify a sample based on
7 unknown characteristics?

8 MR. ANSELM: Objection to form.

9 THE WITNESS: No, you can't.

10 BY MR. EVERT:

11 Q. So, if, for example, in the trust data
12 requested by the subpoenas there are exposure
13 contact groups that are unknown to the debtors,
14 the debtors would be unable to stratify a sample
15 for that data, for those unknown parameters?

16 A. I mean, I'm not really sure what that
17 is. So, unknown -- I'm sorry what --

18 Q. I asked you at the beginning to please
19 tell me if you didn't understand my question and
20 you are fully in your right to tell me you don't
21 understand my question.

22 A. I don't understand the question.

23 Q. For example, if there is information in
24 the trust data that provides exposure contact

1 groups in terms of occupations and industries, all
2 other sorts of exposure related information that
3 are unknown to the debtors, then the debtors are
4 unable at this time to stratify a sample based on
5 those unknown characteristics?

6 A. You don't generally want to stratify an
7 unknown. It's never something that -- because you
8 can't do it. You don't do it and you don't know
9 why you would do that. Again, just a
10 restatement -- there are things that they don't
11 know, they can't stratify them.

12 Q. That's fair. Would you agree that if
13 analyzing the entire population of a data set is
14 costless, you should look at the entire
15 population?

16 MR. ANSEMI: Objection to form.

17 THE WITNESS: Can you repeat
18 that?

19 BY MR. EVERT:

20 Q. Would you agree that if analyzing the
21 entire population of the data set is costless,
22 then you should look -- you should analyze the
23 entire data set rather than a sample?

24 MR. ANSEMI: Objection to form.

1 THE WITNESS: So, I'll slightly
2 rephrase it. You're saying if the cost is zero,
3 then you should always prefer the population to be
4 sampled, yes.

5 BY MR. EVERT:

6 Q. You said it better than I did. I'm not
7 surprised.

8 MR. EVERT: Thank you very much.

9 THE COURT REPORTER: Counsel, can
10 I get your transcript orders, please. Mr.
11 Anselmi, do you want a copy of the transcript?

12 MR. ANSELM: Yes.

13 MR. HOGAN: Ordinary course. I
14 don't need it expedited.

15 MS. PHILLIPS: Yes.

16 MS. MOSKOW-SCHNOLL: Yes.

17 (Witness excused.)

18 (Deposition concluded at 3:50
19 p.m.)

20

21


22

23

24

C E R T I F I C A T E

I hereby certify that the witness was duly sworn by me and that the deposition is a true record of the testimony given by the witness.



Dolores M. Horne

Dated: May 19, 2023

(The foregoing certification of this transcript does not apply to any reproduction of the same by any means, unless under the direct control and/or supervision of the certifying shorthand reporter.)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

DEPOSITION ERRATA SHEET

NO. J9684107

ARMSTRONG WORLD INDUSTRIES, INC.

ASBESTOS PERSONAL INJURY SETTLEMENT

TRUST, et al

- vs -

ALDRICH PUMP, LLC, et al

DECLARATION UNDER PENALTY OF PERJURY

I declare under penalty of perjury that I have read the entire transcript of my Deposition taken in the captioned matter or the same has been read to me, and the same is true and accurate, save and except for changes and/or corrections, if any, as indicated by me on the DEPOSITION ERRATA SHEET hereof, with the understanding that I offer these changes as if still under oath.

Signed on the _____ day of _____, 20 --.

ABRAHAM J. WYNER, Ph.D.

DEPOSITION ERRATA SHEET

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Page No. ___ Line No. ___ Change to: _____

Reason for change: _____

Page No. ___ Line No. ___ Change to: _____

Reason for change: _____

Page No. ___ Line No. ___ Change to: _____

Reason for change: _____

Page No. ___ Line No. ___ Change to: _____

Reason for change: _____

Page No. ___ Line No. ___ Change to: _____

Reason for change: _____

Page No. ___ Line No. ___ Change to: _____

Reason for change: _____

Page No. ___ Line No. ___ Change to: _____

Reason for change: _____

SIGNATURE: _____ DATE: _____

ABRAHAM J. WYNER, Ph.D.

DEPOSITION ERRATA SHEET

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Page No. ___ Line No. ___ Change to: _____

Reason for change: _____

Page No. ___ Line No. ___ Change to: _____

Reason for change: _____

Page No. ___ Line No. ___ Change to: _____

Reason for change: _____

Page No. ___ Line No. ___ Change to: _____

Reason for change: _____

Page No. ___ Line No. ___ Change to: _____

Reason for change: _____

Page No. ___ Line No. ___ Change to: _____

Reason for change: _____

Page No. ___ Line No. ___ Change to: _____

Reason for change: _____

SIGNATURE: _____ DATE: _____

ABRAHAM J. WYNER, Ph.D.

EXHIBIT B

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

UNITED STATES BANKRUPTCY COURT
WESTERN DISTRICT OF NORTH CAROLINA
CHARLOTTE DIVISION

-----X
 ARMSTRONG WORLD INDUSTRIES,)
 INC. ASBESTOS PERSONAL) Miscellaneous Proceeding
 INJURY SETTLEMENT TRUST,)
 et al.,) No. 22-00303 (JCW)
)
 Plaintiffs,) (Transferred from
) District of Delaware)
 v.)
)
 ALDRICH PUMP LLC, et al.,)
)
 Defendants.)
 -----X
 In re) Chapter 11
)
 ALDRICH PUMP LLC, et al.,) Case No. 20-30608
)
 Debtors.)
 -----X

DEPOSITION OF CHARLES HENRY MULLIN, PH.D.
Monday, May 8, 2023; 1:06 p.m. EDT

Reported by: Cindy L. Sebo, RMR, CRR, RPR, CSR, CCR,
CLR, RSA, NYRCR, NYACR, Remote CA CSR #14409, NJ CCR
#30XI00244600, NJ CRT #30XR00019500, Washington State
CSR #23005926, Oregon CSR #230105, TN CSR 998, Remote
Counsel Reporter, LiveLitigation Authorized Reporter,
Notary Public
Job No. 5905066

1 Deposition of CHARLES HENRY MULLIN, PH.D.,
2 held at the law offices of Jones Day, 51 Louisiana
3 Avenue, Northwest, Washington, D.C. 20001, before
4 Cindy L. Sebo, Registered Merit Court Reporter,
5 Certified Real-Time Reporter, Registered Professional
6 Reporter, Certified Shorthand Reporter, Certified
7 Court Reporter, Certified LiveNote Reporter, Real-Time
8 Systems Administrator, California Shorthand Reporter
9 #14409, New Jersey Certified Court Reporter,
10 #30XI00244600, New Jersey Certified Realtime Reporter
11 #30XR00019500, New York Realtime Certified Reporter,
12 New York Association Certified Reporter, Washington
13 State CSR #23005926, Oregon CSR #230105, Tennessee CSR
14 #998, Remote Counsel Reporter, LiveLitigation
15 Authorized Reporter and Notary Public, beginning at
16 approximately 1:06 p.m. EDT, when were present on
17 behalf of the respective parties:

18
19
20
21
22

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

A P P E A R A N C E S:

Attorneys for Plaintiff ACC:

ROBINSON & COLE LLP

AMANDA R. PHILLIPS, ESQUIRE

One Boston Place, 26th Floor

Boston, Massachusetts 02108

617.557.5916

aphillips@rc.com

-and-

LAURIE A. KREPTO, ESQUIRE

1650 Market Street, Suite 3030

Philadelphia, Pennsylvania 19103

215.398.0554

lkrepto@rc.com

-and-

CAPLIN & DRYSDALE

JEANNA RICKARDS KOSKI, ESQUIRE (Via Zoom)

One Thomas Circle, Northwest, Suite 1100

Washington, D.C. 20005

202.862.5069

jkoski@capdale.com

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

A P P E A R A N C E S (Continued):

Attorneys for Plaintiff Claimants' Representative,
Joseph Grier:

ORRICK HERRINGTON & SUTCLIFFE LLP
DEBRA L. FELDER, ESQUIRE
Columbia Center
1152 15th Street, Northwest
Washington, D.C. 20005-1706
202.339.8567
dfelder@orrick.com

Attorneys for Custom Matching Claimants:

HOGAN MCDANIEL
DANIEL K. HOGAN, ESQUIRE
1311 Delaware Avenue
Wilmington, Delaware 19806
302.656.7540
dkhogan@dkhogan.com

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

A P P E A R A N C E S (Continued):
Attorneys for Debtors/Defendants Aldrich Pump LLC
and Murray Boiler LLC:

EVERT WEATHERSBY HOUFF

C. MICHAEL EVERT, JR., ESQUIRE

3455 Peachtree Road, Northeast, Suite 1550

Atlanta, Georgia 30326

678.651.1250

cmevert@ewhlaw.com

-and-

CLARE M. MAISANO, ESQUIRE

111 South Calvert Street, Suite 1910

Baltimore, Maryland 21202

443.573.8507

cmmaisano@ewhlaw.com

1 A P P E A R A N C E S (Continued):

2 Attorneys for DCPF:

3 YOUNG CONAWAY STARGATT & TAYLOR, LLP

4 KEVIN A. GUERKE, ESQUIRE

5 1000 North King Street

6 Wilmington, Delaware 19801

7 302.571.6616

8 kguerke@ycst.com

9

10 Attorneys for DCPF Trust:

11 BALLARD SPAHR LLP

12 BETH MOSKOW-SCHNOLL, ESQUIRE (Via Zoom)

13 919 North Market Street, 11th Floor

14 Wilmington, Delaware 19801-3034

15 302.252.4447

16 moskowb@ballardspahr.com

17 -and-

18 BRIAN N. KEARNEY, ESQUIRE

19 1735 Market Street, 51st Floor

20 Philadelphia, Pennsylvania 19103-7599

21 215.864.8265

22 kearneyb@ballardspahr.com

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

A P P E A R A N C E S (Continued):

Attorneys for Debtors and Debtors in Possession:

JONES DAY

BRAD B. ERENS, ESQUIRE (Via Zoom)

MORGAN R. HIRST, ESQUIRE

110 North Wacker Drive, Suite 4800

Chicago, Illinois 60606

312.782.3939

bberens@jonesday.com

mhirst@jonesday.com

Attorneys for Trane Technologies Company LLC and
Trane U.S. Inc.:

MCCARTER & ENGLISH, LLP

PHILLIP S. PAVLICK, ESQUIRE (Via Zoom)

Four Gateway Center

100 Mulberry Street

Newark, New Jersey 07102

973.849.4181

ppavlick@mccarter.com

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

A P P E A R A N C E S (Continued):
Attorneys for Non-Party Verus Trust:
LOWENSTEIN SANDLER LLP
MICHAEL A. KAPLAN, ESQUIRE
One Lowenstein Drive
Roseland, New Jersey 07068
973.597.2302
mkaplan@lowenstein.com

Attorneys for Verus Claim Services, LLC:

ANSELM I & CARVELLI, LLP

ANDREW E. ANSELM I, ESQUIRE

101 Avenue of the Americas

8th & 9th Floors

New York, New York 10013

212.308.0070

aanselmi@acllp.com

ALSO PRESENT:
PETER CUMBO, Bates White (Via Zoom)
ALLAN TANANBAUM, Vice President, Deputy General
Counsel, Product Litigation at Trane
Technologies (Via Zoom)
JOSEPH GRIER, Claimants' Representative

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

--oOo--

INDEX OF EXAMINATION

CHARLES HENRY MULLIN, PH.D.

Armstrong World, et al. v Aldrich Pump LLC, et al.

Monday, May 8, 2023

--oOo--

EXAMINATION BY	PAGE
Mr. Kaplan	11
Mr. Guerke	144
Mr. Hogan	207
CERTIFICATE OF REPORTER	217
INSTRUCTIONS TO WITNESS	218
ERRATA	219
ACKNOWLEDGMENT OF WITNESS	221

--oOo--

INDEX TO EXHIBITS

CHARLES HENRY MULLIN, PH.D.

Armstrong World, et al. v Aldrich Pump LLC, et al.

Monday, May 8, 2023

--oOo--

(Exhibits Provided Electronically to Reporter.)

CM DEPOSITION

EXHIBIT NUMBER	DESCRIPTION	PAGE
----------------	-------------	------

Number 1	Declaration of Charles H. Mullin, Ph.D.	17
----------	--	----

Number 2	Subpoena to Produce Documents, Information, or Objects or to Permit Inspection of Premises in a Bankruptcy Case (or Adversary Proceeding)	51
----------	---	----

Number 3	Expert Report of Abraham J. Wyner, Ph.D.	101
----------	---	-----

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

--oOo--

P R O C E E D I N G S

--oOo--

Washington, D.C.

--oOo--

Monday, May 8, 2023; 1:06 p.m. EDT

--oOo--

--oOo--

CHARLES HENRY MULLIN, PH.D.,

after having been first duly sworn by the certified
stenographer to tell the truth, the whole truth, and
nothing but the truth, testified as follows:

--oOo--

CERTIFIED STENOGRAPHER: Thank

you.

The witness is sworn.

MR. KAPLAN: Thank you.

--oOo--

EXAMINATION BY COUNSEL FOR NON-PARTY VERUS TRUST

--oOo--

BY MR. KAPLAN:

Q. Good afternoon, Dr. Mullin. I'm

1 Michael Kaplan. We met briefly off the record. I
2 represent the nonparty Verus Trust.

3 And I think I've drawn the short
4 straw of -- of going first today, and maybe the
5 only. We'll see.

6 You have been deposed before,
7 correct?

8 A. Correct.

9 Q. I'd be lying if I told you I didn't
10 know that.

11 So I'm going to give you the very
12 abbreviated version of today's sort of ground rules
13 so that we can't ever have a disagreement.

14 You know all of your answers have to
15 be verbal?

16 A. Correct.

17 Q. We have to do our best not to talk
18 over one another, right?

19 A. That's the goal.

20 Q. Right.

21 You understand you're testifying
22 under the penalty of perjury, correct?

1 A. Correct.

2 Q. You understand that from time to
3 time, maybe in response to every question, your
4 counsel is going to potentially object to something
5 that I'm saying.

6 Unless he instructs you not to
7 answer, you know you can answer, right?

8 A. I have the option of answering, yes.

9 Q. Okay. Lastly and, I think, most
10 importantly is if you don't understand my question,
11 I'd like you to tell me that you don't understand
12 it, and maybe we'll -- and I'll be able to rephrase
13 it for you so that you get a question you
14 understand.

15 If you answer, I'm going to assume
16 that you understood the question.

17 Correct?

18 A. That may be a poor assumption.

19 If I answer, I had a clear
20 understanding of the question. I have no way of
21 knowing if that aligned with your intent of the
22 question.

1 So it doesn't necessarily mean that
2 your understanding and mine are the same; it just
3 means we both have one.

4 Q. Well, the benefit will be that if you
5 think there's a problem with the question in any
6 way, you shouldn't answer; you should tell me.
7 Because if you do, I promise you, when, we get to
8 court, I'm going to hold up the deposition
9 transcript and say you answered, so you understood.

10 All right?

11 A. And I will tell the judge what I
12 understood, so it will be fine.

13 Q. Terrific. And we will be off to the
14 races there.

15 Lastly, if you need a break in this
16 very, very short session, hopefully, that we
17 have -- we'll take one for sure, but please let me
18 know at any time.

19 And, obviously, if there's any
20 question of privilege, somehow, that came up, we
21 can stop, take a break and get the privilege issue
22 resolved and come back in. But I don't think we're

1 going to have that issue today.

2 All right.

3 (Pause.)

4 BY MR. KAPLAN:

5 Q. So, Doctor, what is it that you're
6 being -- being proffered as an expert in here?

7 A. I'm -- the proffer I don't control.
8 I've been asked to really explain the difference
9 between using a 10 percent sample or -- 10 percent
10 sample of what's really about a 3 percent sample of
11 the claims data already or using the 3 percent we
12 asked for in the \$12,000 in totality and how that
13 would affect the precision of the ultimate analyses
14 offered in estimation down the road.

15 Q. Okay. My question was a little more
16 straightforward than that. Let me rephrase it for
17 you because it might be you didn't understand.

18 What is your expertise in?

19 A. I'm trained as an economist. I have
20 extensive expertise in statistics, econometrics,
21 economic modeling. I have applied those in a mass
22 tort setting frequently.

1 And probably most germane to this
2 process, I have expertise in estimating future
3 liabilities under various different sets of
4 assumptions and -- which get into the estimation
5 process itself but in terms of the data inputs and
6 how they affect that and the statistical properties
7 and, hence, the precision.

8 So it's really estimation and
9 statistics are probably the two applications, but
10 there's a lot of underlying training and expertise
11 that underlies those two areas.

12 Q. Okay. Did anyone assist you in
13 preparing your declaration that was submitted here?

14 A. Yes.

15 Q. Okay. And who are those people?

16 A. I couldn't give you a whole list
17 sitting here. My process -- I work with a team --

18 Q. Okay.

19 A. -- and I draft reports with the team.
20 I ultimately review them and edit them to make sure
21 they reflect my opinions. And that work done is
22 under my direction.

1 Q. Okay. And I'm going to mark for you,
2 just so that we have and we can get started with
3 it --

4 MR. KAPLAN: Can we just call it
5 CM-1? Anyone have a problem with that?

6 MR. EVERT: Sure, that's fine.

7 MR. KAPLAN: CM-1.

8 It is your -- and I apologize for
9 those in Zoom world. I don't have electronic
10 copies to share, but it's Dr. Mullin's
11 declaration at Docket 55, filed on March 9th,
12 2023.

13 I do have copies for the room --
14 some copies for the room.

15 --oOo--

16 (CM Deposition Exhibit Number 1,
17 Declaration of Charles H. Mullin,
18 Ph.D., marked for identification, as
19 of this date.)

20 --oOo--

21 BY MR. KAPLAN:

22 Q. Okay. Do you recognize this

1 document, Dr. Mullin?

2 MR. EVERT: Hang on one second.

3 I just wanted to make sure, for
4 everybody on the phone, that they know
5 it's -- because he's filed more than one
6 declaration in the case. So it's Docket
7 -- it's -- the declaration at Docket 55 is
8 the declaration filed in association with the
9 -- I believe with the Motion for
10 Reconsideration, although . . .

11 MR. KAPLAN: Sure hope it is.

12 MR. EVERT: Yeah, that's right.

13 MR. KAPLAN: Okay.

14 BY MR. KAPLAN:

15 Q. You recognize that document,
16 Dr. Mullin?

17 A. I do.

18 Q. Okay. And the team that you talked
19 about in the process you use -- is that what you
20 used to prepare what we're calling CM-1?

21 A. Correct.

22 Q. Okay. Do you know how many hours you

1 spent in preparing this?

2 A. I do not.

3 Q. Okay. How much time did you spend
4 preparing for your deposition today?

5 A. Specifically for the deposition?

6 Probably five to eight hours.

7 Q. Okay. Did you speak to anyone
8 besides counsel about your deposition today?

9 A. I spoke with a couple members of my
10 team.

11 Q. Okay. And what did you talk about
12 there?

13 A. So, first, I'll clarify what I mean
14 by "prepare," because that will give context, which
15 is I reviewed Dr. Wyner's rebuttal report --

16 Q. Okay.

17 A. -- and so I talked to my team about
18 that report and talked to -- principally, that was
19 the main topic of conversation with my team.

20 Q. It was about Dr. Wyner's report?

21 A. Correct.

22 Q. Okay. We'll get to that at some

1 point today.

2 Did you meet with counsel in advance
3 of the deposition?

4 A. I did.

5 Q. Okay. How many hours did you meet
6 with counsel for?

7 A. In terms of this is the topic?

8 Around an hour, maybe an hour and a
9 half.

10 Q. Okay. And when was that?

11 A. So a meeting on Thursday or Friday of
12 last week and then a little bit of time before the
13 start of the deposition this morning.

14 Q. Let me just say this: The document
15 which we've showed you as CM-1, this declaration
16 for the motion for reconsideration -- is this the
17 only document that you are planning on relying on
18 in the -- for the June 6th hearing?

19 MR. EVERT: I'm sorry. Let me
20 ask, when you say "document," do you mean
21 declaration?

22 MR. KAPLAN: I'm sorry.

1 Declaration. Bad wording. Yes.

2 THE WITNESS: I don't know the
3 technicalities of it. I had a similar
4 declaration that I think was in response to
5 an action in New Jersey, and I don't know the
6 technicalities of how that transfers over.
7 But there's a lot of overlap in the content
8 of those two. But, really, the content
9 across those would be the focus of that
10 testimony as I see it.

11 BY MR. KAPLAN:

12 Q. Okay. Are you preparing any kind of
13 supplemental declaration in response to Dr. Wyner?

14 MR. EVERT: I'm just going to
15 break in, Michael.

16 I think we agreed we weren't going
17 to do that, that this was going to be his
18 supplemental declaration.

19 You weren't part of those
20 discussions, so I apologize for jumping in
21 and answering the question, but -- yeah. So
22 I think, at least from a legal perspective,

1 we would be relying on any declarations
2 Dr. Mullin has filed that are applicable to
3 the Trust discovery issue; but, no, he's not
4 going to file -- his deposition is going to
5 serve sort of as his response.

6 MR. KAPLAN: Excellent. All
7 right. Good. That will short-circuit some
8 of -- some of those questions.

9 BY MR. KAPLAN:

10 Q. I apologize, Dr. Mullin. I was
11 not -- were you present at the March 30th, 2023
12 hearing that sort of preceded this round of
13 exercises we're doing right now?

14 A. I was present at a hearing. If that
15 was the date of it --

16 Q. Yeah.

17 A. -- probably.

18 MR. EVERT: Yes, he was.

19 MR. KAPLAN: He was there.

20 BY MR. KAPLAN:

21 Q. Okay. Excellent.

22 All right. So I want to focus you in

1 on -- on, really, two questions -- two sets of
2 questions today -- others may have other questions,
3 but I want to focus you in on two. The first is
4 that judge's question about why sampling doesn't
5 work for the Debtors' side, and the second is why
6 sampling wouldn't reduce the risk of even human
7 error of missing some PII being disclosed.

8 Okay?

9 A. Okay.

10 Q. All right. By background, have you
11 offered an expert opinion previously on the
12 sufficiency of a sample side?

13 A. Yes.

14 MR. EVERT: In any case?

15 MR. KAPLAN: In any case.

16 MR. EVERT: Okay.

17 BY MR. KAPLAN:

18 Q. How many of the cases?

19 A. I couldn't give you a count. I know
20 it's a common topic in the insurance coverage work
21 that I've done, so it comes up frequently in that
22 context. So that's going to be the principal

1 context.

2 I've done sampling in, I guess --
3 with the Consumers Finance Bureau [sic]. There's
4 probably other cases as well, but I've used
5 sampling in an array of different positions.

6 Q. How about in any type of mass tort
7 case?

8 A. Most of those insurance coverage
9 actions involve mass tort claims --

10 Q. Okay.

11 A. -- so definitely, in relation to mass
12 torts, I've given opinions on sampling before.

13 Q. Okay. Can you recall the last time
14 you gave an opinion on sampling in -- in a mass
15 tort case?

16 A. It's common. I'd have to go look. I
17 don't know the last time I did it.

18 Q. Okay. And you said in the insurance
19 context.

20 Who is it that retained you in those
21 contexts -- in those cases -- excuse me, not
22 contexts, cases?

1 A. I've been retained by policyholders;
2 I've been retained by insurance companies; I've
3 been retained by reinsurance companies, whether
4 it's reinsurance and insurers in litigation, and
5 retrocession errors. So it's kind of up and down
6 the line.

7 Sampling is common regardless of who
8 my clients are in those contexts.

9 Q. Okay. You were involved in the -- in
10 the Mallinckrodt case, correct?

11 A. Correct.

12 Q. What was it that you did there?

13 A. I was retained relatively late in
14 that case. There was a settlement in place. There
15 were objectors to that plan, and I was brought in
16 to discuss the reasonableness of the settlement --

17 Q. Okay.

18 A. -- with regard to opioid claimants in
19 particular was the emphasis of that.

20 Q. Okay. If you flip to Page 17 of 30,
21 the ECF page numbers on the top of your
22 declaration, there is a list of selected

1 experience.

2 Does that document help refresh your
3 recollection at all in terms of the case in which
4 you offered an expert opinion on sampling, outside
5 of this case, of course?

6 A. In general, this is the cases I'm
7 allowed to publicly disclose at this point --

8 Q. Okay.

9 A. -- so there's numerous cases on this
10 list where I would have offered opinions on
11 sampling.

12 Q. Can you give me an example of -- of
13 an opinion -- again, obviously, we can only ask you
14 about publicly available cases and you can only
15 disclose publicly available cases.

16 So looking at this list, which is the
17 universe we're working off here, can you give me an
18 example of a case which you offered an opinion on
19 sampling in?

20 A. Some of the analyses that are in the
21 public domain of what I've done on the Aearo
22 bankruptcy originally dealt with the 1 percent

1 sample that had been drawn in the MDL --

2 Q. Okay.

3 A. -- so I didn't design that sample,
4 but I utilized that sample.

5 (Whereupon, the witness reviews the
6 material provided.)

7 THE WITNESS: Fourth bullet on
8 what's Page 18 of 30 --

9 BY MR. KAPLAN:

10 Q. Yeah.

11 A. -- is the Consumer Finance Protection
12 Bureau case in which I've designed and utilized a
13 sample.

14 (Whereupon, the witness continues to
15 review the material provided.)

16 THE WITNESS: I had input in some
17 of the sampling discussions in Bestwall. I
18 was not ultimately the person who signed off,
19 but I had input into those.

20 (Whereupon, the witness continues to
21 review the material provided.)

22 THE WITNESS: There was some

1 sampling in the ACE Bermuda Insurance versus
2 3M arbitration.

3 (Whereupon, the witness continues to
4 review the material provided.)

5 THE WITNESS: The General Re-SCOR
6 matter, about two-thirds, three-quarters of
7 the way down Page 19, had sampling.

8 (Whereupon, the witness continues to
9 review the material provided.)

10 THE WITNESS: My recollection is
11 there was sampling in the bottom two on that
12 page.

13 MR. EVERT: That would be the
14 AIU Insurance and the THAN?

15 THE WITNESS: Yep.

16 (Whereupon, the witness continues to
17 review the material provided.)

18 THE WITNESS: I believe the fourth
19 bullet on Page 20, the National Indemnity
20 matter there versus the State of Montana.

21 I believe the next one, Newco
22 versus Allianz, had sampling.

1 The U.S. Silica versus Ace matter
2 two-thirds the way down the page had
3 sampling.

4 I think the third from the bottom,
5 Cannon Electric versus Affiliated, had
6 sampling.

7 The Goodrich matter, penultimate
8 one on the page, had sampling.

9 I did a lot more insurance work
10 earlier in my career, and we're going to
11 start to get a long list of them if not, we
12 can keep going if that's sufficient.

13 BY MR. KAPLAN:

14 Q. Let me stop you there for a second --
15 no. Let me stop you there, which is -- in -- in
16 the cases that you identified on these first few
17 pages -- and I understand there's potentially
18 more -- were you a proponent or opponent of
19 sampling in those cases?

20 A. I don't really view it as either.

21 Q. Okay.

22 A. I mean, I'm trying to work towards

1 getting sufficiently precise opinions for the
2 parties to resolve a matter. And it's
3 fact-specific as to any given matter whether
4 sampling or a census or some other process is
5 what's going to be most efficient in getting to
6 resolution of the case, in reality.

7 And so that's really how I approach
8 these. I'm neither pro sampling or against
9 sampling. I'm what's going to work most
10 effectively in a given setting.

11 Q. So let me understand.

12 Is it your testimony that different
13 cases can have different outcomes with respect to
14 sampling in terms of whether it's efficient or not
15 efficient?

16 A. Correct. It's a cost-benefit
17 analysis --

18 Q. Sure.

19 A. -- and you're looking at that
20 cost-benefit analysis, which is going to be
21 fact-specific to the case. And sometimes it makes
22 sense to look at the census.

1 In this case, for example, we are
2 using the entire Debtors' historical claims
3 database. We're not saying let's use a 10 percent
4 sample of data already in electronic format. We're
5 saying no, we use all of it because it's all
6 already in electronic form. And that's going to,
7 on a cost-benefit analysis, make sense as opposed
8 to sampling from the historical claims data.

9 You know, in contrast, when you look
10 at claim files in the case and you say what
11 historical claim files might want to get produced
12 and reviewed, that's an expensive operation; you do
13 sampling.

14 So in one case, you turn over
15 everything because it's already in electronic
16 format. In the other case, because there's a large
17 volume of manual labor and cost and time, you use a
18 sample.

19 So even within this case, there's
20 places where my opinions are use all the data, and
21 there's other places where it's use a sample of the
22 data. It's not one or the other; it's what makes

1 sense for the question at hand and the facts at
2 issue.

3 Q. Let's look at -- see if I can put
4 this into some specifics here.

5 You said that you offered an opinion
6 on sampling in the Aearo Technologies case,
7 correct?

8 A. I said I used -- I had opinions that
9 utilized a sample --

10 Q. Okay.

11 A. -- and I utilized the 1 percent
12 sample that was preexisting from the underlying MDL
13 proceeding.

14 Q. All right. And in your opinion, was
15 that sample sufficient for the purpose you were
16 using it for?

17 A. For the scope of the opinion I was
18 doing, I mean, it was a constraint. It was the
19 only thing available at the time, so it more
20 prescribed the strength of the opinion I was able
21 to offer.

22 So by construction, it was sufficient

1 for the opinion I offered. With more data, I could
2 have offered a more refined opinion.

3 Q. Okay. How about in the Consumer
4 Financial Protection Bureau case? You said you
5 offered an opinion -- I don't want to misstate
6 it -- that utilized sampling or on sampling.

7 Which was it?

8 A. I designed the sample on that case --

9 Q. Okay.

10 A. -- it involves literally millions of
11 phone calls. So it would be completely time
12 prohibitive to have people listen to the millions
13 of phone calls and do something comprehensive. So
14 from a cost-benefit analysis, it was necessary
15 there to use sampling.

16 Q. I think you said you participated in
17 Bestwall, but I think we all understand you didn't
18 offer the principal opinion there, correct?

19 A. I haven't filed any declarations or
20 reports in Bestwall.

21 Q. Okay. Good.

22 How about -- you said ACE Bermuda --

1 you utilized a sample there?

2 A. Correct.

3 Q. And what was the context in that
4 case?

5 A. Well, it's a Bermuda form insurance
6 action, which I think means it's all
7 confidential --

8 Q. Okay.

9 A. -- so I don't think I can really tell
10 you the substance of it outside of it's insurance
11 coverage.

12 Q. Okay. That makes it a little
13 difficult to -- how about let's go down to the
14 bottom of the page to the AIU versus
15 Philips Electric that's in Delaware Chancery?
16 Public that you can talk about?

17 A. I know the two -- the general
18 theme -- the two that are there are connected to
19 each other. It's really the same opinion in both.
20 They both stem from the THAN Trust. And AIG and
21 the THAN Trust had coverage litigation, and they
22 were seeking discovery on the underlying records

1 from the THAN Trust itself.

2 Q. Okay. And what was it -- how did the
3 opinion on sampling work in there?

4 A. I have a recollection sampling was in
5 it, but I don't recall, sitting here. I haven't
6 reread that even if I have it still. I don't think
7 those are both in the public domain, but I'm not
8 100 percent certain of that.

9 Q. It's in the SDNY. Everything is in
10 public there.

11 Have you ever offered an expert
12 opinion on data privacy before?

13 A. No.

14 Q. All right. Do you have any type of
15 specialized training in data privacy?

16 A. I don't know what you consider
17 specialized. We have an entire technological
18 services department; we have HITRUST certification;
19 we have SOC 2 certification. Part of all of that
20 certification is training for everybody at
21 Bates White, including myself. So I've had all of
22 the training that goes with those certifications.

1 This is where, if you say
2 "specialized," I think HITRUST would say some of
3 that is specialized, but I'm not sure what you mean
4 by that.

5 So I've gone through the training
6 that goes along with the company getting all of the
7 security credentials.

8 Q. Okay. Have you taken any -- beyond
9 what the company is -- is offering, any specific
10 type of coursework on data privacy?

11 A. No.

12 Q. Do you have any certifications, you,
13 yourself, in data privacy?

14 A. No.

15 Q. All right. Have you ever been
16 proffered as an expert in data privacy previously?

17 A. No.

18 Q. Okay. And finally -- I'm fairly
19 certain I know the answer to this, but if you tell
20 me "yes," I'm going to be pretty surprised -- which
21 is is you're not a lawyer, correct?

22 A. No.

1 Q. All right. We're off to a good
2 start.

3 You're not qualified to offer a legal
4 opinion on the question of law, right?

5 A. That's a whole different question,
6 but I don't intend to offer any.

7 Q. Are you qualified to offer a legal
8 opinion on the Federal Rules of Civil Procedure?

9 A. I don't intend to offer any.

10 Q. Not my question.

11 Are you qualified to offer an opinion
12 on the Federal Rules of Civil Procedure, in your
13 view? This is only your view.

14 A. No.

15 Q. Okay.

16 All right. I showed you before -- if
17 we can flip back to the meat of your -- sort of
18 your declaration there, CM-1.

19 Anything in there that needs to be
20 corrected before we dive into it?

21 A. Not that I'm aware of.

22 Q. All right. Excellent.

1 All right. In looking through the
2 declaration, Dr. Mullin, can you point me to which
3 paragraph or paragraphs contain your opinion on why
4 the proposed 10 percent sample is not sufficient
5 for the Debtors?

6 (Whereupon, the witness reviews the
7 material provided.)

8 THE WITNESS: I think the core of
9 that starts in Paragraph 15 --

10 BY MR. KAPLAN:

11 Q. Okay.

12 A. -- and probably runs through
13 Paragraph 18 of how the data would be used in broad
14 brush strokes.

15 Q. Okay. And is it your opinion that a
16 10 percent sample is not sufficient for the
17 purposes?

18 A. So it's my opinion that on a
19 cost-benefit assessment, which is how you decide
20 whether you should sample or not, the benefits
21 greatly outweigh the costs here, so it makes sense
22 to get those benefits when they outweigh the costs.

1 So it's going to allow me an estimation to give a
2 much more precise answer and address some questions
3 that otherwise I may not be able to address or
4 quantify reliably, so it -- so, yes, because it
5 passes that cross -- cost-benefit analysis.

6 Q. Okay. Yeah, the -- is your entire
7 opinion related to the sufficiency tied to just
8 cost-benefit?

9 A. I mean, that is the fundamental
10 principle of designing a sample and when do you
11 sample and when don't you, so you can't really
12 answer these questions about is sampling
13 appropriate or not in the absence of talking about
14 what it costs.

15 If there's zero cost to having all
16 the data, you should use all the data because
17 you'll be more precise, and why would you give up
18 the precision? If it's impossible to get all the
19 data, it's a silly exercise to talk about what
20 would happen if we did get it. So the two are --
21 can't be separated, the -- what are the benefits,
22 what are the things that the data enable you to do

1 and what's the cost of gaining access to that data.

2 That's the trade-off of sampling
3 always. So to -- you can't answer questions absent
4 that framework about sampling.

5 Q. Okay. Let me try it this way: Why
6 is -- why is a 10 percent sample not sufficient for
7 the stated purposes?

8 A. Well, so I think this is a place
9 where we need to clarify. One, the Debtors have
10 over 400,000 historical claims. I have not asked
11 for 400,000 data through counsel as a request to
12 assist in our work. We asked for 12,000; less than
13 3 percent.

14 So this isn't like the examples where
15 the Trusts say, Federal-Mogul asked for 435,000
16 Claimants; they asked for 12,000; 3 percent. So I
17 was prudent. I did take into a sense the costs of
18 this, and I asked for 3 percent through counsel to
19 get data on a very limited set of 3. And now I'm
20 being asked to go, for the sake of the analysis,
21 from 3 percent to .3, 10 percent of 3 percent.

22 So you're going to say it's

1 10 percent?

2 I think you're asking me to take
3 .3 percent of the available data, not 10, and move
4 from what was already a request for 3 down to .3.

5 So if we're going to say 10 percent,
6 let's make sure it's 10 percent of 3 percent, which
7 I think is the intent of your question. But I want
8 to make that very clear, if that's how we're going
9 to use the terms.

10 Q. Well, let's see -- let's drill down
11 on that because I don't represent the Debtor as,
12 you know; I represent one non-party.

13 So can you explain to me how it is
14 you're getting from this 10 percent to 3 percent to
15 .3 percent? Because I'm not -- I'm not following.

16 A. Okay.

17 So the Debtors have faced hundreds of
18 thousands historical claims in the tort system.
19 Some requests that have gone to the Trusts from
20 prior parties have requested their entire
21 historical data, so hundreds of thousands of
22 claims.

1 I don't think I need that. I have
2 tried to filter this down in how we think about
3 this request. We asked for 12,000. We -- I
4 already said, anything before 2005, it's not going
5 to give me enough information that I need to go
6 after that right now.

7 I eliminated all dismissed claims.
8 Dismissed claims have been produced in other
9 contexts. They were produced in Garlock. They
10 contain a little bit of information that would help
11 but not a lot. That's -- 80 percent of the
12 mesothelioma claims, for example, against Murray
13 resulted in dismissal. I've already eliminated
14 those. I've constrained it to just mesothelioma
15 claims.

16 So it's not that I asked for the
17 ocean through counsel in these requests. I'm
18 seeking for estimation a very targeted subset
19 that's going to be most informative. That's about
20 3 percent of the historical Claimants. I'm seeking
21 information on those three through the subpoenas --
22 or, really, the Debtors, on my behalf, are seeking

1 that. So that's where I'm saying we're starting at
2 3 percent. And now others are saying, Let's go
3 from 3 to .3, take 10 percent of that 3 percent.

4 Q. Okay. So you're talking about the
5 totality of the universe; you aren't being specific
6 to -- for instance, I represent the Verus Trusts.

7 Are you familiar with those?

8 A. Yes.

9 Q. Okay. Your testimony is that
10 in -- in looking at the information the Verus
11 Trusts potentially possess as a whole, that's how
12 you're drilling down from 10 percent to 3 percent
13 to .3 percent, correct?

14 A. No.

15 Q. Okay.

16 Are you only looking for -- what is
17 the limitation on the Verus Trust, then?

18 A. So the Debtors, Aldrich and Murray,
19 combined have over 400,000 -- received claims on
20 behalf of 400,000-plus Claimants. So if you wanted
21 to collect information on all the historical
22 Claimants that have brought claims against the

1 Debtors, you would be asking a request for over
2 400,000 people.

3 That's not what the request was. It
4 was for 12,000, around 3 percent of the universe of
5 historical Claimants that these two Debtors have
6 received claims from.

7 So it started targeting at 3 percent,
8 3 out 100, and so it's the universe of Claimants
9 who brought tort claims against the Debtors'
10 prepetition. That's the initial universe.

11 Q. Is it your testimony that the Verus
12 Trusts possess 400,000 Claimants' worth of
13 information?

14 A. I think you can look at reports, and
15 they have more than 400,000 Claimants that filed
16 claims against entities by the Verus Trusts, but
17 what's the overlap -- the question of what's the
18 overlap between the 400,000-plus the Debtors faced
19 and which ones are in -- file a Trust claim against
20 Verus. But the Verus entities have received more
21 than -- claims on behalf of more than 400,000
22 individuals.

1 Q. Let's try it this way: What is it
2 that the Debtors need -- excuse me.

3 Strike that.

4 What is it that you need this
5 information for that you asked the Debtors to go
6 get it?

7 A. So when estimating future
8 liabilities, there's a few different steps in that
9 process. One is, how many future people will
10 develop mesothelioma with the types of
11 characteristics that would make them compensable
12 against these Debtors?

13 When doing that exercise, the
14 industry and occupational work backgrounds of
15 Claimants matters. That affects the odds that they
16 will be compensable. So when you're doing this
17 forecast, you'd really like to break Claimants down
18 into industry and occupational groups that have
19 different levels of valuation associated with them.

20 So one of the things that this data
21 provides is, in electronic form already, a rich set
22 of industry and occupational work history

1 information, so you're able, then to forecast by
2 different industry and occupational groups because
3 they have different demographic characteristics.
4 So some of those groups taper off more quickly, so
5 the claims would decrease faster. Some will
6 decrease more slowly.

7 So to get a more precise estimate of
8 the number of future claims that the Trust would
9 receive, you really want to do the analysis by
10 industry and occupational groups; that both gives
11 you a more precise estimate of the totality of the
12 liability and, probably just as importantly, it
13 helps you better protect future Claimants relative
14 to pending Claimants. Because when you do this
15 type of a forecast, forecasting the number of
16 claims the Debtor would have received one year post
17 petition, that's easy, relative to forecasting the
18 number of claims the Debtor would receive 20 years
19 post petition.

20 The further into the future you go,
21 the more uncertainty. And so we want to minimize
22 that because we really don't want to be in a

1 position where future Claimants are getting paid
2 less than the pending Claimants, so improving that
3 forecast is important.

4 Q. Okay. Any other reason the Debtor
5 needs the information?

6 A. So there's a second piece besides --
7 that uses that same type of information to help you
8 design a claims resolution process and then,
9 similarly, helps you show that that claims
10 resolution process is feasible at confirmation, so
11 you're using it for those purposes as well.

12 Depending on the exercise you're
13 doing, but, in particular, under what is often the
14 Plaintiff's theory in these cases, you're trying to
15 do an estimate of what Claimants would have been
16 paid in the tort system; and that's something that
17 varies by both industry, occupation but also law
18 firm, jurisdiction.

19 And so when you start asking these
20 questions, it may be that only 100 of the 1,200
21 claims apply to a question of interest, so that's
22 constrained to a 1,200-claim sample, but only one

1 in 12 go to a subpopulation that I need to estimate
2 something on behalf of; now I have only a sample
3 size of 100 to answer that question. And that's
4 not sufficient.

5 So when you start peeling down, if
6 you really want to ask a question that's just one
7 average for the whole population, 1,200 claims, in
8 general, would be enough. But as soon as you start
9 saying there's a subpopulation of interest, like
10 maybe pipefitters and electricians are different
11 from carpenters, maybe certain jurisdictions are
12 different from others, so you need to look at a
13 subset, I no longer get to look at 1,200 claims,
14 and so I need those subsets to also be big enough
15 to give reliable opinions and accurately estimate
16 the future.

17 Q. Okay. So let me -- is it -- before
18 we go further, any other reasons why you ask the
19 Debtor to go get this information?

20 A. There's what's the bulk of
21 Paragraphs 15 and 16, which is really what fraction
22 of a Claimant's exposures were known to the Debtors

1 at the time of settlement. So that's the thrust of
2 Paragraphs 15 and 16 in my declaration, so that's
3 another issue where this information would be
4 important.

5 Q. All right. Let's start with that
6 one, which is you say, What information was known
7 to the Debtors at the time of settlement?

8 That is, it's -- how does that help
9 advance the ball of the case?

10 MR. EVERT: I'm going to object to
11 the form of the question. I'm not sure what
12 you're asking.

13 THE WITNESS: So little bit of
14 history: Key aspect of the Garlock case was
15 that Judge Hodges found that not all that
16 information had been revealed and concluded
17 that tainted the tort history, so
18 extrapolating historical tort settlements
19 into the future wasn't appropriate.

20 The Plaintiffs assert -- and it
21 may turn out to be true -- that post Garlock,
22 that behavior stopped.

1 BY MR. KAPLAN:

2 Q. What behavior specifically?

3 A. Not revealing the totality --
4 suppressing information or not revealing --

5 Q. Okay.

6 A. -- all the alternative exposure
7 information.

8 Whether or not that stopped is an
9 empirical question. For mine, maybe that did stop
10 completely. Maybe it's identical to what was in
11 Garlock. I don't have an opinion about that. I
12 want to look at the data and have the data tell me,
13 is that going on or not going on.

14 That was a very salient fact in the
15 estimation in Garlock. I would expect the outcome
16 of that empirical exercise to be a salient fact
17 here. So that speaks directly to an aspect of what
18 you could potentially rely on a tort system
19 settlement for or not. So that's one spot where
20 answering that question is going to directly enter
21 into an estimation process.

22 Q. Okay. I want to show you the -- this

1 is just an exemplar subpoena of one. I believe
2 they all were fairly similar, but this was one that
3 was issued to the ACandS Asbestos Trust in
4 connection with the -- when it was grouped
5 in New Jersey.

6 MR. KAPLAN: We'll mark this as
7 CM-2, and I have copies to share with
8 everybody.

9 (Sotto voce discussion.)

10 --oOo--

11 (CM Deposition Exhibit Number 2,
12 Subpoena to Produce Documents,
13 Information, or Objects or to Permit
14 Inspection of Premises in a
15 Bankruptcy Case (or Adversary
16 Proceeding), marked for
17 identification, as of this date.)

18 --oOo--

19 BY MR. KAPLAN:

20 Q. Take a look at that, and let me know
21 whenever you're ready.

22 MR. KAPLAN: Just for those on the

1 Zoom world, the cover page is not filed
2 anywhere, but the thrust of what I'm about to
3 talk about is filed at --

4 MR. EVERT: It's the order
5 granting the subpoenas --

6 MR. KAPLAN: Yeah, Docket 1240.

7 Yep.

8 MR. EVERT: -- right, Docket 1240
9 in the main case.

10 MR. KAPLAN: Yes.

11 BY MR. KAPLAN:

12 Q. All right. Have you seen that
13 document -- again, I want to focus in on the order
14 here, Dr. Mullin.

15 Have you seen this document before?

16 A. I believe I've seen the order before.

17 Q. Okay. Excellent.

18 I want to focus you in on Paragraph 5
19 of the order, which is, I believe, what we were
20 just covering a moment ago, which talks about what
21 the subpoenas are seeking evidence for.

22 Do you see that?

1 A. I do.

2 Q. All right. And I believe that the
3 first thing you spoke to me about was the -- the
4 estimation of the Debtors' liability for current
5 and future asbestos-related claims and the
6 negotiation, formulation and confirmation of the
7 plan, correct?

8 MR. EVERT: I'm sorry.

9 Could you repeat that question?

10 MR. KAPLAN: Sure. I'm just
11 trying to -- he gave me -- if I recall, there
12 were three areas which he gave me to --

13 BY MR. KAPLAN:

14 Q. -- that you needed the data for: One
15 was forecasting; one was -- call it claims
16 resolution and -- and the Trust distribution; and
17 the third I'll generally refer to as the "Garlock
18 problem."

19 Okay?

20 Did I get those right, those three --
21 what -- the three purposes?

22 A. So estimating liability, of which you

1 have a lot of inputs into, the Garlock problem is a
2 subset of that, if it exists. You know, so there's
3 estimating liability; and there's designing the
4 plan; and then there's showing the plan as feasible
5 in confirmation.

6 Q. Okay.

7 MR. ANSELM: I'm sorry.

8 Could you repeat that last answer?

9 I couldn't hear.

10 Or could you repeat it back, what
11 the answer was?

12 --oOo--

13 (Whereupon, the certified
14 stenographer read back the pertinent
15 part of the record.)

16 --oOo.

17 MR. ANSELM: Okay.

18 BY MR. KAPLAN:

19 Q. So that's what I was trying to drill
20 down on, what this is.

21 Your testimony is that this -- this
22 -- if we look at the colon past "specifically,"

1 there's a semicolon, and then we get to -- The
2 estimation of the Debtors' asbestos liability is
3 the second phrase or clause there, correct?

4 A. Correct.

5 Q. And that's where your testimony is is
6 that the -- determining whether that there was a
7 similar issue in Garlock falls in?

8 A. Correct. This is broken out a little
9 different, probably the phrase before that
10 semicolon --

11 Q. The reliable basis --

12 A. -- in this context, is probably where
13 the Garlock part falls; but yes.

14 Q. Okay. And this "permitted purposes"
15 term is a defined term that I didn't design, but
16 I'm going to go with it.

17 You see that term there which talks
18 about the permitted purposes?

19 A. I do.

20 Q. Okay. My question is this: With
21 respect to the first permitted purpose, the
22 determination of whether prepetition settlements of

1 mesothelioma claims provide a reliable basis for
2 estimating the Debtors' asbestos liability, is it
3 your opinion that a 10 percent sample would not be
4 sufficient?

5 A. For most aspects of that, I'm
6 actually constraining myself to a 10 percent sample
7 already.

8 So for most aspects of that -- like,
9 for example, whether or not all the exposures have
10 been revealed -- there's a comparison of Trust data
11 to underlying Claimant information as collected
12 from the claim files, that's being envisioned as a
13 comparison of claim file sample to the Trust data
14 and would likely be done with approximately 1,200
15 Claimants.

16 So for most of the things that I
17 think would fall under that, the 10 percent sample
18 is already being used, because it would be --
19 that's where the claim file production, which is
20 not already in electronic format so has a different
21 level of expense associated with it, has a
22 different cost-benefit analysis. And so that's the

1 binding constraint on addressing the bulk of what
2 would fall under that first item.

3 Q. Okay. How about with respect to the
4 estimation of the Debtors' asbestos liability -- is
5 it your opinion that a 10 percent sample would not
6 be sufficient for that?

7 A. "Sufficient" is probably not the term
8 I would use.

9 Could I perform an estimate with a
10 10 percent sample if constrained? Yes. That
11 estimate would have a much broader range of
12 uncertainty about it, and so the Court would have
13 less guidance; the Trust would have a higher risk
14 of not reserving enough funds for future claims.

15 So this is a question of precision,
16 right? It's -- is it worth gaining the extra
17 precision for whatever costs are associated with
18 producing those data?

19 It's still feasible to give an
20 opinion, but you're just going to have a lot less
21 precise about that opinion.

22 Q. Let's stop there for a second with

1 respect to precision.

2 Can you quantify how much less
3 precise 10 percent would be versus, say, for
4 example, a 12 percent sample size?

5 A. So there are areas where I was
6 comfortable doing that. You know, I did drop all
7 the dismissed claims from the request. I dropped
8 everything that wasn't a mesothelioma from the
9 request. So there's areas where I felt like I had
10 the information to have confidence that
11 constraining myself to 3 percent of the historical
12 claims that the Debtors have received would still
13 leave me in a position where I hadn't given very
14 much up in terms of precision.

15 Beyond that, it's very hard to
16 quantify until you have the data, because you don't
17 know what you're going to find.

18 So, for example, if you take the
19 Garlock-style question, if it turns out that the
20 assertions of the Plaintiffs' bar is validated and
21 all exposures are being revealed in a
22 contemporaneous manner, that issue just drops out

1 of the estimation. So I wouldn't need a large
2 sample size if it turns out -- for that question if
3 it turns out it never happens.

4 In contrast, if it happens but it
5 only happens in select jurisdictions or for select
6 types of claims, then I need a lot more data,
7 potentially, to address that.

8 So saying exactly how much data you
9 need and the critique that Dr. Wyner said, if I
10 haven't quantified it, that's because it's not
11 actually quantifiable at the moment, but you're
12 taking a big risk for -- you know, on that front.

13 On other aspects, like estimating
14 claims by industry and occupation group, I haven't
15 run it in this particular context, but I know the
16 -- for example, the occupational exposure curve for
17 construction claims goes out about 10 years further
18 as a shift from lots of traditional industrial
19 exposures. So having a good understanding of that
20 can move your estimate 5 or 10 percentage points.

21 And so knowing the breakdown of those
22 in a fulsome manner could easily add, you know, 5

1 or 10 percentage points of precision to the type of
2 estimate you're making, and that would be -- when
3 you're talking hundreds of millions of dollars, 5
4 or 10 percentage points can be a lot of money.

5 You know, I haven't done all that
6 work. I don't have the data, so I don't know
7 exactly what it's going to move it. That's
8 something you can't know until after the fact.

9 Q. Again, I'm trying to understand if
10 there is a way to -- so I think I understand you
11 said it's not quantifiable, but let me just make
12 sure.

13 The precision of a 10 percent versus
14 a 15 percent sample size -- again, this is all
15 before you have the data -- you're not able to
16 quantify the mathematical difference in terms of
17 how precise they would be?

18 A. So there are places where you could
19 be concrete.

20 Q. Okay.

21 A. So if you took, for example, a law
22 firm that has 400 resolved claims and now we take a

1 10 percent sample of 400 paid claims during the
2 sampling period. Now we take a 10 percent sample;
3 we'd expect to get 40. If it turns out that
4 breaking that law firm out and doing analyses by a
5 law firm is important, I now have a sample size of
6 40, which is going to have three-and-a-half times
7 the uncertainty of what I would have had with 400.
8 400 for that law firm probably would be enough; 40
9 is almost assuredly not. And so now, I'm going to
10 introduce a whole bunch of uncertainty.

11 Most of the law firms have well under
12 400, so there's only a handful of law firms that
13 have more than 400 paid claims during this period,
14 so is -- for all but a handful of them, if you
15 needed to do something by law firm, you'd want the
16 totality of the available claims out of the 12,000.

17 There's a couple that have more than
18 4- or 500 claims, but it's only a couple. So
19 that's an example where I know which law firms I'll
20 need to break out and treat separately -- I don't
21 know yet. When we do financial reporting work,
22 it's common to break out 10 or 20 law firms in the

1 analysis to get the most precise estimate of what
2 we would expect in the tort system.

3 So I expect I have to break it out by
4 law firm. I expect that analysis to matter
5 materially to the precision. And if I only get
6 10 percent, I'm going to lose an awful lot of
7 information from there and my work is going to be
8 materially less precise.

9 Q. How much less precise?

10 A. So at the law firm level, you're
11 going to be, again, more than tripling the amount
12 of uncertainty. The baseline level of uncertainty
13 is unknown. You're tripling the uncertainty, but
14 you don't know the baseline until the data comes in
15 and you do the analysis. So that's not answerable;
16 the relative loss is.

17 Q. Okay. Let me turn to the sort of
18 last point there, and then I'll take a break for a
19 couple of minutes.

20 The development and evaluation of
21 Trust distribution procedures for any plan of
22 reorganization confirmed in these cases, the third

1 purpose.

2 Okay?

3 Is a 10 percent sample sufficient for
4 that purpose?

5 A. It may turn out to be sufficient for
6 some occupational groups you'd want to look at and
7 almost assuredly insufficient for others. So,
8 again, it's similar to law firm. Until you've done
9 the work, you don't know how you're going to bundle
10 those groups together, but it's typical to have
11 multiple groups.

12 The smallest groups are frequently
13 the most highly paid claims, so you have a very
14 high per-claim value in a CRP for relatively small
15 number of people fitting it, is the typical fact
16 pattern. So you're expecting the place that the
17 precision matters most to be the place exactly
18 where getting a 10 percent sample instead of all
19 the data is going to cause you the biggest problem
20 because it may only be that 5 percent of the claims
21 are in that group; and so then, instead of having
22 1,200 claims to work with, suddenly I have 60. And

1 60 is not going to be enough for almost any
2 reasonable statistical analysis.

3 In contrast, 600 would be.

4 Q. Is it your testimony here that there
5 is no percentage, in terms of sample size, that
6 would be sufficient?

7 MR. EVERT: I'm just going to
8 object. I don't think that's what he said.
9 I think the problem is with the word
10 "sufficient," but . . .

11 THE WITNESS: I think quite to the
12 opposite --

13 BY MR. KAPLAN:

14 Q. Okay.

15 A. -- I didn't -- I asked for 3 percent
16 of the data to start with.

17 And so the context that's being lost
18 in your questioning is before the Trusts ever
19 received a request, I had already concluded I don't
20 need this for 97 percent of the Claimants to do my
21 work and get to a sufficiently precise estimate.

22 So quite to the contrary, I'm more

1 saying 3 percent's sufficient; .3 is not. Taking
2 away 90 percent of the 3 percent request? No, that
3 wouldn't be sufficient; the 3 percent is.

4 So I did that work up front and
5 constrained the request to only 3 percent of the
6 data.

7 MR. KAPLAN: Okay. All right.
8 Why don't we take five minutes here? Try to
9 actually make it five minutes, if we can. If
10 not, it will be 10.

11 We'll go off the record.

12 --oOo--

13 (Whereupon, a recess was taken from
14 1:59 p.m. EDT to 2:10 p.m. EDT.)

15 --oOo--

16 BY MR. KAPLAN:

17 Q. All right. Dr. Mullin, we're back
18 from the break.

19 Any reason you can't continue?

20 A. No.

21 Q. Okay. Not at least this break.

22 Before we left, you said, a couple

1 different times -- you were talking about you
2 had -- there was a universe of 400,000 claims which
3 you limited to -- which you said was 3 percent of
4 that and then took it down to .3 -- were being
5 asked to take it to .3 percent.

6 Do you remember we were discussing
7 that?

8 A. Yes.

9 Q. Okay. The 400,000 claims that you --
10 that the claims universe was starting with -- are
11 they all mesothelioma claims?

12 A. No.

13 Q. Okay. Approximately how many of the
14 400,000 are mesothelioma claims?

15 A. I don't know the exact count.

16 Q. That's why I asked for an
17 approximation, because I figured you didn't.

18 A. More than 25,000, less than 50-.

19 Q. Okay. And were you asked to do an
20 analysis of nonmesothelioma claims?

21 A. Estimation is currently constrained
22 to mesothelioma claims, but any plan of

1 reorganization will have to address all claims.

2 So for the purposes of the current
3 scope of estimation, mesothelioma claims is what is
4 needed, but eventually you'll have to design a
5 claims resolution process for all claims.

6 Q. Okay. And you also talked about
7 claims -- you eliminated claims that were
8 dismissed, correct?

9 A. Correct.

10 Q. Were you asked to analyze claims that
11 were dismissed?

12 A. Yes.

13 Q. Okay. And how is it that you would
14 be analyzing the claims that were dismissed?

15 A. A fundamental question when valuing
16 claims is which ones will be dismissed and which
17 ones will be paid. So you often compare the
18 characteristics of dismissed claims to paid claims.

19 If you only look at characteristics
20 of paid claims and say these characteristics are
21 associated with payment, it may turn out that those
22 exact same characteristics are also associated with

1 claims that don't get paid. So you -- to figure
2 out what subsets of claims would be paid, dismissed
3 claims are relevant.

4 Q. How about -- where do administrative
5 settlements factor into your analysis?

6 A. So administrative settlements, in
7 many ways, for estimating liability make the
8 problem more difficult because, frequently, in the
9 context of administrative settlements, underlying
10 Defendants and these Debtors, in particular, have
11 not gone through as exhaustive a discovery process,
12 so they contain less information about the
13 characteristics of those claims. And understanding
14 the characteristics of the actual claims is
15 relevant for projecting the number of future
16 claims.

17 Q. Okay. So I think you said just a
18 moment ago that you were approximating somewhere
19 between 25- to 50- mesothelioma claims of the
20 universe of 400.

21 Did I get that right?

22 A. It's thousands on end of all of those

1 numbers, but yes.

2 Q. For -- yes. Let's get that right for
3 the record purposes because, otherwise, one of us
4 will try and use it later.

5 A. Don't know which one that would be.

6 Q. You can bank on that --

7 MR. ANSELM: It depends.

8 BY MR. KAPLAN:

9 Q. -- you can bank on -- no, I'm
10 kidding.

11 Your testimony was, if I'm correct,
12 that of the 400,000 or so claims, you believe that
13 25- to 50,000 are mesothelioma claims?

14 A. Claims, yes. Claimants -- it might
15 be a little lower. I'm -- 80 percent of the Murray
16 claims were dismissed; 50 percent of the Aldrich
17 claims are dismissed. So you need more than double
18 the 12,000 because, over half, you have a dismissal
19 rate even for one that's half and 80 percent for
20 the other. So that's really where I got to the
21 lower number of about 25,000.

22 But it could go -- how much higher

1 than that it goes -- that could go -- I haven't
2 tabulated it. So it's more than 25,000, and I'm
3 confident it's less than 50- but probably closer to
4 25- than 50-.

5 Q. And the subpoenas that brought us all
6 together on this lovely spring day in
7 Washington, D.C. -- they are seeking information
8 about mesothelioma -- mesothelioma claims, correct?

9 A. The request was constrained to 12,000
10 mesothelioma claims; that's correct.

11 Q. Okay. So how is it that we get to
12 the 3 percent, .3 percent when you have -- you're
13 looking for information from 12,000 mesothelioma --
14 mesothelioma Claimants out of 25- to 50,000? That
15 seems like a higher percentage. I'm not a
16 statistician, but . . .

17 A. I answered this question before,
18 which is there's over 400,000 Claimants. I chose
19 not to -- I chose -- I asked -- I did not ask the
20 client to seek information on nonmesothelioma
21 Claimants despite the fact that those could be
22 relevant for designing claims resolution processes

1 or claim -- or claim feasibility. They could still
2 be helpful in terms of the questions that are
3 relevant, but they are not as important as the
4 mesothelioma.

5 So I made a choice to constrain and
6 not ask for anything that wasn't mesothelioma.

7 Q. You would agree with me that if there
8 were, for example, 25,000 mesothelioma Claimants
9 total, 12,000 is just shy of half, right?

10 A. It would be 48 percent if there were
11 25,000. I can do that math on the fly.

12 Q. Thank goodness, because all the
13 lawyers in the room were looking for their iPhones.

14 All right. That's -- that's
15 48 percent.

16 And if it were 50,000, can you do
17 that math on the fly?

18 A. Just multiply by 2, so 24 percent.

19 Q. Excellent.

20 So that's not 3 percent, correct?

21 A. It's more than 3 percent of the
22 mesothelioma claims. I always said it was

1 3 percent of the approximately 400,000. And I've
2 been clear with you the whole time that that was
3 all diseases.

4 So if you switch the denominator, the
5 percentage will change no matter -- and you can
6 switch it to anything else, and it will be a new
7 percentage, too. It's not what I was saying
8 before.

9 I was actually using the universe of
10 claims historically brought against the debts is
11 what's north of 400,000.

12 Q. Right. And we agree that the
13 universe of mesothelioma claims are lower than
14 that, correct?

15 A. Correct. They have claims of people
16 without mesothelioma.

17 Q. Let's turn back -- let's look at
18 Paragraph 15 of your declaration, which is CM 1 for
19 the record purposes.

20 And certainly feel free to look at
21 whatever, but I want to focus in on the last
22 sentence.

1 Whenever you're ready, Doctor, the
2 last sentence in Paragraph 15.

3 A. Yes.

4 Q. Yeah. So what you're talking about
5 here is that -- provide more data that will improve
6 the quality of our estimation and
7 claims forecasting work.

8 And we've talked a lot about this
9 previously.

10 Do you see that?

11 A. I do see that.

12 Q. The number that we're sort of arguing
13 about in the context of this hearing are
14 somewhere -- a number between 1,200 claim files and
15 12,000 claim files, correct? Can we agree on that?

16 A. I think these are electronic records,
17 not claim files. But 1,200 -- 12,000 Claimants --
18 the information on 12,000 Claimants versus the
19 information on 1,200 Claimants.

20 Q. Okay. Let's talk -- let's use
21 Claimants, then, so we're both saying the same
22 thing.

1 We're talking about the difference
2 between 1,200 Claimants and 12,000 Claimants,
3 correct?

4 A. Correct.

5 Q. All right. How much -- can you
6 quantify for me how much getting the, say, 2,400
7 Claimant files would improve the estimation in
8 claims forecasting?

9 A. So -- and what you can do
10 definitively is talk about what's the relative
11 improvement in precision. This is actually a place
12 where Dr. Wyner and I don't disagree. The basic
13 statistical formulas move with the square root of
14 the sample size. So if you quadruple the sample
15 size, you double your precision. You take the
16 square root of the relative movement.

17 So asking to take a 10th of the
18 sample is asking you to slightly more than triple
19 your level of uncertainty in everything you're
20 doing.

21 So we're going to present things to
22 the Court that have three times -- a little bit

1 more than three times the uncertainty about them
2 than if we had the 12,000. We know that's going to
3 be the relative impact.

4 Q. Let's start with the 1,200 out of the
5 12,000.

6 What -- can you quantify the level of
7 precision there?

8 A. Again, it depends on the question.
9 So I don't disagree with what Dr. Wyner put in,
10 where he said, If you're asking the question about
11 a proportion for the totality of the population.
12 He applied that formula correctly.

13 If, on the other hand, you want a
14 proportion for one law firm, and that law firm has
15 300 records that now we only sampled 30, you're
16 going to apply that same formula to a population or
17 a sample of 30 and you're going to have very large
18 confidence intervals. You can apply the same
19 mathematical formula. I don't do those in my head.
20 But you will have confidence intervals that are
21 quite broad that -- in my experience, broad enough
22 that most courts would say, that's not very

1 precise; I don't know if we're going to rely on it.

2 So it's a question of how large of a
3 subpopulation are we able to analyze. And that's,
4 I think, the main difference between what Dr. Wyner
5 was looking at and myself. He's implicitly assumed
6 you always only care about a question for the
7 entire population so you get to use all 1,200
8 files.

9 And as soon as you go to questions
10 that involve a subset of the population -- maybe
11 the liability differs by gender, and you want to
12 look at females separately, but they're only
13 20 percent of the Claimants.

14 Now, if gender matters, I don't have
15 1,200; I have 240. I don't have 12,000. I'm
16 already down to a 20 percent sample, in essence,
17 because only 20 percent of the Claimants are
18 female.

19 So as soon as you start looking at
20 subpopulations of interest, 1,200 within a
21 subpopulation would be sufficient, but there's many
22 subpopulations that would have less than 1,200 if I

1 take a 10 percent sample.

2 Q. Is there a way to design the sample
3 so that it addresses the subpopulations you're
4 interested in?

5 A. You could attempt to mitigate. So
6 you could say I want 1,200 females out of the 2,400
7 or so females, if you were to -- out of the --
8 yeah, 2,400 out of -- if it's about 20 percent, and
9 then 1,200 males. You could make it bigger, and
10 that might address that question.

11 But then if you go to law firm -- if
12 there's a law firm that only has 300 claims --
13 Dr. Wyner and I, I think, agree that 30 claims is
14 not enough. We'll probably learn in his deposition
15 whether he thinks 30 claims is sufficient, but, you
16 know, at 300, we'd probably agree -- I don't want
17 to put words in his mouth, but -- on the
18 statistical formulas, that you'd need all 300.

19 So for any law firm that has less
20 than somewhere usually in the 3- to 500 range, most
21 statisticians are going to say you really need to
22 look at all of them if you want to be able to use

1 that data to make projections about the future.

2 Q. Let's talk about -- turning back to
3 the -- the 10 percent sample that is being
4 discussed here, is there a way to design the sample
5 size to address the stated purposes that you're
6 looking for?

7 A. You can mitigate, right -- you can
8 mitigate the risk. And that is what you do in
9 sample design. Whenever you take a sample, you're
10 always taking a risk that you actually won't have
11 the information you need. It's in -- it's
12 intrinsic to sampling.

13 And the smaller you make the sample,
14 the greater that risk becomes because the ultimate
15 answer is only known after the fact. You don't
16 know ahead of time.

17 And so, in this context, yes, you can
18 design things that mitigate that risk, but you
19 can't eliminate it. And the smaller you make the
20 sample, the greater that risk becomes.

21 Q. And sitting here today, can you give
22 me -- can you quantify what the risk is if the

1 Court were to order just the 10 percent sample, or
2 1,200 Claimants?

3 A. As I said, I can't give you a
4 specific number because that's not known until
5 after you have the data and you do the analysis.

6 That said, in general, if you want to
7 forecast liability, particularly if you want to
8 forecast what Claimants would have received in the
9 tort system, you need to control for law firm and
10 jurisdiction. Those are two things that, when I do
11 financial reporting disclosure work, I will control
12 for. When you're looking at future tort system
13 spend, you control for those two elements.

14 If you start controlling for those
15 two here and you look at a law firm in a given
16 jurisdiction, there's only a couple law firms and
17 jurisdictions that have more than 400 claims. So
18 in those, maybe you could sample, and you would
19 still end up with more than 10,000 claims, because
20 for the vast majority, this -- you're already at a
21 size where you wish you had more data.

22 Q. Maybe I just missed it.

1 I guess your testimony -- am I
2 correct your testimony is you cannot quantify the
3 risk sitting here today, put a number on it? If
4 the sample -- what I mean -- by "quantify," I mean
5 it's only 30 percent reliable or 40 percent
6 reliable or 50 percent reliable.

7 A. So, ultimately, the Court, in my
8 experience, is who tells me whether it's reliable
9 or not. What I tell the Court is what's the
10 uncertainty of the estimate.

11 And so every time you tell me to
12 triple my uncertainty, I get nervous. If three
13 different inputs all tell me to triple my
14 uncertainty -- this is one input into estimation.
15 Now the uncertainty is 27 times as big.

16 Going into a court where I might have
17 been able to say, Here's an estimate plus or minus
18 30 million, you tell me to triple, and now I have
19 to say, Here's an estimate plus or minus 90. But I
20 have another input that also adds uncertainty of
21 threefold. Now, instead of plus or minus 90, it's
22 plus or minus 270.

1 Each uncertainty interacts with the
2 other ones, and they -- it's more multiplicative in
3 nature. So it's not that this is the only
4 parameter that matters and creates uncertainty;
5 there are others. And as you fold them, they start
6 to get larger.

7 So this is a place where sampling at
8 10 percent will likely approximately triple the
9 uncertainty for key inputs into the model.
10 Tripling that uncertainty means I'm going to triple
11 my confidence with the uncertainty at the end.

12 And I don't see the costs as
13 justifying that, given the benefit of being able to
14 triple my precision and the guidance I give a
15 court, when, in the best case, a scenario is
16 already going to be you have tens of millions of
17 uncertainty; so now you're going to triple that.
18 That's adding an awful lot of uncertainty -- tens
19 of millions at least of uncertainty to the
20 estimate.

21 So you said "quantify." Going to the
22 10 percent sample will add tens of millions of

1 uncertainty, maybe 100 million. I don't know. I
2 haven't done that work. But it will be at least in
3 the tens of millions based on historical
4 experience.

5 Q. When you say "uncertainty," can you
6 explain what it is you mean there? There's
7 factors -- is that factors or variables you can't
8 account for? Or what is that?

9 A. I would have less data to be able to
10 refine an estimate. So that future estimate will
11 have greater statistical -- that will add
12 statistical uncertainty on top of the other types
13 of uncertainty that already exist. And so it's
14 going to expand any level of confidence you have in
15 an estimate; "expand" in the sense of degrade your
16 confidence, expand the uncertainty.

17 Q. Let's look at Paragraph 16, which
18 is -- again, I'm focusing on the end of it, which
19 is where you say, This would enable us to quantify
20 the proportion of alternative exposure disclosed to
21 the Debtors at the time of settlement.

22 You see that?

1 A. I do.

2 Q. Is it your testimony that the
3 1,200-Claimant sample is not sufficient for that
4 purpose?

5 A. No.

6 Q. It is sufficient for that purpose?

7 A. I'm actually -- the sample of claim
8 files were going to juxtapose that with this
9 currently approximately 1,200. So that compares --
10 that requires the comparison of the two. So that's
11 already being envisioned for that specific question
12 of only looking at 1,200.

13 And that's really motivated by the
14 cost of producing and reviewing claim files,
15 because they're not already in electronic format.
16 If all that information was in electronic format,
17 I'd use more data than that, but it's not, so the
18 cost is materially higher.

19 Q. Paragraph 17, you talk about The
20 variations in disclosure patterns would allow us to
21 model the impact of the partial information on
22 settlement amounts.

1 Do you see that, Doctor?

2 A. I do.

3 Q. Is it your testimony that a
4 10 percent sample of 1,200 Claimants wouldn't be
5 sufficient for that purpose?

6 A. It may be. And, initially, that's
7 what I'm going to try to do it with because, again,
8 I'm only going to have that quantified for the ones
9 that are contrasted with claim files.

10 If you learn, for example -- a
11 complete hypothetical -- say Claimants represented
12 by counsel -- or counsel represented by 25- -- let
13 me get it right. I'll start that over.

14 Let's say there's a subset of law
15 firms that represent 25 percent of the historical
16 Claimants, where a small fraction of the exposures
17 are being disclosed, but for the law firms that
18 represent the other 75 percent of Claimants, almost
19 everything's been disclosed.

20 I may not have enough data for that
21 25 percent, but then I would do a targeted
22 follow-up of -- to try to fill that information in,

1 and -- as opposed to asking for it over the whole
2 universe.

3 So I really view this as a two-step
4 process: the first, which is really Paragraph 16,
5 where, if at all, is full disclosure not occurring,
6 which gets -- so for which claims is the --
7 Paragraph 17 even a relevant question.

8 And then not knowing the answer to
9 that, I view this as -- I may be able to do it with
10 1,200. I may need to supplement at some point to
11 get precision.

12 Q. Okay. Short of a -- I think you
13 referred to it as a "census" or a "population,"
14 when you talk about all the claims.

15 Correct? That's what you're
16 referring to?

17 You said in your report a couple
18 times, you know, a census -- a population-level
19 census analysis.

20 That would be all 12,000, correct?

21 A. Correct.

22 Q. Okay. Is there a number -- you know,

1 as you said a moment ago, it's the judge who's
2 going to tell you what ultimately is reliable, and
3 I would probably agree with that statement to the
4 extent that I'm sure you're going to give the judge
5 an opinion on what number he should come out at.

6 Is there some number short of 12,000
7 that you are comfortable opining to the judge would
8 be sufficiently reliable for the purposes we
9 discussed?

10 A. As I said, I went about this really
11 asking that question ex ante and how could I
12 minimize the size of the request counsel would make
13 on my behalf for data. And I already -- the things
14 that I was comfortable eliminating, I've
15 eliminated, which got me down to the 12,000. And
16 so I've gone through that process already.

17 So I'm not at the point where I'd say
18 I'm comfortable making it smaller. You can do all
19 the analysis with a sample of 1,200; you can do all
20 the analyses with a sample of 6,000. You'll just
21 have less precision.

22 Whether that precision turns out to

1 be binding on the ultimate reliability in the
2 Court's eyes, one, it's a question for the Court;
3 but, two, it's where those numbers work out at the
4 end.

5 If you could give an estimate that
6 was plus or minus, you know, a dollar and it became
7 plus or minus \$3, the Court would probably be fine
8 with that; but if it was plus or minus 50 million,
9 it became plus or minus 150 million, the Court may
10 really not be okay with that. That may be too
11 broad of a range.

12 But that's where, when you say
13 "trip" -- when I think of it as tripling my
14 uncertainty, until you've done the work, I don't
15 know if I'm going -- no, I'm not going from \$1 to
16 \$3; I can't be that precise -- but I don't know if
17 I'm going from 50 to 150 million or if I'm going
18 from 20 million to 60 million. I don't know the
19 answer to those things until I've done the work.

20 Q. Again, I want to focus you on just
21 the mesothelioma claims, because that's what --
22 what we're talking about here is -- your testimony

1 is that you are not prepared to offer -- to suggest
2 that any number short of 12,000 is sufficient,
3 correct?

4 MR. EVERT: Object to the form of
5 the question.

6 THE WITNESS: Again, "sufficient"
7 I -- I don't think is the right term, which
8 is why I struggle with answering that
9 question. I think you are taking unnecessary
10 risks relative to the cost of data production
11 to reduce it further. And I would advise
12 against it.

13 BY MR. KAPLAN:

14 Q. Okay. I'm using "sufficient" because
15 I believe the Judge's words were "doesn't work."

16 So let me ask it this way, which is:
17 Is it your testimony that only the 12,000 Claimants
18 will work for the Debtors' purposes?

19 A. I'll try this a different way, see if
20 we can get on the same page.

21 No statistician can tell you the
22 sample size you need before the data is produced in

1 a discovery exercise like this to say the number of
2 claims at which it will work. What happens is the
3 more claims you get, the higher the probability
4 that it will work becomes.

5 So it's not -- whether you -- there's
6 almost no difference, right, if you give 12,000
7 claims or 11,999. The odds that that 12,000th
8 claim was the linchpin to take you from working to
9 not working is almost zero, right? But at the same
10 time, no one can tell if you go from 12,000 to
11 11,000, that may be what swings it. Going from 11
12 to 10 may be what does.

13 But as you shrink, the odds that the
14 analysis you would want to perform to give the
15 Court better guidance would become unfeasible. And
16 it's a statistical probability. It's not a known
17 thing until you have the data and it's after the
18 fact.

19 It's like default risk in that sense.
20 As somebody becomes riskier, their odds of default
21 goes up. But it doesn't -- you don't know yet if
22 they're going to default or not; you just know the

1 odds are up.

2 As you shrink the sample size, the
3 odds that you won't be able to give sufficient
4 guidance rise.

5 Q. Let me just see if we can get on the
6 same page -- I appreciate that -- which is is can
7 you estimate and forecast based on 1,200 Claimants?

8 A. It is feasible to do all the math,
9 and you will have a broader confidence interval, so
10 you will give up precision. But you -- you will
11 get an estimate with a substantially broader
12 confidence interval of degree of uncertainty about
13 that estimate.

14 Q. Can you quantify the proportion of
15 alternative exposures disclosed to the Debtors at
16 the time of settlement with the 1,200 Claimants?

17 A. As we said before, that's what I'm
18 trying to do, is I'm using the 1,200 for which --
19 the claim files. That sample isn't finalized yet,
20 but that's the size that's being discussed of the
21 claims result for positive payment -- would be
22 using those 1,200 and comparing those to the Trust

1 data to do that.

2 My intent is to do that. I am
3 optimistic that will work. I can't guarantee it.
4 And if you needed to supplement, you may, for
5 certain law firms, need to supplement additional
6 claim files, but you would already have the Trust
7 data necessary.

8 Q. Can you create the model you discuss
9 in Paragraph 17 and the impact of partial
10 information on settlement amounts with the 1,200
11 Claimants?

12 A. Not as a materially higher
13 probability of not being feasible with the 1,200
14 than the analysis in Paragraph 16, but it depends
15 on how large of a subpopulation actually is failing
16 to disclose all of the exposures contemporaneously.

17 It's really going to hinge on the
18 answer to a question that is unknown until we
19 observe the Trust data.

20 Q. So let me just ask it this way, which
21 is easiest: I know you're talking about the
22 reliability of the model. Can you create the model

1 you're envisioning with the 1,200 Claimants?

2 A. You can do it mathematically. Will
3 it result in a level of precision -- I'll phrase it
4 differently.

5 I can always do the math, but if the
6 precision is lacking sufficiently, it should still
7 be thrown out on Daubert because you don't have
8 sufficient guidance. There are standards where you
9 can't just say, Here's an estimate; I have no idea
10 how accurate it is. You actually need to give
11 sufficient precision for someone to rely on it.

12 The Court ultimately decides what
13 that level of precision is; I don't. But I can do
14 the math. It doesn't mean that the math will
15 produce a number that the Court finds useful.

16 So the model can mechanically work.
17 But will it provide sufficient guidance to be
18 deemed reliable by the Court? The odds that the
19 answer to that is no go up as you shrink the sample
20 size.

21 Q. Okay. Turn to Paragraph 19 of your
22 declaration, if we could. You talk about cost and

1 benefits of sampling, which is in a -- I have
2 some -- just specific questions for you here, which
3 is, let's start with, What kind of sample is it
4 that's being proposed here?

5 Assuming that the 1,200 would be --
6 is how the Court -- what they stick with, what kind
7 of sample is being proposed?

8 A. Stratified random sampling.

9 Q. Is there a different type of sample
10 that would be more or less reliable -- or let's
11 just stick with more reliable.

12 A. So ex post, again, once you know the
13 answer, you can always go back and design a better
14 sample than the one you did ex ante because you
15 have more information.

16 So when you design a sample, you use
17 historical experience to guide you on where there's
18 likely to be more information or what types of
19 Claimants are more important to the questions that
20 you're asking, so the stratification is imposing
21 certain assumptions. If those assumptions turn out
22 to be directionally correct, then the sample

1 stratifying will be more efficient than taking a
2 simple random sample.

3 There's really good reasons to
4 believe that, for example, oversampling the
5 high-value claims will lead to more precision. It
6 could turn out not to be true, but in almost every
7 case like this in the past, almost every case I've
8 ever done that's involved a mass tort, that
9 produces greater efficiency than not doing it.

10 Q. Okay. Let's skip ahead a
11 couple minutes here, and I want to talk to you a
12 little bit about the Court's second question, which
13 is the -- why sampling wouldn't reduce the risk of
14 even just human error, missing some of the PII
15 being disclosed.

16 Where in your declaration is it that
17 you're discussing that?

18 MR. EVERT: While he's looking,
19 Andrew and Michael, I was going to say
20 earlier, the declaration sort of says what it
21 says, so I'd object. It's something that
22 limits the paragraph he picks, but I hear --

1 I hear the fair point of your question.

2 (Whereupon, the witness reviews the
3 material provided.)

4 THE WITNESS: The bulk of that
5 information expands Paragraphs 23 to
6 Paragraph 30.

7 BY MR. KAPLAN:

8 Q. And these are the paragraphs that
9 talk about the process in place to scrub the PII,
10 correct, as well as the base and what's the ability
11 to maintain that information, or are we looking at
12 different ones?

13 A. That is part of the content.

14 Q. Outside of what is contained in --
15 and, again, I certainly appreciate counsel's
16 point -- outside of what is contained in this -- in
17 these paragraphs, are you going to offer any other
18 opinion as to why the proposed 10 percent sample,
19 or 1,200 Claimants, doesn't reduce the risk of PII
20 being disclosed?

21 A. So for the Claimants themselves -- I
22 mean, I don't know -- I don't think this is

1 inconsistent with what's in here in any way, but
2 for the Claimants themselves, Bates White already
3 possesses the PII. If we don't have the PII, it's
4 not in the request. It's only people where we know
5 the name and we know the Social Security number.

6 We're never asking the Trust to send
7 us PII. So the only PII that's at risk that would
8 be incremental would be information that
9 Bates White actually doesn't want. It's
10 information that was in an exposure field that, as
11 I understand it, the Delaware facility is going to
12 take a pass at redacting that. Bates White has its
13 own obligation to redact that. So it has to be in
14 the field to start with, failed to get redacted by
15 the Delaware facility, failed to get redacted by
16 Bates White, and then have a data breach.

17 So if we had 12,000 Claimants, if
18 5 percent of the Claimants had a field with some
19 additional PII, 99 percent of it gets redacted by
20 Delaware, 99 percent of what they gets missed gets
21 redacted by Bates White, you're talking .01
22 incremental piece of PII, when you would have

1 already 12,000 people's PII in a data breach.

2 So going from 12,000 people to
3 12,001, I don't want to be trivial about anybody's
4 PII, but it's one more out of 12,000. So when you
5 say, is this materially increasing the risk that
6 already exists, going from 12,000 to 12,001, that's
7 not a particularly material increase.

8 So this process, this specter that's
9 being put out there for this, is so remote that,
10 no, I don't put a lot of weight on it, because by
11 the time you go through two levels of redaction and
12 you need a data breach on top of it, you know, this
13 is not going to produce a material number of people
14 relative to the PII that is already out there.

15 Q. When you say "out there," you mean
16 already in Bates and White's system?

17 A. Well, it's in Bates White; it's in
18 the Debtors', it's in Verus; it's in the Delaware
19 facility --

20 Q. Sure.

21 A. -- it's with, you know, Ankara, if
22 they downloaded the claims database; it's with LAS.

1 I mean, all the various parties working in the case
2 who have the Debtors' database or have the same
3 Claimants in a different context also all have that
4 PII, so all of these parties, in general, possess
5 the PII to start with. You're not fundamentally
6 changing that risk.

7 Q. You talked a moment ago about a data
8 breach.

9 Are Bates and White's systems
10 infallible?

11 A. I don't think there's any system
12 that's infallible.

13 Q. Okay. Are you aware of whether
14 Bates and White's systems have ever been breached
15 prior to today?

16 A. They have not.

17 Q. In any form at all? No hacks? No
18 phishing? No nothing?

19 I'm not talking about the Claimant
20 files.

21 A. So my technical services people will
22 tell me people attempt to breach our systems

1 multiple times every day. That's probably the
2 training that all of you get, too, right?

3 We've never had a data loss.

4 A breach, has somebody ever clicked
5 on a link somewhere, but there's so many layers of
6 security, it doesn't go anywhere.

7 We've never had a data loss.

8 You know, what you call a "breach,"
9 depending on how you define that, every single
10 entity in the world has. If you say, Did any of
11 your employees ever click on a false link, then
12 every organization has. So -- but did it result in
13 anything?

14 Bates White has never had a data
15 loss.

16 Q. Okay. And when you say -- I want to
17 make sure that we're talking about the same thing
18 because this would be a scenario where we -- we
19 would talk past each other.

20 Are you aware of proprietary
21 information on Bates White's system ever being
22 accessed by an external actor?

1 A. No.

2 Q. Okay. Your testimony is not that
3 Bates and White's -- Bates and White cannot be
4 hacked, correct?

5 A. As I said, I don't think there's any
6 system out there --

7 Q. Right.

8 A. -- that it's impossible for a
9 sufficiently motivated party to potentially hack.

10 MR. EVERT: If the Russian
11 government wants your data, they can get your
12 data.

13 MR. KAPLAN: I'm fairly certain
14 they have mine, so I'm okay with it already,
15 just to be clear.

16 MR. EVERT: We heard that, but --
17 (Laughter.)

18 MR. KAPLAN: Yeah. It's because
19 I'm a Philadelphia fan; they have everyone's.

20 BY MR. KAPLAN:

21 Q. You agree with me, Doctor, that you
22 can't be 100 percent certain that the data will not

1 be improperly accessed, correct?

2 A. I agree. I don't think anybody in
3 any -- I mean, I don't think the data sitting at
4 Verus or the Delaware facility can be 100 percent
5 certain. There's no such system.

6 Q. Thankfully, they're not sitting here
7 for your deposition today, so I'll ask them another
8 time, maybe.

9 All right. Let's turn now, as
10 promised much earlier, to Dr. Wyner's report.

11 MR. KAPLAN: And we'll mark this
12 as -- I think we're up to 3, correct -- to 3.

13 I was able to keep track of that,
14 look at that.

15 --oOo--

16 (CM Deposition Exhibit Number 3,
17 Expert Report of Abraham J. Wyner,
18 Ph.D., marked for identification, as
19 of this date.)

20 --oOo--

21 MR. KAPLAN: I don't know how many
22 I printed so . . .

1 (Sotto voce discussion.)

2 BY MR. KAPLAN:

3 Q. Given that -- you've seen this
4 before, correct, Dr. Mullin?

5 A. Correct.

6 Q. I believe you said you were
7 discussing it with your team in advance of today.
8 Which part or parts of Dr. Wyner's
9 opinion is it that you take issue with?

10 MR. EVERT: I object to the form
11 of the question.

12 Is that really fair?

13 Do you want to walk him through
14 each paragraph, or do you want to --

15 MR. KAPLAN: I just want to know
16 what he disagrees with. You told me he's not
17 going to produce a rebuttal report, so I'm
18 not going to get an opportunity to hear -- to
19 get it on a line-by-line. I want to know
20 what he's got an issue with here.

21 MR. EVERT: Do you think you can
22 do that?

1 THE WITNESS: I'm going to be
2 talking for a while. That's a very broad,
3 open question. I'm happy to answer it, but
4 I'm going to ask you not to ask follow-up
5 questions until I finish, because I need to
6 give a complete answer if we're going to do
7 that. I don't want to get segued halfway
8 through by a follow-up and then be told that,
9 no, you didn't finish and so that's it.

10 BY MR. KAPLAN:

11 Q. You have my absolute word. I'm ready
12 for you to tell me what it is you have an issue
13 with.

14 A. Start on Paragraph 6.

15 Q. Okay.

16 A. He says, As described in detail
17 below, it is my opinion that a random sample -- a
18 random 10 percent sample of 1,200 Claimants would
19 fulfill all of the Debtors' reasonable needs.

20 He never defines "reasonable needs."
21 He never defines "all." So he's made this blanket
22 statement with a universal qualifier. And at no

1 point he -- does he -- he covers two specific
2 questions in his report, two. He entirely ignores
3 the question that the 90 percent of the data that
4 the Trusts are requesting that not get produced
5 would be used. He only addresses two questions,
6 where my intent was to only use the 10 percent of
7 the data that would be produced in the sample.

8 So if -- and the critique is, On the
9 questions where Dr. Mullin's already only going to
10 use a 10 percent sample, a 10 percent sample
11 suffices; ergo, it suffices for everything.

12 The latter doesn't follow. He
13 addressed the two places where I'm already
14 constraining myself to a 10 percent sample and
15 saying, There, it's enough.

16 He doesn't talk anything outside of
17 that scope anywhere. Yet it doesn't even define
18 what those other reasonable uses would be, yet has
19 this universal statement with no backing anywhere
20 in the report.

21 So at its highest level, you can put
22 almost every complaint I have under that category.

1 I don't think he has any idea how I'm going to use
2 the data. I don't know how he could.

3 I'm going to go forward and do an
4 estimation report. I've given broad categories of
5 how I would use that. And he's made a statement
6 that "all reasonable" ways.

7 As we talked through earlier, I
8 expect to have to condition things on law firm and
9 jurisdiction because that's frequently very
10 important.

11 It may turn out not to be here, but
12 it's much more likely that it would be than not.
13 And he has no opinions about what happens as soon
14 as you need to address the subpopulation. All of
15 his opinions are assuming I'm only looking at the
16 entire universe at once, that he's disclosed here
17 at least.

18 And so I expect to have to look at
19 subpopulations. Jurisdiction, law firm would be a
20 key one. Gender could easily come up as one, you
21 know, and industry and occupational groups. I
22 expect to use that data to put people into

1 clustered groups that behave similarly and then do
2 extrapolations based on each of those subgroups.

3 So he has entirely ignored what
4 happens when only a subset of the sample is
5 applicable to the question of interest.

6 And if you look at simple tabulations
7 in the data, like paid mesothelioma claims by law
8 firm, paid mesothelioma claims by gender, paid
9 mesothelioma claims by jurisdiction, you see really
10 quickly that if you sample, you're not going to
11 have enough data to answer those questions.

12 You know, so at a big level, that's
13 the overarching problem with his whole report.

14 He very much mischaracterizes the
15 testimony of my partner, Dr. Jorge Gallardo-Garcia.
16 He asserts in Paragraph 8 that Dr. Gallardo-Garcia
17 clearly states that sampling is sufficient.

18 He does not state that. If you go
19 read his report, he makes it clear that there's a
20 court order that constrains him to 10 percent, and
21 within that, he's going to design the most
22 sufficient sample -- the most efficient sample he

1 can -- but he actually is explicit that that's not
2 what he believes is best, but he's got an external
3 constraint forcing him.

4 To that point, I speak with
5 Dr. Gallardo-Garcia on a regular basis. His office
6 is a few doors from mine. I know that is not his
7 opinion. So I don't know how he's reaching that
8 when you read that report in totality, but it is
9 explicitly wrong.

10 There's an irony. Well, he complains
11 that At no point does Dr. Mullin quantify the
12 potential loss of accuracy.

13 I think he very much knows that is an
14 exercise you can't do ex ante when the very data
15 you're seeking is fundamental to what
16 subpopulations you need to analyze later. That's
17 an impossibility.

18 The irony is, he reaches a conclusion
19 that the 10 percent sample is enough in a
20 cost-benefit without ever quantifying the cost. So
21 if he's going to complain that you have to quantify
22 an element of it and he's reaching the opposite

1 conclusion without ever quantifying the loss, the
2 cost, and his -- one of his clients has done this
3 exercise, so one of his clients has already
4 redacted information for a different request.

5 So instead of all of us sitting here
6 in the dark and saying, How often does this PII
7 show up in these exposure fields, there's one --
8 one of his clients knows the answer to that in the
9 context of DPMP. He either didn't ask him for
10 that, they didn't disclose it to him, but he could
11 know, oh, that occurs in one in a thousand records,
12 one in 100 records, one in two records, which could
13 greatly inform this question.

14 He could also ask them, when they did
15 their redaction process and their quality control
16 on it, did they think they eliminated half of them?
17 Ninety-five percent? Ninety-nine percent? So how
18 many do you think slipped through?

19 He's silent even though his client
20 actually has done this exercise once and has the
21 data. So the person who could actually quantify
22 the cost whose client has access to know exactly

1 how many records have this information and
2 presumably has done quality control on that process
3 to know what their rate of eliminating it is, he
4 stays silent on, you know, that information. Yet
5 he concludes at the same time, even though his
6 client has this data, that the cost-benefit
7 analysis isn't justified.

8 So if we had that information, you
9 would be able to be much more precise. I gave a
10 hypothetical; 5 percent of the fields have it;
11 99 percent get cleaned up by the facility;
12 99 percent get cleaned up of what was missed by
13 Bates White to get to 0 or 1.

14 The first two numbers in that, they
15 actually know. So those are knowable. So are we
16 really looking at a handful of PII coming through?
17 Thousands? I hope not thousands of records, given
18 they went through that process. But he doesn't
19 access any of that even though his client has it.

20 As an expert, if my client has
21 information directly on point and doesn't share it
22 with me -- you should ask for it; hopefully, they

1 volunteer it. So I'm -- that part confuses me as
2 to why that's not in his report, given he has
3 access. As I said, there's an irony because he has
4 the ability to quantify and stays silent.

5 Going back to Paragraph 9, the second
6 sentence, Such a sample has already been discussed
7 in the Bestwall declaration, which does not
8 identify any attribute of the population that
9 cannot be accurately studied with a sample.

10 The purpose of that declaration is
11 not to answer that question. The purpose of that
12 declaration is to say, What's the most efficient
13 sample we can get, given a third-party constraint
14 that it's at 10 percent?

15 It wasn't a declaration intending to
16 say, And these are the things that we can't do
17 accurately with that.

18 So its absence drawing inference from
19 that, when that's not the topic of the declaration,
20 is misleading.

21 So Paragraph 10, I think I've largely
22 already covered.

1 And his NFL analogy, in 11, is really
2 quite misleading. We're talking about a tenfold
3 difference in sample size, and he's talking about a
4 .0 -- .01 difference in inches of height.

5 So the right analogy there is the one
6 I gave you before, where if you said -- if you told
7 me I can't have 12,000 claims, I get 11,999, we
8 would probably just all go home. Right? That's
9 the analogy to that. It's not -- you know, the
10 proper analogy here would be more like, Oh, you
11 have one that's 6-foot, 1 inches tall, and the
12 other is 5'4". You're talking about a very large
13 difference, a tenfold difference, not a very small
14 difference. So while the -- I think the proper
15 conclusion from that is actually in the exact
16 opposite direction.

17 Paragraph 12 suffers the same flaw of
18 him saying, for the purposes described by
19 Dr. Mullin and the Debtors' reasonable needs.

20 He never says what that's meant to
21 cover. He doesn't define "reasonable needs." I
22 don't know how, you know -- without specifying what

1 he's putting in that bucket, how he can reach that
2 conclusion.

3 His premise in Paragraph 13 is
4 actually incorrect. He -- we actually do have a
5 potential problem of sampling bias. We're using
6 the historical Claimants to draw inferences about
7 future Claimants. The demographics of Claimants is
8 not constant through time. And so if you take --
9 if you erroneously conclude that I'm going to have
10 the same ratio of men to women, the same age
11 distribution over the next 30 years of Claimants as
12 I have in the last 10, you'll be very wrong. Those
13 things shift through time.

14 So we have a historical sample where
15 we're not actually trying to value the historical
16 claims; we're trying to use information about the
17 historical Claimants to draw inferences about
18 future claims.

19 So while the group I have to sample
20 is fixed, that group has different characteristics
21 than the future claims, and I need to control for
22 those differences or I will have bias.

1 So it's actually very much in the
2 opposite direction of his conclusion. If he
3 understood that, it reverses the point from what he
4 is making.

5 That same flaw in logic really
6 applies throughout.

7 So while I don't disagree with any of
8 his math on Paragraphs 15 through 20, he bases it
9 all on examples where the undisclosed alternative
10 exposures is either 5 percent of what was available
11 or 10 percent, and then he ends up concluding that
12 this will, in percentage points, create a really
13 small confidence interval amount. If he just
14 assumed that it never happened, then he would say
15 it's 0 and his confidence interval would be, I know
16 that with virtual certainty and it's 0.

17 So when you push a probability
18 towards 0 or 1, you actually minimize the impact of
19 these factors.

20 So if you ran the exact same math but
21 it turned out there's a subpopulation where half of
22 the alternative exposures are not being disclosed,

1 it's not in Paragraph 20, 1.5 percentage points any
2 longer. It gets dramatically bigger, and the
3 difference is about fivefold. So you would be
4 saying, instead of 1.5 percent, 7.5 percent.

5 So he's chosen an example that skews
6 things low in the direction of the outcome that his
7 client desires as opposed to choosing the example
8 that's more -- that could go in the other
9 direction, but it's not the -- you know, so this
10 idea that, in practice, however, the standard error
11 for a simple sample of 1,200 observations will
12 usually be a lot smaller than 1.5 percent,
13 that's -- you know, you can get to certain things
14 -- if you're not looking at a subpopulation, you're
15 looking at certain scenarios, that may be the
16 outcome, but you may have a very large confidence
17 interval if you end up with there's a subpopulation
18 of interest and you need to get it for that.

19 And so his mathematical formulas are
20 right, but he's really assuming throughout you only
21 care about the whole population, which, of course,
22 gives you no ability to change for changing

1 demographic characteristics because you have an
2 estimate for one mix of demographics only, and you
3 really need the estimates for each of the
4 demographic groups to know how to remix that going
5 forward to match the future population. And he's
6 completely ignoring that fact through this whole
7 process.

8 So Paragraph 24, he gets into
9 estimating impact of potential nondisclosure of
10 alternative exposures. His first sentence, Because
11 the proportion of nondisclosed Claimants has a very
12 small standard error, it follows, if all the
13 settlements were the same size, that the standard
14 error of the overall average impact would also be
15 small.

16 Not only does it follow that; under
17 that assumption, the impact is zero and you don't
18 need to estimate anything. So if you assume the
19 problem away, because everybody gets the same
20 settlement amount whether they disclosed or not --
21 so he's assumed there's no impact -- if we assume
22 that it can't happen and has no impact, then we are

1 very precise when under that assumption, our
2 estimate is no impact.

3 So that -- it's a complete
4 misrepresentation of the real world. He's
5 literally assumed it has no impact. It's like
6 assuming it never occurs and then estimating that
7 you don't need a lot of data for things that never
8 occurred to get -- get the probabilities very low.

9 So he's really in a corner solution
10 that makes no sense. If settlements are not the
11 same size, so now we're, at least, in the relevant
12 framework, a stratified sample can be drawn that
13 over-samples the claims with the highest variation.

14 You really can't. This, again, shows
15 a fundamental misunderstanding.

16 What we're trying to get is the
17 connection between the amount of disclosed
18 exposures, which is unknown at the time of
19 designing the sample. So he's saying, Let's look
20 at a parameter that we don't know right now and
21 stratify on it.

22 This is not a classic statistics

1 exercise. It also has discovery in it.

2 You're learning about one of these
3 variables. You can't stratify on the variable that
4 you don't know yet. And that's what he's telling
5 me to do in this paragraph, is to stratify on a
6 variable that I won't know until after I get the
7 data in the sample.

8 So that's actually completely
9 infeasible, but it shows a fundamental lack of
10 understanding that this is a discovery exercise and
11 I don't know that. If I already knew it, I
12 wouldn't need a sample, right? I would already
13 have the information.

14 So that's a place that it's just
15 disconnected from the exercise that's going on.
16 He's suggesting something that's completely
17 infeasible.

18 There is no finite sample correction
19 factor, which he has in Paragraph 14, because we
20 aren't trying to estimate the impact for the
21 historical Claimants. We're trying to use the
22 historical Claimants to talk about pending and

1 future claims. So we are always estimating.

2 The finite sample correction factor
3 applies to people you want to estimate that you
4 don't need to estimate now because the sample told
5 you the answer for those people.

6 We don't have any of those. These
7 are all historical claims.

8 We're not estimating what they get
9 paid. They've been paid. They've been released.
10 So, again, it shows that fundamental
11 misunderstanding of what we're actually trying to
12 accomplish.

13 If you don't understand how the data
14 is being used, you don't know how to design the
15 sample, you don't know what sample size you need,
16 and he's just repeatedly displaying his ignorance
17 as to how the data are actually being used in
18 estimations.

19 And, you know, it's things like this
20 that are huge red flags that he doesn't actually
21 know the facts of the situation, so he's applying
22 the wrong statistical tools to the question.

1 Paragraph 25 is just wrong. He says,
2 Beyond the two parameters discussed above,
3 Dr. Mullin doesn't specify precisely or intimate at
4 any other parameter of -- parameters of interest.

5 We can go back, where -- this is
6 where he has entirely ignored Paragraph 15 of my
7 report. He chose to do an example for
8 Paragraph 16, an example for Paragraph 17. But
9 Paragraph 16, where you're really talking about the
10 need to control maybe for industry and occupational
11 groups, the need -- all the uses beyond is where
12 all the composure is revealed, he's ignored that
13 entire discussion in my report.

14 And, apparently, according to him, I
15 didn't even intimate any other parameters of
16 interest. So he seems to have skipped certain
17 paragraphs in the reading of my report to reach
18 that conclusion.

19 He talks, in Paragraph 26, about
20 anecdotes. In my experience, it's common for both
21 sides in a litigation to use anecdotes. They're
22 not necessarily statistically representative, but

1 developing anecdotes is frequently done by both
2 defendants and plaintiffs in cases. So I don't
3 know if he's trying to insinuate that's bad or
4 good. It's a little unclear. But he at least
5 acknowledges that, to the degree anecdotes by
6 either side are important, a larger sample would
7 enable that better.

8 So it seems to be the one place where
9 he acknowledges that that's something where a
10 larger sample may be worthwhile.

11 So when we get into Paragraph 27,
12 again, he doesn't define "reasonable needs." He
13 doesn't appear to understand how it's being used.
14 So I don't know what he actually knows, but based
15 on what's -- he's written, you know, he makes
16 statements that are inconsistent with how the data
17 would be used. So I don't know, without him
18 stating what he believes the reasonable needs
19 are -- either his list is incomplete or his
20 conclusion is wrong.

21 It's wrong either way, but whether
22 it's because he has an incomplete list of the

1 reasonable needs or he actually does know the full
2 list, hasn't specified them, then the data is
3 important for that list.

4 So Paragraph 28 makes me suspicious
5 that Dr. Wyner has not spent much time in a
6 litigation environment. The analytical burden of
7 sampling, I do discuss. When you sample in a
8 discovery process, so you learn more information
9 after having seen it, it is not uncommon for
10 experts to assert some form of ex post
11 stratification on the data to improve the
12 efficiency of an extrapolation.

13 There is lots of room for experts to
14 disagree about that. And I have been in many cases
15 where months, if not more, have been spent on
16 parties litigating over what is the proper way to
17 extrapolate.

18 If you're in the pure ivory tower
19 academic, prespecified population and I'm not
20 extrapolating outside of that population but I'm
21 going right back to the population I sampled from,
22 those problems don't exist, and then it's

1 relatively straightforward mathematically.

2 But in a litigation setting, where
3 you need to control for differences going forward,
4 this can become a very expensive and drawn-out
5 process, and so steps to minimize that, I would
6 advise clients on, because it -- otherwise, you can
7 get into a lot of gamesmanship in that phase.

8 So Paragraph 29, I agree that if you
9 used statistical calculations that are required to
10 compete with the standard errors is not
11 particularly burdensome, that's correct, if all the
12 experts agree on which methodology to use to do it
13 in the first place. So it's a methodological
14 fight, not a computational fight. The computations
15 are straightforward. The methodology is not
16 necessarily straightforward.

17 He is correct -- and he nods a little
18 bit to this in the next sentence -- data analysis
19 on the full data set. He says, It's not
20 substantial -- substantively easier, especially
21 since there will be statistical challenges of all
22 types that will arise, sampling or no sampling.

1 It's an interesting sentence because
2 most of his opinions are based in the framework
3 where that doesn't happen, so acknowledging that,
4 you're exacerbating that if you sample from this
5 group. So he's correct that many of the problems
6 will still exist, but you will exacerbate those
7 problems and you will get likely more litigation
8 around it as opposed to -- if you exacerbate the
9 issue.

10 He's definitely correct at the end of
11 that paragraph that he puts in bold. The sentence
12 before it defines the "these," but These will
13 introduce new uncertainty, distinct and
14 irreducible, and not due to sampling.

15 That is correct, but that emphasizes
16 the need for as much precision as you can get
17 through the sampling exercise. If I have two
18 sources of error, they compound each other; so the
19 gain in precision, knowing that I have other
20 irreducible error of improving my precision through
21 this sampling exercise, gets larger. That means
22 there's a bigger return having a larger sample size

1 than if there wasn't irreducible error for other
2 sources.

3 So the fact that those other things
4 are irreducible and you can't reduce them
5 dramatically increases the return for reducing them
6 in the places where you can, because these interact
7 with each other.

8 That's really the same critique of
9 Paragraph 30.

10 The IRS critique in Paragraph 31, I
11 don't agree with. The IRS does not have the
12 resources to do what he is asking them to do, as he
13 says is their charge, so they definitely, because
14 they are resource-constrained, can't do that. So
15 they do at times use sampling. Other times, they
16 use a census.

17 They're making the point that when
18 it's all available electronically, a census doesn't
19 cost particularly more, so, okay, when it's all
20 available electronically, we'll take a much broader
21 review than if it's not available electronically.

22 They are resource-constrained. The

1 cost of doing nonelectronic records is higher, so
2 we take fewer. The cost of electronic records is
3 lower, so we take more. That's the only point of
4 citing to it. It's no different than the Debtors
5 here who said, Our historical claims database will
6 produce the entirety of it; you can have all of it;
7 it's in electronic form; no need to sample.

8 Underlying claim files, there's a
9 need to sample. Those aren't already in electronic
10 form.

11 So the main point is, things in
12 electronic form are low cost to produce and you
13 take dramatically more, potentially all, than
14 things not already in electronic form.

15 Paragraph 32, he says, Because
16 there's no practical loss in accuracy created by
17 sampling -- and he goes on -- there's no need for,
18 draws other conclusions.

19 He appears to be focused entirely on
20 estimating a proportion for the entire universe of
21 12,000 historically paid claims. And on that,
22 there isn't really a practical loss in accuracy.

1 And if that was the only thing you needed, I, too,
2 am already only using 1,200 claims for that because
3 that's what the claims file sample is. But to go
4 broader, if you're using it to estimate the number
5 of future claims and you want to do that by
6 industry and occupational groups, again, if you're
7 going to value by law firm or by jurisdiction, that
8 no longer applies.

9 So, again, it shows -- it just goes
10 back to that lack of fundamental understanding of
11 what is the exercise.

12 His last part about a data breach, in
13 Paragraph 32, there's already 12,000 people whose
14 PII is at risk. We're going to add a small number
15 to that, a number that were in the data field -- in
16 the exposure fields that the Trusts failed to
17 redact and Bates White fails to redact.

18 So we're not really getting -- if
19 there were a data breach, we aren't going from --
20 we don't get a 90 percent reduction. The 12,000 is
21 the same 12,000. So you're going to have the
22 12,000 and you're going to add a few more, or

1 instead of saying adding 10 more, maybe add one
2 more; instead of adding one more, maybe add 0, but
3 the 12,000 is still there.

4 So the real risk of the data breach
5 is the 12,000 we already have, not the handful that
6 are going to make it through all the screenings
7 that come along first. So saying this is
8 fundamentally changing the risk of data breach is
9 ignoring the amount of data that's sitting at risk.
10 You know, and there's lots of things being done to
11 minimize the odds of that. I don't disagree that
12 you can't drive it to 0, but it's a very low
13 possibility.

14 Q. Excellent.

15 I kept my bargain that I wasn't going
16 to interrupt you in the middle of it, so --

17 MR. EVERT: That, you did. Thank
18 you very much, Michael.

19 MR. KAPLAN: Yes.

20 BY MR. KAPLAN:

21 Q. Let me ask you a couple of questions,
22 then I think it's time for another break, which is,

1 you discussed very early on -- and I wrote this
2 down -- this fundamental misunderstanding of the
3 subpopulation that you would like to study and work
4 off of. I think you said it in response to almost
5 the first paragraph, Paragraph 6, where you were
6 talking about -- when we were discussing reasonable
7 needs.

8 Do you recall that?

9 A. Yes.

10 Q. Where in your declaration,
11 Dr. Mullin, do you talk about the subpopulations
12 that you want to study?

13 (Whereupon, the witness reviews the
14 material provided.)

15 THE WITNESS: So this is in
16 Paragraph 15. In particular, if you go to
17 the middle of that paragraph, there's a
18 sentence, Further, the relationship of
19 exposures alleged to the various occupations
20 and trades of the Debtors' historical
21 Claimants and the extent to which the full
22 range of the alleged exposures is changing

1 over time are important to estimating a
2 Defendant's legal liability share.

3 So that's talking specifically
4 about industry and occupation and being able
5 to do things at that level to control for
6 those changes through time.

7 BY MR. KAPLAN:

8 Q. You agree with me that sentence
9 doesn't talk about various law firms, though,
10 correct?

11 A. That does not. The reference to --
12 if you're familiar with the Garlock record, I
13 didn't try to rehash the entire Garlock record.
14 There's a paragraph on that.

15 In Garlock, Claimants represented by
16 about -- or law firms who represented about
17 25 percent of the Claimants are the ones where
18 there appeared to be -- you know, not all the
19 exposures were being revealed, and for the other
20 75 percent, they were.

21 So I wrote this assuming you had some
22 knowledge of the case. I understand from this that

1 you, personally, do not, in terms of these details
2 in the background, but with the -- with that
3 knowledge, I didn't try to give the whole history
4 again.

5 But if you're familiar with the
6 process and you're an expert in this field:
7 Controlling by law firm, controlling by
8 jurisdiction are fundamental things. It's done
9 routinely.

10 So I didn't state things that, to any
11 expert or person who does this regularly, would
12 seem obvious --

13 Q. You assumed?

14 A. -- it's very much in the Garlock
15 record.

16 I didn't -- I didn't write it for a
17 complete layperson who knew nothing about the
18 context of estimation. That is correct. I did not
19 write it for a person completely ignorant about
20 that entire process.

21 MR. KAPLAN: All right. Let's
22 take -- I don't know -- five or so minutes,

1 same as we did last time, and we'll come on
2 back.

3 --oOo--

4 (Whereupon, a recess was taken from
5 3:26 p.m. EDT to 3:39 p.m. EDT.)

6 --oOo--

7 BY MR. KAPLAN:

8 Q. Dr. Mullin, I just have a few more
9 questions, and then I'm going to switch -- pass
10 and -- and move on, which is, we were -- before the
11 break, we were talking about the -- the
12 subpopulations, and you pointed me to Paragraph 15.
13 And then you spoke about Garlock and the
14 assumptions you would make.

15 Where is it in your report that you
16 talk about the gender subpopulations that you
17 wanted to analyze?

18 A. I don't think I call out gender
19 specifically. There's numerous subpopulations that
20 could turn out to be relevant. It's not intended
21 to be an itemized list of everything.

22 Q. All right. Let's turn to the --

1 the -- one of the questions you -- one of the areas
2 you do talk about is Claimants that have multiple
3 areas of exposure -- multiple potential exposure
4 sources, correct? That's one of the issues, you
5 said, and you talk about it in the context of
6 Garlock also.

7 Am I right?

8 A. I'm in the wrong report. Give me a
9 second.

10 Q. I'm sure Dr. Wyner's report has a lot
11 of excellent information for you.

12 MR. ANSELM: If you want to adopt
13 his findings, we'll be fine.

14 (Laughter.)

15 THE WITNESS: I'm going to have to
16 ask you to repeat your question.

17 BY MR. KAPLAN:

18 Q. Yeah. It's not a problem. I'm just
19 trying to bring us into -- in Paragraph 15, one of
20 the things you talk about is the alternative
21 exposure allegations. And that was one of the
22 things you -- I believe that you criticized

1 Dr. Wyner for not talking about, was the
2 alternative exposure sources.

3 Correct?

4 A. He talks about that in the sense of
5 what proportion of them are disclosed, right.

6 What I was making reference to, in
7 particular, was to the fact that the occupational
8 industrial mix changes through time. So you
9 actually need to estimate those by industry or
10 occupational groups, and you can't just have one
11 answer for the whole population.

12 So industry and occupation is going
13 to create subpopulations of interest where you're
14 going to need to estimate parameters for each of
15 those subpopulations.

16 Q. I want to focus on something a little
17 more narrow, which is we can agree, correct,
18 because -- although I'm not an expert in this
19 particular field -- that a mesothelioma Claimant
20 likely has multiple sources of exposure?

21 A. Many do --

22 Q. Okay.

1 A. -- those that have material exposure
2 to gaskets typically do. In other settings, that
3 may not be true, so I don't want to overgeneralize.
4 But for these Debtors, I think, typically, a
5 Claimant would have exposure to a multitude of
6 products.

7 Q. Okay. And one of the -- you've made
8 the point of highlighting the Garlock matter, which
9 is where, you know, as you stated, certain
10 Claimants did not disclose all of their alternative
11 sources of exposure, correct?

12 A. That was ultimately the findings of
13 Judge Hodges.

14 Q. Sure.

15 Let's -- I want to understand with
16 this subset of data that you -- this set of data
17 that we're looking at here with the 12,000
18 Claimants, which is, how is it that you're counting
19 it? And let me break that down for you, which is
20 that if one Claimant has five sources of exposure,
21 we agree that's five potential separate claims they
22 could make, right?

1 A. It could be more than that depending
2 on what the exposure is to.

3 Q. I agree. I'm using five because
4 that's how many fingers I have on one hand.

5 Okay?

6 A. Okay.

7 Q. It looked good when I held it up.
8 How is it that you are counting that?
9 Because -- is that five separate claims for
10 estimation, or is that one Claimant?

11 A. So the unit of analysis is going to
12 be the Claimant. You're ultimately evaluating a
13 future Claimant or a pending Claimant's claim
14 against these Debtors. So it may be two claims in
15 that sense that you may value: one, their claim
16 against Aldrich; and, two, their claim against
17 Murray.

18 But you want to know what are the
19 totality of exposures for that one individual. And
20 the breadth of alternative exposures is directly
21 relevant to the strength of their claim against
22 Aldrich or Murray.

1 Q. Okay. So we're -- the unit, then, is
2 Claimant and not claim for estimation purposes?

3 A. To be clear, it's two distinct
4 Debtors in a consolidated action. But as I
5 understand my charge, I don't say, Here's their
6 combined liability at the end of the day. At the
7 end of the day, I may be asked to have one estimate
8 for Aldrich and an alternative estimate for Murray.

9 So there's -- it's not -- if there's
10 an individual that claimed against Aldrich but
11 never filed a claim against Murray, that Claimant
12 is not going to be informative about estimating
13 Murray's future liability.

14 So I won't have all -- that's
15 probably your most obvious two-set populations of
16 interest, the two Debtors. Some Claimants sued --
17 named both. Many Claimants named one but not the
18 other.

19 Q. Where is that discussed in your
20 report?

21 A. In the report?

22 Q. Yeah.

1 A. That's -- that's not discussed. I
2 mean, many things in this report -- this
3 declaration is filed within the context of the case
4 to the benefit of the judge, who actually confirmed
5 the Garlock plan and has seen prior filings.

6 So I'm not writing, as I said, to a
7 lay audience that has zero context or knowledge.
8 I'm writing to an individual that has a lot of
9 context and knowledge. So many of those things
10 aren't stated for a second time here.

11 Q. How is it, then, that parties --
12 excuse me -- nonparties to the case who aren't the
13 judge, who didn't confirm the Garlock plan -- how
14 are they supposed to know what the basis of your
15 opinion are, then, if they're not stated?

16 MR. EVERT: I'm going to object to
17 the form of the question.

18 THE WITNESS: Again, it's done
19 within the context. There's a lot of other
20 filings in the case. I think the -- the
21 two -- I don't -- I would never assume -- I
22 don't know why a party would assume you

1 estimate one number for two Debtors. That's
2 a strange assumption, in my mind.

3 So if you're saying that's -- to
4 me, that's obvious. So if that's not obvious
5 to a reading audience, okay. I didn't call
6 out that particular item. I don't really
7 view that as fault, although it may be
8 beneficial to some parties.

9 But, typically, I think you hire
10 somebody who's familiar with the context who
11 can fill you in on context. That's, in my
12 experience, what my clients do. If something
13 comes in their lap that they don't have
14 firsthand knowledge of, they gain that
15 knowledge through who they hire to advise
16 them.

17 BY MR. KAPLAN:

18 Q. Okay. You've talked a few times
19 today about tripling your uncertainty or
20 quadrupling your uncertainty or doubling your
21 uncertainty.

22 We've had a few of those exchanges,

1 correct?

2 A. Correct.

3 Q. When you say "tripling your
4 uncertainty," what number is it that you're
5 starting from?

6 A. So we've gone around this barn two or
7 three times now, at least.

8 Q. I'm aware. Yeah.

9 A. Do you want me to say asked and
10 answered, or -- I mean, you're saying you're aware
11 --

12 MR. ANSELM: That's his --

13 THE WITNESS: -- okay. I don't
14 understand your question because it seems to
15 be identical to what you've already asked me
16 three times. And if you are asking me the
17 same thing again, I stand by my answer.

18 If you intend a different meaning
19 than what you asked me before, I don't
20 understand your question, and please clarify.

21 BY MR. KAPLAN:

22 Q. Excellent. I enjoy when experts play

1 lawyer. It looks great.

2 The -- my question for you is this:
3 If you start with an uncertainty of, let's say, for
4 instance, 1 percent uncertainty and you're tripling
5 that, you're now at 3 percent uncertainty, correct?

6 A. Correct.

7 Q. So my question for you is -- and you
8 have said -- you have said 50 million, 100 million,
9 150 million. You've said 400,000 today. You've
10 said a lot of big numbers, but what -- what you
11 haven't said to me is what level -- what is the --
12 the uncertainty associated with using 1,200
13 Claimants for this sample.

14 MR. EVERT: I think this is when
15 I'm supposed to say asked and answered.

16 MR. KAPLAN: Okay. That's fine.
17 That's good. You say whatever you want.
18 You're fine.

19 BY MR. KAPLAN:

20 Q. You answer the questions.

21 MR. EVERT: I think he's said,
22 Michael, a number of times --

1 MR. ANSELM: Let him say it.

2 MR. EVERT: Okay.

3 THE WITNESS: Again, I believe
4 I've addressed this at least two if not three
5 times. I believe those answers were
6 complete. I will try this one more time for
7 you.

8 You can't know the answer to how
9 much uncertainty you have before you have the
10 data in front of you. That is impossible.
11 So nobody can tell you -- and this is true of
12 every single sampling exercise that's done
13 when it has a discovery component leading to
14 an analysis not estimating a proportion for
15 the historical population but an actual
16 estimation component to it, particularly out
17 of sample, like this would be done. You
18 don't know that ahead of time. It's -- it's
19 an infeasible question to give a precise
20 number to.

21 That said, based on my experience
22 doing this, if I'm going to look at something

1 like but-for tort spend, which is typically
2 the plaintiff theory in these cases -- and
3 I'm probably going to have to address that at
4 some point -- the uncertainty -- if we had --
5 the baseline uncertainty is very likely
6 initially in the tens of millions. Whether
7 that's 15 million, 30 million, I don't know,
8 but it's -- it's very likely in the tens of
9 millions, not single-digit millions, not
10 hundreds. That's just based on having done
11 this exercise across numerous entities
12 through time.

13 Now, if I triple that, I'm adding
14 30 to maybe 200 million of uncertainty,
15 depending on where we are initial -- our
16 initial uncertainty may be 20. If our
17 initial uncertainty was 10 -- I don't think
18 we're going to be that low -- you would be
19 adding plus or minus 20 million. If the
20 initial uncertainty was 70 million, now
21 you're at plus or minus 210 million.

22 It's going to have an effect in

1 that range. I don't know where, but it's
2 almost assuredly going to fall somewhere in
3 that range, based on historical experience.

4 But I can't give you a precise
5 number. I can only give you that kind of
6 general guidance because no one can answer
7 the question you're actually asking.

8 BY MR. KAPLAN:

9 Q. Okay. Last question is, Is the sort
10 of mathematical extrapolation we did from the
11 400,000 down to the 12,000 -- where is that in your
12 declaration?

13 You can phone a friend, and he's
14 shaking his head.

15 MR. EVERT: Yeah. I'm just going
16 to interrupt. You're thinking of your
17 earlier declaration -- it was in your initial
18 declaration; it wasn't in this the sample
19 declaration.

20 THE WITNESS: I was going to say
21 that information is in the record; it's not
22 in this declaration. So that information has

1 been provided and at least -- I guess not the
2 Trust, but the FCR, the ACC have all had
3 access to that underlying database for a long
4 time.

5 MR. KAPLAN: Okay. That's all the
6 questions I have for now. I'm going to step
7 aside to whoever -- Mr. Guerke.

8 MR. GUERKE: I will go next.

9 --oOo--

10 EXAMINATION BY COUNSEL FOR DCPF

11 --oOo--

12 BY MR. GUERKE:

13 Q. Good afternoon, Dr. Mullin.

14 A. Good afternoon.

15 Q. My name is Kevin Guerke.

16 I represent the Delaware Claims
17 Processing Facility, sometimes referred to as
18 "DCPF."

19 Are you familiar with that?

20 A. I am.

21 Q. If -- if I ask you questions and
22 refer to "DCPF," will you know what I'm talking

1 about?

2 A. Yes.

3 Q. You just were discussing that 400,000
4 Claimants with -- with counsel.

5 And I think, earlier today, you
6 testified that there were roughly 400,000 Claimants
7 that submitted claims to the two Debtor entities;
8 is that correct?

9 A. I said there's more than 400,000.

10 Q. More than 400,000?

11 A. Claimants?

12 Q. Yeah. Is that your testimony?

13 A. Across the two, that's my
14 recollection, sitting here. I think there's an
15 exact tabulation somewhere.

16 Q. And of those 400,000 or so, roughly
17 25- to 50,000 were mesothelioma Claimants, correct?

18 A. That was -- I hadn't looked at the
19 exact number, but it's likely in that range.

20 Q. How many of those 25- to 50-
21 mesothelioma Claimants also submitted claims to one
22 of the DCPF Trusts?

1 A. I don't know the answer to that.
2 It's a high proportion, I think, as we've gone
3 through the reconciliation -- we've done some of
4 the claims reconciliation process, but I don't
5 remember what the number is, sitting here.

6 Q. Can you quantify any better what you
7 mean by "high proportion"?

8 MR. EVERT: I'm sorry. I want to
9 make sure -- he's asking, of the 25- to
10 50,000 mesothelioma Claimants in total, what
11 proportion. I just want to make sure -- that
12 is the question, right?

13 MR. GUERKE: I mean, the question
14 is what I asked him, and he gave an answer.

15 BY MR. GUERKE:

16 Q. Did you understand my question, and
17 was your answer responsive to my question?

18 A. I was answering with regard to the
19 12,000 because those are the only ones I directly
20 see any information on that were in the request.
21 Any claims outside of that request, I could make
22 inferences or draw from experience and other

1 places, but I don't have knowledge of within this
2 case.

3 Q. Are there more than 12,000 Claimants
4 who have submitted claims to the Debtor entities
5 and also have submitted claims to DCPF Trusts?

6 A. Yes.

7 Q. So there's more than 12,000?

8 A. Who have submitted claims to the
9 Debtor entities and submitted a claim to one or
10 more of the Trusts, yes, there's more than 12,000.

11 Q. Are there more than 12,000
12 mesothelioma claims that both submitted claims to
13 the Debtor entities and also one of the DCPF
14 Trusts?

15 A. Almost assuredly, but I haven't read
16 an exact number. But almost assuredly.

17 Q. In relation to the 12,000 that have
18 been requested, how many more, roughly?

19 A. It's going to double or triple the
20 number because there's all the dismissed claims.
21 And just because they were dismissed against
22 Aldrich or Murray doesn't mean they would be

1 dismissed against all the predecessor entities that
2 could file against the Trust.

3 There would also be a number of
4 mesothelioma claims that predate 2005 that could
5 have submitted claims against those Trusts. I
6 haven't sought discovery on those, so there's no
7 reconciliation process. I can't -- I haven't seen
8 data that will give a precise qualification for
9 those.

10 But those two populations of claims
11 would produce a material number of additional
12 mesothelioma Claimants against the two Debtors that
13 would file one or more claims against entities in
14 the Delaware facility.

15 Q. I'm eliminating dismissed claims,
16 focusing only on mesothelioma claims.

17 Do you know how many more than the
18 12,000 Claimants submitted claims to the Debtor
19 entities and also the DCPF Trusts?

20 MR. EVERT: Object to the form of
21 the question because I don't understand --
22 there are dismissed mesothelioma claims you

1 said you're eliminating, right?

2 THE WITNESS: I ask a couple of
3 clarifying questions.

4 BY MR. GUERKE:

5 Q. Sure.

6 A. There's two Debtors --

7 Q. Two Debtors.

8 A. -- one fact pattern is Aldrich paid a
9 claim. The same Claimant had a claim against
10 Murray, and the claim against Murray was dismissed.
11 So they both have a paid claim against one Debtor
12 and a dismissed claim against the other Debtor.

13 When you say I can differentiate the
14 two claims -- but the Claimant was paid by one
15 Debtor, right? So the Claimant's neither dismissed
16 nor paid; they're both, right? We have two
17 individual claims.

18 So when you say "dismissed," I need a
19 little more clarity as to what you mean because I
20 have two Debtors involved, when you asked the
21 questions, to be precise, so we don't commingle
22 terms.

1 Q. The subpoena that's directed at DCPF
2 seeks information on 12,000 Claimants, correct?

3 A. Yes.

4 Q. What I'm trying to get at is -- is,
5 for the subject of the subpoena, how many more
6 Claimants are out there beyond the 12,000?

7 A. Well, the subpoena constrains itself
8 to a Claimant who was paid by one or both Debtors
9 where that payment occurred 2005 or later, all
10 right -- it's got a date cutoff for the date of the
11 payment -- and it has to be mesothelioma. All the
12 mesothelioma Claimants that don't fit one of those
13 three criteria have been excluded.

14 So that's if you were dismissed
15 against -- if neither Debtor paid you, if you were
16 paid earlier in time than the temporal cutoff or if
17 you were not nonmesothelioma, you've been excluded
18 from the data request.

19 Q. So the 12,000 Claimants -- the entire
20 population has been included?

21 A. Well, it's got a definition --

22 Q. Using that definition --

1 A. -- so the definition -- it is the --
2 it is a census or the total population of Claimants
3 who resolved after the cutoff date, who had
4 mesothelioma and one or both Debtors made a
5 positive payment. That's the definition of what
6 went in. So by construct, it's 100 percent of that
7 definition.

8 Q. All right. When did you start
9 working on this bankruptcy case?

10 Based on -- and I'll just tell you,
11 based on the docket, Bates White was formally
12 retained August 18th, 2020.

13 A. I mean, we were working for the
14 Debtors as of the petition date. I think the
15 retention went through subsequent to that. There's
16 a lag between when -- typically in a bankruptcy
17 when you first start doing work for a client and
18 when all the paperwork goes through the bankruptcy
19 court.

20 Q. How about you, personally? When did
21 you, personally, start working on this bankruptcy
22 case?

1 A. For the Debtors as clients, it would
2 have been roughly contemporaneous with that.

3 Q. Bates White is also involved in
4 Bestwall and DBMP, correct?

5 A. Correct.

6 Q. What's your personal involvement in
7 those two cases?

8 A. I advise on those at times. There's
9 select issues where my colleagues, counsel or
10 client seek me out on certain topics.

11 I don't think I'm at liberty to
12 disclose what those topics are at the current time,
13 particularly in the context of this case, but it's
14 been constrained to advising on select issues at
15 the moment.

16 Q. Do you anticipate using sampling in
17 either Bestwall or DBMP?

18 A. At the moment, I don't anticipate
19 testifying in either of those cases. So if you're
20 asking am I, personally, going to do that, I don't
21 anticipate testifying in either of those cases.

22 Q. Do you know if Bates White

1 anticipates using sampling in either Bestwall or
2 DBMP?

3 MR. KAPLAN: Kevin, I'm going to
4 object.

5 Is that appropriate for this
6 setting? He said he's not a testifying
7 expert in those cases or the fact that his
8 firm is.

9 Do you know?

10 THE WITNESS: I mean, I'm going to
11 stick to what's in the public record, because
12 it's -- I don't think I should talk in the
13 context of Aldrich/Murray about anything
14 that's not in the public record for Bestwall
15 or DBMP.

16 There's been back-and-forth in
17 Bestwall about what sample of historical
18 claim files to take. The fact that there's
19 back-and-forth on that is in the public
20 record. So the fact that they're looking at
21 various samples of claim files in the same
22 way that that issue is being looked at in

1 this case, that's true.

2 I don't know the DBMP public
3 record well enough to know what's in it or
4 not, so I'm not going to say anything because
5 I just don't have confidence as to what's in
6 the public domain.

7 BY MR. GUERKE:

8 Q. You testified earlier that you -- you
9 anticipate that sampling will be used in the
10 Aldrich Pump case, in some respect, right?

11 A. With regard to the historical claim
12 files, I suspect that's correct. It's also -- I
13 mean, with regard to Trust data, I would say that's
14 exactly what we're doing here, too. We didn't ask
15 for all the claims; we asked for a subset. So it's
16 a version of sampling.

17 Q. That's what I was getting at earlier
18 about the -- the 12,000 Claimants.

19 What's the -- what are the 12,000
20 Claimants that you seek in the subpoena -- or
21 your -- your attorneys seek in the subpoena -- what
22 is that a sample of?

1 A. The over 400,000 historical claims.

2 Q. But modified based on the parameters
3 of the -- of the subpoena, correct?

4 A. Well, I -- I did not feel I needed
5 all 400,000 claims to do my work, information from
6 the Trusts. I reduced that down. So it's -- we're
7 not requesting a census from the Trusts of every
8 historical claim to merge to the claims database of
9 all of the Claimants. That's not what we're doing.

10 We're taking a very select
11 subpopulation that's about 3 percentage of the
12 total population of Claimants and asking for the
13 data for that 3 percent of the subpopulation --
14 that subpopulation. We're asking for 100 percent
15 of that subpopulation.

16 So it's a census of that
17 subpopulation, which is 3 percent of the total
18 data.

19 Q. And other than sampling for
20 historically -- historical claim files, do you
21 anticipate any other sampling in the Aldrich Pump
22 or Murray bankruptcy case?

1 A. We're likely to rely on various
2 historical samples. So, for example, prior to
3 2001, there's not a census of historical
4 mesothelioma diagnoses in the United States. So
5 what's available is a sample by the Survey of
6 Epidemiological End Results.

7 2001 forward, we have census. So we
8 use the census for 2001 forward, but when we're
9 looking at things of forecasting future disease
10 incidents in the population, we'll rely on samples,
11 but we're not -- that's because it's a constraint;
12 it's what's -- the only thing that was available.
13 You can't go back to 1995 and complete that sample
14 any longer.

15 Q. The subpoena that was issued to DCPF
16 and, I think, all of them go back to 2005 -- seek
17 data that goes back to 2005; is that correct?

18 A. Correct.

19 Q. Why do you need data going back to
20 2005?

21 A. So part of this is you do have
22 changing demographics through time. So, ideally,

1 you don't just look at a snapshot of the most
2 current. You want to be able to see if there's
3 trends or changes, and you want to be able to model
4 those changes.

5 So for questions such as Dr. Wyner
6 focused on are all the disclosures being revealed.
7 2005 is not particularly important to my analysis.
8 The more recent data is going to be much more
9 important because it's really what's happening more
10 recently in the tort system.

11 In contrast, for controlling for
12 industry and occupational group mixes and seeing
13 how those are evolving through time, you need a
14 time series of data. So the reason to reach back
15 further is so, as opposed to getting a snapshot at
16 a moment in time, you can see the underlying trends
17 in data, line that up with large government
18 datasets that are informative and create a more
19 reliable forecast.

20 So the reaching back further has a
21 lot more to do with accurately estimating the
22 number of future Claimants than the questions

1 related to are the totality of exposures being
2 contemporaneously revealed.

3 Q. Doesn't Bates White already have the
4 Garlock database?

5 A. So there's a public version of the
6 Garlock database that any party who cares to get,
7 can have it. And Bates White has a copy of those
8 data.

9 Q. Does Bates White have a copy of a
10 nonpublic version of the Garlock database?

11 A. No. That was destroyed at the
12 conclusion of the bankruptcy, which is why I made
13 the distinction. There was another version of that
14 database that had more information in it than the
15 public version, which no longer exists.

16 Q. Garlock filed bankruptcy in 2010,
17 right?

18 A. June 2010.

19 Q. Why wouldn't going back only to 2010
20 be sufficient for your purposes, considering
21 Bates White already has the Garlock database?

22 MR. EVERT: I'll just object to

1 the form of the question because no sample
2 back to 2010 has been proposed.

3 Go ahead.

4 THE WITNESS: The Garlock database
5 is constrained to individuals -- at least on
6 Trust discovery aspect of it, is Claimants
7 against Garlock who were resolved prior to
8 their bankruptcy. So in all the pending
9 claims, that database -- there's not the
10 Trust discovery on -- it's similar to this
11 one, resolved claims.

12 And not every Claimant who names
13 Aldrich or Murray named Garlock back then.
14 So that would be a nonrandom subset of the
15 data.

16 And then you'd introduce all sorts
17 of questions about what biases have you
18 brought in by using this nonrandom subset,
19 requiring it to be in the Garlock data and be
20 resolved by Garlock prior to bankruptcy, as
21 opposed to being able to take the universe of
22 claims and not have any of those biases enter

1 the analysis.

2 BY MR. GUERKE:

3 Q. Couldn't -- wouldn't it be sufficient
4 for your purposes to use the -- the Garlock
5 database -- the information you have and supplement
6 it with the subpoenaed information from 2010
7 forward?

8 MR. EVERT: Objection: asked and
9 answered.

10 THE WITNESS: So there's going to
11 be a few issues with that. You could
12 potentially make some progress on that route
13 with regard to the Delaware facility. There
14 was no discovery on the Verus facility in the
15 Garlock matter, so there is no data in the
16 Garlock record of Trusts related to that
17 facility. So any of this would apply only to
18 the Delaware facility as a starting point.

19 Two, to the degree Claimants in
20 Garlock have filed Trust claims post the
21 Garlock discovery, because not all of those
22 claims were resolved at the time -- there's a

1 number of claims that were pending -- you
2 would want to learn the status of those
3 pending claims.

4 So you would need to go back
5 and -- if there was a single pending claim to
6 figure out what was the resolution of that.
7 So it's not as simple as if you got the
8 discovery before, what's the ultimate
9 resolution.

10 BY MR. GUERKE:

11 Q. Can you use for your purposes the
12 data that was produced in Bestwall and DBMP from
13 DCPF and the DCPF Trusts?

14 A. I believe that would violate numerous
15 confidentiality orders and be illegal for us to do.
16 So I don't think, legally, we could do that.

17 If that issue were solved,
18 statistically, it has a similar issue. DBMP is a
19 fundamentally different product than Aldrich. You
20 could see Claimants who were dismissed against DBMP
21 who might be a high-value claim against Aldrich, or
22 vice versa.

1 So -- and they won't be in Claimants
2 who named Aldrich that never named one of those two
3 entities.

4 So, again, you would have these
5 selection effects you're layering over. It
6 wouldn't be a representative sample. And that's
7 going to create potential biases, and then we would
8 be litigating over those biases.

9 Q. I don't want to go through all the
10 questions and answers you gave prior counsel on
11 this subject. And I -- am I correct that -- strike
12 that.

13 In your declaration in Paragraph 9,
14 you discuss the decrease in precision. You had
15 several questions with Mr. Kaplan about decrease in
16 precision.

17 My question is, Specifically, what is
18 the decrease in precision referenced in
19 Paragraph 9? And if -- if your answer is, I
20 already explained that for half an hour, that's
21 fine.

22 But is there a way for you to answer

1 that question?

2 A. You're asking specifically about kind
3 of Romanette i, Decreased precision of the ultimate
4 analysis?

5 Q. Yes.

6 A. I believe -- that's focusing probably
7 on the most salient issue, which is the ultimate --
8 the final design of the CRB, the final estimate of
9 liability in an estimation proceeding.

10 When I say "the ultimate," it's
11 not what's the precision of an intermediate number
12 that then feeds in, but "the ultimate" in that is
13 referring to the final opinions of interest of
14 which the sample is providing inputs into.

15 Q. And -- and the final opinion, is
16 that -- is what you mean the value -- the estimated
17 claim value that you would present to the Court of
18 the ultimate analysis you were referring to?

19 A. It could be the final claim -- the
20 estimate of total value of pending and future
21 claims against Aldrich. It could be the final TDP
22 that's filed where you've used these data to help

1 you structure that TDP. So as opposed to
2 intermediate steps that are building up to
3 something like that, it's these final documents or
4 these final high-level opinions.

5 Q. But a final high-level opinion on
6 estimating present and future claim value, not
7 TDPs, can you tell us specifically what the
8 decrease in precision is that you're referencing in
9 Paragraph 9?

10 A. So one issue in the case, as I
11 understand it, is the parties disagree about what
12 it is we're supposed to be estimating there, which
13 if you want me to get into that, I can, but I'm not
14 really intending to in this answer.

15 The Plaintiffs' theory of what would
16 the Claimants have received in the tort system is
17 likely to have a larger aggregate estimate than the
18 Defendant theory of what's kind of the intrinsic or
19 underlying legal liability. Those two numbers are
20 going to differ.

21 So while the percentage of
22 uncertainty may be the same, suppose they're both

1 plus or minus 15 percent, clearly that's going to
2 be more dollars of uncertainty on something that's
3 at a higher baseline number.

4 So it's going to have a bigger dollar
5 impact under the Plaintiffs' theory than under the
6 Debtors' theory. It's going to approximately, on
7 many of the parameters, triple the uncertainty.

8 But the rest is similar to the answer
9 I gave before, right? I think that uncertainty is
10 probably on the order of tens of millions of
11 dollars as a baseline. Until I do the work and
12 I've seen the data, I can't tell you something more
13 precise than that.

14 Q. Do you expect your final estimated
15 claim number, present and future claims, the
16 ultimate analysis that you're referencing in
17 Paragraph 9 -- will that be in the form of a range?

18 A. These have been presented in
19 different ways in different estimation proceedings,
20 so I don't know if we're at that point.

21 There's -- many times, that's
22 presented as a scenario and a point estimate, but

1 then analyses around that to describe the amount of
2 uncertainty -- you could present that as a range,
3 but likely, if you were to present a range, you
4 would give the Court some indication about what
5 area within that range you find more likely.

6 So I don't view those as too
7 different, but the one may not go all the way to a
8 point estimate. You may say, I'm very confident
9 it's in this \$50 million or most confident it's
10 most likely in a \$50 million range, but maybe it
11 has this broader range that's feasible for
12 uncertainty.

13 So which of those is a better form of
14 exposition depends a little bit on the types of
15 uncertainty and what you learn as you go through
16 the process.

17 Q. You don't anticipate providing the
18 Court with a single final number, correct?

19 A. If I concluded there was a scenario
20 that I found most likely, I will probably present
21 that number but then characterize the uncertainty
22 about that number. If I don't have one scenario

1 that I think is more likely, there may be a range
2 that I think is most likely but within that range,
3 I can't differentiate, and then there's uncertainty
4 about that range.

5 You know, until you do all the
6 analysis, which of those is going to be where I
7 ultimately present opinions, I don't know, sitting
8 here today.

9 Q. You reference in your declaration the
10 legal liability analysis that you're performing in
11 this case.

12 Are you familiar with that?

13 A. Yes.

14 Q. The legal liability analysis that you
15 will go through includes multiple steps, correct?

16 A. It does.

17 Q. Do you agree that legal liability is
18 not a mathematical equation?

19 MR. EVERT: Let me ask, How is
20 that relevant to sampling?

21 MR. GUERKE: It's a foundational
22 question.

1 MR. EVERT: Okay. If you know the
2 answer, if you can answer it.

3 THE WITNESS: So as an empirical
4 exercise, you ultimately reduce these
5 questions to a mathematical model. Whether
6 you're doing legal liability, but-for tort
7 spend, ultimately these become reduced to
8 mathematical models of every expert I've ever
9 seen do it. So the model, like all models,
10 is a simplification of the real world. Every
11 single model simplifies that on some
12 dimension. But, ultimately, they will be
13 expressed as a form of mathematics.

14 BY MR. GUERKE:

15 Q. Along the way in the legal liability
16 process, there will be subjective determinations
17 that are made by Bates White, correct?

18 MR. EVERT: Object to the form of
19 the question.

20 THE WITNESS: There may be.
21 Again, I haven't done all that work.

22 As much as possible, I try to root

1 things in data and empirical analyses, but,
2 at times, there are -- things can arise where
3 that's not feasible. And then you start --
4 you invoke some assumptions and usually do
5 scenario analysis.

6 BY MR. GUERKE:

7 Q. Some of the steps in the legal
8 liability analysis include estimates, right?

9 A. Every estimate of future liability
10 includes estimates. That's correct.

11 Q. And also includes forecasts, correct?

12 A. I don't know what distinction you're
13 drawing between the word "estimate" and "forecast."
14 If you intend those to mean something different,
15 tell me.

16 Q. For the legal liability analysis that
17 you're going through, the -- the end game is for
18 the Debtors to estimate the value of claims,
19 correct?

20 A. Correct, the value of pending and
21 future claims. That's correct.

22 Q. Why is estimating sufficient for the

1 analysis but sampling within the analysis is not?

2 A. I don't agree with the predicate. I
3 am sampling. So certain -- there's a cost-benefit
4 analysis as to when you should sample and when you
5 should use the totality of the available data.

6 So on certain aspects where the cost
7 of producing the data is relatively small, I use
8 the -- I intend to use the totality of the data,
9 like, I will use the entire claims history from the
10 Debtor. I won't take a 10 percent sample of the
11 Debtors' claim history in their settlements.

12 Okay?

13 So things that are already in
14 electronic format, you tend to use all the data;
15 things that aren't already in electronic format,
16 you tend to use the sample.

17 It doesn't always have to work out
18 that way. I've done cases where we took a census
19 of everything that was not in electronic format,
20 too, so it -- it's a cost-benefit analysis that's
21 specific. And I've done ones where I've taken a
22 sample where everything was in electronic format

1 because it was still too large to work with.

2 So it's -- there's no absolutes
3 there, but that's how it generally breaks down. So
4 I'm using the census at times for certain
5 questions; I'm using a sample for other questions,
6 and it's that cost-benefit analysis.

7 Q. Whether DCPF produces 100 percent of
8 the information requested or 10 percent of the
9 information requested, will Bates White review
10 every single document that DCPF produces?

11 A. We will use the totality of the
12 electronic information to the degree that it's
13 populated, so we will review it, but if -- if a
14 record was produced and all the fields were empty,
15 we probably wouldn't incorporate that record into
16 our analysis, because it actually had no data. But
17 we -- the intent is to pull all of that into the
18 analysis. Which of it will ultimately be germane
19 at the end is an empirical question, but I'm
20 expecting in terms of these trends for future
21 Claimants to use all of it.

22 Q. And how will Bates White go about its

1 review of the DCPF-produced information to fulfill
2 its obligation to redact PII that's in the
3 subpoena?

4 A. So I'm not personally in charge of
5 doing that review at the moment, but the -- we do a
6 lot of document review in different settings. This
7 really isn't documents. It's electronic.

8 So I would have to go and ask to see
9 the exact specifics. But we've done similar
10 exercises in the past. We typically will do a
11 review conceptually. There will be a first pass.
12 We'll see what it flags. There will be a second
13 pass to get an error rate. That second pass may
14 not be for the totality of the claims. It may be
15 for a subset to see what the error rate is, how
16 many claims are you missing, if at all, right?

17 And you're really assessing are you
18 getting the vast majority of them, as you're going
19 on, and will determine some acceptable error rate
20 at the end of the day in the same sense that the
21 data being produced to us probably, despite DCPF
22 going through it, will still have missed a few. So

1 we will go through a similar process of quality
2 controlling, quantifying our error rate and then
3 being able to say what's the maximum number of
4 claims statistically where there is remaining PII.

5 Q. Forgive me if this was embedded in
6 your answer, but that first pass and the second
7 pass you just testified about, is that -- is that
8 100 percent review of all the data on a first pass
9 and then a 100 percent review of all the data on a
10 second pass?

11 A. The second pass is likely to be a
12 subset where you're doing a quality control. If
13 you determine that your error rate is too high, you
14 would actually do a full second pass, because
15 you've determined your error rate is too high.

16 So it's -- when you do the quality
17 control pass, if you learn you're missing -- you're
18 getting 99.9 percent of them, you would probably
19 say, We've done a good job, and we're done.

20 If you found that you're only getting
21 80 percent of them, you would probably do a second
22 pass on all the data, because missing 20 percent is

1 not an acceptable error rate.

2 So it's -- the extent of the second
3 pass is a function of what is your effective rate
4 of capturing the information.

5 Q. If a sample is ordered, a 10 percent
6 sample, Bates White would end up reviewing
7 90 percent fewer claims that were produced from
8 DCPF, right?

9 A. I think, yes.

10 Q. That's the extent of my math right
11 there.

12 (Pause.)

13 BY MR. GUERKE:

14 Q. Forgive the pause. I'm trying not to
15 ask you questions that have been asked.

16 MR. EVERT: Much appreciated.

17 BY MR. GUERKE:

18 Q. Can you take a look at the subpoena
19 that I believe is --

20 MR. EVERT: CM-2, I think.

21 BY MR. GUERKE:

22 Q. -- which is Exhibit 2?

1 Paragraph 10 of the subpoena lists
2 data fields that's being requested from the
3 recipient of the subpoena.

4 Do you agree with that?

5 A. It's a list of the requested
6 information; that's correct.

7 Q. And this isn't the DCPF subpoena, but
8 they're all very similar, with the same paragraph
9 and the same request.

10 Part g, 10, requests information for
11 all exposure-related fields.

12 Do you see that?

13 A. I do.

14 Q. Why does Bates White need all
15 exposure-related fields for its analysis?

16 A. That's going to enter the analysis in
17 a couple different ways: One, it's going to allow
18 us to get a much more complete picture of people --
19 the nature of Claimants' exposure. So that will go
20 directly to, for example, what share of their
21 exposure would be derivative of Aldrich or Murray
22 as opposed to alternative exposures.

1 It will also be directly relevant to
2 what type of actuarial curve the claim should be
3 mapped to for projecting the number of future
4 claims, so doing this industry/occupation, what
5 trades are they in, what industries are they in for
6 figuring out how to extrapolate to get the best
7 estimate you can of the number of future claims.

8 So it's going to enter into that type
9 of analysis. It will also be direct in terms of
10 what exposures were disclosed at the time -- by the
11 time of the Debtors' settlement versus what had
12 been disclosed in totality across the multitude of
13 Trusts.

14 Q. Is it the -- is it this all-exposure
15 related fields where Bates White will use to
16 compare claims information submitted to the
17 Debtors?

18 A. On the questions that were, if I'm
19 remembering right, Paragraphs 16 and 17 in my
20 declaration, yes.

21 Q. Do you intend to look at every
22 historical claim submitted to the Debtors in the

1 tort system for that comparison process?

2 A. No. We're intending to use a sample
3 for that comparison, but to the extent we can, the
4 totality of claims in terms of these industry and
5 occupational trends for forecasting the counter
6 future claims, so it depends on the -- which
7 analysis you're referring to.

8 Q. And that sample is what you're
9 referring to earlier that's being negotiated with
10 the ACC and the FCR; is that right?

11 A. Correct.

12 Q. So for the -- the 12,000 Claimants
13 that are being requested in the subpoena directed
14 to DCPF, are the Debtors providing Bates White with
15 all the claim files?

16 A. No.

17 Q. Why not?

18 A. So producing a claim file -- it's a
19 set of documents that are typically not in
20 electronic format, and even if the documents
21 themselves are in electronic format, the
22 information you want out of, say, an answer to an

1 interrogatory or out of the deposition haven't been
2 culled from that.

3 So turning a claim file into usable
4 data for analyses is very expensive on a
5 file-by-file basis because it's not already in
6 electronic format to be used, so the cost
7 associated with each datum that you want to pick up
8 is relatively high. And so in the cost-benefit
9 analysis, we have gotten comfortable that looking
10 at the 1,200 claims for that will be sufficient for
11 some of these questions from a cost-benefit
12 perspective.

13 That's around the point benefit where
14 the cost benefits are, as best you can tell -- you
15 don't know for sure -- but as best as you can tell,
16 getting close to even.

17 In contrast, the Trust data is
18 already in electronic format, so the -- compared to
19 a claim file, the ability to turn that exposure
20 history into a -- basically combining that
21 information across Trusts to characterize an
22 exposure history for a Claimant is relatively

1 inexpensive compared to reviewing a claim file and
2 trying to review depositions and Answers to
3 Interrogatories and pull all of that information
4 out. So it goes back to that fundamental
5 cost-benefit analysis.

6 Q. So for that comparison or that
7 evidence suppression analysis, don't you need to
8 have the same Claimants from the Debtors' sample
9 matched up with the same Claimants in the DCPF
10 subpoena?

11 A. Yes.

12 Q. And how are you doing that?

13 A. So for the 1,200 that are in the paid
14 claims sample, those same 1,200 would be in the --
15 would be in the Trust data because it's a subset of
16 the 12,000. So for those 1,200, we can make that
17 comparison.

18 If we were constrained to a
19 10 percent sample from the Trusts, we would want
20 that sample to be identical to the claim file
21 sample so you can make the comparison on all 1,200.

22 For the other aspects, like

1 controlling for industry and occupations to
2 forecast the number of future claim counts, that's
3 about getting the totality of the exposure history
4 and that, we would use all 12,000 Claimants for.
5 So there's certain exercises where we would only
6 use the 1,200 Claimants' information that overlaps
7 with the 1,200 for which we went through the claim
8 file exercise. And for other aspects of the
9 estimation, we would use all 12,000 Claimants'
10 information.

11 Q. So if you're ultimately constrained
12 to a 10 percent sample in this case for Trust
13 information, you don't know yet whether that
14 10 percent sample will match up with the sample
15 that you're working on right now with the ACC and
16 the FCR, right?

17 A. So there's no agreement at the moment
18 as to what the sample of claim files will be.
19 There's been back-and-forth. The concept is that
20 it will be the same. If they weren't the same and
21 they were both 10 percent samples, then you would
22 only have on average 1 percent; you would be down

1 to 120 claims which would be in both, which would
2 be insufficient to do almost anything with.

3 Q. You can't use it for the intended
4 purpose unless the two samples line up, right?

5 MR. EVERT: Object to the form of
6 the question.

7 THE WITNESS: If I want to look at
8 a comparison, I need both points in the
9 comparison, for when -- for that exercise, I
10 need both sets of data.

11 BY MR. GUERKE:

12 Q. So before you can determine a
13 sufficient sample for the Trust information, you
14 would first need to know what the agreement is on
15 the sample for the -- the Debtor historical files,
16 right?

17 A. No.

18 Q. What -- why is that "no"?

19 A. So the fact that the historical files
20 are not already in an electronic format means that
21 each Claimant you sample there comes at a
22 materially higher cost, thousands of dollars, if

1 not 10,000, to collect all that information and
2 process it.

3 So there's a substantial cost for
4 each data point you're taking in.

5 So that data, the review of the claim
6 file data and the cost associated with it becomes
7 the binding constraint for doing the comparison
8 because it's the higher cost source of data. So
9 what I need to determine for this comparison is the
10 higher cost source, which is the claim files.

11 I'm using the Trust data for multiple
12 purposes, not just that comparison. The other
13 purposes are what apply to the 90 percent of the
14 sample that doesn't overlap with the 10 percent
15 that would line up with the claim files.

16 So when I'm talking about asking for
17 the 12,000 and constraining myself to 100 percent
18 of that subpopulation, it's because that's the
19 subpopulation that's going to inform me about, in
20 particular, future claim counts, controlling for
21 industry and occupation, potentially controlling
22 for gender, controlling for different demographic

1 characteristics as we go forward.

2 So they're serving -- the binding
3 constraint differs between the two, so in that
4 sense, they don't overlap. I'm going to have a
5 broader sample ideally of Trust data because it's
6 less expensive to produce than claim files, and I'm
7 going to have the claim file sample be a strict
8 subset of the Trust sample.

9 Q. In Paragraph 21 of your declaration,
10 you state that DCPS -- DCPF has already produced
11 the same or substantially similar information for
12 similarly sized and likely substantially
13 overlapping claims population in response to nearly
14 identical subpoenas from DBMP and Bestwall.

15 Do you see that part of your
16 declaration?

17 A. Which paragraph?

18 MR. EVERT: Twenty-one.

19 BY MR. GUERKE:

20 Q. Twenty-one.

21 A. Yes.

22 Q. So what of the 12,000 Claimants' data

1 in this case overlap with the -- the Bestwall and
2 DBMP case?

3 A. I'm not allowed to nor have I merged
4 those databases. They're two separate cases.

5 What I know about each of them that I
6 am allowed to use is that each of them receives
7 about three-quarters of the claims that are filed
8 in the tort system. So if I have two defendants
9 that each are receiving 75 percent of the claims,
10 50 percentage points of that has to overlap because
11 there's only 25 percent left that could go to the
12 other Debtor that's not in the prior one.

13 So I know there's substantial
14 overlap. I know it's at least 50 percent of their
15 claims. It might be much higher. I don't know the
16 exact number. That's why it's written the way it
17 is. I'm not allowed to merge those. They're two
18 separate cases.

19 You know, if parties waived and said,
20 Go ahead and merge them, we could give you an exact
21 answer. But that's not the status. They're --
22 each case is in its own silo. And so I know it's

1 substantial, but I don't know the exact number.

2 Q. In Paragraph 22 of your declaration,
3 you state that retrieving information for any
4 specified Claimant should involve a relatively
5 straightforward automated extraction of data as the
6 match Claimants have already been identified.

7 Do you see that in Paragraph 22?

8 A. I do.

9 Q. What is your basis for that
10 statement?

11 A. Well, as I understand the nature of
12 the databases, there's a Claimant identifier. The
13 crosswalk process of identifying which Claimants in
14 the 12,000 actually filed a claim against any of
15 the Trusts -- as I understand it, that process has
16 been completed, because we've gone through a
17 reconciliation process on the matches that were
18 uncertain.

19 So there's already a mapping from
20 that matching key to the records or at least the
21 key identifier of each Claimant in the Trust data.

22 So now you're extracting specific

1 data fields from a data fact -- a database that's
2 just a query from a database.

3 Any redaction the Trust wants to do
4 after that query is a different question. All
5 right? But the actual extraction of those fields
6 is just a database query at this point.

7 Q. And the review-and-redaction process
8 that DCPF goes through is separate and apart what
9 you're saying in this paragraph, correct?

10 A. Correct.

11 This is just retrieving from the
12 information from the field is straightforward.
13 There is a redaction process that the Trust has
14 stated it wants to do before producing the data.

15 Q. Do you -- do you dispute the fact
16 that the -- that DCPF will do a
17 review-and-redaction process for whatever
18 information is required to be produced in response
19 to these subpoenas?

20 A. They state they will do it. They did
21 it in DBMP. I have no reason to question it.

22 Q. You have no firsthand knowledge of

1 DCPF's business, do you?

2 A. No.

3 Q. You don't know specifically what DCPF
4 has to do in that review-and-redaction process,
5 correct?

6 A. No, I don't know the specifics.

7 Q. And, similarly, you don't know the
8 inner workings of DCPF, correct, on the business
9 side?

10 A. No.

11 Q. And you don't know -- you don't have
12 personal knowledge of DCPF's burden in responding
13 to the subpoena, correct?

14 A. No.

15 Q. "No," you don't have personal
16 knowledge, correct?

17 A. I don't have -- I've seen the bill
18 from other cases. I don't have personal knowledge.

19 Q. Are you offering an expert opinion on
20 DCPF's burden in responding to the subpoena?

21 MR. EVERT: I'll object to the
22 form, actually, because I think that's a

1 legal question, are we offering him to have
2 an opinion. So to the extent, yes, he's
3 going to testify about the fact of what it
4 costs DCPF to do it and DBMP, then I think,
5 yes, we are offering him.

6 BY MR. GUERKE:

7 Q. You can answer.

8 A. The opinions in my report, if I'm
9 asked, I'm going to give. Whether they fall under
10 that definition, I don't know.

11 Q. What are your qualifications for
12 offering an opinion on DCPF's burden?

13 A. I think if the opinions in the report
14 talk about doing an extract from a relational
15 database, once you've completed the matching, that
16 is simple. That takes almost no time to write a
17 query, to take an extract from a relational
18 database.

19 I work with relational databases all
20 the time. You know, that -- if you consider that
21 as following as an expert opinion on their burden,
22 it's one aspect of looking at what's the actual

1 cost, given they've already done the matching
2 exercise, to extract the fields. That's minimal.

3 Otherwise, in terms of the redaction,
4 the evidence I have as an economist to look at is
5 the bill that got in the public for what that cost
6 in DBMP, so that gives us a benchmark of what it
7 may cost here to put a dollar figure on that
8 burden.

9 Q. Is there anything else -- any other
10 information you're relying on to offer an opinion
11 on DCPF's burden in this case?

12 A. Not beyond anything that's in my
13 report.

14 Q. You rely on the Richard Wyner
15 declaration in your declaration, correct?

16 A. On the -- if you can point me to
17 where.

18 Q. The Richard -- Richard Wyner is the
19 DCPF COO, and there was a declaration submitted.
20 It's cited in your report.

21 I can --

22 A. I'm just asking you to reference --

1 where in my report do I rely on it?

2 I'm not -- I don't have that mapping
3 at the tip of my fingertips.

4 If you point me to where, that's --

5 Q. Sure.

6 It's Footnote 16 -- 13 and 16.

7 A. Okay.

8 Q. You are relying on the Richard Wyner
9 declaration in forming your opinions related to
10 DCPF's burden in this case, correct?

11 A. I'm relying on the specific statement
12 that the data all resides in electronic format.

13 Q. Any other part of the declaration
14 that you're relying on?

15 A. I'm looking at these two sentences in
16 the footnotes therein and that it's organized by
17 Claimant.

18 Q. Anything else?

19 A. Without reviewing the totality, I'm
20 not sure it relates to anything else. The two
21 sentences of those two footnotes -- that's what the
22 footnotes are supporting.

1 Q. Have you reviewed the entirety of
2 Richard Wyner's deposition -- declaration submitted
3 in this case?

4 A. I did read that at one point in time.

5 Q. Do you dispute any part of it?

6 A. I don't recall, one way or the other,
7 sitting here.

8 Q. Sitting here today, do you dispute
9 any statement made in Mr. Wyner's declaration?

10 A. I don't -- to the degree he has a
11 statement that any of my opinions are contradictory
12 of, then the answer to that would be yes, but I
13 haven't tried to map specifically his statements to
14 my opinions.

15 Q. In Paragraph 22 of your declaration,
16 you state, In fact, I would expect the
17 Aldrich/Murray data production process would be
18 even less burdensome than the Bestwall and DBMP
19 process because DCPF -- DCPF has already developed
20 applicable algorithms through responding to similar
21 requests for the Bestwall and DBMP Debtors.

22 Did I read that part of your

1 declaration correctly?

2 A. You did.

3 Q. Specifically, what are the algorithms
4 DCPF has already developed that are referenced in
5 that declaration?

6 A. Extracting the data fields would be
7 an almost identical query to the query that was run
8 in the other, particularly DBMP. The review for
9 looking for whatever protocols -- I don't know what
10 protocols they used -- but whatever protocols they
11 developed to review and remove any PII or PHI that
12 might be in the fields. They've already developed
13 those protocols and applied them before. So they
14 have the benefit of that experience to work on when
15 they do it again. And so almost always, your
16 second time doing that exercise is less expensive
17 than your first time because you have the benefit
18 of that experience.

19 Q. So -- so the benefit of the
20 experience, is that what you're referring to as an
21 algorithm?

22 A. Writing the algorithm and then the

1 protocols, the processes they put in place. They
2 had to develop some process for reviewing and
3 redacting. And the other piece that's in there
4 because of the likely overlap, if they chose to
5 cross-reference with the records that they already
6 produced in DBMP in their production process, the
7 ones that had information that needed to be
8 redacted from DBMP, they could bring over the
9 redacted field and not have to redo the redaction.

10 So the overlap should make it less
11 expensive because they've already done it for
12 subpopulation, and the fact that they have the
13 experience of having done it before and they aren't
14 developing the protocols should make it less
15 expensive.

16 Q. Do you have any firsthand knowledge
17 of the process that DCPF employs to review and
18 redact these records?

19 MR. EVERT: Objection: asked and
20 answered.

21 THE WITNESS: No.
22

1 BY MR. GUERKE:

2 Q. Even though the subpoena doesn't
3 specifically request personal identifying
4 information, you agree that it would capture
5 certain personal identifying information, right?

6 A. That is the allegation by the Trusts.
7 I understand their allegation. You know, it is
8 not -- there's traces when you build a database and
9 the exposure fields. If they've chosen to include
10 that type of information in an exposure field, then
11 it could be there.

12 They assert that some of those
13 exposure fields contain that information. So
14 that's -- their position is it does.

15 You could imagine a database about
16 exposure that doesn't have PII in because that's
17 really not relevant to the exposure.

18 So if you had a clean exposure field,
19 then you wouldn't have that issue. Right? So it's
20 the fact that their exposure field isn't clean,
21 it's contaminated with PII, that creates this
22 issue. It wasn't obvious at the time of issuing,

1 seeking the data that that would be the case.

2 Q. But you don't dispute that that is
3 the case, right?

4 A. I -- I don't dispute the assertion.

5 Q. Are you measuring DCPF's burden by
6 using the \$86,000 billed in production costs in
7 DBMP?

8 A. I view it as a relevant data point.
9 I don't think they're going to be at the exact same
10 number next time.

11 I mean, from a burden perspective,
12 it's more about the hours, because that's --
13 ultimately, that was paid by the Debtors and DBMP,
14 as I understand it. So the financial burden was
15 borne by the Debtors, but it's the scope of the
16 exercise.

17 Q. You don't know what the per record
18 review costs for these Debtors' subpoenas will be
19 for DCPF, right?

20 A. So you can get a rough estimate. And
21 if -- you can look at things like the Garlock data
22 and estimate how many Trusts a typical Claimant

1 goes -- would file a claim against. You can take
2 the \$86,000, the number of claims that were
3 reviewed, divide, and you're going to be on the
4 order for that of about ten cents a record.

5 Now, that doesn't mean we will come
6 in at exactly ten cents a record here, but it was
7 kind of if you do that back-of-the-envelope math,
8 you'll see it more on that order.

9 Q. You're speculating what -- what -- it
10 would be speculation to try to determine what
11 DCPF's costs would be to respond to these Debtors'
12 subpoena, right?

13 A. I wouldn't go and say it's
14 speculation. You have an estimate. You can look
15 at what did it cost them to respond to the DBMP
16 subpoena, which was substantively identical in
17 nature. And so you have a very good benchmarking
18 exercise.

19 It's not pure speculation. That
20 would be -- you know, it is an estimate, but I
21 wouldn't call that pure speculation. You know, the
22 -- almost perfect comparable to gauge what the cost

1 would be.

2 Q. DBMP included roughly 9,000
3 Claimants, right?

4 A. Correct.

5 Q. Aldrich and Murray include roughly
6 12,000 Claimants, correct?

7 A. Correct.

8 Q. So there are 3,000 more Claimants in
9 play in this case, right?

10 A. Correct.

11 Q. So you would expect the costs of
12 production in this case to be greater than in DBMP,
13 correct?

14 A. I don't think you can draw that
15 conclusion. If there was zero overlap in the
16 Claimants and your exercise is one-third larger,
17 rough order, you would probably expect it to cost
18 one-third more.

19 There may be some start-up costs, and
20 so the start-up costs you have once, and then the
21 per-claim file review. So maybe it's a little less
22 than one-third more, because you don't have to do

1 the start-up costs an extra time. You still have
2 that once, but that's ignoring the overlap in the
3 Claimants.

4 So if, hypothetically, 6,000 of the
5 Claimants overlapped and that redaction had already
6 been completed, maybe you only have to look at
7 6,000 Claimants, because those are the ones that
8 haven't been done. And then you would expect it
9 would be less expensive.

10 If only 2,000 overlapped and so you
11 had to look at 10,000, you would expect it to be a
12 little more expensive. I don't know the exact
13 overlap, but I would think they would take
14 advantage over that overlap because they could
15 materially reduce their cost.

16 Q. Whatever the review costs would be,
17 it would be less with a sample, correct?

18 A. Correct.

19 MR. EVERT: Kevin, let me
20 interrupt you for a second.

21 He's available from 1:00 to 5:00,
22 and it will be 5:00 -- it's four minutes to

1 5:00. We -- I know you got a little more to
2 go, but I'm just wondering would it assist
3 things if we can try to expedite to take
4 five minutes and get organized, or are you
5 close to finishing or just trying to get a
6 sense --

7 MR. GUERKE: I'm using the
8 5:00 p.m. as where I'm trying to finish.
9 It's up to you. I will take five minutes and
10 try to streamline it --

11 MR. EVERT: No. If you think
12 you're there --

13 MR. GUERKE: -- I will go until
14 you tell me to stop.

15 So you -- when are you going to
16 tell me to stop?

17 MR. EVERT: I'm not going to tell
18 you stop at dead 5:00 -- is he last? Anybody
19 else?

20 MR. HOGAN: I have one -- I had
21 one series of questions about Paragraph 16,
22 and that will take me probably 10 minutes.

1 MR. GUERKE: Let me just go

2 through --

3 MR. EVERT: You want to try to
4 make it to 5:00, and then Dan will take it
5 from there?

6 MR. GUERKE: I will go through
7 this series of questions and hand it off.
8 Thank you.

9 BY MR. GUERKE:

10 Q. Are you aware that November 30th, the
11 Court ruled on DCPF and the DCPF's Trusts motion to
12 quash?

13 A. I know there was such a ruling. I
14 couldn't tell you the date.

15 Q. And it was a 10 percent sample
16 ruling, right?

17 A. There -- I'm aware that -- his
18 decision for 10 percent sample, yes.

19 Q. In December, after that -- that
20 decision was rendered, the Debtors proposed a
21 stratified random sampling protocol to the parties
22 involved in -- in this case.

1 Are you familiar with that?

2 A. I'm very familiar with that.

3 Q. Were you involved in preparing that
4 stratified random sample?

5 A. Yes.

6 Q. Were you in charge of that -- that
7 process? Is that your work product?

8 A. I directed all the work on that;
9 that's correct.

10 Q. The proposed sample that was
11 circulated December 19th was sufficient for your
12 purposes in this case, correct?

13 MR. EVERT: Object to the form of
14 the question.

15 THE WITNESS: I would not describe
16 it that way.

17 So given there's now external
18 constraint, the most data you can have is
19 10 percent. I want all 10 percent. That's
20 the most I'm allowed to have, and I'm going
21 to try to design a sample that will get me
22 the greatest level of efficiency I can out of

1 those data.

2 All right. But it's a constraint
3 now. If the Court orders it, whether you
4 like it or not, whether you think it's the
5 right decision or not, you live with it.

6 So it was going -- I just accepted
7 that things weren't going to be as precise
8 and I'd give less guidance to the Court than
9 I believe was optimal given the cost-benefit
10 analysis here.

11 BY MR. GUERKE:

12 Q. And the sample that you prepared
13 would have worked in your analysis, correct?

14 MR. EVERT: Object to the form of
15 the question.

16 THE WITNESS: So the question I
17 gave before to work could be the same answer
18 now -- the answer I gave to the similar
19 question would be the same now.

20 BY MR. GUERKE:

21 Q. The -- are you finished with your
22 answer? I didn't mean to interrupt you.

1 A. Yes.

2 Q. The proposed stratified random sample
3 that -- that the Debtors circulated is a
4 representative and efficient sample.

5 You would agree with that, correct?

6 A. That is its intent, is to be as
7 efficient -- it is definitively representative.
8 It's trying to squeeze as much efficiency out of
9 the sample of 1,200 as one can.

10 Q. And the -- the -- the proposed
11 stratified random sample would provide a reliable
12 cross-section of Debtors' mesothelioma claims
13 settlement history, correct?

14 A. Reliable? I can't go to that point
15 at this. I haven't done the analysis.

16 This is where it goes back to the
17 same as does it work. For certain questions, that
18 is very likely to turn out to be enough. And for
19 other questions, I think there's a very high
20 probability that it's not sufficient and will end
21 up with very broad confidence intervals.

22 Q. The sample that you prepared and was

1 circulated to the parties was seeking information
2 for the period 2014 to the present, right?

3 A. Well, part of that negotiation was if
4 we are going to be constrained to just 1,200
5 Claimants, the more recent Claimants are -- answer
6 more questions than the ones further back. I gave
7 some answers before about the further back ones are
8 to get demographic trends. The more recent ones
9 contribute both to the demographic trends and to
10 this question of were all the exposures disclosed.
11 So there's more information for the purpose of
12 estimation.

13 So I made the determination that
14 dropping all the earlier claims and losing that
15 information on trend was better than risking not
16 being able to answer the questions on full
17 disclosure. It's a trade-off. It may render,
18 being able to control for the trends properly,
19 impossible. But I'm now facing an external
20 constraint, and I'm trying to do the best I can
21 within that constraint.

22 Q. And you could have performed your

1 analysis with Trust data from 2014 to the present,
2 right?

3 MR. EVERT: I object.

4 And, Kevin, I've got to say I
5 object to this entire line of questioning,
6 because that was a 408 effort to compromise a
7 disputed issue in the case. And I think it's
8 inappropriate to use an e-mail that a lawyer
9 wrote to cross-examine him about what --
10 about what the lawyer's intent was in trying
11 to get the case settled.

12 MR. GUERKE: This was after the
13 ruling --

14 MR. EVERT: I understand, but we
15 still had a disputed issue about how to draw
16 the sample.

17 But I just -- I'm sorry. Note --
18 note for the record my objection to the -- to
19 the entire line of questioning. I think it's
20 inappropriate.

21 But you're welcome to have the
22 question read back or ask it again.

1 THE WITNESS: I, as a person who
2 is going to ultimately potentially file an
3 estimation report, made the judgment call
4 that I'd rather risk not being able to -- I'd
5 rather risk not being able to control for the
6 industry and occupation mix of Claimants and
7 those trends demographically than not being
8 able to reliably quantify the number of
9 exposures that were being disclosed.

10 I was forced into having to make a
11 trade-off I would not want to make that I
12 don't think the cost-benefit analysis
13 supports. But I'm very much putting at risk
14 being able to properly control for the
15 demographic trends by constrained 2014.

16 But I had to give something up. I
17 had a Court order. So I decided what would
18 create an expectation the least harmful
19 within that month.

20 MR. GUERKE: Based on the time,
21 Dr. Mullin, I'm going to pass the witness.
22 Thank you very much.

1 THE WITNESS: Thank you.

2 --oOo--

3 EXAMINATION BY COUNSEL FOR
4 CERTAIN MATCHING CLAIMANTS

5 --oOo--

6 BY MR. HOGAN:

7 Q. Good afternoon, Dr. Mullin. It's
8 Daniel Hogan on behalf of the Certain Matching
9 Claimants. I will try not to take too much of your
10 time, but I appreciate your time today.

11 A. Good afternoon.

12 Q. I'd ask you to direct your attention
13 to Paragraph 16 of your declaration. I'm going to
14 attempt to endeavor to limit it -- my questions to
15 this paragraph.

16 If you would, the first sentence
17 provides that The Trust data are also needed to
18 assess whether the Debtors entered into settlements
19 aware of the totality of alternative exposures.

20 Would you agree with me that that's a
21 temporal exercise?

22 A. What do you mean by "temporal

1 exercise"?

2 Q. Well, the statement, in -- in and of
3 itself, is a statement about what the Debtors were
4 aware of.

5 An awareness is a state of mind.

6 Would you agree?

7 A. "Knowledge" in this sense is probably
8 the word I would use.

9 Q. Okay. And from a temporal aspect,
10 there's a point in time at which somebody is either
11 aware or has knowledge of something or they don't
12 have knowledge of something.

13 Would you agree?

14 A. Correct.

15 Q. Okay. And so from -- from this
16 statement's standpoint, at some point in the
17 Trust -- or in -- in the Debtors' database, there
18 is a determination about what the Debtor knew and
19 when they knew it.

20 Would you agree?

21 MR. EVERT: Object to the form of
22 the question.

1 THE WITNESS: I don't think, in
2 their database, that information is there. I
3 think that's something, generally, you have
4 to go to underlying claim records for.
5 That's not, in general, available in their
6 claims database in electronic form.

7 BY MR. HOGAN:

8 Q. Okay. So your statement is that the
9 Trust data from DCPF from Verus is needed to assess
10 whether the Debtors entered into settlements aware
11 of the totality of alternative exposures.

12 So let's just break it down.

13 At some point, there's a -- there's a
14 state of mind of the Debtors about what they knew
15 about alternative exposures. And if you look at
16 that on a timeline, there's some point at which
17 they didn't know it. And somewhere along that
18 continuum up till now, they became aware.

19 Would you agree?

20 MR. EVERT: Object to the form of
21 the question.

22 THE WITNESS: I don't agree with

1 the temporal part. I don't know if they're,
2 even as of today, aware of the totality of
3 the exposures. So I don't -- I can't agree
4 that as of -- at some point in time, they
5 became aware of the totality.

6 This sentence is very much looking
7 at the time of settlement.

8 BY MR. HOGAN:

9 Q. At the time of what settlement?
10 Maybe that'll help.

11 A. When the Debtors entered into a
12 settlement with a given Claimant.

13 Q. Okay. So you would agree with me, I
14 hope, that at the time that the Debtors entered
15 into a settlement with any particular matching
16 Claimant or any Claimant that they settled with,
17 that they -- they either knew or didn't know of
18 alternative exposures?

19 A. There would be a set of alternative
20 exposures they would be aware of, typically, and
21 there may be zero or multiple exposures they're not
22 aware of.

1 Q. Okay. And how they came to that
2 awareness is critical.

3 Yes or no?

4 MR. EVERT: Object to the form of
5 the question.

6 Critical to what?

7 BY MR. HOGAN:

8 Q. Critical to their understanding and
9 determination about whether to make the settlement.

10 A. So it's -- the -- that is not the
11 only determinant that goes into a settlement
12 decision --

13 Q. I understand that --

14 A. -- so --

15 Q. -- but it is --

16 A. -- context --

17 Q. -- but it is one -- pardon me.

18 A. -- it is one -- it is one element
19 that goes into a settlement. It's not the only
20 element. So context of many other things could
21 matter.

22 Q. But you state that, Specifically, the

1 data would also allow us to compare exposure
2 allegations to the products of the reorganized
3 entities for which the Trusts were established with
4 exposure -- with exposure those same Claimants
5 disclosed in their tort litigation against the
6 Debtors.

7 Is that a fair statement?

8 Did I read that correctly?

9 A. Pretty close, I think.

10 Q. You had testified earlier that you
11 largely have a mathematical model for everything;
12 isn't that right?

13 A. Ultimately, you're going to reduce
14 things to computations if you're doing a damages
15 analysis, which is what I'm doing.

16 Q. So have you reduced the Debtors'
17 knowledge as it relates to settlements about what
18 their knowledge of other alternative exposures
19 were?

20 MR. EVERT: Object to the form of
21 the question.

22 THE WITNESS: Not at this stage.

1 BY MR. HOGAN:

2 Q. Will you?

3 A. Ultimately, my task is to give a
4 numerical quantification, so I have to reduce
5 everything to numbers eventually. So that's
6 mathematics. So, ultimately, I will be doing that
7 through mathematics.

8 Q. So the answer is yes, you will be
9 doing that? You will be reducing the Debtors'
10 knowledge of alternative exposures at the time of
11 settlement?

12 MR. EVERT: Object to the form of
13 the question.

14 BY MR. HOGAN:

15 Q. Is that a correct answer -- is that a
16 correct question -- do you understand the question?

17 A. No. I think you needed another
18 phrase at the end of it for it to make sense.

19 Q. My apologies. I'll rephrase the
20 question. I'll strike that.

21 You testified that there is a
22 mathematical model that you will reduce information

1 to.

2 And I'm asking you about -- with
3 regard to settlements that the Debtor entered into,
4 you're going to make a determination in a
5 mathematical model which will address whether or
6 not they were aware of alternative exposures when
7 they made that settlement?

8 A. Well, there's a factual question of
9 what fraction of them they're aware of. That's a
10 ratio --

11 Q. Sure.

12 A. -- so the impact of that on the
13 settlement is really going to Paragraph 17.

14 So if we're transitioning to
15 Paragraph 17, which I didn't think we were doing,
16 we're getting into the impact. The -- Paragraph 16
17 is just if you're exposed to 38 products and the
18 Debtor only knew about three of those at the time
19 they settled or maybe the Debtor knew about 38 at
20 the time they settled, that's a factual question --

21 Q. Sure.

22 A. -- that's all Paragraph 16 is talking

1 about, that factual question.

2 How that enters into an estimate --
3 estimate of future liability becomes a modeling
4 question, which is moving into Paragraph 17.

5 Q. Okay. Before we do that, let's talk
6 about what you just said about the mathematical
7 aspect of that.

8 If I take that calculus that you just
9 undertook and overlay an administrative settlement
10 on top of it, how does that factor into that
11 calculation?

12 MR. EVERT: Object to the form of
13 the question.

14 THE WITNESS: It depends on the
15 nature of the administrative settlement. It
16 becomes fact-specific.

17 BY MR. HOGAN:

18 Q. Okay. And you understand generally
19 how administrative settlements work?

20 A. There's a whole range of them --

21 Q. I --

22 A. -- I understand generally the range

1 of administrative settlements in the asbestos
2 environment.

3 Q. Okay. So you understand that in a
4 large share of those administrative settlement
5 constructs, that there weren't questions asked
6 about alternative exposures.

7 Do you understand that?

8 A. I am aware that there are
9 administrative settlements where that information
10 is not exchanged.

11 Q. You're aware that there's
12 administrative settlements where that information
13 is not requested?

14 A. I believe that's true as well.

15 MR. HOGAN: All right. I don't
16 have anything else. Thanks for your time.

17 MR. EVERT: All right. Thanks,
18 everybody.

19 (Witness excused.)


20

21 (Deposition concluded at
22 approximately 5:11 p.m. EDT.)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

C E R T I F I C A T E

I, Cindy L. Sebo, Nationally Certified Court Reporter herein do hereby certify that the foregoing continued deposition of CHARLES HENRY MULLIN, PH.D. was taken before me pursuant to notice, at the time and place indicated; that said witness was previously duly sworn remotely by a certified stenographer to tell the truth, the whole truth, and nothing but the truth under penalty of perjury; that the testimony of said witness was correctly recorded to the best of my ability in machine shorthand and thereafter transcribed under my supervision with computer-aided transcription; that the deposition is a true and accurate record of the testimony given by the witness; and that I am neither of counsel nor kin to any party in said action, nor interested in the outcome thereof.



Cindy L. Sebo, RMR, CRR, RPR, CSR, CCR,
CLR, RSA, NYRCR, NYACR, CA CSR #14409,
NJ CCR #30XI00244600, NJ CRT
#30XR00019500, Washington CSR
#23005926, Oregon State #230105,
TN #CSR 998, Remote Counsel Reporter,
LiveLitigation Authorized Reporter

1 C. Michael Evert, Jr., Esq.

2 cmevert@ewhlaw.com

3 May 9, 2023.

4 RE: Armstrong World Industries, Inc., et al. v. Aldrich Pump
5 LLC, et al.

6 5/8/2023, Charles Henry Mullin , Ph.D. (#5905066)

7 The above-referenced transcript is available for
8 review.

9 Within the applicable timeframe, the witness should
10 read the testimony to verify its accuracy. If there are
11 any changes, the witness should note those with the
12 reason, on the attached Errata Sheet.

13 The witness should sign the Acknowledgment of
14 Deponent and Errata and return to the deposing attorney.
15 Copies should be sent to all counsel, and to Veritext at
16 cs-ny@veritext.com.

17 Return completed errata within 30 days from
18 receipt of testimony.

19 If the witness fails to do so within the time
20 allotted, the transcript may be used as if signed.

21 Yours,

22 Veritext Legal Solutions

EXHIBIT C

1 APPEARANCES (via Teams continued):

2 For the ACC:

Robinson & Cole LLP
BY: NATALIE RAMSEY, ESQ.
1201 N. Market Street, Suite 1406
Wilmington, DE 19801

4

5

Caplin & Drysdale
BY: TODD PHILLIPS, ESQ.
One Thomas Circle, N.W.,
Washington, DC 20005

6

7 For the FCR:

Young Conaway
BY: TRAVIS BUCHANAN, ESQ.
1000 North King Street
Wilmington, DE 19801

8

9

10 For CertainTeed LLC, et al.:

Goodwin Procter LLP
BY: HOWARD S. STEEL, ESQ.
620 Eighth Avenue
New York, NY 10018

11

12

13

Rayburn Cooper & Durham, P.A.
BY: MATTHEW TOMSIC, ESQ.
227 West Trade Street, Suite 1200
Charlotte, NC 28202

14

15

For the Bankruptcy
Administrator:

Office of Bankruptcy
Administrator
BY: ALEXANDRIA KENNY, ESQ.
402 West Trade Street, Suite 200
Charlotte, NC 28202

16

17

18 ALSO PRESENT (via Teams):

SANDER L. ESSERMAN
Future Claimants' Representative
2323 Bryan Street, Suite 2200
Dallas, TX 75201-2689

19

20

21

22

23

24

25

1 could not tell you which way I will go in an estimation
2 hearing.

3 I also don't have an opinion as to whether or not
4 there has been suppression of evidence. Those are serious
5 charges and notwithstanding the fact that Judge Hodges found on
6 the record that he had in Garlock what he did, I'm going to
7 take a very close and careful look at that. Because those are
8 very damning charges.

9 So I just want to tell you if you're worried about
10 being in the Western District of North Carolina, please
11 understand we take our cases one at a time and we've got three
12 different judges who've had these cases and you can't count on
13 any of us, totally, in agreeing with one another on, on these
14 matters at this point in time, okay?

15 So that said, I think we ought to give it a go. I'll
16 leave it to you to try to talk about how to frame this up and
17 who to pick as the mediator and we can talk about that next
18 month or I'll make myself available and set up a
19 videoconference call if you have issues. But I believe we
20 ought to at least make the effort here if for no other good
21 reason than where we're going right now is going to be a great
22 deal of work and expense and all concerned probably have better
23 things to do if we don't have to go through these, these
24 particular litigation thickets.

25 So let's just find out. We won't slow things down,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

CERTIFICATE

I, court-approved transcriber, certify that the foregoing is a correct transcript from the official electronic sound recording of the proceedings in the above-entitled matter.

/s/ Janice Russell

April 17, 2023

Janice Russell, Transcriber

Date

EXHIBIT D

UNITED STATES BANKRUPTCY COURT
WESTERN DISTRICT OF NORTH CAROLINA
CHARLOTTE DIVISION

In re BESTWALL LLC, ¹ Debtor.	Chapter 11 Case No. 17-31795 (LTB)
--	---------------------------------------

DECLARATION OF JORGE GALLARDO-GARCIA, PHD

I, Jorge Gallardo-García, PhD declare:

- (1) I am a Partner with Bates White, LLC (“Bates White”), an economic consulting firm with its primary office located in Washington, DC. The U.S. Bankruptcy Court for the Western District of North Carolina (the “Bankruptcy Court”) authorized Bestwall LLC (“Bestwall”) to retain Bates White in its chapter 11 case by an *Ex Parte Order Authorizing the Debtor to Retain and Employ Bates White, LLC as Asbestos Consultants as of the Petition Date*.² I am duly authorized to make this Declaration as a consultant for Bestwall in this action.

Qualifications

- (2) I specialize in the application of statistics and computer modeling to economic and financial issues, and I have extensive experience working on the construction and design of complex databases for econometric and statistical analyses. I have more than 20 years of experience in the management, design, and analysis of large complex databases using statistical and econometric tools. Further, I have 15 years of experience in the management, design, and analysis of large complex asbestos personal injury and wrongful death claims’ databases using statistical and econometric tools for valuation and forecasting. In particular, I have designed representative and efficient random samples of claims for multiple asbestos-related matters, and those samples have been used in central valuation analyses in those matters. I have submitted expert reports and

¹ The last four digits of the Debtor’s taxpayer identification number are 5815. The Debtor’s address is 133 Peachtree Street, N.E., Atlanta, GA 30303.

² *Ex Parte Order Authorizing the Debtor to Retain and Employ Bates White, LLC, as Asbestos Consultants as of the Petition Date*, No. 17-31795 (Bankr. W.D.N.C. Nov. 2, 2017) (Dkt. 40).

testified in U.S. Bankruptcy Court regarding the construction and reliability of asbestos claims databases.

- (3) I received a PhD and an MA in Economics from the University of Pennsylvania, and a BS in Economics, a BS in Business Administration, and an MA in Economics from the Instituto Autónomo de México in Mexico City.
- (4) A complete and accurate copy of my curriculum vitae is attached as Exhibit 1 to this Declaration.
- (5) I have personal knowledge of the facts set forth in this Declaration and, if called as a witness, would testify competently to such facts under oath.

Background

- (6) Bestwall retained Bates White in its chapter 11 case to perform, among other things, a reliable estimation of Bestwall's legal liability for mesothelioma claims; that is, estimating Bestwall's share of final judgments that would be obtained by current and future Bestwall mesothelioma claimants.
- (7) Since the commencement of Bestwall's chapter 11 case, I have been leading Bates White's work to construct an analytical database containing information about the asbestos personal injury and wrongful death claims filed against Bestwall and its predecessors (the "Bestwall Analytical Database"). This Bestwall Analytical Database will be the foundation for most of the analyses Bates White will perform in Bestwall's case, including Bates White's estimate of Bestwall's legal liability.
- (8) I led Bates White's design, construction, and implementation of a random sample of historical Bestwall mesothelioma claims for further review and analysis (the "Bestwall Random Sample"), as one of the components for the Bestwall Analytical Database. The Bestwall Random Sample is comprised of 2,407 claims, of which 35 are verdicts, 1,466 are settled claims, and 906 are dismissed claims. I described the statistical foundation, the methodology, and the design for the Bestwall Random Sample in my June 29, 2021 Declaration (the "June Declaration").³ In the June Declaration, I also explained that the Bestwall Random Sample was designed to be a representative and efficient sample that can provide a reliable characterization of Bestwall's

³ Declaration of Jorge Gallardo-García, PhD, June 29, 2021 (Dkt. 1924-G).

mesothelioma resolution history. The opinions I offered in the June Declaration concerning the reliability and efficiency of the Bestwall Random Sample remain unchanged.

- (9) It is my understanding that Bestwall’s counsel provided the list of 2,407 Bestwall claims comprising the Bestwall Random Sample to the Official Committee of Asbestos Personal Injury Claimants (the “ACC”) and the Future Claimants’ Representative (the “FCR” and, together with the ACC, the “Claimant Representatives”). It is my further understanding that Bestwall’s counsel also provided to the Claimant Representatives information about how Bates White designed the Bestwall Random Sample and that such information was then provided to the FCR’s consultant, Ankura Consulting Group, LLC (“Ankura”). According to an email from the FCR’s counsel,⁴ Ankura, on behalf the Claimant Representatives, randomly selected 500 settled mesothelioma claims (the “ACC/FCR Additional Claims”) that were not already part of the Bestwall Random Sample.⁵ The email from the FCR’s counsel further represented that the ACC/FCR Additional Claims were drawn from the settled claims not sampled in the Bestwall Random Sample using a stratified random sampling technique in which Ankura first assigned the non-sampled settled claims to groups based on claim amount and then drew claims randomly from certain groups using simple random sampling.⁶ Upon review of the ACC/FCR Additional Claims, Bates White has determined that all those claims appear in the Bestwall claims database with settlements for less than \$400,000 each.
- (10) Taken together, the Bestwall Random Sample and the ACC/FCR Additional Claims include a total of 1,966 settled mesothelioma claims. Thus, accounting for the 35 verdicts that were randomly selected in the Bestwall Random Sample, there are a total of 2,001 Bestwall verdict and settled mesothelioma claims within the combined samples (the “Combined Random Sample”).⁷ The Combined Random Sample, when weighted appropriately, is also a

⁴ Sharon M. Zieg, Young Conaway Stargatt & Taylor LLP, email message to Davis L. Wright and Natalie D. Ramsey, Robinson & Cole LLP; James M. Jones, Jennifer L. Del Medico, Gregory M. Gordon, Jeffrey B. Ellman, and Jeff A. Kaplan, Jones Day; Garland Cassada and Stuart Pratt, Robinson Bradshaw; Erin Edwards, Edwin Harron, Elisabeth Bradley, and Paul Loughman, Young Conaway Stargatt & Taylor LLP; Richard Schneider, King & Spalding; with copy to Anne M. Steadman, Young Conaway Stargatt & Taylor LLP (July 8, 2021), attached as Exhibit 2 to this Declaration.

⁵ Thus, the set of ACC/FCR Additional Claims do not overlap with the Bestwall Random Sample.

⁶ I understand that Ankura separated the settled claims that were not part of the Bestwall Random Sample into groups defined by cutoffs of \$50,000. Then, the ACC/FCR Additional Claims were randomly selected from the groups with cutoff values up to \$400,000. At this time, certain questions remain about details of the stratified random sample methodology the ACC and FCR consultants used in selecting the ACC/FCR Additional Claims. For purposes of this Declaration and for designing the subsample described herein, I accept the FCR’s counsel’s representations as accurate.

⁷ $2,001 = 35 \text{ verdicts} + 1,466 \text{ settled claims from the Bestwall Random Sample} + 500 \text{ settled claims from the ACC/FCR Additional Claims}$.

representative sample of Bestwall's mesothelioma verdicts and settlement history because the Bestwall Random Sample is a representative sample of that resolution history and the ACC/FCR Additional Claims were drawn randomly, as described by the FCR's counsel. The Combined Random Sample, however, is less efficient as it includes more claims than necessary given that representativeness was already provided by the Bestwall Random Sample.

- (11) While both the Bestwall Random Sample and Combined Random Sample are reliable random samples for performing analyses related to Bestwall's liability estimation, Bestwall's counsel requested that I prepare a third sample that accounts for the ACC/FCR Additional Claims. In particular, Bestwall's counsel requested that, using the Combined Random Sample, Bates White prepare a random sample of approximately 1,500 verdict and settled claims (the "Joint 10% Random Sample"). As explained below, the claims in the Joint 10% Random Sample were randomly selected from the 2,001 Bestwall verdict and settled mesothelioma claims in the Combined Random Sample, which include the ACC/FCR Additional Claims.

Overview

- (12) I make this Declaration at the request of Bestwall's counsel in connection with Bestwall's *Motion to (A) Approve the Resolved Claim Sample and (B) Authorize Related Disclosure Pursuant to Rule 502(d) of the Federal Rules of Evidence* filed in the above-referenced chapter 11 case. This Declaration describes the Joint 10% Random Sample for use in Bestwall's estimation proceeding.
- (13) The Joint 10% Random Sample was constructed by random sampling from the 2,001 verdict and settled cases in the Combined Random Sample. Like for the Bestwall Random Sample, Bates White followed well-established and generally accepted methods of statistical sampling when designing the Joint 10% Random Sample. This included accounting for Bates White's use of stratified random sampling for the Bestwall Random Sample and Ankura's reported use of stratification and supplemental random sampling methods for the ACC/FCR Additional Claims.
- (14) A stratified random sample of Bestwall mesothelioma claims can be designed to be representative of claims settled with different amounts by ensuring that the resulting sample includes sufficient examples from the whole distribution of amounts. I explained this in detail in my June Declaration. The Joint 10% Random Sample preserves the stratification structure that was in place for the Bestwall Random Sample and accounts for the ACC/FCR Additional Claims. Further, with detailed information about the methodology followed by Ankura in

selecting the ACC/FCR Additional Claims,⁸ the Joint 10% Random Sample can be used as representative of Bestwall's mesothelioma verdicts and settlements history and can be used for robust statistical analyses in this matter.

Random Sampling Techniques

- (15) As explained in my June Declaration, sampling is a useful strategy if gathering and reviewing information for the whole population by conducting a census is not an option, for example, due to the financial cost or time delay associated with such an exercise. Because a sample includes only a fraction of the whole population, it invariably increases the analytical burden and can reduce the precision of results when compared to performing the same analysis on data for the whole population. Thus, any sample of a population should be designed in a manner that reduces the analytical burden and the uncertainty in the results. Such a sample should include elements from all segments of the target population, with sufficient numbers to allow for robust inferences. In order to draw a representative random sample that can be used to make robust inferences about the population, the sampling technique chosen in a specific situation must take into account the characteristics of the population and the level of precision desired.
- (16) Stratified random sampling is a technique that involves dividing the target population based on known characteristics into smaller non-overlapping groups such that every element of the population belongs to one and only one group. Then, within each group, simple random sampling is applied, where each element within the group has an equal probability of being sampled.⁹

⁸ At this time, Bates White has not received the sampling weights Ankura calculated for each of the settled claims not in the Bestwall Random Sample. Additionally, Bates White has not received information on the exact stratification followed by Ankura. However, based on representations from the FCR's counsel, the Joint 10% Random Sample is a representative sample of Bestwall's mesothelioma verdicts and settlements history. Should those representations prove incorrect, I reserve the right to update my opinions in this Declaration.

⁹ Stratified random sampling is used in a wide range of fields and applications by economists, statisticians, researchers, and statistical agencies. For example:

The Current Population Survey (CPS), published by the Bureau of Labor Statistics, is one of the most recognized surveys in the United States (<https://www.bls.gov/cps/>). The CPS technical documentation describes the stratified sampling design for this survey (*see* https://www.bls.gov/cps/sample_redesign_2014.pdf).

The American Community Survey (ACS) is conducted by the Census Bureau (<https://www.census.gov/programs-surveys/acs>). Its "Design and Methodology" publication describes how it uses a stratification strategy based on a measure of the size of the *Census Block* (*see* https://www2.census.gov/programs-surveys/acs/methodology/design_and_methodology/acs_design_methodology_previous.pdf).

For textbook examples of the theoretical foundation and applications of stratified random sampling methods *see*:

The Joint 10% Random Sample

- (17) As described in detail in my June Declaration, Bates White designed and identified the Bestwall Random Sample as a stratified random sample representative of Bestwall’s historical mesothelioma claims that were resolved through verdict, settlement, or that were dismissed by the claimants.
- (18) Bestwall’s asbestos tort experience shows an uneven distribution of the number of claims it resolved, including the divergence of settlement values, and the rarity of cases resolved through verdict and by settlements over \$1 million. My June Declaration provides a detailed description of Bestwall’s distribution of its mesothelioma settlement amounts and rarity of verdicts. For example, of the approximately 15,000 settled mesothelioma claims in Bestwall’s tort history, more than 60% settled for \$50,000 or less while less than 1% were settled for amounts of more than \$1 million. Further, the 35 mesothelioma verdicts (7 plaintiff verdicts and 28 defense verdicts) Bestwall experienced in its tort history represent only about 0.23% of the mesothelioma claims that Bestwall resolved through verdict or settlement.
- (19) Therefore, to ensure that the Joint 10% Random Sample includes sufficient observations of claims with different claimant and claim characteristics, especially those that are rare—e.g., verdicts and claims with high settlement values—I maintained the same stratification used to draw the Bestwall Random Sample.
- (20) The Joint 10% Random Sample is a subsample drawn from the Combined Random Sample which incorporates the Bestwall Random Sample and the ACC/FCR Additional Claims, and that can be used as a representative sample of Bestwall’s historical mesothelioma verdicts and settlements population.
- (21) Specifically, the Joint 10% Random Sample was designed as follows. First, Bates White pooled the 2,001 Bestwall verdict and settled claims from the Bestwall Random Sample and the ACC/FCR Additional Claims into a single set of Bestwall claims (the Combined Random Sample). Second, Bates White classified each of the 2,001 claims in this combined set using the same stratification for verdict and settled claims used for the Bestwall Random Sample.¹⁰ That is,

Paul S. Levy and Stanley Lemeshow, *Sampling of Populations: Methods and Applications*, 4th ed. (Hoboken, N.J.; Wiley, 2013).

William G. Cochran, *Sampling techniques*, 3rd ed. (New York; Wiley, 1977).

¹⁰ As explained in my June Declaration, for purposes of asbestos trust discovery, dismissed claims were not included in the 1,501 random sample described in such declaration and are also not included in the Joint 10% Random Sample described herein.

the pooled set of 2,001¹¹ mesothelioma verdict and settled claims from the Combined Random Sample were parsed into 157¹² non-overlapping groups as follows:

- Verdicts (including plaintiff and defense verdicts)
 - For simplification, these claims were assigned to only one group.
- Settlements
 - Bates White separated settled claims into 156¹³ non-overlapping groups based on the period of claim resolution,¹⁴ injured party/claimant gender,¹⁵ settlement amount category,¹⁶ and an indicator for law firms with the majority of claims resolved through group settlements.¹⁷

(22) Third, within each group defined above, Bates White randomly sampled claims with equal probability.¹⁸

- For simplicity and computational convenience, all 181 claims in the groups including verdicts and settlements of more than \$1 million were included in the Joint 10% Random Sample. This is because, if these 181 claims were assigned to groups using the same factors used for the rest of the settlements, the number of claims in those resulting groups would be small. This would result in having to include all claims within those groups in a representative sample to account for differences across those claims, as those claims present large variation across claimant characteristics of interest for analysis. Further, as

¹¹ 2,001 = 35 verdicts + 1,466 settled claims from the Bestwall Random Sample + 500 settled claims from the ACC/FCR Additional Claims.

¹² This is comprised of one group for verdicts and 156 groups for settlements.

¹³ Bates White divided settled claims into 3 categories by claim resolution period, 2 categories by injured party/claimant gender, 13 categories by settlement amount, and 2 categories by the indicator for law firms with the majority of claims resolved through group settlements. Therefore, there were a total of 156 groups for settled claims ($156 = 3 \times 2 \times 13 \times 2$). The definitions of these categories are described in the next footnotes.

¹⁴ The resolution years in the Bestwall database were divided into three periods: through 2000, from 2001 through 2010, and from 2011 through Bestwall's bankruptcy petition date (November 2, 2017).

¹⁵ Claimants were identified as male or female based on the gender field included in the database.

¹⁶ Settlement amounts were divided into 13 categories, based on cut-off levels observed in the data at \$10,000, \$25,000, \$50,000, \$75,000, \$100,000, \$200,000, \$300,000, \$400,000, \$500,000, \$1 million, \$2 million, \$5 million, and greater than \$5 million.

¹⁷ Bates White classified claim records based on whether a claim was represented by a plaintiff law firm with which Bestwall entered into settlement agreements to resolve multiple claims at once, as part of inventory deals, docket clearing deals, or matrix agreements. That classification had two categories: (1) claims represented by law firms whose group settlements accounted for 50% or less of their Bestwall settled claims, and (2) claims represented by law firms whose group settlements accounted for more than 50% of their Bestwall settled claims.

¹⁸ The random sampling algorithm was designed to select a minimum of two claims from each group.

explained in my June Declaration, because these cases were important in terms of liability concerns for Bestwall, importance sampling techniques also result in their inclusion in the sample.

- Bates White then drew the rest of the random sample from each defined group that contained one or more of the remaining 1,820 (= 2,001 – 181) claims.
 - Because 181 claims (verdicts and settlements for more than \$1 million) out of the approximate 1,500 target sample size¹⁹ were already selected, 1,319 claims remained to be drawn. To approximate the distribution from the 2,001 target population, which includes the ACC/FCR Additional Claims, Bates White drew 72.5% of the claims in each group, with the resulting sample size rounded to the nearest integer.²⁰ The rounding in the number of claims resulted in an additional 1,320 claims drawn in this stage, only one more claim than the initial target.

(23) The resultant Joint 10% Random Sample includes 1,501 claims: 35 verdicts and 1,466 settled claims. Of the 1,466 randomly selected settled claims, 358 were part of the ACC/FCR Additional Claims. Thus, 72% of the ACC/FCR Additional Claims were randomly selected for inclusion in the Joint 10% Random Sample.²¹ Further, the percentage of claims in amount groups to which Ankura added claims (those with settlements of up to \$400,000) increased from about 71% in the Bestwall Random Sample to 76%²² in the Joint 10% Random Sample. Because the 1,501 claims in the Joint 10% Random Sample were randomly selected from the verdict and settled claims from the representative Combined Random Sample using stratified random sampling, the resulting sample is also a representative random sample that can be reliably used for analysis.

(24) To summarize, the Joint 10% Random Sample is a representative random subsample from the representative Combined Random Sample, which is composed of the Bestwall Random Sample and the ACC/FCR Additional Claims.

¹⁹ The 1,500 target represents about 10% of the approximately 15,000 resolved mesothelioma claims.

²⁰ The 72.5% is the result of calculating the percentage that the 1,319 claims still to be drawn (1,319 = 1,500 – 181) represent out of the remaining target population of 1,820 (1,820 = 2,001 – 181); i.e., 72.5% = (1,500 – 181) ÷ (2,001 – 181).

²¹ 72% = 358 ÷ 500.

²² These percentages assume that Ankura included the amount \$400,000 in the boundary for the top group to which they added claims. If Ankura defined that top group as “less than \$400,000” (excluding the amount \$400,000 in the boundary), the percentage represented by the supplemented groups increased from 69% in the Bestwall Random Sample to 74% of the Joint 10% Random Sample.

- (25) My understanding that the claim documents for both the Bestwall Random Sample and the ACC/FCR Additional Claims (and, therefore, for the Joint 10% Random Sample) have already been collected.
- (26) Bates White's work on this matter is ongoing. I reserve the right to update or supplement my Declaration at the request of counsel, or in the event that I receive any new information that has a material impact on my opinions.

I declare under penalty of perjury that the foregoing is true and correct.

Dated: October 28, 2021



Jorge Gallardo-García, Ph.D.
Partner
Bates White, LLC

Exhibit 1

JORGE RAÚL GALLARDO-GARCÍA, PHD

Partner

AREAS OF EXPERTISE

- Product liability forecasting
- Statistical analysis
- Insurance allocation
- Applied econometrics
- Financial reporting
- Labor and health economics



SUMMARY OF EXPERIENCE

Jorge Gallardo-García has authored and submitted expert reports and declarations and provided deposition testimony in several litigation matters. He has extensive experience in statistical modeling and data analysis and performs economic analysis, valuation, forecasting, sample design, and research, as well as discovery support. He has worked on numerous engagements involving product liability issues, in the context of bankruptcy procedures, insurance coverage disputes and settlement support, financial reporting, and strategic consulting. In addition, he has presented results of his work at national conferences on asbestos litigation topics and actuarial methods.

Prior to joining Bates White, Dr. Gallardo-García conducted empirical research on social program evaluation, labor and health economics, and demography. As part of his research, he simulated policy experiments for evaluating effects of different government health policies may have on health outcomes.

EDUCATION

- PhD, Economics, University of Pennsylvania
- MA, Economics, University of Pennsylvania
- MA, Economics, ITAM, México City, México (*summa cum laude*)
- BS, Business Administration, ITAM, México City, México (*summa cum laude*)
- BS, Economics, ITAM, México City, México (*magna cum laude*)

SELECTED BATES WHITE EXPERIENCE

- Retained as a complex database construction and statistics expert on behalf of the debtor in the matter *In re DBMP LLC* pending in the US Bankruptcy Court for the Western District of North Carolina, Charlotte Division.
- Retained and authored declarations as a complex database construction and statistics expert on behalf of the debtor in the matter *In re Bestwall LLC* pending in the US Bankruptcy Court for the Western District of North Carolina, Charlotte Division.

- Retained and authored declarations as a complex database construction and statistics expert on behalf of Truck Insurance Exchange in the matter *In re Kaiser Gypsum Company, Inc., et al.* pending in the US Bankruptcy Court for the Western District of North Carolina, Charlotte Division.
- Retained and authored declarations as a complex database construction and statistics expert on behalf of certain insurance carriers in the matter *Rapid American Corporation, et al., v Travelers Casualty and Surety Company, et al.* in the US Bankruptcy Court for the Southern District of New York.
- Engaged as expert by John Crane Inc. and authored declarations in relation to Racketeer Influenced and Corrupt Organizations Act (RICO) lawsuits it filed against certain law firms in connection with the firms' conduct in previous personal injury and wrongful death cases alleging exposure to John Crane's asbestos-containing products.
- Authored expert reports and declarations and provided deposition and trial testimony on behalf of the Debtors in the matter *In re Garlock Sealing Technologies, LLC*, No. 10-BK-31607 (US Bankruptcy Court for the Western District of North Carolina). Analyzed large, complex data sets and developed robust random samples that were used to assess the value of pending and future asbestos-related personal-injury claims. The resulting database constructed in this matter was described by the presiding Judge as "...the most extensive database about asbestos claims and claimants that has been produced to date. It is the most current data available and is the only data that accurately reflects the pool of claims against Garlock."
- Submitted a declaration on behalf of insurance companies in relation to the matter *In re Pittsburgh Corning Corporation*, No. 00-22876-TPA (US Bankruptcy Court for the Western District of Pennsylvania). Discussed the overlap between the claimants who cast a ballot in the PCC bankruptcy and the claimants who appear in the publicly available Garlock Analytical Database.
- Produce annual and quarterly estimates of companies' potential asbestos and other tort-related expenditures, and author opinion letters to help clients ensure compliance with Sarbanes-Oxley, SEC, and other comprehensive reporting requirements.
- Led team supporting the asbestos claims valuation and forecasting expert in arbitration on behalf of Cooper Industries in *Pepsi-Cola Metropolitan Bottling Co. et al. v. Cooper Industries et al.*
- Led team in support of expert in asbestos claims valuation for financial reporting purposes on behalf of certain Halliburton stockholders (US District Court, Northern District of Texas) regarding Halliburton's financial disclosures of its asbestos liabilities after its acquisition of Dresser.
- Led team supporting the expert in asbestos claims valuation, estimation methodology, and asbestos reinsurance billing on behalf of American Re-Insurance Company and ACE Property and Casualty Company (New York Court of Appeals) regarding the proper reinsurance bill associated with USF&G's reinsurance of its asbestos-related payments to Western MacArthur.
- Estimated and simulated future asbestos-related expenses in litigation contexts.
- Implemented insurance allocation of asbestos-related losses in financial reporting, invoicing, and litigation contexts.
- Designed and implemented statistically representative samples for claim file audits regarding asbestos claims. Samples were used in the estimation of future asbestos-related expenses and insurance allocations in litigation and consulting contexts.

- Directed protocol design and database construction based on data collected through claim file reviews regarding asbestos claims. The products were used to estimate future asbestos-related expenses and insurance allocations in litigation and consulting contexts.

ACADEMIC EXPERIENCE

- At the University of Pennsylvania, conducted empirical research on infant health, labor market participation, and healthcare insurance availability
- Participated as part of the external evaluation team at the University of Pennsylvania in the largest experiment-designed social program, the Progres/Oportunidades from México
- Collaborated as a teaching assistant for the Microeconomic Theory course of the PhD in Economics program at the University of Pennsylvania
- Held recitation sessions on Introductory Macroeconomics at the University of Pennsylvania
- Conducted economic research as visiting researcher at Centre for Economic Research (CIE), ITAM, México City, México
- Taught Applied Econometrics as an invited lecturer at ITAM, México City, México
- Conducted research on inflation as a visiting researcher at the Economic Research Department in Banco de México, México
- Participated as Economic Advisor on topics involving electricity demand estimation at Miguel Estrada Iturbide Foundation, Congress of México, México City, México
- Participated as Economic Analyst at the Centre for Economic Analysis and Research (CAIE), ITAM, México City, México

DISTINCTIONS AND HONORS

- First place in the research category of the 2006 Banamex Economics Award, one of the most prestigious prizes to economic research in México that has been awarded by the Banco Nacional de México since 1951. This international competition is focused on conducting research on development economics and public policy applicable to México. The panel of judges includes the Secretary of Finance, the Governor of the Central Bank, deans of the economics departments from the most prestigious universities in México, and members of the Economics Research Department of Banamex.
- Dissertation Fellowship, Department of Economics, University of Pennsylvania.
- Mellon Award for Latin American Demographic Studies, University of Pennsylvania.
- Inaugural recipient, President Emerita Judith Rodin Graduate Fellowship Award.
- University Fellowships, Department of Economics, University of Pennsylvania.
- Academic Excellence Scholarship, CONACYT, México City, México.

PUBLICATIONS

- “Are Conditional Cash Transfers Effective in Urban Areas? Evidence from Mexico,” joint with Jere R. Behrman, Susan W. Parker, Petra E. Todd, and Viviana Vélez-Grajales, in *Education Economics*, Taylor and Francis Journals, vol. 20, no. 3 (2012): 233–59.

- “*Oportunidades* Impact on Children and Youths Education in Urban Areas after One-year of Program Participation,” (in Spanish) with Petra E. Todd, Jere R. Behrman and Susan W. Parker, in *External Evaluation of the Impact of Oportunidades Program 2004: Education*, eds. B. Hernández-Prado, and M. Hernández-Avila, Chapter 3, Vol. 1, 167–227 Cuernavaca, México: National Institute of Public Health, 2005.

SELECTED SPEAKING ENGAGEMENTS

- “The Future of Mesothelioma in the US and the Increasing Portion of Diagnoses Not Related to Asbestos Exposure: Estimation and Forecasting.” 1st Annual Asbestos Litigation Strategies ExecuSummit, Dec. 2–3, 2014.
- “Emerging Trends in Asbestos Reserving.” Casualty Actuarial Society 2014 Casualty Loss Reserve Seminar, Sept. 15, 2014.
- “An Asbestos Defendant’s Legal Liability—the Experience in Garlock’s Bankruptcy Asbestos Estimation Trial.” Bates White webinar, July 29, 2014.
- “By the Numbers: The Future of Mesothelioma in America.” Perrin Conferences Cutting-Edge Issues in Asbestos Litigation Conference, Mar. 18, 2014.

RESEARCH PAPERS

- “Health Insurance and Pregnancy Outcomes: An Analysis of Fertility, Prenatal Care and Employment in México,” PhD Dissertation, University of Pennsylvania, 2006
- “How School Subsidies Impact Schooling and Working Behaviors of Children and Youth in Urban México,” joint with Jere R. Behrman, Susan W. Parker, Petra E. Todd and Viviana Vélez-Grajales (working paper, University of Pennsylvania, 2005)
- “Forecasting Inflation with Factor Analysis: A Two Countries Application,” Banco de México and University of Pennsylvania, 2003
- “Interest Rate Parity and Risk Premium in Mexico,” ITAM, 2001, México City, México
- “Evidence of Long Memory in the Mexican Currency Market,” ITAM, 2001, México City, México

LANGUAGES

- Spanish (native)

Exhibit 2

From: Zieg, Sharon <SZIEG@ycst.com>
Sent: Thursday, July 8, 2021 11:49 AM
To: 'Wright, Davis L.'; Jones, James M.; Ramsey, Natalie D.; Del Medico, Jennifer L.; Edwards, Erin; Gregory M. Gordon; Jeffrey B. Ellman; Cassada, Garland; Harron, Edwin; Bradley, Elisabeth; Kaplan, Jeff A.; Schneider Richard (King & Spalding - Atlanta, GA); Pratt, Stuart; Loughman, Paul
Cc: Steadman, Anne M.
Subject: RE: Bestwall - Sampling Meet & Confer

In follow-up to our call yesterday regarding the negotiation of the 502(d) order, the following is a description of how the additional 500 claims were selected:

- Ankura divided the population of settled claims into non-overlapping groups, using cutoffs that were multiples of \$50k
- Ankura randomly selected additional claims so that the overall sample size (Bates + Ankura/LAS) for each of the 5 groups between \$150K and \$400K, is 110
- Next, Ankura randomly sampled from the three most underrepresented groups (other than the "less than \$50K" group) until the overall sampling rate (Bates + Ankura/LAS) in each of the three groups was 17%
- Finally, Ankura randomly sampled 39 claims from the "less than \$50K" group

Regards,
Sharon



Sharon M. Zieg, Partner

Young Conaway Stargatt & Taylor, LLP
Rodney Square, 1000 North King Street
Wilmington, DE 19801

P: 302.571.6655 | F: 302.576.3350

SZIEG@ycst.com | www.youngconaway.com | [vCard](#)

This message may contain confidential attorney-client communications or other protected information. If you believe you are not an intended recipient (even if this message was sent to your e-mail address), you may not use, copy, or retransmit it. If you believe you received this message by mistake, please notify us by return e-mail, and then delete this message. Thank you for your cooperation.

From: Wright, Davis L. <DWright@rc.com>
Sent: Tuesday, July 6, 2021 9:13 PM
To: Jones, James M. <jmjones@JonesDay.com>; Ramsey, Natalie D. <NRamsey@rc.com>; Del Medico, Jennifer L. <jdelmedico@JonesDay.com>; Edwards, Erin <eedwards@ycst.com>; Gregory M. Gordon <gmgordon@jonesday.com>; Jeffrey B. Ellman <jbellman@jonesday.com>; Garland Cassada (GCassada@rbh.com) <GCassada@rbh.com>; Harron, Edwin <eharron@ycst.com>; Bradley, Elisabeth <EBradley@ycst.com>; Kaplan, Jeff A. <jkaplan@jonesday.com>; Schneider Richard (King & Spalding - Atlanta, GA) <dschneider@kslaw.com>; Pratt, Stuart <SPratt@robinsonbradshaw.com>; Loughman, Paul <PLoughman@ycst.com>; Zieg, Sharon <SZIEG@ycst.com>
Cc: Steadman, Anne M. <ASteadman@ycst.com>
Subject: Re: Bestwall - Sampling Meet & Confer
Jim,

Following last week's meet and confer and further discussions with LAS and the FCR, we would propose the following options for addressing the scope of the 502(d) proposal:

1. The Committee and the FCR would be willing to consider a smaller sample size of approximately 1,500 to 1,600 claims files (out of the total 2,907 Sample Resolved Mesothelioma Files) as the scope of the 502(d) production.

The Committee/FCR would provide a spreadsheet of the claimants that would form the sample. The Debtor, the Committee, and the FCR would all have to agree that this would be the sample for estimation.

2. The 502(d) order would apply to the claims files of all claimants identified in the Bates Reliance Materials and the Debtor would produce all documents, including privileged documents, related to those claim files. The Committee would be amenable to granting an extension on the production of the Additional 500 claims files, however these additional files would not be subject to the 502(d) Order; or
3. The Debtor would provide all documents for all 2,907 claim files (less the 200 or so for which there is allegedly no documentation) pursuant to the 502(d) order.

With respect to each of the above options, the Committee and the FCR reserve all rights with respect to seeking additional 502(d) documents or claims files depending on the outcome of the trust-related litigation pending in Delaware and/or any decision by the Debtor or its agents to modify the scope of the sample size, utilize a different sample or sample size, or modify the individuals assigned to the sample. We can discuss further on tomorrow's call but thought it would make sense to provide the Debtor with insight on our current thinking.

Best,
Davis
Davis Lee Wright

Robinson & Cole LLP
1201 North Market Street
Suite 1406
Wilmington, DE 19801
Direct 302.516.1703 | Fax 302.516.1699
dwright@rc.com | www.rc.com

Robinson+Cole
Celebrating 175 Years

Boston | Hartford | New York | Providence | Miami | Stamford
Los Angeles | Wilmington | Philadelphia | Albany | New London

From: "Jones, James M." <jmjones@JonesDay.com>

Date: Tuesday, July 6, 2021 at 2:25 PM

To: "Wright, Davis L." <DWright@rc.com>, "Ramsey, Natalie D." <NRamsey@rc.com>, "Del Medico, Jennifer L." <idelmedico@JonesDay.com>, "Edwards, Erin" <eedwards@ycst.com>, Gregory Gordon <gmgordon@jonesday.com>, Jeffrey Ellman <jbellman@jonesday.com>, "Garland Cassada (GCassada@rbh.com)" <GCassada@rbh.com>, "eharron@ycst.com" <eharron@ycst.com>, "Bradley, Elisabeth" <EBradley@ycst.com>, "Kaplan, Jeff A." <jkaplan@jonesday.com>, "Schneider Richard (King & Spalding - Atlanta, GA)" <dschneider@kslaw.com>, "Pratt, Stuart" <SPratt@robinsonbradshaw.com>, "Loughman, Paul" <PLoughman@ycst.com>, Sharon Zieg <szieg@ycst.com>

Cc: "Steadman, Anne M." <ASteadman@ycst.com>

Subject: RE: Bestwall - Sampling Meet & Confer
I can make that work.

James M. Jones ([bio](#))
Partner
[JONES DAY® - One Firm WorldwideSM](#)
250 Vesey Street
New York, NY 10281-1047
Office +1.212.326.7838

From: Wright, Davis L. <DWright@rc.com>
Sent: Tuesday, July 6, 2021 2:22 PM
To: Ramsey, Natalie D. <NRamsey@rc.com>; Del Medico, Jennifer L. <jdelmedico@JonesDay.com>; Edwards, Erin <eedwards@ycst.com>; Gordon, Gregory M. <gmgordon@JonesDay.com>; Ellman, Jeffrey B. <jbellman@JonesDay.com>; Garland Cassada (GCassada@rbh.com) <GCassada@rbh.com>; Edwin J. Harron <eharron@ycst.com>; Bradley, Elisabeth <EBradley@ycst.com>; Kaplan, Jeff A. <jkaplan@jonesday.com>; Schneider Richard (King & Spalding - Atlanta, GA) <dschneider@kslaw.com>; Pratt, Stuart <SPratt@robinsonbradshaw.com>; Loughman, Paul <PLoughman@ycst.com>; Sharon Zieg <szieg@ycst.com>; Jones, James M. <jmjones@JonesDay.com>
Cc: Steadman, Anne M. <ASteadman@ycst.com>
Subject: RE: Bestwall - Sampling Meet & Confer

** External mail **

All,
We think we need some additional time to address some issues on our side. Could we reschedule this for 1:30 pm tomorrow?
Thanks,
Davis
Davis Lee Wright

Robinson & Cole LLP
1201 North Market Street
Suite 1406
Wilmington, DE 19801
Direct 302.516.1703 | Fax 302.516.1699
dwright@rc.com | www.rc.com

Robinson+Cole
Celebrating 175 Years

Boston | Hartford | New York | Providence | Miami | Stamford
Los Angeles | Wilmington | Philadelphia | Albany | New London
-----Original Appointment-----

From: Wright, Davis L.
Sent: Friday, July 2, 2021 10:44 AM
To: Wright, Davis L.; Ramsey, Natalie D.; Del Medico, Jennifer L.; Edwards, Erin; Gregory M. Gordon; Jeffrey B. Ellman; Garland Cassada (GCassada@rbh.com); Edwin J. Harron; Bradley, Elisabeth; Kaplan, Jeff A.; Schneider Richard (King & Spalding - Atlanta, GA); Pratt, Stuart; Loughman, Paul; Zieg, Sharon; Jones, James M.
Cc: Steadman, Anne M.
Subject: Bestwall - Sampling Meet & Confer
When: Tuesday, July 6, 2021 3:00 PM - 4:00 PM (UTC-04:00) Eastern Time (US & Canada).
Where: <https://robinsoncole.zoom.us/j/99440279877?pwd=UXlMwKJ3OGVVRWNzOE51cWVTT01nUT09>



Davis Lee Wright is inviting you to a scheduled Zoom meeting.

[Join Zoom Meeting](#)

Meeting URL: <https://robinsoncole.zoom.us/j/99440279877?pwd=UXIMWkJ3OGVVRWNzOE51cWVTT01nUT09>

URL:

Meeting ID: 994 4027 9877

ID:

Passcode: 334727

Dial In 334727

Passcode:

Join by Telephone

Phone US: [+13017158592](tel:+13017158592), [99440279877#](tel:+13017158592) or [+13126266799](tel:+13126266799), [99440279877#](tel:+13126266799)

one-tap:

Dial: US: +1 301 715 8592 or +1 312 626 6799 or +1 646 876 9923

Meeting ID: 994 4027 9877

ID:

Dial In 334727

Passcode:

[International numbers](#)

Join from an H.323/SIP room system

H.323: [162.255.37.11](tel:+1622553711) (US West) or [162.255.36.11](tel:+1622553611) (US East)

H.323 994 4027 9877 (Passcode: 334727)

Meeting

ID:

SIP: 99440279877@zoomcrc.com (Passcode: 334727)

If you have difficulty logging into this webinar/meeting please contact the Robinson+Cole help desk at 1-888-727-2457.

This transmittal may be a confidential R+C attorney-client communication or may otherwise be privileged or confidential. If it is not clear that you are the intended recipient, you are hereby notified that you have received this transmittal in error; any review, dissemination, distribution, or copying of this transmittal is strictly prohibited. If you suspect that you have received this communication in error, please notify us immediately by telephone at 1-860-275-8200, or e-mail at it-admin@rc.com, and immediately delete this message and all its attachments.

This e-mail (including any attachments) may contain information that is private, confidential, or protected by attorney-client or other privilege. If you received this e-mail in error, please delete it from your system without copying it and notify sender by reply e-mail, so that our records can be corrected.

EXHIBIT C

EXHIBIT E

1 APPEARANCES (continued):

2 For Debtor/Defendant,
3 DBMP LLC:

Jones Day
BY: JEFFREY B. ELLMAN, ESQ.
1221 Peachtree Street, N.E., #400
Atlanta, GA 30361

4

5

Jones Day
BY: JAMES M. JONES, ESQ.
250 Vesey Street
New York, NY 10281

6

7 For Plaintiff, ACC:

Robinson & Cole LLP
BY: DAVIS LEE WRIGHT, ESQ.
1201 N. Market Street, Suite 1406
Wilmington, DE 19801

8

9

10

Winston & Strawn LLP
BY: DAVID NEIER, ESQ.
CRISTINA CALVAR, ESQ.
200 Park Avenue
New York, NY 10166-4193

11

12

Caplin & Drysdale
BY: JAMES P. WEHNER, ESQ.
One Thomas Circle, N.W.,
Washington, DC 20005

13

14

Hamilton Stephens
BY: ROBERT A. COX, JR., ESQ.
525 North Tryon St., Suite 1400
Charlotte, NC 28202

15

16

NATHANIEL ROSE, ESQ.

17

18

For Plaintiff, Future
19 Claimants' Representative,
Sander L. Esserman:

Young Conaway
BY: SEAN GREECHER, ESQ.
SHARON ZIEG, ESQ.
1000 North King Street
Wilmington, DE 19801

20

21

Alexander Ricks PLLC
BY: FELTON E. PARRISH, ESQ.
1420 E. 7th Street, Suite 100
Charlotte, NC 28204

22

23

24

25

1 APPEARANCES (continued):

2 For Defendants, CertainTeed
3 LLC, et al.:

Goodwin Procter LLP
BY: HOWARD S. STEEL, ESQ.
STACY DASARO, ESQ.
620 Eighth Avenue
New York, NY 10018

5

Rayburn Cooper & Durham, P.A.
BY: JOHN R. MILLER, JR., ESQ.
227 West Trade Street, Suite 1200
Charlotte, NC 28202

6

7

8 For Certain Matching
9 Claimants:

Waldrep Wall
BY: DIANA SANTOS JOHNSON, ESQ.
370 Knollwood Street, Suite 600
Winston-Salem, NC 27103

10

11 APPEARANCES (via telephone):

12

13 For Certain Matching
14 Claimants:

Hogan McDaniel
BY: DANIEL K. HOGAN, ESQ.
1311 Delaware Avenue
Wilmington, DE 19806

15

16 For Plaintiff, ACC:

Winston & Strawn LLP
BY: CARRIE HARDMAN, ESQ.
200 Park Avenue
New York, NY 10166-4193

17

18

SANDER L. ESSERMAN
Future Claimants' Representative
2323 Bryan Street, Suite 2200
Dallas, TX 75201-2689

19

20

21

22

23

24

25

1 subpoena. The Delaware Court transferred the subpoena
2 proceedings to this Court. In the meantime, I, I think it was
3 early October, you actually heard the motions to quash. No
4 mention at that hearing of any PII and exposure fields that we
5 needed to be concerned about.

6 In the meantime, as indicated before, the DCPF
7 scrubbed and produced, first, what we call the stub production.
8 These were the --

9 THE COURT: Uh-huh (indicating an affirmative
10 response).

11 MR. CASSADA: -- Matching Claimants who didn't oppose
12 the subpoenas and then after your Honor entered the order the
13 DCPF produced the remaining data, again scrubbed of any PII.
14 The cost to DBMP is, roughly, \$86,000, your Honor. You can see
15 those, those two figures are on the timeline.

16 Your Honor may recall that in the original request
17 DBMP did request not only information about the claims made and
18 what exposures were indicated in those claims, but did request
19 a litany of, of personal information. And this, this was
20 requested in the Bestwall subpoena as well. There was a
21 anonymization process there that was suggested to take place
22 after the production where the personal information would be
23 separated from the exposure information. That process is
24 actually, has been undertaken in, in the Bestwall case.

25 Your Honor, when Judge Connolly quashed the subpoena

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

CERTIFICATE

I, court-approved transcriber, certify that the foregoing is a correct transcript from the official electronic sound recording of the proceedings in the above-entitled matter.

/s/ Janice Russell

February 13, 2023

Janice Russell, Transcriber

Date

EXHIBIT F

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023

1

UNITED STATES BANKRUPTCY COURT
WESTERN DISTRICT OF NORTH CAROLINA
CHARLOTTE DIVISION

Deposition of:

MARK EVELAND

In re

ALDRICH PUMP LLC, et al.,
Debtors.

Chapter 11

Case No. 20-30608

(Jointly
Administered)

ARMSTRONG WORLD INDUSTRIES, INC.
ASBESTOS PERSONAL INJURY
SETTLEMENT TRUST, et al.,

Miscellaneous
Proceeding

Plaintiffs,

No. 22-00303 (JCW)

-vs-

ALDRICH PUMP LLC, et al.,

(Transferred from
District of
Delaware)

Defendants.

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023

2

AC&S ASBESTOS SETTLEMENT TRUST,
COMBUSTION ENGINEERING 524(G)
ASBESTOS PI TRUST, GI HOLDINGS
INC. ASBESTOS PERSONAL INJURY
SETTLEMENT TRUST, GST SETTLEMENT
FACILITY, KAISER ALUMINUM &
CHEMICAL CORPORATION ASBESTOS
PERSONAL INJURY TRUST, QUIGLEY
COMPANY, INC. ASBESTOS PI TRUST,
T H AGRICULTURE & NUTRITION,
L.L.C. ASBESTOS PERSONAL INJURY
TRUST, and YARWAY ASBESTOS
PERSONAL INJURY TRUST,

Miscellaneous
Proceeding

No. 23-00300 (JCW)

(Transferred from
District of
New Jersey)

Petitioners,

-vs-

ALDRICH PUMP LLC, et al.,

Respondents,

VERUS CLAIM SERVICES, LLC,

Interested Party,

NON-PARTY CERTAIN MATCHING
CLAIMANTS,

Interested Party.

T R A N S C R I P T of Deposition

Proceedings held in the above-entitled matter, as taken by and before MARY ADAMCIK, a Certified Court Reporter and Notary Public of the State of New Jersey, held at the law offices of ANSELM I & CARVELLI, ESQS., 56 Headquarters Plaza, West Tower, Fifth Floor, Morristown, New Jersey, on Tuesday, May 16, 2023, commencing at 9:20 a.m.

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023

3

1 A P P E A R A N C E S :

2

JONES DAY
3 BY: MORGAN R. HIRST, ESQ.,
110 North Wacker Drive
4 Suite 4800
Chicago, IL 60606
5 312-782-3939
mhirst@jonesday.com
6 Representing Debtors Aldrich Pump, LLC, et al.

7

ANSELM & CARVELLI, LLP
8 BY: ANDREW E. ANSELM, ESQ.,
56 Headquarters Plaza
9 West Tower, Fifth Floor
Morristown, NJ 07960
10 973-635-6300
aanselmi@acllp.com
11 Representing Verus Claim Services, LLC.

12

LOWENSTEIN SANDLER, LLP
13 BY: MICHAEL A. KAPLAN, ESQ.,
One Lowenstein Drive
14 Roseland, NJ 07068
973-597-2302
15 mkaplan@lowenstein.com
Representing Verus Claim Services, LLC.

16

ROBISON & COLE, LLP
17 BY: AMANDA PHILLIPS, ESQ.,
One Boston Place
18 26th Floor
Boston, MA 02108
19 617-557-5916
aphillips@rc.com
20 Representing the ACC.

21

22

23

24

25

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023

4

1 TELEPHONIC APPEARANCES:

2

JONES DAY
3 BY: BRAD B. ERENS, ESQ.,
110 North Wacker Drive
4 Suite 4800
Chicago, IL 60606
5 312-782-3939
Representing Debtors Aldrich Pump, LLC, et al.

6

7

CAPLIN & DRYSDALE, ESQS,
8 BY: JEANNA RICKARDS KOSKI, ESQ.,
One Thomas Circle NW
9 Suite 1100
Washington, DC 20005
202-862-5069
10 jkoski@capdale.com
Representing the ACC.

11

12

ROBINSON & COLE, LLP
13 BY: RYAN M. MESSINA, ESQ.,
One Boston Place
26th Floor
14 Boston, MA 02108
617-557-5916
15 Representing the ACC.

16

17

LOWENSTEIN SANDLER, LLP
18 BY: NICHOLAS D. VELEZ, ESQ.,
One Lowenstein Drive
Roseland, NJ 07068
973-597-2302
19 Representing Verus Claim Services, LLC.

20

21

22

23

24

25

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023

5

I N D E X

WITNESS	DIRECT	CROSS	REDIRECT	RECROSS
MARK EVELAND:				
By MR. HIRST	6	--	--	--

E X H I B I T S

No.		Ident.
Exhibit 1	Supplemental Declaration of Lynda A. Bennett, 9 pgs.	15
Exhibit 2	Subpoena to Produce Documents, Information, or Objects or to Permit Inspection of Premises in a Bankruptcy Case (or Adversary Proceeding), 23 pgs.	22
Exhibit 3	Reply Declaration of Mark T. Eveland, 8 pgs.	30
Exhibit 4	Declaration of Mark T. Eveland, 10 pgs.	71
Exhibit 5	Declaration of Mark Eveland Pursuant to Rules 2014 and 2016 of the Federal Rules of Bankruptcy Procedure and Section 328 of the United States Bankruptcy Code in Support of the Ex Parte Application of the Official Committee of Asbestos Personal Injury Claimants to Retain and Employ Verus LLC as PIQ Data Administrator for the Personal Injury Questionnaire Responses, 16 pgs.	81

(Exhibits attached herein.)

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023

6

1 M A R K E V E L A N D,
2 with a business address of 3967 Princeton
3 Pike, Princeton, New Jersey 08540,
4 having first been duly sworn, testified as follows:

5 DIRECT EXAMINATION BY MR. HIRST:

6 Q. Good morning, Mr. Eveland.

7 A. Good morning.

8 Q. We met out in the hallway. My name is Morgan
9 Hirst. I represent the debtors in this case.

10 Have you been deposed before, sir?

11 A. Yes.

12 Q. About how many times?

13 A. Once that I recall.

14 Q. Okay. Was it a deposition in your capacity as
15 an employee or officer of Verus?

16 A. It was.

17 Q. Okay. And what was the case about that you
18 were deposed in?

19 A. It was an insurance recovery dispute.

20 Q. How many years ago was it?

21 A. At least a decade ago.

22 Q. Okay. So I'll give you at least a reminder of
23 some of the rules of the road today.

24 Important thing will be audible responses to
25 my questions. She can't take down head nods or sighs

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023

7

1 or things like that, so if you would just audibly
2 respond. I will do my best not to talk over you, if
3 you could do your best not to talk over me, and she'll
4 get a clear record. Andrew and I may talk over each
5 other, but that's a different issue.

6 If you answer my question, I am going to
7 assume you understood it. If you don't understand my
8 question, ask me to rephrase or tell me you don't
9 understand it, and I'll do my best to rephrase it for
10 you.

11 Mr. Anselmi and others in the room, and maybe
12 even on the phone, may make objections from time to
13 time. I am going to anticipate you are going to answer
14 the question unless you are instructed otherwise.

15 If you need a break at any point, let us know.
16 It's not an inquisition, it's a deposition, so we'll
17 obviously take a break. I just ask if there is a
18 question pending, answer the question and we'll take
19 the break after.

20 Is there anything, Mr. Eveland, that would
21 prevent you from testifying truthfully today or
22 accurately?

23 A. No.

24 Q. And did you prepare for your deposition today?

25 A. I did.

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
8

1 Q. What did you do?

2 A. I reviewed my Declaration and various other
3 papers in the case.

4 Q. Do you know how many Declarations you
5 reviewed?

6 A. I filed two Declarations in this case. I
7 reviewed the Declaration of Dr. Muller (phonetic), his
8 deposition transcript, and I believe the report filed
9 by Dr. Wyner.

10 Q. And when you say Dr. Muller, is that Dr.
11 Mullin?

12 A. Mullin, sorry.

13 Q. No problem. He won't be insulted.
14 Did you also meet with counsel, sir?

15 A. I did.

16 Q. Who did you meet with?

17 A. Mr. Anselmi and Mr. Kaplan and Mr. Wellbrook,
18 as well.

19 Q. When did you have that meeting?

20 A. Friday afternoon, I believe.

21 Q. Was that in person or via some other --

22 A. It was a videoconference.

23 Q. About how long was your meeting with counsel?

24 A. I don't recall precisely. Maybe 90 minutes.

25 Q. Did you talk to anyone else at Verus in

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023

9

1 preparation for today's deposition?

2 A. No.

3 Q. Have you ever spoken to Dr. Wyner, Abraham
4 Wyner?

5 A. I have met him.

6 Q. In connection with his work in this case or
7 separately?

8 A. No, I met him years ago in connection with
9 another case.

10 Q. Okay. Have you spoken to him at all in
11 connection with this case we are all here for?

12 A. I have not.

13 Q. Mr. Eveland, you're the chief executive
14 officer of Verus, LLC. Is that the proper name or --

15 A. Yes.

16 Q. Okay. And if you could describe for us what
17 Verus does.

18 A. We are a litigation support firm, so we
19 provide litigation support for firms that are involved
20 in mass tort and class action litigation, early-stage
21 litigation all the way through administration of
22 settlement funds and distribution of funds.

23 Q. And the firms that Verus provides services
24 for, are they both plaintiffs' firms, defendants'
25 firms, primarily one or the other?

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
10

1 A. The settlement administration work is usually
2 being retained by trustees, so essentially neither.
3 It's kind of in the middle, in that gray area between
4 the two parties.

5 Q. Yes.

6 A. And on the early-stage litigation support,
7 it's primarily plaintiff firms.

8 Q. And Mr. Eveland, if you could just describe
9 briefly your educational background beginning with
10 college.

11 A. Okay. I attended Pennsylvania State
12 University, where I obtained a bachelor's degree in
13 political science and history. I went on to graduate
14 school, a Ph.D. program in philosophy. I am an APD, I
15 did not defend my dissertation.

16 Q. Are you a statistician, Mr. Eveland?

17 A. I am not.

18 Q. And I assume you're not an economist, either?

19 A. I am not.

20 Q. Your degree sounded a lot like mine other than
21 the part with the APD, so do you have any special
22 training or experience in statistics?

23 A. No.

24 Q. How about in sampling?

25 A. No.

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
11

1 Q. And why don't you describe for me your work
2 history beginning after -- well, just your work history
3 after college.

4 A. Okay. Well, when I left graduate school, I
5 was -- my first real job was with a management
6 consulting firm, Peterson Consulting. They had a
7 client, and my first engagement that they assigned me
8 to was with a client called Center For Claims
9 Resolution, which was a captive organization that
10 managed the liabilities for 20 major asbestos
11 defendants at the time. This was 1992 or early 1993.

12 I worked with them for a couple of years,
13 primarily on that engagement as well as a handful of
14 others. And the CCR, as it was known, eventually hired
15 me inhouse, where I rose to become the director of
16 their operations. I was intimately familiar with all
17 of the aspects of managing those liabilities.

18 When the CCR eventually dissolved in 2001,
19 because of many of the members filing for Chapter 11
20 protection, I went to work shortly thereafter to launch
21 a class action administration firm called RG3 Claims --
22 or RG2 Claims, sorry. I worked with them for about a
23 year and then founded Verus in 2003. I've been with
24 Verus ever since.

25 Q. And is your title -- or putting aside your

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
12

1 title, has your responsibilities with Verus largely
2 been the same since you founded the company 20 years
3 ago?

4 A. Pretty much, yeah.

5 Q. Has it changed in any material way?

6 A. The company is a lot bigger than it was in
7 2003 but --

8 Q. How many employees does Verus have today?

9 A. Just right around 90.

10 Q. Okay. And in addition to employees, do you
11 guys regularly employ contractors or nonemployees?

12 A. We do employ contractors for certain
13 functions.

14 Q. About how many contractors that aren't
15 full-time employees are working for Verus as of now?

16 A. Approximately 25 as of now.

17 Q. Now, part of Verus's work, as I understand it,
18 is providing claims administration processing services
19 to asbestos trusts, if I've got that correct?

20 A. That's correct.

21 Q. And as it relates to that work, how many
22 trusts does Verus provide those services for? And I
23 don't need an exact number, just a rough estimate.

24 A. Two dozen, a little more than that.

25 Q. Okay. And you are aware that in this case --

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
13

1 or relating to this Subpoena proceeding, the Subpoena
2 that was directed to Verus sought information
3 concerning eight of the trusts that Verus provided
4 services for. Is that right?

5 A. I am aware of that, yes.

6 Q. Now, we'll get to the Subpoena in this case,
7 but Verus has received other Subpoenas before in the
8 20 years you had the company. Correct?

9 A. We have, yes.

10 Q. Do you have any idea of approximately how many
11 Subpoenas you have received in that time?

12 A. Including Subpoenas for individual things
13 filed? Countless. Countless. No real estimate.

14 Q. And at least in some cases, Verus has provided
15 responses to those Subpoenas. Is that fair to say?

16 A. In some cases, yes.

17 Q. In some of those cases, has Verus moved to
18 quash those Subpoenas?

19 A. Yes.

20 Q. And has Verus been successful in some of those
21 cases?

22 A. We have.

23 Q. Who has the primary responsibility at Verus
24 for dealing with a Subpoena when it comes in?

25 A. It's principally me.

1 Q. Lucky you.

2 And what is that role when a Subpoena arrives
3 at Verus? What do you do?

4 A. Well, the first step is to contact the counsel
5 for the trust whose records are being sought, make them
6 aware, notify them of the fact that we have received a
7 Subpoena. If it's been directed at Verus, we'll then
8 retain outside counsel to defend us in that Subpoena
9 and file the necessary motions.

10 Q. Are there any instances where Verus doesn't
11 seek to quash or -- seek to quash that you can
12 remember?

13 MR. ANSELM: Objection to form.

14 MS. PHILLIPS: I'm sorry, the ACC
15 joins in any objections made by the trusts today.

16 A. We receive a lot of Subpoenas that are not
17 directed at Verus, in which case we just refer them on
18 to trust counsel and they take the necessary actions.

19 Q. Okay. How about for Subpoenas directed to
20 Verus? Can you ever think of any instance where Verus
21 didn't seek to quash a Subpoena that was directed at
22 Verus?

23 A. I can't recall any as I sit here today.

24 Q. And actually, that raised a point that led to
25 another question.

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
16

1 can have a standing objection that they join counsel
2 for Verus on any objections he makes.

3 MS. PHILLIPS: And counsel for the
4 trust, if the trusts eventually do make any objections.

5 MR. HIRST: Sounds good.

6

7 BY MR. HIRST:

8 Q. All right. Mr. Eveland, I have handed you
9 what we have marked as Exhibit 1. This is actually a
10 Declaration by an attorney named Lynda Bennett, who I
11 believe works at Michael's firm.

12 I am actually interested in the chart that's
13 attached as Exhibit A, and the title of it is Subpoenas
14 Involving Verus or Verus Trusts.

15 Do you see that?

16 A. I do see that.

17 Q. Did you have any role in creating this table
18 in here that's Exhibit A to Exhibit 1?

19 MR. KAPLAN: Objection to form. To
20 the extent that it calls for work product or common
21 interest communications between the Verus Trust and
22 Verus, I would advise that we are not waiving any such
23 privilege, and Mr. Anselmi can make the appropriate
24 instruction from there.

25 MR. ANSELM: I agree. I make the

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
17

1 same objection. If it's a yes-or-no question --

2 MR. HIRST: It's a yes --

3 MR. ANSELM: -- I think that's fair,
4 but beyond any content, I would instruct him not to
5 answer.

6

7 BY MR. HIRST:

8 Q. So why don't we start there, Mr. Eveland, and
9 see if we can work around the objections.

10 My question is solely did you have any role in
11 creating this chart we see as Exhibit A to Exhibit 1?

12 A. No.

13 Q. Okay. And I just do want to look at a few of
14 the entries here to see if you recognize the cases
15 referenced or the Subpoenas referred to.

16 The very first one on page one of this
17 document, it refers to a case called Congoleum Corp.
18 versus ACE American Insurance, and it describes the
19 discovery sought as all documents and data relating to
20 122,000 claimants. It then appears the Subpoena was
21 issued back in 2009.

22 Do you recall this Subpoena?

23 A. I don't have any specific recall of it.

24 Q. It mentions 122,000 claimants on order of
25 magnitude for Subpoenas that Verus receives. Is that a

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
18

1 typical volume of information sought?

2 MR. ANSELM: Objection to form.

3 A. It's fairly typical.

4 Q. So I may not have heard your answer right. Do
5 you have any specific memory of the Subpoena at all?

6 A. I remember receiving a Subpoena. I don't
7 recall the specifics of it.

8 Q. Okay. Do you recall whether Verus responded
9 to that Subpoena by providing any information?

10 A. I don't recall if there was a production that
11 was ordered in that case.

12 Q. Okay. Let's go down to the next one then,
13 Federal Mogul Insurance Litigation. Claim submissions,
14 files, claim status, and settlements related to Wagner
15 claimants about 109,000, and it's dated May of 2010.

16 Do you have any recollection of this Subpoena?

17 A. I do recall that one.

18 Q. Okay. And what do you recall about it?

19 A. I recall receiving it. I recall that went on
20 for a while. I don't recall the specifics of what the
21 outcome was.

22 Q. And when you say you recall it went on for a
23 while, I am assuming you are referring to litigation
24 related to that Subpoena?

25 A. Yes, litigation related to that Subpoena.

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
19

1 Q. Do you recall whether Verus produced any
2 information in response to the Federal Mogul Subpoena
3 for Exhibit 1?

4 A. I recall there was a production. I don't
5 recall the specifics.

6 Q. Actually, let me make sure, because we have
7 the Verus trusts here and we have Verus. Do you recall
8 if the Verus trusts made any productions separate and
9 apart from Verus in response to the Federal Mogul
10 Subpoena?

11 A. I wouldn't know if they made any separate
12 productions.

13 Q. Okay. Do you recall whether Verus produced
14 all the information sought by the Subpoena or a sample
15 of the information sought or do you recall anything
16 about what Verus produced in response to this Subpoena?

17 A. I recall that the production was much narrower
18 than the original Subpoena. I don't recall the scope.

19 Q. And was that the result of a Court Order
20 narrowing the Subpoena or was that a result of
21 negotiations with the party seeking the information
22 that narrowed result?

23 A. I don't recall.

24 Q. Okay. You'll be thrilled to know I am not
25 actually going to go through all of these, but I do

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
20

1 want to turn to the last page of Exhibit 1. At the top
2 there is a case referenced, In Re Rapid-American
3 Corporation, and their first two claim files and other
4 information on 455,000 specific individuals identified
5 on attachment to Subpoena. The date of the issuance is
6 July 2017.

7 Do you recall this Subpoena, Mr. Eveland?

8 A. I do.

9 Q. What do you recall about it?

10 A. I recall receiving it. I recall it was
11 very -- a fairly broad Subpoena. I recall referring it
12 on to the trusts as soon as we received it.

13 MR. ANSELM: I just want to put a
14 caution out here before the next question. Be careful
15 about any conversations you had with counsel for the
16 trust, because those are protected, if there is going
17 to be more questions about this.

18 MR. HIRST: There will be more
19 questions, but I don't think they'll call for specific
20 information.

21

22 BY MR. HIRST:

23 Q. Do you recall whether or not Verus provided
24 any information in response to the Rapid Subpoena?

25 A. I don't recall that we did.

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
21

1 Q. Okay. Do you recall whether the trust
2 produced any information in response to the Rapid
3 Subpoena?

4 A. That I don't know.

5 Q. First to claim files and other information on
6 455,000 specific individuals. What is your
7 understanding as to what claim files is referring to?

8 MR. ANSELM: Objection to form.

9 A. My understanding of what a claim file refers
10 to is all of the contents of the original proof of
11 claim and any supplemental information related to that
12 claim and our review of that claim.

13 Q. We'll get back to that in a bit.

14 Actually, I do want to go back to one other
15 Subpoena back two pages. There is actually three
16 references to this case or a similar case named
17 Garlock. Do you see that?

18 And I am looking at page three of six at the
19 top, Mr. Eveland, of Exhibit 1. Page three of six on
20 the top.

21 A. Page three? Okay.

22 Q. Do you see the second entry there is
23 Garlock -- In Re Garlock Sealing Technologies?

24 A. I do see that.

25 Q. Okay. And there it refers to the discovery

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
22

1 sought in the trust as a complete database of all
2 asbestos claims. Do you see that?

3 A. I see that.

4 Q. And that's dated February of 2012. Do you
5 recall this Subpoena?

6 A. I have a vague recollection of that Subpoena.

7 Q. Okay. What do you recall from your vague
8 recollection?

9 A. I recall receiving it.

10 Q. Okay. Do you recall anything about your
11 response to that Subpoena, Verus's response?

12 A. Nothing specific.

13 Q. Okay. Do you recall whether or not Verus
14 produced information in response to that Subpoena?

15 A. I do not recall producing information in
16 response to that.

17 Q. Do you recall anything else about the Garlock
18 Subpoena referenced here in Exhibit 1?

19 A. No.

20 Q. You can put Exhibit 1 away, Mr. Eveland.
21 Let's actually talk about the Subpoena you received in
22 this case. This is Exhibit 2.

23 (Exhibit 2 marked for identification.)

24 Q. I am handing you what I have marked,
25 Mr. Eveland, as Exhibit Number 2, which is a copy of

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
23

1 the Subpoena that I think I actually issued to you in
2 this case on July 5th, 2022.

3 MR. ANSELM: Very neat signature,
4 yeah.

5 MR. HIRST: I know. Well, thanks to
6 the computer inputting it for me.

7

8 BY MR. HIRST:

9 Q. Have you seen this Subpoena before,
10 Mr. Eveland?

11 A. I have.

12 Q. And what role did you have in responding to
13 this Subpoena on Exhibit 2?

14 A. I retained outside counsel, and outside
15 counsel took it from there.

16 Q. Any other role not involving counsel that you
17 had in responding to Exhibit 2?

18 A. I oversaw the matching exercise to compare the
19 key. I am forgetting the term they used for it, the
20 list of pseudonyms to our databases to determine how
21 many matching claims there were.

22 Q. Okay. And let's break that down a little bit.
23 Matching Key, is that what you're referring to --

24 A. Yes.

25 Q. -- that was provided by Bates White?

1 A. Correct.

2 Q. And you said you oversaw that work, so what
3 exactly did Verus do to compare the Matching Key to
4 your own databases?

5 A. Our analyst team took that Matching Key,
6 created a database table from it, and compared that,
7 matched it by the information on that Matching Key to
8 the records in the claims databases for the -- I
9 believe it was eight trusts that were included in the
10 Subpoena.

11 Q. And who specifically from your analyst team
12 was involved in performing that work?

13 A. I don't recall everyone who may have been
14 involved in it.

15 Q. How many people?

16 A. There were at least two people who were
17 involved in that.

18 Q. Are they full-time Verus employees?

19 A. One of them is.

20 Q. And is the other one a contractor?

21 A. No, but part-time.

22 Q. Do both still work for Verus today?

23 A. They do.

24 Q. And what are their names?

25 A. A gentleman by the name of Mark Zabel and Lynn

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
25

1 Burdwood. There may have been others, but those two I
2 know were involved.

3 Q. Do Mr. Zabel and Miss Burdwood -- did I get
4 that right? Do they regularly assist in responding to
5 Subpoenas that Verus receives?

6 A. Only when we are required to produce.

7 Q. And you mentioned -- and I'm paraphrasing
8 here, so please correct anything I get wrong, but you
9 mentioned that they ran some sort of search against
10 some of the Verus trusts to see where the matches
11 between the Matching Key and the trusts were. Is that
12 correct?

13 A. That's correct.

14 Q. Okay. How many databases did your team run
15 that search against?

16 A. It's eight different trusts, so there were
17 eight different searches involved.

18 Q. And so I am clear, to search all of the eight
19 trust databases that are implicated here, you can't do
20 a single query across a master database? It's got to
21 be individual queries across the eight trust databases?

22 A. There is a master table of all the injured
23 parties, but the trust claims are stored in a separate
24 schemas.

25 Q. So the master table of all of the claimants,

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
26

1 describe that for me. What is that, and what
2 information -- what categories of information are
3 captured in the master table?

4 A. It's not really claimants, it's injured
5 parties. So it's every unique individual who's alleged
6 an asbestos related injury, and it's basically just the
7 demographic information; name, social, date of birth.
8 Not much else besides that.

9 Q. Did you -- in performing the work you just
10 described, comparing the Matching Key that was provided
11 by Bates White to the data that Verus had, did you run
12 a search of that master table?

13 A. That's a starting point.

14 Q. And then after that, you ran a search against
15 each of the eight individual trust databases?

16 A. To determine if -- yes.

17 Q. And you are aware here that the Matching
18 Key -- and, actually, let's look at the Subpoena so we
19 make sure we get our terminology.

20 If you turn to -- let me use some of the page
21 numbers at the very top, Mr. Eveland, to try and
22 coordinate us. So at the very top, it says page 31 of
23 47.

24 A. Okay.

25 Q. Do you see that?

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
27

1 A. I do.

2 Q. And down there in paragraph six, you'll see in
3 the second line the reference to the Matching Key we
4 have been talking about. And is what you see there in
5 paragraph six consistent with the way we have been
6 using the term "Matching Key" together?

7 A. Yeah. Mm-Hmm.

8 Q. Okay. And do you recall the Matching Key in
9 this case included approximately 12,000 names or 12,000
10 individual claimants, I guess. Is that correct?

11 MR. ANSELM: Objection to form.

12 MR. HIRST: It was a terrible
13 question, so let me start over again.

14 Q. Do you recall that the Matching Key that was
15 provided to you by Bates White in this case included
16 approximately 12,000 last names and Social Security
17 numbers?

18 A. That's my recollection, yes.

19 Q. And then in paragraph seven, Mr. Eveland, at
20 the next page, there is a reference in paragraph seven
21 about midway down to matching the claimants. Do you
22 see that?

23 A. I do.

24 Q. And do you have an understanding of what
25 matching claimants refers to?

1 A. Give me a moment to read this.

2 Q. Of course.

3 A. Okay.

4 Q. And, actually, let me ask a better question.

5 Do you understand that the matching claimants
6 here is referring to essentially those hits from the
7 Matching Key that match with one of the Verus trust
8 databases. Is that correct?

9 A. I do understand that, yes.

10 Q. And do you recall approximately how many of
11 the 12,000 individuals in the Matching Key were a match
12 with one of the Verus trust databases?

13 MR. ANSELM: Objection to form.

14 A. I don't recall the precise number. I believe
15 that's in my Reply Declaration.

16 Q. And we'll go through that in a second.

17 Let's also talk about the categories of
18 information sought by the Subpoena. If you move on,
19 it's page 36 of 47 on the top. It's paragraph ten. It
20 says page nine on the bottom. This is still Exhibit 2.

21 If you see at the top there, you see the
22 letters A through G?

23 A. I see that.

24 Q. Okay. And you understand that these are the
25 categories -- or these are the data fields, I guess,

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
29

1 requested to be produced by Verus concerning the
2 matching claimants. Is that correct?

3 A. That's my understanding.

4 Q. Okay. And for these categories of
5 information, A through G, does Verus maintain
6 claimant-level electronic information matches, each of
7 these fields?

8 MR. ANSELM: Objection to form.

9 A. We maintain electronic information that
10 relates to each of these fields but for A, which came
11 from the Matching Key.

12 Q. And A is claimant pseudonym, which was a
13 random number assigned by Bates White as part of the
14 Matching Key. Is that correct?

15 A. That's correct.

16 Q. Okay. And let ask a more precise question.

17 For the eight trust databases that are
18 implicated by this Subpoena, do those databases include
19 electronic information for each of the categories --
20 other than category A, each of the categories sought in
21 paragraph ten of the Subpoena?

22 A. It will include electronic information related
23 to each of those categories, yes.

24 Q. All right. Put Exhibit 2 to the side for the
25 moment. We may go back to it.

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
30

1 Verus moved to quash these Subpoenas.

2 Correct? That's why we're here?

3 A. That is correct.

4 Q. Okay. And you signed -- as I think you
5 mentioned in your prep, you had some Declarations
6 related to the motion practice. Correct?

7 A. Correct.

8 Q. Let's look at some of those. We'll start
9 with -- we are going to mark this as Exhibit 3.

10 (Exhibit 3 marked for identification.)

11

12 BY MR. HIRST:

13 Q. All right. The court reporter handed you,
14 Mr. Eveland, what we marked as Exhibit 3. This is the
15 second, I think, of the two Declarations you filed
16 relating to the Motion to Quash here. It's called
17 Reply Declaration of Mark T. Eveland
18 dated October 11th, 2022. Is that correct?

19 A. That is correct.

20 Q. And if you turn to the last page, you'll see
21 your signature. Not as pretty as my electronic one we
22 saw earlier, but is that your signature on the last
23 page?

24 A. It is. It is what it is.

25 Q. Okay. I want to spend a little time going

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
31

1 through some of this Declaration. Let's start with
2 paragraph three, which is on page two of Exhibit 3.

3 In paragraph three you write that, "Debtors
4 contend that compliance with the Subpoena will require
5 Verus to only," quote, "extract certain data fields
6 from within the database it admits it possesses, which
7 should be an entirely automated process, and place that
8 data in an Excel or database file for production," end
9 quote.

10 And then you continued, "This is not the
11 case."

12 What is incorrect about the way you phrased
13 the debtor's contention there?

14 MR. KAPLAN: Objection to form. I am
15 going to put a standing objection so I don't interrupt
16 all of Morgan's questions here. The Verus trust
17 objection to any testimony regarding anything outside
18 the scope of the hearing or outside the briefs filed.
19 That's it. It's discovery, and I am not going to
20 interrupt what you're doing.

21 MR. HIRST: That's fine. This is one
22 of the Subpoenas that was -- I'm sorry, this is one of
23 the Declarations that was filed in support of the
24 Motion to Quash.

25

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
32

1 BY MR. HIRST:

2 Q. Go ahead. I can repeat the question.

3 A. Can you repeat the question?

4 Q. Sure.

5 So I just read to you paragraph three of your
6 October 11th, 2022, Declaration, where you indicate
7 that the debtor's contention about the compliance with
8 the Subpoena is incorrect, and what I want to
9 understand there is what is incorrect about the quote
10 from paragraph three?

11 A. Specifically the parenthetical which states,
12 "This should be an entirely automated process." That
13 is not the case.

14 Q. And I do want to get to that in a second.
15 Anything else besides the fact that you
16 disagree that this is an entirely automated process
17 that is incorrect about the debtor's contention in
18 paragraph three?

19 MR. ANSELM: Objection to form.

20 A. Nothing specific.

21 Q. Okay. So obviously if you disagree that it
22 should be entirely automated, you disagree with the
23 fact that the debtors contend this should be an
24 entirely automated process, so I assume that means it
25 is not an entirely automated process to respond to this

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
33

1 Subpoena?

2 A. You would assume correctly.

3 Q. Okay. And what is it about responding to this
4 Subpoena that would be anything other than an entirely
5 automated process?

6 A. Specifically certain categories of information
7 sought may contain personal identifying information of
8 other parties other than the injured party, and we
9 cannot automate the redaction of that information.

10 Q. Anything else besides that? And I want to
11 talk about that.

12 A. That's the heart of it.

13 Q. Okay. If we can go back then to Exhibit 2,
14 the Subpoena itself, and back to that paragraph 10 we
15 looked at before, which is on page -- it says page 36
16 of 47 at the top -- the very top. It should start with
17 the letter A at the top.

18 MR. ANSELM: Number 10?

19 MR. HIRST: It's number 10, yeah. It
20 starts with letter A. Again, this is Exhibit 2, page
21 36 of 47 at the top.

22

23 BY MR. HIRST:

24 Q. You referenced, Mr. Eveland, that some of the
25 fields of information sought include personal

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
34

1 identifying information of others beyond the individual
2 claimants themselves, are contained in some of the
3 fields.

4 I think I paraphrased there, but is that an
5 accurate statement about your testimony there?

6 A. It's an accurate paraphrase of what I said,
7 yes.

8 Q. That's the best I can do.

9 Okay. Which of the fields here in Exhibit 2,
10 paragraph 10, are implicated -- or scratch that.

11 Which of the fields here in paragraph 10
12 potentially contain that type of information?

13 MR. ANSELM: Objection to form.

14 A. I can't say there is a specific field, but it
15 is item G on the list, and specifically calls for all
16 exposure-related fields, which -- which doesn't exclude
17 fields not specifically listed in the Roman numerals
18 below.

19 Q. Okay. So to be clear, letter B, claimant's
20 law firm with email and address of contact person, that
21 particular field does not include -- scratch that. Let
22 me try this again.

23 Letters B through F here in paragraph 10 of
24 Exhibit 2, you don't have any concerns that those
25 fields include any personally identifying information

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
35

1 of individuals other than the claimants?

2 MR. ANSELM: Objection to form. And
3 I promise, I am trying to be helpful here. I just
4 don't want get to confused as to fields with these
5 subparts. These are subparts to this Subpoena.

6 MR. HIRST: Correct.

7 MR. ANSELM: And I don't want there
8 to be an incorrect assumption that they are fields.

9 MR. HIRST: Let me try and clean that
10 up so it's clear.

11

12 BY MR. HIRST:

13 Q. The categories of information sought in
14 paragraphs 10B through 10F. Do you see that,
15 Mr. Eveland?

16 A. I see that.

17 Q. Okay. To be clear, it's your testimony that
18 those requests do not implicate any confidential or
19 personally identifiable information of any
20 non-claimants?

21 A. I would dispute the application of the term --
22 or your phrase doesn't include any confidential
23 information.

24 We are held to very strict confidentiality
25 provisions in our contracts, in trust distribution

1 procedures, and in electronic filing agreements between
2 the trust, Verus, and the law firms submitting these
3 claims. So all of this information under those
4 agreements is confidential.

5 Q. Let me ask the question in a different way.

6 You spoke a second ago about what parts of the
7 Subpoena require anything other than an automated
8 process to collect the information. Correct?

9 A. Yes.

10 Q. Okay. The information that's requested from
11 paragraphs 10B through 10F, those are not among the
12 categories of information that require anything other
13 than an automated process to collect?

14 MR. ANSEMI: Objection to form.

15 A. Can you repeat that?

16 Q. Sure, I can try.

17 You testified about your disagreement with the
18 debtor's statement that the process of responding to
19 Subpoenas is entirely automated. Right?

20 A. I did, yes.

21 Q. All right. And you specifically identified, I
22 believe, a moment ago that the fields that require
23 something other than an automated process to collect
24 and review were the exposure-related fields requested
25 in paragraph 10G of the Subpoena. Is that correct?

1 A. That is correct.

2 Q. Okay. So am I correct then that for
3 paragraphs 10B through 10F, for the categories of
4 information sought by those subparagraphs of the
5 Subpoena, Verus can run an entirely automated process
6 to collect and produce that information?

7 A. After writing the necessary scripts, yes, we
8 could automate the extraction of those categories of
9 information.

10 Q. And writing necessary scripts, what does that
11 entail?

12 A. That entails a database analyst writing a
13 query to extract those fields related to those
14 categories of information.

15 Q. And is this something your database analysts
16 regularly perform, writing scripts?

17 A. On a routine basis.

18 Q. Do you know approximately how long it takes a
19 database analyst to write a script to query information
20 like that sought in paragraphs 10B through 10F?

21 MR. ANSELM: Objection to form.

22 A. I don't know exactly precisely how long it
23 would take.

24 Q. Hours?

25 A. A few hours, maybe, for a simple query to

1 access that information.

2 Q. Okay. Let's move on then and keep Exhibit 2
3 nearby because we are going to come back to it, but I
4 want to go back to Exhibit 3, your October 11th, 2022,
5 Declaration. I want to skip ahead to paragraph seven,
6 and that's page three on the top.

7 In paragraph seven you write, "While the
8 debtor's Subpoena specifies certain data fields to be
9 produced, it casts a broad net for all exposure-related
10 data without limitations."

11 Do you see that?

12 A. I do see that.

13 Q. Okay. And that is what we have just been
14 referring to in the Subpoena, Exhibit 2, paragraph 10G.
15 Is that right?

16 A. That's right.

17 Q. Okay. Let me first ask, going back to the
18 Subpoena, Exhibit 2, and specifically focusing on
19 paragraph 10G, and I do want to focus on the subparts
20 of 10G here, the Romanettes one through five. Do you
21 see that?

22 A. I do see that.

23 Q. Okay. And for these five categories of
24 information requested, the specific ones in subparts G
25 one through G five. Does Verus maintain that data in

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
39

1 electronic form, data responsive to those requests in
2 electronic form?

3 A. Can you repeat that question so I understand?

4 Q. Sure.

5 So in Exhibit 2, paragraph 10G, that's one
6 through five. Does Verus maintain electronic
7 information that is responsive to those five requested
8 categories of information?

9 A. We do.

10 Q. Okay. And you referenced earlier the concern
11 about claimant -- scratch that.

12 You referenced earlier the concern about
13 information concerning other individuals other than the
14 claimants being found in exposure fields. Is that
15 correct?

16 A. That's correct.

17 Q. Okay. For the specific subparts in paragraphs
18 10G one through 10G five, are you aware of information
19 about individuals other than the individual claimant
20 being contained in the Verus electronic data that is
21 responsive to these five categories?

22 MR. ANSEMI: Objection to form.

23 A. Could you -- could you repeat or rephrase that
24 question?

25 Q. Sure, I can. Let's break it down one by one.

1 10G one requests that Verus produce for each
2 of the matching claimants the date exposure began. For
3 the electronic data fields that Verus possesses that's
4 responsive to paragraph 10G one, have you seen any
5 claimant -- or I'm sorry, have you seen any information
6 from anyone other than the individual claimant
7 implicated?

8 MR. ANSELM: Objection to form.

9 Q. You can go ahead.

10 A. Not in that specific data point.

11 Q. 10G two requests for the matching claimant's
12 information about the date exposure ended for the
13 electronic information maintained in Verus's databases.
14 Have you seen any information regarding other claimants
15 other than the matching claimant in the field for date
16 exposure ended?

17 MR. ANSELM: You're asking if he's
18 seen it to date?

19 MR. HIRST: Let's start with seen it
20 to date.

21 A. I have not.

22 Q. Okay. Are you aware of any such information
23 being included in that field within the Verus
24 databases?

25 A. I am not.

1 Q. Do you have any concerns sitting here today
2 that such information may be included in the Verus
3 databases for the date exposure ended?

4 A. Not as I sit here today.

5 Q. Paragraph 10G three requests that Verus
6 provide for the matching claimants information
7 concerning the manner of exposure, and your testimony,
8 I think, is that Verus does have electronic information
9 that's responsive to the request in 10G three. Is that
10 correct?

11 A. It's correct. Given my interpretation of what
12 you're driving at with manner of exposure, it would be
13 correct that we would have information related to that.

14 Q. And for the electronic information that Verus
15 has that's responsive to 10G three, have you seen
16 information concerning claimants other than the
17 matching claimants contained within those fields of
18 information?

19 A. I have.

20 Q. Okay. And specific in response to this
21 individual Subpoena or just generally in your
22 experience with Verus?

23 A. Generally in my experience with Verus.

24 Q. And how frequently do you see that? What
25 percentage of claimants have information concerning

1 other individuals in the manner-of-exposure fields?

2 MR. ANSELM: Objection to form.

3 A. I couldn't put a percentage on it.

4 Q. So that is one field in particular that you
5 would maintain you would need to individually review
6 that field of information before producing it?

7 A. I would, yes.

8 Q. Let's go to 10G four. 10G four asks Verus to
9 produce for the matching claimants the occupation and
10 industry when exposed. Do you see that?

11 A. I see that.

12 Q. Okay. Does Verus maintain electronic
13 information for the matching claimants for the
14 occupation and industry when exposed?

15 A. Most trusts require that information.

16 Q. Any of the trusts implicated by this Subpoena
17 that don't require that information?

18 A. I don't recall.

19 Q. For the information that Verus possesses
20 that's responsive to 10G four for the matching
21 claimants, have you observed any information about
22 other individuals within those fields?

23 A. I don't have any specific recollection of
24 seeing such information, but I can't rule it out.

25 Q. Sitting here today, do you have any concern

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
43

1 that there is information about other individuals
2 contained within those fields that are responsive to
3 the occupation and industry-when-exposed request?

4 A. I have some concern to the extent that in
5 certain cases those may be narrative fields where
6 claimants can put any response they want into those
7 fields.

8 Q. For those fields of information that you're
9 aware of, have you ever seen -- putting aside this
10 Subpoena, have you ever seen in the occupation and
11 industry fields that Verus maintains information
12 concerning other individuals other than the individual
13 claimant?

14 A. I don't have any specific recollection.

15 Q. Okay. The last one in 10G is requests for the
16 matching claimants Verus produced, the products to
17 which the claimant was exposed. Do you see that?

18 A. I do.

19 Q. Is that a field of information -- does Verus
20 maintain electronic information that's responsive to
21 that request in 10G five?

22 A. We do.

23 Q. Okay. Have you seen for the matching
24 claimants in the fields -- the electronic fields that
25 Verus does maintain that are responsive to 10G five,

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
44

1 have you seen information concerning other individuals
2 other than the matching claimant?

3 MR. ANSELM: Can I lodge an objection
4 and I can ask him to leave the room? Because I really
5 need a clarification on something, and I don't want it
6 to be seen as telling him something, so if you want
7 him --

8 MR. HIRST: Why don't we let him
9 answer the question?

10 MR. ANSELM: Sure.

11 MR. HIRST: If he doesn't understand
12 it, he can let me know and --

13 MR. ANSELM: Then I would like to ask
14 that question of you afterwards.

15 THE WITNESS: I believe you asked for
16 the matching claimants, have I seen any information --

17
18 BY MR. HIRST:

19 Q. Correct.

20 A. I have not, because I have not reviewed the
21 specific information for the matching claimants.

22 Q. Okay. How about let's take outside the
23 matching claimants. For in the various databases
24 generally, for those fields that you have identified
25 that include responsive information for the products to

1 which an individual claimant is exposed, have you seen
2 in those fields information concerning other
3 individuals other than the particular claimant in
4 question?

5 MR. ANSELM: Objection to form. You
6 are talking about other cases?

7 MR. HIRST: Yup. Other cases.

8 A. I don't have any specific recollections but,
9 again, these are -- these are narrative or memo fields,
10 so the claimants can respond with practically any
11 information, so I can't rule it out.

12 MR. HIRST: Okay. If you want to take
13 a break now?

14 MR. ANSELM: Sure. Sure.

15 (Discussion held off the record.)

16 (Recess taken.)

17

18 BY MR. HIRST:

19 Q. Back to the Subpoena again, Mr. Eveland, which
20 is Exhibit 2, and back to paragraph 10G. That's 36 of
21 47 at the top.

22 Now, I think you testified and pointed out
23 that paragraph 10G itself asks for all exposure-related
24 fields without limitation. Correct?

25 A. That's correct.

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
46

1 Q. Not just the subparts --

2 A. Yes.

3 Q. -- in Romanettes one through five?

4 A. That is my understanding.

5 Q. To be clear, how many fields of information
6 are contained in the Verus trust databases that you
7 believe are potentially responsive to exposure -- or
8 are potentially exposure-related fields?

9 MR. ANSELM: Objection to form.

10 A. There are dozens. Literally dozens.

11 Q. And what are they?

12 A. It varies from trust to trust because the
13 exposure requirements are not the same for each trust,
14 so certain trusts require different information. And
15 it would include, beyond what's listed here, things
16 such as your internal claims analyst's notes and
17 communications related to exposure issues and policy
18 related matters, communications with counsel
19 representing the trusts.

20 Q. Anything else you can recall that falls into
21 an exposure-related field?

22 A. Names of coworkers, information extracted from
23 Affidavits of Exposure. There is a host of different
24 fields that could be in play here.

25 Q. And you testified that depends -- or that

1 varies trust to trust?

2 A. It varies from trust to trust.

3 Q. All right. Let's go back to your Declaration,
4 Exhibit 3.

5 MR. ANSELMINI: The Reply Declaration?

6 MR. HIRST: Correct.

7 Q. I'll have you turn to paragraph 10, which is
8 at page three. It looks like you are there,
9 Mr. Eveland.

10 So this goes back to a question I had asked
11 earlier. So in paragraph 10, you write that for the
12 approximately 12,000 claimants on the Matching Key,
13 that corresponds to 63,000 unique claims filed with the
14 trust. Do you see that?

15 A. I see that.

16 Q. Okay. And so when you say 63,000 unique
17 claims, what are you referring to?

18 A. Well, the Matching Key contained approximately
19 12,000, the name -- the last name and Social Security
20 number of approximately 12,000 injured parties. Those
21 injured parties could have filed with one or more of
22 the eight trusts for which the debtor is seeking
23 information.

24 And when we completed the matching, it turned
25 out that there was multiple of claims that on average

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
48

1 each of those individuals filed more than one claim.
2 We matched over 63,000 claims across those eight
3 different trust databases.

4 Q. Okay. So I want to make sure I understand how
5 it works. So if me, Morgan Hirst, if I'm a claimant, I
6 could have up to eight unique claims across the eight
7 databases for which the Subpoena seeks information?

8 A. That is possible.

9 Q. And if Mr. Anselmi, on the other hand, is a
10 claimant and he only has claims on two of the trusts,
11 that would be two unique claims the way you're using it
12 here in paragraph 10?

13 A. That is correct.

14 Q. Okay. Okay. So now I am going to make the
15 two political science majors do a bit of math here.

16 MR. ANSELMI: He's a philosophy major.

17 MR. HIRST: That's true so --

18 THE WITNESS: Even worse.

19 MR. KAPLAN: I'm a political science
20 major.

21

22 BY MR. HIRST:

23 Q. So given there are 63,000 unique claims
24 across the eight trust databases, would you agree with
25 me that means at a minimum there is approximately 8,000

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
49

1 individual claimants on the Matching Key who match up
2 with at least one of the trust databases?

3 MR. ANSELM: Objection to form.

4 A. I don't know how you got to the 8,000.

5 Q. And I'll try and explain it. So if all of the
6 individual -- if all the matching claimants had filed
7 claims against each of the eight trusts implicated,
8 that would be -- if I am doing my math right, eight
9 trusts -- that would be approximately just under 8,000
10 claimants total, if they had filed claims against all
11 eight of the trusts in all cases. Is that correct? Is
12 that the way you're using the eight claims here?

13 A. Correct. Correct.

14 Q. Okay. All right. So later in this paragraph
15 you write, "The exposure records related to these over
16 63,000 unique claims numbers" -- I'm sorry, I read that
17 wrong. Let me try that again.

18 "The exposure records related to these over
19 63,000 unique claims number approximately 200,000."

20 Do you see that?

21 A. I see that, yes.

22 Q. Okay. So you referenced some of the exposure
23 fields before and that they vary across the databases,
24 but I just want to make sure I understand paragraph 10
25 here.

1 There is approximately 200,000
2 exposure-related data fields that are implicated by the
3 Subpoena here?

4 MR. ANSELMI: Objection to form.

5 Q. Is that correct?

6 A. You referenced fields.

7 Q. Yup. I did reference fields. Is that
8 incorrect?

9 A. That would be incorrect.

10 Q. Okay. So tell me what the 200,000 -- the
11 200,000 number is for the exposure records. What does
12 that consist of?

13 A. Those are unique. In my lingo, I refer to
14 them as base exposure records.

15 So each individual claimant can provide more
16 than one exposure record. And an exposure record is
17 basically a date of first exposure, date of last
18 exposure, a job site, an occupation. That's the base
19 exposure record.

20 There could be other records related to those
21 base exposure records, and a claimant who was exposed
22 over a period of decades could have worked at multiple
23 job sites and multiple occupations, so you could see
24 how you could have a series of those base exposure
25 records related to a unique claim.

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
51

1 Q. And do you know one way or the other whether
2 the 200,000 exposure records that you reference here in
3 paragraph 10, do all of those records include
4 information responsive to the Subpoena, Exhibit 2?

5 MR. ANSELM: Objection to form. Same
6 objection you and I talked about.

7 A. Could you repeat the question?

8 Q. Sure. And let's clear it up, because I want
9 to be specific.

10 In paragraph 10, you are specifically
11 referring to the 12,000 matching claimants in this --
12 sorry, the 12,000 individuals in the Matching Key
13 provided as part of the Subpoena that's Exhibit 2.
14 Correct?

15 A. That is correct.

16 Q. Okay. And you reference that they're -- for
17 those individuals, there are 200,000 exposure records.
18 Correct?

19 A. Correct.

20 Q. And that was information you were able to
21 gather from the work your team did in querying the
22 Matching Key. Is that right?

23 A. That is correct.

24 Q. Okay. So my question is this. Is it your
25 testimony that all 200,000 exposure records that you

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
52

1 were able to locate included information that is
2 responsive to the Subpoena, Exhibit 2?

3 MR. ANSELM: Objection to form.

4 A. Those are the base records. That's not the
5 sum total of the exposure information related to those
6 claims, but those are the base records which would
7 contain certain elements of what's responsive to the
8 Subpoena.

9 Q. Then you go on to state that these 200,000
10 records are the rough equivalent of over 3300 pages of
11 densely printed tabular information just for the
12 exposure data. Do you see that?

13 A. I see that.

14 Q. How did you reach that determination?

15 A. By doing some quick math on how many rows I
16 could print on a piece of paper.

17 Q. How many rows did you assume you could print
18 on each page?

19 A. I don't recall. I would have to do that
20 division in my head, and I am terrible at doing math in
21 my head. Probably in the range of 50 or 60.

22 Q. So then turning to paragraph 11, Mr. Eveland,
23 in Exhibit 3. The last sentence you write, "Complying
24 with the Subpoena will, therefore, be labor intensive
25 and expensive."

1 A. Well, which page were you referring to again?

2 Q. I'm sorry, the next page, last sentence.

3 "Complying with the Subpoena will, therefore, be labor
4 intensive and expensive."

5 And please read all of paragraph 11, but am I
6 correct that what you were referring to as the labor
7 intensive and expensive activities is reviewing the
8 approximately 3300 pages of exposure-related data that
9 you identified in paragraph 10?

10 A. In part that is the most labor intensive
11 aspect of it.

12 Q. What else is there besides that part that's
13 also labor intensive?

14 A. Well, I mentioned earlier the confidentiality
15 provisions that were bound to in our various documents
16 related to the administration of these trusts; the
17 PDP's, the trust agreements, the electronic filer
18 agreements between the law firms, the trust in Verus,
19 and our contracts with the trusts.

20 Those confidentiality provisions require us to
21 exercise a very high level of details to make sure that
22 we, are in order to produce, not producing anything
23 that should not be. So that's one element.

24 There's a high level of review that would be
25 required to make sure that we are responding in full,

1 but not responding with any information that should not
2 be included.

3 Q. Well, other than reviewing the 3300 pages that
4 you referenced, what else to comply with paragraph 10
5 of Exhibit 2, the Subpoena, would you need to do to
6 satisfy those confidentiality obligations in the PDP's
7 and your agreements with the trusts?

8 A. I believe I have already answered that
9 question, in that we would have to do the quality
10 control review to make sure that we were not including
11 any records in the response that should not be
12 included.

13 Q. And what would that consist of? What would
14 that quality control check -- what would it consist of
15 or what does it consist of?

16 A. That's an analyst who did not do the original
17 extraction of the data, double-checking that analyst's
18 work to make sure that they can confirm that the data
19 included in the extraction does not include any records
20 beyond what should have been included.

21 Q. And what does that double-check consist of?

22 A. Writing some control queries to make sure that
23 the counts agree with what the original analyst
24 produced.

25 Q. And we talked about --

1 A. It may go beyond that, but at a high level,
2 that's what it would consist of.

3 Q. Writing a piece of computer code?

4 A. Writing computer code to confirm record counts
5 and such.

6 Q. Does it include any manual reviews?

7 A. It may require some sampling and reviewing of
8 samples.

9 Q. For the Subpoena at Exhibit 2, have you done
10 any approximation for how long that quality check that
11 you just described would take?

12 A. I have not.

13 Q. And you testified earlier that writing code of
14 this type takes a few hours?

15 A. The query --

16 MR. ANSELM: Objection to form.

17 A. I testified earlier the query to get at those
18 few fields that would not potentially include personal
19 identifying information or privileged confidential
20 information that would be corresponding internally with
21 trust counsel, et cetera, that those fields -- and I
22 think it was G -- or paragraph 10 in the Subpoena,
23 B through F. That's a pretty simple query. That would
24 take a few hours to write.

25 Q. And by the same token, for paragraphs 10B

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
56

1 through 10F, the quality control check you just
2 referenced, how long would -- how long does it take to
3 write computer code to do the quality control check for
4 those fields?

5 A. Probably a similar amount of time.

6 Q. How about for the specific fields in 10G one
7 through five?

8 A. That gets more complex because we are talking
9 about differences in the database schema across the
10 trusts that are at issue here, so I can't really say
11 without looking at or talking to the analysts that
12 would be involved in this how long that might take.

13 Q. But that would still involve querying -- I'm
14 sorry, that would still involve writing code -- that
15 would still involve writing code. Is that correct?

16 A. Yes.

17 MR. ANSELM: For the quality control?

18 Q. For the quality control?

19 A. For the extraction, and the quality control to
20 make sure the extraction did not include any
21 information beyond what was being requested, yes. That
22 is still writing computer code.

23 Q. Okay. Back to the Subpoena, your Reply
24 Subpoena, Exhibit 3, and paragraph 12 now, which is
25 right in front of you.

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
57

1 In there -- and I am looking at the end of
2 this paragraph near the bottom of the page. You write,
3 "The total labor for identifying claimant records and
4 extracting, reviewing, and redacting data for other
5 recent third-party Subpoenas has ranged from 350 hours
6 to over 975 hours, at a cost to the trusts ranging from
7 approximately 51,000 to over 162,000."

8 Do you see that?

9 A. I do see that.

10 Q. Okay. Now, you do understand pursuant to the
11 Subpoena in this case and the Court's Order in this
12 case that the debtors, my client, are responsible for
13 reimbursing Verus and the trusts for any costs in
14 responding to the Subpoena. Is that correct?

15 A. I understand that.

16 Q. Okay. Now, in paragraph 12, for these other
17 recent Subpoenas, third-party Subpoenas you referred
18 to, what are they? What Subpoenas are you referring
19 to?

20 A. Sorry, could you ask that again?

21 Q. Sure.

22 You reference the costs relating to complying
23 with other recent third-party Subpoenas here in
24 paragraph 12, and I wanted to know what Subpoenas
25 you're referring to.

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
58

1 A. At the low end of the range, I believe that
2 was the Subpoena that was related to the Bestwall case.
3 That was not served on Verus or the Verus trusts, but
4 we were involved in producing information for other
5 parties who were involved in that case.

6 And at the top end of the range, that was a
7 civil investigative demand filed by the Department of
8 Justice, if I am recalling correctly.

9 Q. Okay. Let's start with the Bestwall one on
10 the low end of the range. You mentioned the Subpoenas
11 were not directed to Verus or any Verus trusts?

12 A. That's correct.

13 Q. But you, nevertheless -- or Verus,
14 nevertheless, was involved in assisting others in
15 responding to the Subpoena?

16 A. Yes.

17 Q. Okay. Who was Verus involved in assisting in
18 responding to Subpoenas in the Bestwall bankruptcy?

19 A. We were working on behalf of the trust to
20 produce records in coordination with the debtor in that
21 case that were Subpoenaed directly from the plaintiff
22 firms. It was producing the records that they had --
23 copies of all the records they had submitted to the
24 various trusts involved there.

25 Q. How many plaintiffs' firms were involved?

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
59

1 A. I don't recall how many firms it was.

2 Q. Was it more than ten?

3 A. It was a fairly small number of claims. I
4 don't know if it was more than ten. Law firms,
5 specifically.

6 Q. Okay. Approximately how many claims were
7 involved?

8 A. It was fewer than 700, if I am remembering
9 correctly. Sorry, you asked claims?

10 Q. Yeah.

11 A. It was fewer than 700 injured parties. It was
12 approximately six to 7,000 unique claims.

13 Q. And what types of information were you
14 producing in response to that Subpoena?

15 A. Copies of the proofs of claims submitted to
16 the trusts and their supporting documentation.

17 Q. And what is the supporting documentation?

18 A. Medical records, exposure records such as
19 Affidavits, deposition transcripts. A host of
20 different things.

21 Q. So this was not simply querying a database,
22 this was producing actual records and files and
23 documents?

24 A. That's correct.

25 Q. And this Bestwall Subpoena, this is the

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
60

1 Subpoena that took approximately 350 hours at a cost of
2 approximately \$51,000?

3 A. Correct.

4 Q. Okay. Was that \$51,000 reimbursed by
5 Bestwall?

6 A. We invoiced them. I don't recall if they have
7 paid it yet.

8 Q. They are in bankruptcy, so you've got to be
9 careful.

10 All right. The CID from the DOJ, and I don't
11 want specifics about what the topic was. I am
12 interested, though, in what types of information were
13 produced in response to that Civil Investigative
14 Demand?

15 A. I don't recall all the details of what was --
16 the specifics of what was produced, but it was data.
17 There were no documents involved there.

18 Q. Do you recall, was it claimant-level data?

19 A. It was claimant-level data.

20 Q. Do you recall approximately how many
21 claimants, we'll start with, were involved?

22 A. Off the top of my head, I do not.

23 Q. How about how many claims were involved?

24 A. It was all -- it was all claims paid over a
25 period of years. It was a -- it was a fairly large

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
61

1 number of claims, but I don't recall the exact count.

2 Q. And is this all claims paid by Verus or by a
3 particular Verus trust?

4 A. By the trusts who were subject to that CID.

5 Q. How many trusts were subject to it?

6 A. I do not recall.

7 Q. More than five?

8 A. Probably.

9 Q. There were eight trusts that are subject to
10 the Subpoena here in Exhibit 2. Was it the -- how did
11 the number implicated by the CID that you are referring
12 to compare to the number here?

13 A. I seem to recall it's in the same ballpark. I
14 just don't recall exactly how many.

15 Q. And how many years of paid -- strike that.
16 How many years of information did the CID
17 seek?

18 A. It was several years.

19 Q. So CID sought electronic information about
20 several years of all payments made by approximately
21 eight trusts?

22 A. I don't recall the specifics. I wouldn't say
23 all claimants. There were other criteria applied, so
24 it wasn't every claim paid by those subject trusts.

25 Q. And I know you don't have a specific

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
62

1 recollection how many claims were involved, but on a
2 magnitude are we talking a million claims?

3 A. No.

4 MR. ANSELM: Objection to form.

5 Q. Half a million claims?

6 A. I --

7 MR. ANSELM: Same objection.

8 A. I don't remember.

9 Q. Over a hundred thousand claims?

10 A. It was probably in excess of a hundred
11 thousand.

12 Q. In responding to that CID, was Verus -- did
13 Verus have to undertake any manual review of the
14 information before it was produced?

15 A. There was some manual review.

16 Q. Do you recall what that consisted of?

17 A. No, I don't recall.

18 Q. Okay. Did Verus have to perform some of the
19 same quality checks you testified about earlier?

20 A. Yes, we did.

21 Q. And is this the CID -- the CID, is this
22 what -- is this the 975 hour and \$162,000 Subpoena, I
23 guess it was, that you referred to in paragraph 12?

24 A. That is correct.

25 Q. Okay. And I know the answer to this one, but

1 I am guessing the DOJ did not reimburse the trust for
2 that?

3 A. Not one dime.

4 Q. Besides the Bestwall Subpoena and this DOJ
5 CID that you referred to, are there any other Subpoenas
6 or document requests that you are referring here to in
7 paragraph 12, when you refer to other recent
8 third-party Subpoenas?

9 A. Those are the two that represent the top end
10 and bottom end of the range.

11 Q. Okay. Going back to this DOJ Civil
12 Investigative Demand you have been testifying about.
13 We talked a lot this morning about the exposure-related
14 fields implicated by the Aldrich Subpoena. Were there
15 any exposure-related fields implicated by the DOJ's
16 Civil Investigative Demand you have been testifying
17 about?

18 MR. ANSEMI: Objection to form.

19 A. Could you ask that again?

20 Q. Sure.

21 You have testified a lot about
22 exposure-related fields. Correct?

23 A. Correct.

24 Q. Okay. Did the DOJ's Civil Investigative
25 Demand seek Verus to produce any information from

1 exposure-related fields in the trust databases?

2 A. I don't recall that it did.

3 Q. And the Bestwall Subpoena, the DOJ CID, when
4 you responded to those information requests and
5 Subpoenas, did your current staff at Verus do the work
6 to respond to those requests?

7 A. Yes, they did.

8 Q. You didn't hire outside third parties to do
9 so?

10 A. No.

11 Q. Were you able to continue to meet Verus's
12 other contractual requirements to its clients while
13 responding to these Subpoenas and CIDs?

14 MR. ANSELM: Objection to form.

15 A. Could you ask that again?

16 Q. Sure.

17 Were you able to continue to satisfy your
18 contractual obligations to Verus's clients while
19 responding to the DOJ CID and the Bestwall Subpoena you
20 referred to in paragraph 12?

21 MR. ANSELM: Objection to form.

22 A. Those responses -- those productions did put a
23 strain on the system and delay deliverables for certain
24 contracts.

25 Q. What was delayed by that?

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
65

1 A. In some cases it was the review of claims,
2 taking claims analysts out of their regular work to
3 assign them these projects. They obviously could not
4 be reviewing claims and adjudicating them to liquidate
5 those claims, so it delayed payment of certain claims
6 that would ultimately qualify.

7 It delayed our contractual milestones with our
8 trusts and, therefore, our ability to get paid for our
9 work on those trusts, and the data analysts involved
10 were delayed in delivering for certain reporting
11 contracts we have with certain of our trusts.

12 Q. You said delayed the payment of claims. Do
13 you know how many claims were delayed as a result of
14 the work your team was forced to do in response to the
15 Subpoena in the CID?

16 MR. ANSELM: Objection to form.

17 A. I don't recall off the top of my head.

18 Q. Do you know the magnitude of the delay, how
19 long the delays in payments were?

20 A. Both of those projects stretched on for over a
21 month, so it was in excess of a month.

22 Q. So it's your testimony that individual
23 claimant's payments were delayed by a month as a result
24 of the Subpoena and the CID you referred to in
25 paragraph 12?

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
66

1 A. A month, possibly longer.

2 Q. But you don't know how many particular
3 claimants were implicated by that?

4 A. Not in those particular cases, no.

5 Q. Okay. And we are talking about thousands of
6 claimants?

7 A. Probably, given the number of people involved
8 in that, yes.

9 Q. Did you receive any complaints from claimants
10 and their families or their lawyers?

11 A. On a daily basis.

12 Q. Did you receive complaints from claimants and
13 lawyers on a daily basis even when you were not
14 responding to Subpoenas?

15 MR. ANSELM: Again, objection to
16 form.

17 A. Less frequently.

18 Q. You mentioned the delayed contractual
19 milestones. What contractual milestones were delayed
20 by the Bestwall Subpoena and the DOJ CID?

21 A. Well, our claims analysts who were
22 adjudicating claims, when we finish our review of a
23 claim, we get paid for the review work that we have
24 done. If we can't -- if we're not reviewing claims,
25 we're not getting paid for that work.

1 Q. So do you know how many claims -- do you know
2 how many claims were delayed -- how many review of
3 claims were delayed by the Bestwall Subpoena and the
4 DOJ CID?

5 MR. ANSELM: Objection to form.

6 A. I do not have an exact number.

7 Q. Do you have a rough approximation?

8 MR. ANSELM: Objection to form.

9 A. As I sit here today, no. I haven't gone back
10 and looked at that.

11 Q. Did you lose any staff as a result of the work
12 they had to do on the Subpoenas or the CIDs? Did
13 anybody resign?

14 A. As a direct result of that work? There was
15 turnover during that time period, but I don't know that
16 anybody said specifically that they were resigning as a
17 result of that work, that particular project.

18 Q. In the 20 years that you have run Verus, has
19 any staff member ever said -- ever resigned and given
20 as a reason the work they were forced to do in
21 responding to Subpoenas or information requests?

22 MR. ANSELM: Objection to form.

23 A. I have heard complaints about overtime.

24 Q. And I assume it's fair to say there is plenty
25 of activities that involve overtime work besides

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
68

1 Subpoenas or information requests for Verus. Is that
2 accurate?

3 MR. ANSELM: Objection to form.

4 A. There are other instances where overtime
5 occurs, but these put additional overtime burdens on
6 the staff.

7 Q. Okay. Back to Exhibit 3, paragraph 20. So I
8 am on --

9 A. Which is Exhibit 3?

10 Q. Your Reply Declaration. I want to go to page
11 seven of eight on the top, Mr. Eveland, paragraph 20.
12 This is a paragraph by Bates White.

13 So you write here in paragraph 20 that you are
14 aware -- or that, "While it is true that Bates White
15 does not process trust claims, it does work for
16 numerous asbestos defendants and insurance carriers."

17 Do you see that?

18 A. I see that.

19 Q. And you write, "Therefore, its interests,"
20 referring to Bates White, "and the interests of its
21 clients are potentially adverse to those of Verus's
22 trust clients, to which Verus bears contractual and
23 other obligations."

24 Do you see that?

25 A. I see that.

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
69

1 Q. And you believe that -- you believe Bates
2 White's interests are adverse to Verus and the Verus
3 trusts?

4 A. Potentially so.

5 Q. Why do you think that?

6 A. Because the trust has an obligation to
7 maintain the confidentiality of the information
8 submitted by claimants for adjudication of their
9 claims. Disclosing that information to other parties
10 creates risk that that confidentiality could be
11 breached.

12 Q. Are you aware of any instances where Bates
13 White has breached confidentiality of trust data or
14 trust claimant data it's received?

15 A. I am not aware of any, but that doesn't reduce
16 the risk to zero.

17 Q. Well, you providing -- doesn't the trust even
18 providing the information to Verus creates some risk of
19 exposure of that data, doesn't it?

20 MR. ANSELM: Objection to form.

21 A. It does, but I control that risk.

22 Q. So this is more an issue that you know what
23 you control at Verus, you don't know what the controls
24 are at Bates White?

25 A. I do not know.

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
70

1 Q. Okay. You don't have any specific reason to
2 believe, though, that Bates White is doing anything to
3 misuse or expose claimant-level data, do you?

4 A. No, I do not.

5 Q. Okay. Now, the debtors here, my clients here,
6 are asbestos defendants. You are aware of that.

7 Correct?

8 A. I am aware of that.

9 Q. Do you believe Verus has interests that are
10 potentially adverse to my clients?

11 A. Not specifically.

12 Q. So I guess I am trying to understand the
13 difference between your statements about Bates White
14 and its adversity to the Verus trust clients and your
15 concern there, and the fact that you don't believe that
16 Verus can be adverse to the debtors. How do you
17 explain to me the difference between the two?

18 A. Well, perhaps I didn't follow your question
19 there.

20 Q. Sure, so let me ask it again.

21 So you understand that my clients are asbestos
22 defendants?

23 A. I do.

24 Q. Okay. And given Verus's role, do you believe
25 Verus -- Verus's interests are potentially adverse to

1 the debtors in this case?

2 A. It would trace back to that whole -- that same
3 concern about confidentiality and the risk of
4 information being shared beyond the walls of people who
5 are supposed to have access to it or could potentially
6 breach.

7 Q. Is there anything other than -- other than the
8 sharing of data to any third party, is there anything
9 else that you believe causes potential adversity
10 between the debtors and Verus in this case?

11 MR. ANSELM: Objection to form.

12 A. Nothing that comes to mind.

13 Q. Okay. I want to mark your other Declaration
14 concerning the Motion to Quash as Exhibit 4, although I
15 can promise you we will spend less time with that.

16 (At this point in the proceedings,
17 Mr. Kaplan exited the deposition room.)

18 MR. ANSELM: Let the record reflect,
19 I think, Nicholas Velez from Lowenstein Sandler is now
20 on the phone in the absence of Michael Kaplan.

21 (Exhibit 4 marked for identification.)

22

23 BY MR. HIRST:

24 Q. Mr. Eveland, I am handing you what we have
25 marked as Exhibit 4. This is your August 19th, 2022,

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
72

1 Declaration in support of Verus's Motion to Quash.

2 Do you recognize this document, sir?

3 A. I do.

4 Q. That was one of the documents you looked at in
5 preparation for today's deposition?

6 A. Yes.

7 Q. And that is your signature, again, at the last
8 page, page nine?

9 A. It is.

10 Q. Okay. Just a few questions about this one. I
11 want to start with paragraph seven, page three of the
12 Declaration here, Exhibit 4.

13 And, again, so we get our time right,
14 Exhibit 4 here was filed on August 19th, 2022, and the
15 Reply Declaration we are looking at, at Exhibit 3, was
16 filed about two months later on August -- I'm sorry,
17 October 11th.

18 Here in Exhibit 4, the August 19th
19 Declaration, in paragraph seven you refer to Bates
20 White as a competitor. Do you see that?

21 A. I do see that.

22 Q. Okay. Do you still believe Bates White is a
23 competitor of Verus?

24 A. Not a direct competitor, but we are operating
25 within the same space of providing services in mass

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
73

1 tort and class action litigation.

2 Q. So what areas does Bates White compete with
3 Verus in?

4 A. Specifically on the analytic front. Verus
5 also has a team that is involved in providing
6 estimations of liabilities for mass tort cases.

7 Q. As it relates to processing trust claims,
8 Bates White and Verus are not competitors, are they?

9 A. No.

10 MR. ANSELM: Objection to form.

11 Q. And to your knowledge, Bates White doesn't
12 process trust claims?

13 A. To my knowledge, they do not.

14 Q. And they don't provide claims administration
15 services to trusts?

16 A. No, not that I am aware of.

17 Q. Okay. Now, also in paragraph seven, you write
18 that Bates White -- you write Bates White could
19 potentially reverse engineer the data produced to
20 recreate Verus's proprietary algorithms. Do you see
21 that?

22 A. I do see that.

23 Q. Okay. I just want to make sure I understand
24 this subject.

25 So how would responding to the Subpoena,

1 Exhibit 2, and the information requested there in
2 paragraph 10, how would that expose Verus's proprietary
3 algorithms to anyone?

4 A. Data in the hands of a good statistician could
5 be used to approximate the criteria used to adjudicate
6 claims, a sufficient quantity of data.

7 Q. But I thought we established a minute ago
8 Bates White doesn't adjudicate claims. Correct?

9 A. They do not.

10 Q. Okay. Do you have any reason to believe Bates
11 White would use the data here to reverse engineer
12 Verus's proprietary algorithms?

13 A. I have no reason to believe that they would do
14 that of their own volition for their own purposes to
15 compete with us in the claims administration space, but
16 I don't know what their other clients are doing, and I
17 don't know what the other databases they're compiling
18 on using this data are used for.

19 Q. You are aware that the Court's Order in this
20 case, which is attached to the Subpoena, includes very
21 stringent restrictions on how the data can be used.
22 Correct?

23 A. I am aware of that.

24 Q. Okay. So for Bates White to reverse engineer
25 Verus's proprietary algorithms using the data produced

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
75

1 in response to this Subpoena here, you would agree with
2 me they would have to violate the Court's Order.

3 Correct?

4 MR. ANSELM: Objection to form.

5 A. I don't know that as I sit here, that they
6 would have to violate that. I also don't know if other
7 parties could get access to this information through a
8 data breach or some other event.

9 Q. Are you aware of any data breach incidents
10 that have happened to Bates White?

11 A. I am not.

12 Q. Have you ever had any data breaches at Verus?

13 A. We have not.

14 Q. And going back all the way to Exhibit 1. That
15 was this table that was attached to Miss Bennett's --

16 MR. ANSELM: Yes, this is it.

17 Q. I am specifically referring to the table here,
18 and you can go to the first page of the table.

19 Do you see there is a footnote at the bottom,
20 "Bates White was involved in the cases listed in bold."

21 Do you see that?

22 A. I see that.

23 Q. And it looks like of the -- it looks like
24 there is six of the nine entries on this table that are
25 bolded. Do you see that?

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
76

1 A. My eyesight is not the best but --

2 Q. My counting skills aren't, either, so I think
3 it's six of the nine.

4 A. Yeah.

5 Q. Okay. In any of these cases where Bates White
6 was involved, to your knowledge did Bates White ever
7 attempt to reverse engineer the data produced by Verus
8 to recreate Verus's proprietary algorithms?

9 MR. ANSELM: Objection.

10 A. Could you ask that again?

11 Q. Sure.

12 In any of the cases here where Verus was
13 subject to a Subpoena in the case where Bates White was
14 involved, do you have any knowledge of Bates White
15 attempting to reverse engineer Verus's proprietary
16 algorithms using the data produced?

17 A. I have no personal knowledge of that.

18 Q. All right. Back to your August Declaration,
19 Exhibit 4, Mr. Eveland, paragraph 13 this time. So
20 this is page five of nine at the top. It is a short
21 paragraph.

22 A. Okay.

23 Q. You write, "Oftentimes claimants' counsel
24 mistakenly upload the personal information and
25 confidential documents to the incorrect claimants'

1 electronic files."

2 Do you see that?

3 A. I see that.

4 Q. Okay. What are you referring to there?

5 A. I am referring to clerical errors, where we
6 may have information related to another claimant
7 commingled with information for that specific injured
8 party.

9 Q. Okay. So to make sure I got the example
10 right. I am a claimant, Mr. Anselmi is a claimant, and
11 my lawyer uploads my personal information to
12 Mr. Anselmi's file?

13 A. That is essentially correct, yes.

14 Q. How often does this happen?

15 MR. ANSELMI: Objection to form.

16 A. I couldn't put an exact number on it, but it's
17 not infrequent.

18 Q. Does Verus take any measures on the front end
19 to ensure that my information is not uploaded into
20 Mr. Anselmi's file?

21 MR. ANSELMI: Objection to form.

22 MR. HIRST: Scrap that.

23 Q. Does Verus take any measures to ensure that
24 the correct claimant information is included in the
25 correct claimant's file?

1 MR. ANSELM: Same objection.

2 A. We have -- in our review protocols, we have
3 procedures for identifying information related to other
4 claimants when we -- when we see it. It is almost --
5 it's practically impossible to prevent such commingling
6 from occurring, but our reviewers when they identify it
7 flag those discrepancies.

8 Q. And when do reviewers undertake that process
9 you just referred to?

10 A. It's part of the adjudication process.

11 Q. So by the end of the adjudication process, if
12 everything has gone according to plan, there is no
13 longer incorrect claimant information in a claimant's
14 file. Is that correct?

15 MR. ANSELM: Objection to form.

16 A. Could you restate that question?

17 Q. Sure.

18 The issue you identify here in paragraph 13 of
19 your Affidavit, Exhibit 4. You have set up a process
20 such by the end of the review that should no longer be
21 an issue?

22 MR. ANSELM: Objection to form.

23 A. That information -- or as part of our process,
24 we never delete information from a proof of claim
25 that's been submitted to the trust. If it is incorrect

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
79

1 information or it relates to another party, we will
2 flag it as such, but it is still part of the record.

3 Q. What happens after you flag it?

4 A. It depends on what the information is. I
5 mean, that's a very broad question.

6 Q. Well, is it possible after you flag it --
7 using my example of my information showing up in
8 Mr. Anselmi's file. If one of your reviewers flags
9 that information, is it possible it's just going to
10 stay in that file?

11 A. It would stay in that file as part of what was
12 submitted, but there would be a note appended somehow
13 to that claim file. Depending on what information --
14 what specific field or document it is, there would be a
15 note related to that, that it does not refer to that
16 specific injured party.

17 Q. In the event such a note were included in
18 responding to a Subpoena like the one we are seeing in
19 Exhibit 2, would a reviewer see that when querying
20 Mr. Anselmi's file, that my information is located in
21 there?

22 MR. ANSELM: Objection to form.

23 A. Could you repeat that question?

24 Q. Sure.

25 So back to the Subpoena, Exhibit 2, and back

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
80

1 to my example of me and Mr. Anselmi. If Mr. Anselmi's
2 information were called for in Exhibit 2, and a
3 reviewer flagged the fact that my personal information
4 ended up in Mr. Anselmi's file, would the individuals
5 responsible for responding to the Subpoena, would
6 they -- would they see that? Would they see that
7 flagged information?

8 A. They would, yes.

9 Q. So they would have the ability to extract that
10 out and not produce it?

11 MR. ANSELMI: Objection to form.

12 A. They would have the ability to extract that
13 out.

14 Q. Okay.

15 A. Now, that is a manual process, and even the
16 process of flagging that information in the
17 adjudication process is subject to human error, so it
18 could be overlooked in that process.

19 Q. But you have no idea of how frequently this
20 occurs?

21 A. I could not put a specific number on it, but
22 it is not an infrequent occurrence.

23 Q. Are you okay? We can keep going now or take a
24 break.

25 MR. ANSELMI: What do you think?

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
81

1 MR. HIRST: Twenty-five minutes?

2 MR. ANSEMI: Why don't we take a
3 quick break?

4 (Recess taken.)

5 (Exhibit 5 marked for identification.)

6

7 BY MR. HIRST:

8 Q. All right. Mr. Eveland, I am going to hand
9 you -- during the break we marked this as Exhibit 5,
10 and this is another Declaration of yours. This one was
11 actually filed in this bankruptcy case, in the Aldrich
12 Pump case, on March 8th, 2023.

13 It's called the Declaration of Mark Eveland
14 pursuant to a number of rules in support of the
15 ex parte application of the official committee of
16 asbestos personal injury claimants to retain and employ
17 Verus LLC as PIQ data administrator for the Personal
18 Injury Questionnaire responses.

19 Do you see that, sir?

20 A. I see that.

21 Q. Okay. And this Declaration is our most recent
22 one, filed March 8th, 2023.

23 A. Okay.

24 Q. Do you see that on the top?

25 A. I see that.

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
82

1 Q. Okay. And if you go to page seven of 16,
2 Mr. Eveland, it looks like you signed it on
3 February 21st, 2023. Is that correct?

4 A. That is correct.

5 Q. And that's your signature?

6 A. That is my signature.

7 Q. Okay. So in your own words, Mr. Eveland, what
8 is Verus seeking to be retained to do in the bankruptcy
9 case?

10 A. Essentially to review the PIQs that plaintiff
11 firms have been required to produce in the -- for a
12 limited number of claimants, and to create a data set
13 that would then be used by the claims estimators.

14 Q. And the PIQs are the Personal Injury
15 Questionnaires?

16 A. That is correct.

17 Q. And Verus is seeking to be retained by the ACC
18 in this case. Correct?

19 A. That is who's asked to retain us, yes.

20 Q. Okay. And if you look at page three of your
21 Declaration, Exhibit 5, paragraph four, Scope of
22 Service. This details specifically the tasks Verus
23 intends to perform on behalf of the committee?

24 A. That's correct.

25 Q. And there is, I think, nine separate specific

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
83

1 items there, A through I?

2 A. That's correct.

3 Q. Do you have any idea how many total hours
4 Verus anticipates spending on the work it's seeking to
5 do here as outlined in your Affidavit, Exhibit 5?

6 A. No, I do not have an estimate of that.

7 Q. Okay. I assume it's going to be more than ten
8 hours on that one?

9 A. Most likely.

10 Q. More than a hundred hours?

11 A. Probably far in excess of that.

12 Q. We are talking thousands of hours of work?

13 A. Possibly, but I have not seen any of the PIQs
14 or know how many there are.

15 Q. Okay. I have. They're long.

16 Does Verus have the necessary personnel to
17 perform the services identified in paragraph four of
18 your Declaration?

19 A. This is -- I view this as going to be a
20 longer-term engagement, and we will hire and train
21 people.

22 Q. How many individuals do you think you'll need
23 to hire to perform those services?

24 A. Until I know the extent of the documents that
25 need to be reviewed and the protocols for reviewing

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
84

1 them, I don't have an estimation of that.

2 Q. But you're confident you'll be able to hire
3 the necessary personnel in order to perform these tasks
4 you're asking the Court to approve?

5 A. Yes.

6 Q. And you're confident you can allocate the
7 resources needed to perform this work. Is that
8 correct?

9 A. Given sufficient time, yes.

10 Q. And will performing the services identified
11 here in paragraph four of your Declaration, will that
12 negatively impact in any way your duties to your
13 current clients?

14 MR. ANSEMI: Objection.

15 Q. Or Verus's duties to its current clients?

16 A. No.

17 MR. ANSEMI: Objection to form.

18 A. As with any new client, we hire and staff
19 appropriately.

20 Q. Okay. So do you foresee the work outlined in
21 paragraph four causing Verus to delay payments of any
22 trust claims?

23 A. No. As I said previously in response to one
24 of your earlier questions, our intent is to hire and
25 staff this as a separate team.

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
85

1 Q. So I assume the same answer to my question.
2 Do you anticipate or do you have any concern that it's
3 going to cause Verus to delay any contractual
4 milestones that it has?

5 A. No. As I said, it's a separate -- we will
6 hire and train a separate team to perform this work.

7 Q. And who do you understand will pay Verus for
8 the work outlined here in your Declaration, Exhibit 5?

9 A. I understand that we would be retained by the
10 Asbestos Creditor's Committee.

11 MS. PHILLIPS: I object to this line
12 of questioning to the extent it proceeds, you know,
13 beyond the relevance of the Subpoena to the trust.

14 MR. HIRST: Okay. I think I can see
15 the relevance, but we'll figure it out.

16

17 BY MR. HIRST:

18 Q. And do you know who ultimately pays those
19 bills on behalf of the Asbestos Creditor's Committee,
20 including the bill that Verus is potentially going to
21 be serving if they're hired for these tasks?

22 MS. PHILLIPS: Same objection.

23 A. That I do not know, the specific entities that
24 would be paying those bills.

25 Q. So you're not aware it's the debtors' estates

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
86

1 who would be paying Verus's bills for this work?

2 A. I am vaguely aware of that.

3 Q. Okay. And you're also vaguely aware that it
4 would be the debtors who would be paying Verus for any
5 of the work performed in responding to the Subpoena we
6 saw in Exhibit 2?

7 MS. PHILLIPS: Same objection.

8 A. That is my understanding.

9 Q. Okay. You can put number five aside.

10 Mr. Eveland, are you familiar -- and I am not,
11 but are you familiar with what SOC 2 certification
12 refers to?

13 MR. ANSELMINI: Could you repeat that?

14 Q. Are you familiar with SOC 2? S-O-C.

15 A. I am familiar with SOC certifications.

16 Q. And what is SOC certification?

17 A. Service Organizational Controls to accounting
18 standards for auditing service providers.

19 Q. Okay. And does that include -- your
20 familiarity with SOC services, does that include data
21 integrity, confidentiality, and those types of issues?

22 MR. ANSELMINI: Objection to form.

23 A. My familiarity with it, it depends on which
24 version of SOC audit is being undertaken the extent of
25 the controls that are tested.

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
87

1 Q. Does Verus have SOC certification?

2 A. We do have an SOC audit.

3 Q. Okay. And what is that?

4 A. It's an SOC 1 audit.

5 Q. Okay. Does Verus have SOC 2 certification?

6 A. Not currently.

7 Q. Has Verus ever sought SOC 2 certification?

8 A. Not currently.

9 Q. Is Verus intending to seek SOC 2
10 certification?

11 A. We will probably do so eventually.

12 Q. And why is Verus interested in seeking SOC 2
13 certification eventually?

14 A. It's part of our growth strategy as we expand
15 into new market segments and the company grows. It's
16 just an added level of certification that assures new
17 clients of Verus's capabilities.

18 Q. How about are you familiar with HITRUST
19 certification?

20 A. I am generally familiar with HITRUST.

21 Q. Okay. And what's your familiarity with
22 HITRUST certification? What does that involve?

23 A. I don't know the specifics of HITRUST, but I
24 am aware of it as a general concept.

25 Q. So given your lack of familiarity, I assume

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
88

1 Verus does not have HITRUST certification?

2 A. We do not currently have HITRUST
3 certification.

4 Q. Is Verus anticipating seeking HITRUST
5 certification at any point in the future?

6 MR. ANSEMI: Objection to form.

7 A. We have spoken with our outside audit firm
8 about seeking that in the future.

9 Q. And why is Verus interested in seeking HITRUST
10 certification in the future?

11 A. As a general rule, the certifications are
12 additional marketing collateral, for want of a better
13 term.

14 Q. Do you know what is involved in becoming
15 HITRUST certified?

16 A. I know there is a certification process that
17 would involve reviewing controls around data integrity
18 and security. I do not know all the specifics.

19 Q. And you haven't undertaken those yet, have
20 you, sir?

21 A. We have not undertaken the certification
22 process yet.

23 Q. Okay. Same question on the SOC 2 side. Are
24 you aware of what is involved in obtaining SOC 2
25 certification?

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
89

1 A. Yes, I am.

2 Q. And what's involved in that?

3 A. Well, it's a test of a number of different --
4 I forget what they refer to them as, but standards in
5 different categories, and there is a standard list of
6 controls that must be tested in order to seek -- to
7 obtain SOC 2 certification in each of those control
8 areas.

9 Q. And Verus has not undertaken those tasks yet,
10 have they, sir?

11 A. Not for SOC 2 certification.

12 Q. Correct?

13 A. We have an SOC 1.

14 Q. What does two-factor authentication refer to,
15 Mr. Eveland?

16 A. Two-factor authentication is a means of
17 controlling access to computer systems. It requires
18 not just the username and password to obtain access,
19 but also a secondary confirmation that you are who you
20 claim to be through either a code sent through a text
21 message, an email, or through an authentication
22 application.

23 Q. And to access the Verus trust databases that
24 Verus maintains -- scrap that.

25 To access the trust databases that Verus

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
90

1 maintains, does Verus require two-factor
2 authentication?

3 A. We do.

4 Q. Okay. And what is the two-factor
5 authentication you require? What are the steps?

6 A. It's a -- well, first you enter your username
7 and password, and then you have to enter a six-digit
8 code obtained through a text message or an
9 authentication application.

10 Q. And what is a managed security service
11 provider?

12 A. A managed security service provider?

13 Q. Yes.

14 A. Essentially a network administrator monitors
15 network infrastructure, firewalls, network traffic.

16 Q. Does Verus employ a managed security service
17 provider?

18 A. We do.

19 Q. And who is that?

20 A. That would be a firm called STF Consulting.

21 Q. Okay. Does Verus require its employees to
22 complete annual cyber security training?

23 A. Not just annual, but regular and recurring
24 throughout the year.

25 Q. And what does that consist of?

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
91

1 A. We require monthly training that consists
2 of -- we have a third party that we contract with
3 called KnowBe4 that provides training collateral that
4 they all have to go through on a monthly basis.

5 There is also random testing, where there
6 is -- they receive emails and text messages, things of
7 that nature, that are testing whether they respond to
8 phishing attacks and such, and if they do -- if they do
9 inappropriate click on one of those messages, they have
10 to go through additional supplemental training.

11 MR. HIRST: This might be my
12 25 minutes, Andrew, if we can take five minutes.

13 (Recess taken.)

14 MR. HIRST: This is the happiest part
15 of many depositions, because I have no more questions
16 for you.

17 THE WITNESS: Thank you.

18 MR. ANSELMI: I have no questions.

19 MS. PHILLIPS: I have no questions.

20 MR. ANSELMI: Does anyone on the phone
21 have any questions? I think that does it.

22 (Discussion held off the record.)

23 MR. HIRST: So overnight for the
24 debtors requested for the transcript.

25 MR. ANSELMI: Overnight for Verus.

1 MS. PHILLIPS: And overnight for the
2 ACC, please.

3 MR. HIRST: Anyone on the phone with a
4 transcript order? All right. Unless anyone else has
5 anything on the phone, we are going to hang up on you
6 guys.

7 (Deposition adjourned at 11:38 a.m.)

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
93

C E R T I F I C A T E

I, MARY ADAMCIK, a Certified Court Reporter and Notary Public of the State of New Jersey, certify that the foregoing is a true and accurate transcript of the testimony taken at the place and on the date hereinbefore set forth.

I FURTHER CERTIFY that I am neither attorney nor counsel for, nor related to or employed by any of the parties to the action in which this deposition was taken; and further, that I am not a relative or employee of any attorney or counsel employed in this case, nor am I financially ^{in any} interested in the action.

MARY ADAMCIK
CERTIFIED COURT REPORTER
LICENSE NO. 30X100103100

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
94

1 Reference No.: 9684106

2

3 Case: IN RE ALDRICH PUMP LLC, ET AL.

4

DECLARATION UNDER PENALTY OF PERJURY

5

6 I declare under penalty of perjury that
7 I have read the entire transcript of my Depo-
8 sition taken in the captioned matter or the
9 same has been read to me, and the same is
10 true and accurate, save and except for
11 changes and/or corrections, if any, as indi-
12 cated by me on the DEPOSITION ERRATA SHEET
13 hereof, with the understanding that I offer
14 these changes as if still under oath.

10

11

12

Mark Eveland

13

14

NOTARIZATION OF CHANGES

15

(If Required)

16

17

Subscribed and sworn to on the _____ day of

18

19

_____, 20____ before me,

20

21

(Notary Sign) _____

22

23

(Print Name) _____ Notary Public,

24

25

in and for the State of _____

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
95

1 Reference No.: 9684106
Case: IN RE ALDRICH PUMP LLC, ET AL.

2

3 Page No. _____ Line No. _____ Change to: _____

4 _____

5 Reason for change: _____

6 Page No. _____ Line No. _____ Change to: _____

7 _____

8 Reason for change: _____

9 Page No. _____ Line No. _____ Change to: _____

10 _____

11 Reason for change: _____

12 Page No. _____ Line No. _____ Change to: _____

13 _____

14 Reason for change: _____

15 Page No. _____ Line No. _____ Change to: _____

16 _____

17 Reason for change: _____

18 Page No. _____ Line No. _____ Change to: _____

19 _____

20 Reason for change: _____

21 Page No. _____ Line No. _____ Change to: _____

22 _____

23 Reason for change: _____

24

25 SIGNATURE: _____ DATE: _____
Mark Eveland

MARK EVELAND
IN RE ALDRICH PUMP LLC, ET AL.

May 16, 2023
96

1 Reference No.: 9684106
Case: IN RE ALDRICH PUMP LLC, ET AL.

2
3 Page No. _____ Line No. _____ Change to: _____
4 _____

5 Reason for change: _____

6 Page No. _____ Line No. _____ Change to: _____

7 _____

8 Reason for change: _____

9 Page No. _____ Line No. _____ Change to: _____

10 _____

11 Reason for change: _____

12 Page No. _____ Line No. _____ Change to: _____

13 _____

14 Reason for change: _____

15 Page No. _____ Line No. _____ Change to: _____

16 _____

17 Reason for change: _____

18 Page No. _____ Line No. _____ Change to: _____

19 _____

20 Reason for change: _____

21 Page No. _____ Line No. _____ Change to: _____

22 _____

23 Reason for change: _____

24 SIGNATURE: _____ DATE: _____

25 Mark Eveland

EXHIBIT G

RICHARD WINNER
ARMSTRONG WORLD INDUSTRIES V. ALDRICH PUMP

May 16, 2023

1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

UNITED STATES BANKRUPTCY COURT
WESTERN DISTRICT OF NORTH CAROLINA
CHARLOTTE DIVISION

- - -
IN RE: : CIVIL ACTION
ALDRICH PUMP LLC, :
et al, : Case no. 20-30608
Debtors. :
----- (Jointly Administered)
ARMSTRONG WORLD :
INDUSTRIES, INC. :
ASBESTOS PERSONAL : Miscellaneous
INJURY SETTLEMENT : Proceeding
TRUST,et al. :
Plaintiffs, : No. 22-00303 (JCW)
V. : (Transferred from
ALDRICH PUMP, LLC, : District of
et al. : Delaware)
Defendants :

(Continued on Page 2.)

- - -
May 16, 2023
- - -

Oral deposition of RICHARD WINNER,
held in the offices of Young Conaway Stargatt
& Taylor, 1000 N. King Street, Wilmington,
Delaware 19801, commencing at 8:59 a.m. on
the above date, before Teresa M. Beaver, a
Professional Court Reporter and Notary
Public.

- - -
ESQUIRE DEPOSITION SOLUTIONS
1835 Market Street
5th Floor
Philadelphia, Pennsylvania 19103
(215) 988-9191



RICHARD WINNER
ARMSTRONG WORLD INDUSTRIES V. ALDRICH PUMP

May 16, 2023
2

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA

- - -

AC&S ASBESTOS :
SETTLEMENT TRUST, : Miscellaneous
COMBUSTION ENGINEERING : Proceeding
524(G) ASBESTOS PI :
TRUST, GI HOLDINGS : No. 23-00300 (JCW)
INC. ASBESTOS PERSONAL :
INJURY SETTLEMENT : (Transferred from
TRUST, GST SETTLEMENT : District of New
FACILITY, KAISER : Jersey)
ALUMINUM & CHEMICAL :
CORPORATION ASBESTOS :
PERSONAL INJURY TRUST, :
QUIGLEY COMPANY, INC. :
ASBESTOS PI TRUST, TH :
AGRICULTURE & :
NUTRITION, L.L.C. :
ASBESTOS PERSONAL :
INJURY TRUST, and :
YARWAY ASBESTOS :
PERSONAL INJURY TRUST, :
Petitioners, :
V. :
ALDRICH PUMP LLC, :
et al. :
Respondents, :
VERUS CLAIM SERVICES, :
LLC, :
Interested :
Party, :
NON-PARTY CERTAIN :
MATCHING CLAIMANTS, :
Interested :
Party. :

- - -
May 16, 2023
- - -
Oral deposition of RICHARD WINNER.
- - -

ESQUIRE DEPOSITION SOLUTIONS
1835 Market Street
5th Floor
Philadelphia, Pennsylvania 19103
(215) 988-9191



1 A P P E A R A N C E S :

2

HOGAN McDANIEL
3 BY: DANIEL K. HOGAN, ESQUIRE
1311 Delaware Avenue
4 Wilmington, Delaware 19806
dkhogan@dkhogan.com
5 Counsel for Certain Matching
Claimants

6

7

ROBINSON & COLE
8 BY: LAURIE KREPTO, ESQUIRE
1650 Market Street
30th Floor
9 Philadelphia, Pennsylvania 19103
Lkrepto@rc.com
10 Counsel for Asbestos Creditors
Committee

11

12

YOUNG CONAWAY STARGATT & TAYLOR, LLP
13 BY: KEVIN A. GUERKE, ESQUIRE
and
ROXANNE M. EASTES, ESQUIRE
14 1000 North King Street
Wilmington, Delaware 19801
15 reastes@ycst.com
kguerke@ycst.com
16 Counsel for the DCPF and the Witness

17

18

BALLARD SPAHR, LLP
19 BY: BETH MOSKOW-SCHNOLL, ESQUIRE
919 North Market Street
11th Floor
20 Wilmington, Delaware 19801
Moskowb@ballardspahr.com
Counsel for OCPF Trust

21

22

23

24

1 A P P E A R A N C E S :

2 (VIA VIDEOCONFERENCE)
3 ORRICK, HERRINGTON & SUTCLIFFE, LLP
4 BY: JONATHAN P. GUY, ESQUIRE
5 1152 15th Street NW
6 Washington, D.C. 20005
7 jguy@orrick.com
8 Counsel for Future Claim
9 Representative Joseph Grier

10 (VIA VIDEOCONFERENCE)
11 LOWENSTEIN SANDLER, LLP
12 BY: NICHOLAS VELEZ, ESQUIRE
13 One Lowenstein Drive
14 Roseland, New Jersey 07068
15 nvelez@lowenstein.com
16 Counsel for Verus Trusts

17 (VIA VIDEOCONFERENCE)
18 McCARTER & ENGLISH
19 BY: SHAWN SMITH, ESQUIRE
20 185 Asylum Street
21 Hartford, Connecticut 06103
22 Counsel for Non-Debtor Affiliates,
23 Trane Technologies Company LLC and
24 Trane U.S., Inc.

25 (VIA VIDEOCONFERENCE)
26 EVERT WEATHERSBY HOUFF
27 BY: CLARE M. MAISANO, ESQUIRE
28 111 S. Calvert Street
29 Suite 1910
30 Baltimore, Maryland 21202
31 cmmaisano@ewhlaw.com
32 Counsel for The Debtors

1 A P P E A R A N C E S :

2 (VIA VIDEOCONFERENCE)
3 ANSELM I & CARVELLI, LLP
4 BY: ZACHARY D. WELLBROCK, ESQUIRE
5 56 Headquarters Plaza
6 West Tower, Fifth Floor
7 Morristown, New Jersey 07960
8 zwellbrock@acllp.com
9 Counsel for Verus Claims Services, LLC

10 (VIA VIDEOCONFERENCE)
11 CAPLIN & DRYSDALE
12 BY: KATY ZENDEH, ESQUIRE
13 One Thomas Circle, NW
14 Suite 1100
15 Washington, D.C. 20005
16 kzendeh@capdale.com
17 Counsel for Official Committee of
18 Asbestos Personal Injury Claims

19 - - -

I N D E X

1		
2	WITNESS	PAGE
3	RICHARD WINNER	
4	BY MS. MAISANO	8

E X H I B I T S

5			
6			
7	MARKED	DESCRIPTION	PAGE
8	Exhibit Winner-1	Subpoena	23
9	Exhibit Winner-2	Declaration of Richard Winner	38
10	Exhibit Winner-3	Delaware Claims Processing Facility Invoice No. 12 dated November 2, 2022	121
11			
12	Exhibit Winner-4	Delaware Claims Processing Facility Invoice No. 13 dated January 18, 2023	121
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			

DEPOSITION SUPPORT INDEX

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Direction to Witness Not to Answer

Page	Line	Page	Line
------	------	------	------

None

Request For Production of Documents

Page	Line	Page	Line
------	------	------	------

None

Questions Marked

Page	Line	Page	Line
------	------	------	------

None

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

- - -

RICHARD WINNER, after having
been duly sworn, was examined and testified
as follows:

- - -

EXAMINATION

- - -

BY MS. MAISANO:

Q. Good morning, Mr. Winner.

A. Good morning.

Q. My name is Clare Maisano. We
met briefly before we started. I represent
the debtors in this case and I'll be taking
your deposition today.

A. Okay.

Q. I know you've had your
deposition taken before but just a few rules
of the road --

A. Okay.

Q. -- so that we have a clean
record.

Please give audible responses to
my questions. A nod of the head or a shake
of the head isn't able to be picked up on the

1 written record.

2 If you could please let me
3 finish my question before you start to
4 answer, we might get into a conversational
5 way and it's much easier for Madam Court
6 Reporter to have us not speaking over each
7 other.

8 If you answer my question, I'll
9 presume that you understood it and so if my
10 question is unclear, if you don't understand,
11 please ask me to rephrase and I'll do that.

12 I know you have a hard stop at
13 12:45 as I understand it today?

14 A. Yes.

15 Q. I hopefully will get you out of
16 here well in advance of that.

17 But that said, should you want
18 to take a break, please let me know. This
19 doesn't need to be an endurance test.

20 In response to some of the
21 questions, you may hear objections from the
22 attorneys from time to time.

23 Unless you're instructed not to
24 answer by your attorney, we can note the

1 objection and then move on.

2 Do you have any questions for me
3 before we start?

4 A. No.

5 Q. Could you state your name for
6 the record, please?

7 A. Richard Winner.

8 Q. And your business address,
9 please?

10 A. It's 1000 Northwest Street in
11 Wilmington, Delaware.

12 Q. Is there anything that would
13 prevent you from testifying truthfully today?

14 A. No.

15 Q. How did you prepare for your
16 deposition today?

17 A. I reviewed some documents,
18 primarily my declaration, the subpoena,
19 looked through the transcript of my previous
20 deposition and looked, skimmed through the
21 declaration for Dr. Winer and Dr. Mullen.

22 Q. Did you meet with counsel in
23 preparation for this deposition?

24 A. Yes, I did.

1 Q. For how long did you meet with
2 counsel?

3 A. We met on three separate
4 occasions. Roughly two hours each time.

5 Q. And when did you meet on those
6 separate occasions?

7 A. We met last week. I'm not
8 sure -- I don't remember the date. We met
9 again on Friday and then yesterday.

10 Q. Did you speak with anyone other
11 than counsel in preparation for your
12 deposition?

13 A. No, I don't believe so.

14 Q. And other than the documents
15 that you cited, any other documents you
16 reviewed in preparation for today's
17 deposition?

18 A. No. The invoices.

19 Q. And so you talked about
20 reviewing your previous deposition. Was that
21 your August 16th, 2021 deposition in the DBMP
22 matter?

23 A. Yes, it was.

24 Q. Have you given any depositions

1 since your deposition in the DBMP case?

2 A. No, I have not.

3 Q. So, I don't want to retread
4 everything that was in DBMP that we could use
5 in this case, also. So, I presume your
6 educational background has not changed since
7 you gave your deposition in 2021 in the DBMP
8 case?

9 A. It has not.

10 Q. So if I were to ask you all
11 those questions about your background and
12 education, they would be the same answers
13 today as they were in your August, 2021
14 deposition?

15 A. Yes.

16 Q. Has there been any change in
17 your job role at the DCPF since your August,
18 2021 deposition in the DBMP case?

19 A. The difference, there have been
20 two additional trusts that have come on board
21 that we've started processing.

22 Q. Okay. And what are the two
23 trusts that have come on board?

24 A. Owens Illinois and Rapid

1 American.

2 Q. And we can go back to those in a
3 bit.

4 At your deposition in 2021, you
5 testified that you were doing some work for a
6 DCPF, I believe it's a subsidiary called
7 NextClaim?

8 A. Uh-huh.

9 Q. Do you remember that testimony?

10 A. Yes.

11 Q. And at that time, you testified
12 that NextClaim was a relatively new entity
13 and not processing claims.

14 Is NextClaim processing any
15 claims now?

16 A. They are not processing claims.
17 They are doing some work on some different
18 projects; mostly call center-type and support
19 with emails and that, things of that nature.
20 Administrative.

21 Q. Is there any work that NextClaim
22 is doing currently regarding processing
23 asbestos personal injury claims?

24 A. No.

1 Q. And what is your role with
2 NextClaim at this time?

3 A. I'm the chief operating officer,
4 again, would be for NextClaim as well. We
5 have other people who are overseeing this
6 project, so I don't have very much direct
7 involvement in those projects.

8 Q. And is the CEO of NextClaim, is
9 it still Mr. Mekus?

10 A. Yes.

11 Q. John Mekus?

12 A. Yes.

13 Q. Does NextClaim offer any of the
14 same services that the DCPF does?

15 A. I'm not sure what you mean by
16 that.

17 Q. The DCPF processes asbestos
18 personal injury claims and as I understand it
19 some other mass tort claims?

20 A. Uh-huh.

21 Q. Does NextClaim do any of that
22 overlapping work?

23 A. I don't think anything would
24 overlap with asbestos. They assist, do some

1 like I said call center, maybe some data
2 entry. So, there is, you know, there's data
3 entry certainly in the DCPF, but as far as
4 the type and nature of the work, there's no
5 overlap between the two.

6 Q. And putting aside the two new
7 trusts that we'll talk about in just a
8 minute, what are the asbestos personal injury
9 trusts that the DCPF processes claims for?

10 A. All right. It's the Armstrong
11 World Industry, Babcock and Wilcox, Celotex,
12 DII and they have two entities, Halliburton,
13 Hubs and Walker, OC, Owens Corning
14 Fiberboard.

15 There's also Pittsburgh Corning,
16 WRG, USG and Federal Mogul which has four
17 entities. I believe that's everyone.

18 Q. And you just told me that since
19 August of 2021 the DCPF started processing
20 claims for two new trusts, the Owens Illinois
21 Trust and also the Rapid American Trust;
22 correct?

23 A. Correct.

24 Q. When did the Owens Illinois

1 Trust come online?

2 A. I believe that was last October.

3 Q. And is that when DCPF started
4 processing claims?

5 A. Started receiving the claims,
6 yes.

7 Q. And when did the Rapid American
8 Trust come online?

9 A. That would have been in
10 November.

11 Q. November of --

12 A. Of last year.

13 Q. Of 2022?

14 A. Yeah.

15 Q. Okay. And has DCPF received any
16 claims --

17 A. Yeah.

18 Q. -- for that one?

19 A. Yeah.

20 Q. And is the Owens Illinois Trust
21 data housed in the claims' online database?

22 MR. GUERKE: Objection.
23 Relevance.

24 MS. MAISANO: I think we're

1 going to be talking about the claims' online
2 database as a whole. I just wanted to
3 establish that all the DCPF member trusts
4 have their claims in that claims' online
5 database.

6 THE WITNESS: Yes. They use
7 Trust Online for their claims.

8 BY MS. MAISANO:

9 Q. Does Rapid American also have
10 it's data housed in the Trust Online
11 database?

12 A. Yes, they do.

13 Q. Is the DCPF still owned by the
14 seven asbestos trusts that you testified to
15 in your August, 2021 deposition?

16 A. Yes.

17 Q. Is DCPF still governed by a
18 board of directors?

19 A. Yes.

20 Q. Are the members of that board of
21 directors still the trustees of the seven
22 asbestos trusts that own the DCPF?

23 A. Yes.

24 Q. Who are the members of the DCPF

1 board of directors currently?

2 A. Ann Farazzi and there's Jack
3 Marionneaux, Phil Pahigian, Leanne Jackson,
4 Chip Robertson, Lewis Sifford. Let me make
5 sure I got them all.

6 It's Ann Farazzi, Jack
7 Marionneaux, Leanne Jackson, Chip Robertson,
8 Lewis Sifford, Phil Pahigian and oh, Andy
9 MacQueen.

10 Q. Thank you. Do you still report
11 to Mr. Mekus, the CEO of the DCPF?

12 A. Yes, I do.

13 Q. Does he still, Mr. Mekus still
14 report to the board of the DCPF?

15 A. Yes.

16 Q. And I'm going to refer to
17 Aldrich and Murray as the debtors in this
18 case just as shorthand.

19 Do you know if the board of the
20 DCPF had any involvement with the response to
21 the subpoenas that were served by the debtors
22 on the DCPF in this case?

23 A. No, I'm not involved in that
24 part.

1 Q. Do you know if Mr. Mekus had any
2 involvement with the response to the
3 subpoenas that were served by the debtors on
4 the DCPF in this case?

5 A. No, I do not know.

6 Q. And do you know if any of the
7 member trusts have had any involvement with
8 the responses to the subpoenas that were
9 served by the debtors on the DCPF in this
10 case?

11 A. No, I do not know their
12 involvement.

13 Q. Do you know if the DCPF notified
14 the client trusts about the subpoenas that
15 were served by the debtors -- the subpoena
16 that was served by the debtors onto the DCPF
17 in this case?

18 A. I believe that the DCPF informed
19 the trust of the subpoena, but I'm not
20 involved in that process and I don't know
21 exactly how that was done.

22 Q. Do you know if the DCPF and the
23 DCPF client trusts coordinated any responses
24 to the subpoenas that were served by the

1 debtors on the various entities in this case?

2 A. No, I'm not involved in that.

3 Q. Do you know whether the DCPF
4 regards any of the data requested by the
5 debtors in the subpoenas to be a trade secret
6 that belongs to the DCPF?

7 A. I mean the data that's requested
8 -- the trust own the data. It's their data
9 for the trust, but that's a level, I don't
10 know any trade secret. They are the owners
11 of the data.

12 Q. Who has the primary
13 responsibility for responding to subpoenas
14 and information requests that are served on
15 the DCPF?

16 A. The mechanical parts of the
17 subpoena for doing the matching and that --
18 I'm involved with that and oversee that part
19 of the process.

20 Q. And for the other parts of the
21 process, who would be in charge of that?

22 A. I'm not involved in that part of
23 the process. I'm the internal side who does
24 the operations.

1 Q. Okay. Do you know if the DCPF
2 has any contractual obligations to the DCPF
3 client trusts when responding to any
4 subpoenas or information requests?

5 A. There is a requirement in the
6 claim processing agreements that the data is
7 confidential, we're under contract to keep
8 that information confidential.

9 So, I think there may be
10 something in the claim processing agreements.

11 Q. Do you know what those oblig --
12 the DCPF's obligations are when it receives a
13 subpoena for information related to a DCPF
14 client trust?

15 A. No, I'm not -- we have a legal
16 department that handles when subpoenas come
17 in. I'm not involved in that part of the
18 process.

19 Q. How many people are involved in
20 the legal department in DCPF?

21 A. I think currently there are
22 three individuals.

23 Q. Are they all lawyers?

24 A. I'm not sure.

1 Q. Are you familiar with the DCPF
2 subpoena and authorization procedures?

3 A. No, I am not.

4 Q. Does the DCPF still have to send
5 subpoenas it receives to counsel at Young
6 Conaway?

7 A. Again, I'm not involved in that
8 process. I don't know the steps that are
9 involved.

10 Q. Okay. Do you know how many
11 claims the DCPF has processed for the DCPF
12 client trust?

13 A. Process several million claims.

14 Q. So I think you told me that you
15 were the, did the internal work in some of
16 the matching.

17 Can you tell me everything that
18 would encompass your role as it relates to
19 responding to the debtor's status request in
20 this case?

21 MR. GUERKE: Objection.

22 THE WITNESS: I oversee the
23 process. So, we have different parties that
24 are involved in each step, from the initial

1 matching of the claimants, identifying those
2 that are -- what would be on the meet and
3 confer; whether they match on a Social
4 Security number, but do not match on last
5 name and going through that meet and confer
6 process.

7 Also coordinate on the notice to
8 the law firms who have claims from the
9 matching claims. And DVMP was also
10 overseeing the redaction process and eventual
11 production of the data.

12 There's also some unnoticeable
13 law firms in trying to research some of these
14 older firms in order to provide notice.

15 Q. Why don't we take a look at
16 what's been marked as Exhibit 1.

17 There's a copy of it here in
18 front of you.

19 - - -

20 (Whereupon, Deposition Exhibit
21 Winner-1, Subpoena, was marked for
22 identification.)

23 - - -

24 BY MS. MAISANO:

1 Q. This is the subpoena that was
2 served on the DCPF by the debtors in this
3 case.

4 Have you seen this before?

5 A. Yeah, this looks to be the
6 subpoena.

7 Q. And it was filed as an exhibit
8 to the DCPF joinder in the Delaware trust
9 motion to quash that was filed in Delaware.

10 You're obviously aware that DCPF
11 moved to quash the subpoena; correct?

12 A. I know there's been legal
13 actions back and forth, but I'm not involved
14 in those operations.

15 Q. So, just to kind of set the
16 table we can go through the subpoena and also
17 the order that governs it.

18 I would ask you to please turn
19 to Page 8 of the order. The pagination is a
20 little strange because it's been filed a
21 couple of times in court.

22 Look at the bottom of Page 8,
23 Paragraph 10, On or before the applicable
24 trust production date, DCPF, the Manville

1 Trust and Verus shall produce to Bates White
2 (in electronic database format and with
3 respect to DCPF and Verus separately for each
4 Trust), the following information pertaining
5 to each Trust, Matching Claimant, and then
6 there's a footnote, (to the extent the
7 relevant trust databases contain such
8 information).

9 And that's called the Trust
10 Anonymized Matched Production.

11 Matching claimant, do you have
12 an understanding of what that means?

13 A. I believe so.

14 Q. What's your understanding of
15 what the -- matching claimant is under this
16 order?

17 A. A matching claimant is, they
18 provide us a list with the claimant
19 pseudonym, a Social Security number and the
20 last name. And then we use that information
21 to match the claims by -- first by Social
22 Security number and then by last name.

23 So, that falls into two groups;
24 where the last name was an exact match and

1 then where the last name does not match, that
2 goes on to the meet and confer list.

3 Q. So, in that process, the debtors
4 are providing to the DCPF Social Security
5 numbers and names. Is that your
6 understanding?

7 A. Yes.

8 Q. And the debtors are not asking
9 for names and Social Security numbers to be
10 provided to them by the DCPF under that
11 exchange; correct?

12 MR. GUERKE: Objection.

13 THE WITNESS: They are not
14 asking for it directly, but the information
15 they are asking for does contain that
16 information.

17 BY MS. MAISANO:

18 Q. Okay. We'll get to -- we'll get
19 to that.

20 Is that -- is the basis of that
21 statement the -- strike that.

22 So, your -- the basis of that
23 statement that they are actually, they
24 actually are asking for some of that

1 information, does that arise from the
2 potential for some of that information to
3 inadvertently be someplace it's not supposed
4 to be in the trust data?

5 MR. GUERKE: Objection.

6 THE WITNESS: The information
7 that they are requesting in the subpoena,
8 that information in the database will contain
9 name, Social Security and other personal
10 information.

11 So, yes, the information
12 requested can contain that.

13 BY MS. MAISANO:

14 Q. Okay. So, if we turn the page,
15 to Page 9, there are A through G and those
16 are the fields and the information requested
17 by the debtors from the DCPF; correct?

18 A. Correct.

19 Q. And so we can go through these
20 briefly. A, claimant pseudonym.

21 Is there a potential for names
22 or Social Security numbers to be included in
23 claimant pseudonym?

24 A. No.

1 Q. B is claimant law firm with
2 email and address of contact person.

3 Is there a potential for Social
4 Security numbers or other PII to be included
5 in that category?

6 A. Not for the claimant, no. The
7 only -- well, the only case would be
8 information where it was a pro se claimant
9 and I know the pro se claimants get added to
10 the meet and confer list.

11 So, there are times where the
12 claimant is not represented by an attorney.

13 So, the sort of law firm
14 information, that type of contact information
15 would be the claimant.

16 Q. So, the potential there is that
17 in the event that there's a pro se claimant
18 who doesn't have a lawyer representing him or
19 her, the claimant law firm field could be
20 populated with the name of the claimant who
21 filed the trust claim? Is that correct?

22 A. Correct.

23 Q. And just so that we're talking
24 about the same thing, I think you mentioned

1 before that names and Social Security numbers
2 were the two items that could be contained --
3 that could be here that the debtors might
4 have asked for even though --

5 A. There's other -- it's not just
6 names and Socials that could be in these
7 fields. It's other personal identifying
8 information. It could be date of birth,
9 there could be addresses of the claimant.

10 These fields are free text
11 fields and so there could be various, I know
12 there's marriage dates and things like that.
13 There's personal information from the
14 claimant that is in these fields.

15 Q. Okay. So, the address of the
16 claimant, you would consider that to be
17 personal information?

18 A. It's personal identifiable to
19 identify who the claimant is.

20 Q. Okay. The next on the date
21 claim filed against the trust.

22 Is that a free text field?

23 A. No.

24 Q. So, is there a potential for any

1 personal identifying information to be in
2 that field?

3 A. No.

4 Q. Is the date claim approved by
5 the trust, if approved, a free text field?

6 A. No.

7 Q. Is there a potential for any PII
8 or personal information to be in that field?

9 A. No.

10 Q. The next one is the date claim
11 paid by trust, if paid.

12 Is that a free text field?

13 A. No.

14 Q. Is there any potential for any
15 PII or other personal information to be in
16 that field?

17 A. No.

18 Q. The next one is if not approved
19 or paid, status of claim.

20 Is that a free text field or is
21 that a dropdown?

22 A. It's not a free text field.
23 There are certain categories.

24 Q. So, is there the potential for

1 any personal information or PII to be in that
2 field?

3 A. No.

4 Q. So then G we get to all exposure
5 related fields. And there's a footnote
6 before we get to the subcategories under G.

7 And the footnote says, To the
8 extent that any names or any SSNs appear in
9 any exposure-related field, the Manville
10 Trust, DCPF and Verus may redact such names
11 and SSNs prior to production of the trust
12 anonymized production. In addition, prior to
13 the delivery of the trust anonymized matched
14 production to the other retained experts,
15 Bates White shall search for and permanently
16 delete any such names and SSNs that may be
17 inadvertently included in the trust
18 anonymized matched production.

19 So, do you understand that to
20 mean that DCPF will take the first pass at
21 redaction and then Bates White takes the
22 second pass at redaction or what's your
23 understanding of what that footnote obligates
24 the parties to do?

1 MR. GUERKE: Objection.

2 THE WITNESS: This footnote --
3 we have an obligation to, for the DCPF to
4 keep this information confidential. So, it's
5 our obligation to do this redaction
6 regardless of whether or not some other
7 entity is also going to look at it.

8 Once the data leaves our
9 control, there's security risks and we lose
10 control of that data.

11 So, it's our duty and our
12 obligation to redact and remove that
13 information prior to it being produced.

14 BY MS. MAISANO:

15 Q. And that's an obligation that
16 the DCPF takes seriously?

17 A. Very seriously.

18 Q. The DCPF would take all measures
19 possible to ensure that no information that
20 shouldn't leave its control does leave its
21 control?

22 A. Yes. In this production, we
23 would look through those, where it says all
24 exposure fields, the various fields and

1 manually look through and remove the names,
2 the Social, those pieces of information that
3 we've previously talked about.

4 It's a -- it's a burdensome
5 endeavor and it takes many hours. But that's
6 what we have done and would do in this case,
7 is gone through that process and look through
8 all of the fields on all of the exposure
9 records that could contain that information
10 and redact.

11 Q. Is the date exposure began a
12 free text field?

13 A. No.

14 Q. So, there would not be potential
15 for any PII or other information to be in
16 that field?

17 A. Correct.

18 Q. Is the date exposure ended a
19 free text field?

20 A. No.

21 Q. And so is there potential for
22 any PII or Social Security numbers to be in
23 that field?

24 A. No.

1 Q. Manner of exposure, is that a
2 free text field?

3 A. There's no field manner of
4 exposure.

5 Q. Okay.

6 A. So, manner of exposure, there's
7 many different fields in the database and the
8 exposure that go towards the manner of
9 exposure.

10 And some of those fields are
11 free text fields.

12 Q. You said there are many fields.
13 Can you give me an estimate of how many
14 fields would encompass manner of exposure?

15 A. I'm not sure of the exact
16 number, but I believe there's over 20 fields.

17 Q. And how many of those are free
18 text fields?

19 A. Again, I'm not sure of the exact
20 number.

21 There's -- the four main fields
22 that we talked about in my declaration,
23 there's also some additional fields that are
24 free text that could have personal

1 identifiable information.

2 Q. And what sort of personally
3 identifiable information could appear when
4 we're looking at these fields are under
5 manner of exposure?

6 A. In some of these fields, they
7 are asking how the injured party was exposed.

8 And so -- and some of this
9 exposure is secondary exposure.

10 So, they'll explain in maybe a
11 husband or a wife explaining their exposure,
12 they'll list the person they were exposed to
13 by name. In some cases they will include
14 Social Security numbers, date of birth.
15 There's also people will give their exposure
16 and list co-workers that they were exposed to
17 or co-worker information.

18 There's also where they were
19 exposed. They may list their address. If it
20 was a home exposure, they may list their
21 personal residence. There's also date of
22 birth that is in there as well.

23 So, there's -- it all goes to
24 sort of people trying to describe how they

1 were exposed. And this other PI information
2 is included in those descriptions.

3 Q. Occupation and industry when
4 exposed, is that -- are those free text
5 fields or -- strike that.

6 Is occupation and industry when
7 exposed, is that a free text field?

8 A. It can be. It gives them the
9 option to write down their industry, their
10 occupation, but they can write whatever their
11 occupation is so it is a free text field.

12 Q. So, there are no options for
13 occupation and industry that are dropdown
14 menus or that are populated and they would
15 just select one?

16 A. There are. There's industries
17 where -- that's what I said, sort of a
18 combination. You could pick and then you
19 could always pick other and then be able to
20 write in the specific industry or occupation.

21 Q. Do you know, among the claims
22 that the DCPF processes, how many claimants
23 select just a dropdown and how many select
24 the other and then do a free text field?

1 A. I do not know.

2 Q. So what potential PII could be
3 included in occupation and industry when
4 exposed?

5 A. Again, any time you're dealing
6 with a free text field, there could be some
7 information in there.

8 Sometimes, even to the extent of
9 their -- they enter information into an
10 incorrect field. So, by having a free text
11 field, they can enter in whatever they want.
12 Sometimes they'll enter information maybe
13 inadvertently. But I don't know specifically
14 what would be in those fields, but there is
15 that possibility.

16 Q. And then the last one is
17 products to which exposed.

18 Is that a free text field?

19 A. Yes.

20 Q. Is that a free text field for
21 every trust that the DCPF processes claims
22 for?

23 A. Yeah, I believe it is a free
24 text field for all of the trusts.

1 Q. So, the trusts don't have
2 dropdown menus for the products --

3 A. No.

4 Q. -- in terms of choosing. Okay.
5 We can put the subpoena aside
6 for a second and then we'll take a look at
7 your declaration, which has been marked as
8 Exhibit 2.

9 - - -

10 (Whereupon, Deposition Exhibit
11 Winner-2, Declaration of Richard Winner, was
12 marked for identification.)

13 - - -

14 BY MS. MAISANO:

15 Q. I presume you're familiar with
16 this document?

17 A. Yes.

18 Q. Who drafted your declaration
19 that was filed on July 26th, 2022?

20 A. I worked with the DCPF counsel
21 to -- in drafting this declaration.

22 Q. Did you work with anybody else?

23 A. Not that I'm aware of.

24 Q. In Paragraph 1, the last

1 sentence says, The statements in this
2 declaration are based on my personal
3 knowledge or information collected at my
4 direction.

5 What information was collected
6 at your direction relative to this
7 declaration?

8 MR. GUERKE: Objection.

9 MS. MAISANO: Basis?

10 MR. GUERKE: Vague, open ended.

11 THE WITNESS: I think the
12 information potentially that would have been
13 collected were maybe information on specific
14 counts or how many claimants and how many
15 matching claims.

16 But I can't think of anything
17 else.

18 Q. Do you know who collected that
19 information for you?

20 A. I would have asked our data
21 analyst for that information.

22 Q. Was it one data analyst or more
23 than one?

24 A. Probably just have been one.

1 Q. Do you remember who that data
2 analyst was?

3 A. Todd Hampton would probably be
4 the person.

5 Q. And other than that claim
6 information, any other information that was
7 collected for you in connection with this
8 declaration?

9 A. Not that I can think of, no.

10 Q. Was there any additional
11 information collected at your direction in
12 this case that was not collected in
13 connection with your declaration in the DBMP
14 case?

15 A. Again, not that I'm aware of.

16 Q. Did anyone from the DCPF review
17 a draft of your declaration before it was
18 filed?

19 A. Not that I'm aware of.

20 Q. If we go to Paragraph 7 of your
21 declaration, you talk about some of the PII
22 that could be implicated by a trust claimant
23 submission.

24 And you note name, Social

1 Security number, date of birth, other
2 personal demographic information about
3 claimants, such as dates of death, if
4 applicable, and medical records.

5 You also noted that trust
6 submissions include medical records that can
7 detail sensitive personal information that is
8 unrelated to asbestos injuries and other
9 private health information.

10 You also noted that claimants'
11 submissions to the DCPF client trusts often
12 include confidential information, including
13 claimant's finances or their spouses and
14 dependents.

15 Did I read that correctly? I
16 didn't go through all of it.

17 A. Yeah.

18 Q. Are you aware that the subpoenas
19 issued by the debtors in this case and served
20 on the DCPF do not request any of that
21 information?

22 MR. GUERKE: Objection.

23 THE WITNESS: They may not
24 specifically request it. But the information

1 they are requesting does contain this
2 sensitive information.

3 BY MS. MAISANO:

4 Q. And when we talk about PII, is
5 it safe to say that when we're referring to
6 PII or when you're referring to PII, you're
7 referring to all of these things that you
8 listed out in Paragraph 7; name, Social
9 Security numbers, dates of birth and all of
10 that medical information?

11 A. Yes. The SPI or personal
12 identifiable information, the definition of
13 personal identifiable information continues
14 to change and it continues to broaden.

15 So, yes, these pieces of
16 information and the medical information would
17 be considered personal identifiable
18 information.

19 Q. In Paragraph 8 you note that,
20 Given the extraordinary sensitivity of this
21 information, it is essential that claimants
22 trust that the DCPF will take all appropriate
23 measures to protect their claims submissions.

24 When you're referring to this

1 information, does that refer back to all of
2 the categories we just talked about in
3 Paragraph 7?

4 A. All of the information that the
5 claimant submits, not just this PII
6 information, is confidential information that
7 we have a duty to protect.

8 Q. So, even if a claimant submitted
9 information to the DCPF that was disclosed in
10 say a public court filing, would you consider
11 that to be sensitive or confidential
12 information?

13 A. Per the trust distribution
14 procedures, per our agreements with the
15 trust, all -- the DCPF, would consider all of
16 that information to be sensitive information
17 and confidential that we would be required to
18 protect.

19 Q. Even if the claimant had
20 disclosed that information publically
21 previously?

22 A. Whatever happens outside of the
23 DCPF, what we're responsible for and the
24 claims we have, we're responsible for that

1 data.

2 Q. If we move on to Paragraph 11 of
3 your declaration, you talk about the Trust
4 Online platform that we had a chance to talk
5 about a little bit earlier.

6 DCPF developed the Trust Online
7 platform in 2006. Is that right?

8 A. Correct.

9 Q. And is that where all of the
10 DCPF's asbestos trust claim information is
11 currently held?

12 A. Trust Online is used for the
13 submission and review of claims for each of
14 the trusts.

15 There may be some additional
16 data that is used in the review of the
17 claims. That's not a part of Trust Online.

18 For some of these trusts,
19 there's prepetition information, claims that
20 have been previously paid, things of that
21 nature, that are used to match a claim in
22 Trust Online that says this claim may have
23 been paid prepetition so there may be some
24 other database or things in the prepetition

1 that you would go and be able to do your
2 research to see if this was the same
3 individual who was previously paid.

4 Q. So, does DCPF store any asbestos
5 claimant data anywhere other than in Trust
6 Online?

7 A. The Trust Online is where we
8 store the claim data related to specific
9 claims.

10 Q. So, all of the -- all of that is
11 in one place?

12 A. The claims that are submitted
13 for each of the trust are stored in Trust
14 Online, yes.

15 Q. And in Paragraph 11, you
16 reference Trust Online's secure data portal.
17 What kind of security does that
18 entail?

19 A. Trust Online, we have robust
20 security. We have a security committee. We
21 have -- there's many factors on the security.

22 So, there's, you know, we have
23 two factor, you know, in order to access
24 Trust Online for any law firm that wants to

1 access Trust Online, they have to -- we
2 independently verify them prior to giving
3 them access to Trust Online.

4 All the roles and permissions
5 that are -- that a user would have assigned
6 in Trust Online are based on their
7 responsibilities and we have extensive
8 auditing of that.

9 We have next generation
10 firewalls with subscription services. So,
11 they are continually updated throughout the
12 day as the provider identifies new risks out
13 there in the world.

14 There's encryption, all the
15 documents are encrypted, all the names of the
16 database are encrypted. The Social Security
17 numbers are not stored in Trust Online. They
18 are moved to a separate encrypted isolated
19 table.

20 Then there's always the normal
21 virus protection, vulnerability testing, a
22 robust patch management. It's a very
23 detailed security for Trust Online.

24 Q. Okay. You reference in

1 Paragraph 11, claimant's legal
2 representatives.

3 I presume that means their
4 lawyers; correct?

5 A. Correct.

6 Q. Does that also mean nonlawyer
7 staff of the claimant firms?

8 A. The way Trust Online works is we
9 set up a firm administrator and give them
10 access to that firm's account.

11 Then the firm administrator is
12 responsible then for setting up access to
13 individuals at their firm with Trust Online.

14 Q. In Paragraph 12, you noted that
15 DCPF implemented Trust Online in 2006 and
16 since then, the DCPF continues to devote
17 substantial resources to enhancing and
18 updating it.

19 What are those substantial
20 resources?

21 A. We update Trust Online pretty
22 much every month, once a month we'll have an
23 enhancement, an update to the system.

24 And so it includes adding new

1 functionality, new security measures. It
2 also involves updating.

3 There's -- in any system,
4 there's underlying software and things that
5 are used and as the system ages, that
6 software components have to be replaced.

7 So, it's a continual effort to
8 bring the current system up and to maintain
9 the current system to the proper level
10 security but also implement new security and
11 enhancements to meet the ever-changing risks
12 that are out there.

13 Q. In Paragraph 13 you talk about,
14 Data security enhancements are a core
15 component of these regular updates. Data
16 security technology is constantly evolving
17 and DCPF routinely updates Trust Online to
18 implement state-of-the-art data security
19 measures. DCPF deploys security updates to
20 Trust Online at least quarterly and even more
21 frequently.

22 What specific security updates
23 to Trust Online does DCPF deploy at least
24 quarterly?

1 A. DCPF, one, there's -- each of
2 the servers, the equipment, the software,
3 there's matching that gets done.

4 So, they are routinely, we have
5 a routine patch management, you know, every
6 month the system is updated and the software
7 is patched.

8 There's also additional security
9 functionality that's added to the system.

10 For example, one of the things
11 we do for law firms is we monitor the amount
12 of documents that get viewed in a particular
13 amount of time.

14 And we have a setting that
15 limits them to a certain amount and we get
16 warnings if they are approaching their limit.

17 Sometimes they may be doing a
18 project that they need access to the
19 documents, but that's to prevent somebody
20 from, if someone at a law firm account got
21 compromised and someone tried to go in and
22 download a bunch of different documents, we
23 would get a flag that says hey, you know,
24 someone is trying to download an inordinate

1 number of documents and we'll get the heads
2 up on that, even before it turns off their
3 ability and we'll reach out to the firms to
4 see what the issue is.

5 There's various encryptions that
6 we do, encrypting the last name, not only in
7 rest but encrypting the documents as well.

8 So that the only -- that only
9 Trust Online is able to unencrypt a document.
10 If somebody is able to get to the documents
11 themselves, they would not be able to open
12 the documents.

13 So, it's a continuing process.
14 Always look out there to see what the threats
15 are, to see what updates they had and
16 implement those into Trust Online.

17 Q. So, if -- the example you just
18 gave me a minute ago about the law firm,
19 would that be a law firm downloading its
20 claimant's documents?

21 A. It's not just downloading. It's
22 just even viewing it, opening up a document
23 and looking at it online.

24 The documents can contain quite

1 a bit of sensitive information.

2 So, we can restrict -- we keep
3 track of that to provide another layer of
4 security.

5 Q. And who monitors that law firm
6 activity at DCPF?

7 A. We have a web support department
8 that would get notice of that.

9 Q. And in Paragraph 14, you
10 reference comprehensive security measures and
11 state that claimant data are protected by a
12 series of confidential and proprietary
13 security measures.

14 Can you provide me with any
15 information on those measures, other than
16 that they are confidential and proprietary?

17 A. We talked -- I talked briefly,
18 you know, about protecting Social Security
19 numbers, by moving them off the system. You
20 know, encrypting like we said the documents,
21 encrypting the last name throughout the
22 database.

23 There's various -- limiting who
24 can see the data, who can see what data.

1 There's certain medical information that is
2 summarized and only certain people based on
3 needs are able to review that information and
4 all that is monitored by roles and
5 permissions and we have a system that, in
6 order to grant that anybody, a different
7 level of access, all of those are audited at
8 100 percent to ensure it was properly done
9 and then every month, those roles then are
10 also audited -- I think actually it's
11 quarterly -- to see if anybody has a
12 nonstandard role, someone may have worked on
13 the project and then they were given a higher
14 level.

15 And so the manager continually
16 has to approve a given individual to have a
17 higher level role than would be typical for
18 that job title.

19 So, there's many, many security
20 measures, all the way through to, you know, a
21 separate audit of the check file prior to
22 making payments.

23 Q. And so the auditing that you're
24 talking about, is that an internal DCPF

1 process or is that something that's done by
2 an outside entity?

3 A. We have an internal audit.

4 Q. And so following up on what we
5 were just talking about later on in that
6 paragraph, you say in your declaration that
7 the DCPF employees are essentially only able
8 to access the information that they need to
9 do their jobs. And that DCPF maintains
10 supplemental security protocols to prevent
11 misuse of claimant information.

12 How many employees does the DCPF
13 have?

14 A. Currently we have I think it's
15 around 230.

16 Q. Does everyone who works at DCPF
17 have access to claimant data?

18 A. No.

19 Q. Can you give me an estimate of
20 how many of the 230 DCPF employees have
21 access to claimant data as part of their job?

22 A. I don't know the exact number.

23 The majority of the employees
24 are involved in the review process. So they

1 would have access.

2 Q. Can you provide me an example of
3 an employee whose role would not permit him
4 or her to have access to claimant data at
5 DCPF?

6 A. There may be some support
7 functions in the mailroom and things like
8 that who don't have access into Trust Online.

9 Q. Is access to claimant data sort
10 of an all or nothing proposition at DCPF or
11 are there granular levels to access to
12 different levels of claimant data among the
13 employees?

14 A. It's very granular, based on
15 each person's responsibilities.

16 Q. So, for example, there could be
17 some employees who they all have access to
18 claimant data, but perhaps they access it at
19 varying levels?

20 A. Correct. There's different
21 levels of access and there's different
22 than -- levels of ability on what they can
23 do, you know, a reviewer who can review,
24 whether or not it's someone else who can sort

1 of verify. Each of those individual tasks is
2 a separate role that's assigned to the
3 individual and that's also done for each of
4 the different trusts.

5 So, maybe a reviewer who has the
6 ability to review in a specific trust and
7 that's their only access.

8 Q. So, there are some DCPF
9 employees who have different levels of access
10 to client data based on what trust they are
11 working on?

12 A. Correct. It's each trust --
13 each role is assigned to the individual and
14 also then to each -- to whatever trust they
15 are working on. So, yes.

16 Q. And so are employees assigned to
17 a specific trust at a specific time or do
18 people work on various trusts in the course
19 of their employment?

20 A. Typically, what we do -- I mean
21 typically, reviewers are assigned to specific
22 trusts. There may be times based on the
23 backlogs of the trust, where they may then
24 process then for another trust. So, there

1 are some employees who are cross trained for
2 multiple trusts.

3 Q. Okay. Thank you.

4 Moving down that paragraph, DCPF
5 computers used to access Trust Online
6 maintain endpoint security that includes
7 local firewalls and virus protection, among
8 other things.

9 What does endpoint security
10 mean?

11 A. Each of the computers, we also
12 use what's called Thin Clients. We use
13 laptops and Thin Clients, they are the end
14 points. On each of the end points we have
15 software that monitors that. It prevents,
16 you know, each of these endpoints. It
17 doesn't allow a user to put in a thumb drive.
18 It monitors what the users are doing on that
19 machine and has protection on the machines to
20 prevent them from, like I said, loading it on
21 a USB or doing something of that nature.

22 Q. Does the DCPF put any
23 restrictions on non DCPF computers that are
24 used to access Trust Online?

1 A. I'm not sure what you mean by
2 that.

3 Q. So, DCPF, for example, you just
4 told me about a hardware restriction where
5 somebody who's utilizing a DCPF machine can't
6 pop in a thumb drive and put a whole bunch of
7 stuff on it that they shouldn't be able to
8 do.

9 For those machines for users who
10 are accessing Trust Online on non DCPF
11 equipment, are there terms of use or does
12 DCPF put any restrictions or security
13 requirements on any machines that are used to
14 access Trust Online?

15 A. For the reviewers who access
16 Trust Online, they have to use the Trust
17 Online equipment. They have to use their
18 Thin Client. They are not able to access
19 Trust Online from home or any other location.
20 They are required to only access it through
21 the trust -- through our hardware, through
22 their Thin Client.

23 Q. For a claimant law firm that's
24 accessing Trust Online through equipment that

1 is not the property of DCPF, are there any
2 restrictions or requirements that DCPF says
3 hey, claimant law firm, you have to have X
4 sort of hardware or be running X sort of
5 software in order to be able to access Trust
6 Online?

7 A. There are some requirements
8 there. There are some levels of encryption,
9 SL certificates or software, you know, that
10 some of the old Microsoft is no longer
11 supported and they can no longer use that to
12 access it.

13 We also, they require two-factor
14 in order to access the system.

15 Q. So, law firms that are trying to
16 get onto Trust Online are required to submit
17 to two-factor authentication?

18 A. Correct.

19 Q. And in terms of the firewalls
20 that you mentioned, does DCPF use firewalls
21 that have URL web filtering?

22 A. We do have -- are you referring
23 to like geo blocking? It will block IP
24 addresses from other countries. So, yes, we

1 do have that set up.

2 Q. And do you also have firewalls
3 that have intrusion detection capabilities?

4 A. Yes, I believe so.

5 Q. And does the DCPF have any other
6 virus protection or other security measures
7 that it takes to ensure that the hardware in
8 the system aren't compromised?

9 A. I'm sure there's many and I am
10 not the IT director to be able to talk about
11 all of them.

12 But we do have virus protection.
13 We do vulnerability protection. Like I said,
14 the firewalls, we have all the subscription
15 services to update the firewalls. It's a
16 very robust system.

17 But all the specifics on it, you
18 know, I'm not the person who can speak to all
19 of them.

20 Q. I understand.

21 Does DCPF have any industry
22 standard data security certifications that
23 are validated by an external firm?

24 A. We had a SOC audit several years

1 ago and then what we do was we took those
2 controls and we've implemented it in-house
3 for our internal auditor and he continues to
4 audit and we've added to many of those
5 controls throughout the years and those
6 results are reported directly to the board.

7 Q. Does the DCPF have a SOC 2
8 certification?

9 A. It's been several years. We've
10 now moved that in-house and do it in-house,
11 but there hasn't been a SOC audit in several
12 years.

13 Q. So within the last decade there
14 hasn't been a SOC 2?

15 A. It's been -- I'm not sure of the
16 exact years.

17 Q. Does DCPF have high trust
18 certification?

19 A. I'm not sure what that is.

20 Q. And so the DCPF, I think if I
21 understand your testimony, does not allow
22 employees to access Trust Online from a non
23 DCPF machine; correct?

24 A. Correct.

1 Q. So, there's no getting into --
2 actually, strike that.

3 Are DCPF employees allowed to
4 access claimant data remotely?

5 A. The reviewers are able to access
6 working from home for Trust Online. But they
7 use the same Thin Client. They'll bring it
8 home and work it using only that Thin Client.

9 Q. Does DCPF require any of its
10 employees to complete cyber security
11 training?

12 A. Yes.

13 Q. And what kind of training is
14 that?

15 A. We have two levels of training.
16 We have, for all the employees, they receive
17 the security training once they are hired and
18 then again every year. And then there's a
19 second level of security training for people
20 in the IT department.

21 Q. And what kind of training does
22 that entail?

23 A. It's very broad. It's overall
24 security awareness. So, it talks about the

1 latest threats that are out there, things to
2 be concerned about not only in the office,
3 but things that are, you know, from home.
4 Trying to -- we want our employees to be
5 focused on security, not only at the
6 facility, but in their day-to-day life.

7 So, we do all of that training.
8 We do things, we do, you know, clean desk
9 audits. We let them know, you know, always
10 to have any data or documents secure. We do
11 testing of, you know, putting out USB drives
12 as a, you know, 2023 bonuses and see if
13 anybody plugs it in.

14 So, we do a lot of training with
15 them just to be aware of security.

16 You know, even social
17 engineering and all of those things that
18 potentially could cause issues not only for
19 when they are working at the facility but
20 also in their home lives.

21 Q. Does that also include automated
22 phishing simulations and things of that
23 nature?

24 A. We do have our internal audit

1 does send out these routine sort of phishing
2 emails to test and so, yeah, it includes all
3 of that.

4 Q. I just want to talk about some
5 of the law firm access, Paragraph 15.

6 You state that only credentialed
7 law firms may access Trust Online to submit
8 claims.

9 How do you define a credentialed
10 law firm?

11 A. When a law firm submits that
12 they want to have an account on Trust Online,
13 we have a work flow that's multiple steps.

14 So, the law firm has to provide
15 information about their firm and then we also
16 research independent verification, state
17 bars, various other third party to verify
18 that it's actually a true law firm and that
19 the law firm does exist and look to see the
20 person who was submitting that, that they are
21 a partner or a member of the firm.

22 For pro se claimants, we would
23 follow the same. We would independently
24 verify their address and every pro se

1 claimant is actually called by the internal
2 auditor; again, as an additional step to
3 verify their authenticity.

4 Q. Have you ever denied access to a
5 law firm that applied to the electronic claim
6 filer?

7 A. I know there have been ones that
8 have started the process and we requested
9 additional information. They have never
10 completed it. The reasons, I'm not sure, but
11 there are some that have not completed the
12 process.

13 Q. But there's no firm that
14 submitted everything and their -- their
15 access was denied?

16 A. No. From this point, from
17 the -- I'm not sure what you're getting at on
18 that one.

19 We audit -- I mean we verify all
20 the information that the person submits.
21 Whether or not, I believe there are probably
22 are some claims where we then would set up
23 because they provided sufficient information
24 but they never submitted a claim.

1 But I don't know the specifics
2 on that.

3 Q. And so other than what you've
4 told me, is there any other due diligence
5 undertaking that the DCPF will do when
6 deciding whether to approve a law firm that
7 applies to submit claims on Trust Online?

8 A. The process that I described is
9 the process that we -- that we go through to
10 grant them access to Trust Online.

11 Q. And how does the DCPF ensure
12 that only the law firm representing that
13 claimant has access to a particular
14 claimant's information?

15 A. The way it's set up for Trust
16 Online, we grant access to the firm
17 administrator and then it's the firm
18 administrator's responsibility, per the
19 electronic filer agreement that they must
20 submit to provide access.

21 So, we rely on the firm
22 administrator at the firm to be setting up
23 the accounts for people that they are
24 allowing access to their claims.

1 Q. You anticipated my next
2 question. It was going to be whether there
3 was a terms of use agreement that the law
4 firm had to follow. And I think you said
5 that there is.

6 Are penalties assessed against a
7 law firm, a claimant law firm if their
8 personnel violate those terms of service?

9 A. Each of the trusts -- each of
10 the trusts will look at that. And they may
11 have made -- that's something that a trust
12 would look at to see and make a decision, if
13 a particular firm was doing something that
14 would have their access suspended.

15 There may be some that has
16 occurred, I can't think of the specifics, but
17 they do look at that and look at the
18 information and see if there's any issues or
19 inconsistencies that were done by the firms.

20 Q. Do you know any of the specific
21 terms of use that the claimant law firms have
22 to abide by in order to access Trust Online?

23 A. I'm not familiar with everything
24 that's in the FA at the moment.

1 Q. Do you know what these terms of
2 use govern, what happens when an authorized
3 person from a law firm leaves that law firm?

4 A. I'm not sure exactly what's in
5 the electronic file agreement.

6 Q. So does DCPF review and approve
7 every user or does the law firm administrator
8 have the discretion to add and take off users
9 associated with the claimant law firm who
10 wants to access Trust Online?

11 A. We do not involve -- we do not
12 approve the individual law firms. The firm
13 administrator takes responsibility for that,
14 for the access to their claims. They are
15 responsible for setting up the claims.

16 If a user needs their password
17 reset, they need to go to their firm
18 administrator, who will handle that and reset
19 the password.

20 Our -- what we get is working
21 with the firm administrator and setting up
22 the firm administrator account. The firm
23 administrator then is responsible for the
24 firm's claims.

1 Q. And I think we talked earlier
2 and you mentioned that the trust might have
3 something to do with interactions with the
4 claimant law firm if perhaps there's a
5 violation or if something is suspected.

6 Does the trust have anything --
7 does any client trust have anything to do
8 with allowing or revoking access privileges
9 for a claimant law firm or is it all handled
10 just through the DCPF?

11 A. The actual allowing or, you
12 know, turning off access would be done at the
13 DCPF.

14 Q. And going down to Paragraph 16,
15 we've talked about this a little earlier,
16 about Social Security numbers.

17 How does it work such that the
18 Social Security numbers are not stored with
19 or correlated with any claimant data in the
20 Trust Online databases?

21 A. So, when a Social Security
22 number is submitted, that data is sent off to
23 a separate isolated table.

24 So, the Social Security number

1 is submitted to the table. And then it is
2 assigned, sometimes referred to as surrogate
3 key but SSNID, that's a unique identifier for
4 that Social Security number that can't be
5 traced back. You can't take that number and
6 figure out what the Social Security number
7 was.

8 So, each Social Security number
9 has it's own SSNID and then that SSNID is
10 what is used in Trust Online for checking for
11 duplicates or checking against databases to
12 see if a claim was paid prepetition.

13 So, that's the process. If
14 someone wants to come in and they want to
15 change their Social Security number, they can
16 never view the Social Security number again.
17 It's not in Trust Online. It's replaced with
18 just the last four digits of the SSN.

19 So if they wanted to make a
20 change to the SSI, they would submit a new
21 Social Security number that then would be
22 shipped off to this table and replaced then
23 with a new SSNID.

24 Q. So, how do you match up the

1 SSNID and the SSN? Do you use a matching key
2 or how do you --

3 A. There's a table. There's
4 software.

5 So, when we have a -- if we were
6 to need to find out what an SSN was, for a
7 given SSNID, we have a software tool that
8 then in certain restricted individuals can
9 submit the SSNID in order to find out what
10 that original Social Security number was.

11 Q. And I think you also mentioned
12 in your declaration that email is scanned
13 through the DCPF servers to make sure that
14 Social Security numbers that are unencrypted
15 aren't being transmitted? Do you remember
16 putting that in your declaration?

17 A. Yeah. We do have a software
18 that will look for and identify information
19 that appears to be -- could be a Social
20 Security number.

21 Q. Okay. So that's done
22 electronically? That's --

23 A. That's done by a third-party
24 resource that we use for our mail.

1 Q. And do you know if the client
2 trusts have similar email scanning for Social
3 Security numbers built into their processes?

4 A. I'm not sure what's done at the
5 client trust level.

6 Q. Do you know how the DCPF servers
7 scan these emails for the unencrypted Social
8 Security numbers?

9 A. Like I said, for the email, it's
10 a separate service. It's a separate company
11 that -- so, none of the email comes directly
12 to the DCPF. It goes to the service. The
13 service then scans it for viruses, it does
14 all the Social Security checking, it does all
15 of that before it would ever come to the
16 DCPF.

17 Q. And so that would happen if
18 somebody tried to send an unencrypted Social
19 Security number to somebody at a DCPF email
20 address?

21 A. Correct. It scans both incoming
22 and outgoing.

23 Q. What would happen if somebody
24 from DCPF attempted to send an email with an

1 unencrypted Social Security number in it?

2 A. That email would get blocked.

3 Q. And then would the sender be
4 notified or what would happen after that?

5 A. I believe we do get notified if
6 a message, an incoming message would get
7 quarantined or if you tried to send it out,
8 it would say that this appears to contain --
9 and it appears to contain an SSN, I don't
10 know the exact wording of the message, but
11 you would get notice that it was blocked.

12 Q. Paragraph 17 of your declaration
13 you talk about the data. It says, DCPF does
14 not combine or commingle one DCPF client
15 trust data with any other DCPF client trust
16 data.

17 Does the DCPF check claimant
18 data across the trust for consistency?

19 A. The DCPF reviews each claim,
20 just the information that's contained within
21 that claim. It does not do a comparison of
22 cross claims.

23 Q. And so that would also be not --
24 that would be not a cross trust; right?

1 A. Correct.

2 Q. And does the DCPF perform any
3 sort of inter-trust audits as a means for a
4 potential fraud control?

5 A. There is, some of the trusts do
6 have audits that are performed, but I'm not
7 involved in that process.

8 Q. Paragraph 18 of your declaration
9 said, DCPF has never sold or licensed access
10 to any claimant information, nor to my
11 knowledge has any Delaware trust.

12 Why did you include this in your
13 declaration?

14 MR. GUERKE: Objection.

15 THE WITNESS: It goes to, you
16 know, the confidentiality of this information
17 that we always are protecting the
18 information.

19 BY MS. MAISANO:

20 Q. Are you aware of other asbestos
21 personal injury trusts that sell access to
22 claimant information?

23 A. No, I am not.

24 Q. Are you aware of other asbestos

1 personal injury trusts that are licensing
2 access to claimant information?

3 A. No, I am not.

4 Q. Are you aware of any other
5 claims processing facilities that are selling
6 access to claimant information?

7 A. No, I am not.

8 Q. And are you aware of any claims
9 processing facilities that are leasing access
10 to -- or licensing access to any claimant
11 information?

12 A. No, I am not.

13 Q. If we jump down to Paragraph 19
14 of your declaration, you note again this,
15 that the DCPF holds extraordinarily sensitive
16 information.

17 Do you consider every data point
18 that DCPF holds as containing extraordinary
19 sensitive information?

20 A. All the information -- there's
21 different levels of sensitivity on the
22 information, but all the information is
23 regarded as confidential and we have a duty
24 to protect, yes.

1 Q. And you go on to say that DCPF
2 is aware that such information is highly
3 susceptible to abuse and exploitation if it
4 is disclosed improperly, including as the
5 result of a data breach and its security
6 measures are informed by that knowledge.

7 What are some examples of abuse
8 and exploitation?

9 A. There's certainly identity theft
10 where people can get the information, you
11 know, sufficient information. But there's
12 also a lot of -- the information is valuable
13 to hackers and others. And the more
14 information you have about an individual, the
15 easier it is to gain their confidence.

16 And so you may get an email
17 that, you know, you would just disregard in
18 that, you know, a spam email.

19 But the more they have, if they
20 have the information about the law firm or
21 the information about a settlement,
22 information about a particular case, then
23 you're building, you know, a lot of
24 information about an individual that then

1 someone could use to potentially exploit that
2 individual, to, you know, get them to click
3 on a link that then could contain information
4 and viruses or to use that and pretend that
5 you're the person's law firm and you have
6 sufficient information you've collected to
7 gain the confidence of that person where then
8 they disclose other information.

9 So, it's not just the Social
10 Security number and the date of birth. It's
11 the more information, accurate information
12 you have about an individual, there is the
13 potential risk to that individual.

14 Q. And even if that information is
15 already in the public domain by way of a
16 public court filing or other public records?

17 MR. GUERKE: Objection.

18 THE WITNESS: The DCPF has a
19 responsibility to protect all of that data,
20 no matter where it is.

21 The more times the data is out
22 there, the greater the risk.

23 MS. MAISANO: Off the record.

24 - - -

1 (Whereupon, there was an
2 off-the-record discussion.)

3 - - -

4 BY MS. MAISANO:

5 Q. In Paragraph 22 of your
6 declaration, you talk about the volume of
7 data sought by mass subpoenas in litigation
8 and including the data sought by this
9 subpoena and the centralized, easily
10 searchable manner in which such data must be
11 produced creates confidentiality concerns
12 that subpoenas in individual actions do not.

13 What confidentiality concerns
14 are present in a production in a litigation
15 or bankruptcy matter that are not present in
16 an individual action?

17 A. In an individual action, the
18 information is related to an individual
19 claimant and the facts around that claim.

20 When you have a mass production,
21 there's significant information about a
22 number of claimants.

23 And so for, you know, hackers
24 and people who try to abuse this information,

1 having all of that information in one place
2 does provide a greater risk that someone will
3 try to get that information and abuse that
4 information.

5 Q. And has the DCPF ever been
6 hacked?

7 A. No, not that I'm aware of.

8 Q. And so essentially it's just the
9 volume? Is that the basis of your opinion?
10 The volume of information in a mass case
11 versus related to one individual?

12 A. I mean this information then, in
13 a mass -- for example, in this, there's --
14 it's a mass production of a large amount of
15 data that's going to many different parties
16 and the more parties that data can go to, the
17 more risk there is that something could
18 happen to that data.

19 And so it's a combination just
20 of the volume of the data, the number of
21 places that data is going to and the
22 confidentiality, the confidential nature of
23 the data that's provided.

24 Q. So, just to be clear, the data

1 that's being provided to the debtors in this
2 case is the fields we talked about earlier;
3 correct?

4 A. Correct.

5 Q. And the data that's being
6 provided to the debtors in this case is going
7 to be redacted for sensitive confidential, PI
8 information by the DCPF prior to production;
9 correct?

10 A. Correct.

11 Q. And then the court order that
12 governs the production also imposes an
13 obligation on the debtor's expert to review
14 and redact any potential PII or sensitive
15 information from the data production in the
16 event that it got missed on the first pass;
17 correct?

18 A. That's my understanding.

19 Q. Okay. The trust discovery order
20 has confidentiality provisions; correct?

21 A. Excuse me? Can you repeat the
22 question?

23 Q. Sure. Do you know if the order
24 that governs discovery of this or the

1 production of this data has confidentiality
2 provisions?

3 A. I'm not familiar.

4 Q. We can take a look at Page 12
5 and that's Exhibit 1.

6 MR. GUERKE: Are you talking
7 about the subpoena?

8 MS. MAISANO: Yes, with the
9 trust discovery order on the back of it.

10 It's Page 12 on the bottom,
11 Paragraph 13 is up top.

12 MS. MAISANO: Off the record.

13 - - -

14 (Whereupon, there was a recess
15 commencing at 10:20 a.m. and concluding at
16 10:31 a.m.)

17 - - -

18 BY MS. MAISANO:

19 Q. Mr. Winner, we're back from a
20 short break where we attempted to
21 unsuccessfully remedy some technical problems
22 with the Zoom.

23 But before we left, we were
24 talking about the confidentiality provisions

1 that are ordered by the court --

2 A. Uh-huh.

3 Q. -- with regard to the production
4 of the data from the DCPF to the debtors in
5 this case.

6 Have you had a chance to review
7 Paragraph 13 of what's been marked as Exhibit
8 1?

9 A. Yes.

10 Q. And do you agree that there are
11 confidentiality provisions that are set forth
12 in the order that governs the production of
13 the data from DCPF to the debtors in this
14 case?

15 A. There are provisions set forth
16 in this paragraph.

17 Q. Related to the confidentiality
18 of the data?

19 A. Yes.

20 Q. Are you aware of the data use
21 restrictions that are set forth in the trust
22 discovery order that governs the production
23 of the data from the DCPF to the debtors in
24 this case?

1 A. Is this the same?

2 Q. Yes. It's just the following
3 paragraph.

4 A. Yes.

5 Q. Are you aware that the trust
6 discovery order also mandates deletion to the
7 data produced to the debtors by the DCPF at
8 the end of the case? That's in Paragraph 15.

9 A. I see that, yes.

10 Q. Going back to your declaration
11 that was marked as Exhibit 2, in Paragraph 22
12 you say that the DCPF is aware that the use
13 of claimant information in individual
14 litigations generally varies significantly
15 from the use of this information in mass
16 litigations.

17 What's the basis of that
18 awareness?

19 A. Just a general understanding
20 that an individual subpoena is dealing with
21 information and issues on an individual case
22 and on this mass subpoena, it's looking at
23 information and trying to determine
24 information about a larger population.

1 Q. And you also talk about mass
2 adjudications and you note that mass
3 adjudications entail fact finding as to
4 representative claimants and the extensive
5 use of sampling and other statistical
6 techniques to resolve legal and factual
7 issues on an aggregate basis.

8 Which mass adjudications are you
9 referring to there?

10 A. Just in general. That sampling
11 is used, especially in a case where there's a
12 large number of claimants with confidential
13 information that a sampling can be used to
14 draw out inferences about the larger
15 population.

16 Q. Can you give me an example of a
17 mass adjudication where a court made findings
18 of fact as to representative claimants?

19 A. No, I cannot.

20 Q. Can you give me an example of a
21 mass adjudication in which there was
22 extensive use of sampling?

23 A. No, I'm not involved in those
24 areas.

1 Q. What other statistical
2 techniques to resolve factual and legal
3 issues on an aggregate basis were you
4 referring to?

5 A. Here, I was referring to the
6 sampling. The subpoena is requiring us to
7 produce a large number of information that
8 needs to be redacted and so it has the issue
9 of using sampling to reduce the amount of
10 time it would take and the burden on the
11 facility and also the risk of having all of
12 that information out for a larger population
13 of claimants to be released out from the
14 facility.

15 It's using sampling to help
16 reduce those risks.

17 Q. You talked about the burden on
18 the DCPF. The debtors are going to reimburse
19 the DCPF for the costs of complying with the
20 subpoena; correct?

21 A. They are reimbursing the
22 dollars, but they are not reimbursing the
23 almost 1,100 hours that it took for the DCPF
24 to do the redaction, for example, in the

1 DBMP.

2 So, it's the amount of time that
3 it's taken, the amount of employees that get
4 pulled off their regular work in reviewing
5 claims that need to work on, you know, these
6 productions and not just the dollars.

7 Q. Do you have any training in
8 statistics?

9 A. Other than taking a couple of
10 classes in college, I do not.

11 Q. Do you have any specialized
12 knowledge of sampling techniques?

13 A. No, I do not.

14 Q. What legal issues are the
15 debtors seeking to resolve in this case by
16 using the requested data?

17 A. I'm not sure of all the -- what
18 their exact purpose is. I know in the
19 bankruptcy and they are using this
20 information to look at the sampling of
21 claims. But as far as the detailing, exactly
22 what they are looking for and trying to
23 prove, I do not know.

24 Q. You wouldn't be able to speak to

1 the factual issues that the debtors are
2 attempting to resolve in this data?

3 A. No, I cannot.

4 Q. In Paragraph 23 you said,
5 Because of the highly sensitive nature of the
6 claimant data it maintains, DCPF opposes the
7 disclosure of data on a wholesale basis in
8 mass litigations when only a random,
9 anonymized sampling of such data is likely
10 sufficient.

11 What do you mean by random
12 anonymized sampling of the data requested.

13 A. It would be taking a sample, in
14 this case, I think they were talking about a
15 ten percent sample of the claims.

16 So, it would be a randomized
17 sample of that larger population and removing
18 all of the claimant identifiable information
19 from that sample.

20 Q. But you don't have training in
21 sampling; correct?

22 A. No, I do not. Just general
23 knowledge.

24 Q. What do you mean by anonymizing

1 the data?

2 A. That's removing the identifiable
3 information back to, you know, specific
4 individuals.

5 Q. So, and that's -- that's what
6 the debtors -- the debtors haven't asked for
7 any identifying information from the
8 claimants; correct?

9 A. What they've asked for, not
10 specifically, but what they've asked for does
11 include that information.

12 Q. So, what would anonymized
13 production look like then?

14 A. It would be removing all
15 information that could be used to identify
16 particular individuals.

17 Q. Can you recall a case where the
18 DCPF produced data on a mass scale that was
19 all anonymized?

20 A. Can you repeat your question?

21 Q. Sure. Can you recall a specific
22 case where the DCPF produced data on a mass
23 scale that was anonymized?

24 A. I mean that was the aim, I

1 believe. A sample or just in general?

2 Q. Either one.

3 A. We produced information in DBMP
4 where we made the effort to go through and
5 remove the personal identifiable information
6 from the data set.

7 Q. And has there ever been a
8 situation in which DCPF produced data on a
9 mass scale and then there was a data breach
10 on the recipient's end?

11 A. I'm not aware of that.

12 Q. Paragraph 24, you refer to a
13 mass subpoena.

14 How do you define a mass
15 subpoena in terms of how many claimants?

16 A. I don't know that there's a
17 specific number, but when I talked about
18 here, when you're seeking information on
19 thousands or tens of thousands of claimants
20 and when for the DCPF with the, in this case,
21 the 15 different entities, each of those then
22 claimants could have, you know, up to 15 then
23 claims. It quickly gets into a large volume
24 of claims.

1 Q. And so you noted here that when
2 validly served with a mass subpoena seeking
3 information about thousands or tens of
4 thousand of claimants, the DCPF client trust
5 attempts to work with the party seeking
6 disclosure to A, impose meaningful
7 limitations on the use and disclosure of PII
8 and B, craft a sampling protocol that
9 satisfies that party's valid need for
10 disclosure, but limits disclosure of claimant
11 data and documents that not be used by the
12 requesting party for the purpose for which
13 disclosure is sought.

14 For part A, we've already
15 established that the debtors haven't
16 requested the PII here and so how would that
17 be applicable, subpart A to the debtor's
18 request in this case?

19 MR. GUERKE: Objection.

20 THE WITNESS: The subpoena that,
21 in this case, as I mentioned several times,
22 does have SBI data that would be required or
23 in the field that are to be produced.

24 And so that information would

1 have to be redacted in all of those hundreds
2 of thousands of records.

3 BY MS. MAISANO:

4 Q. So, if everybody does what they
5 are supposed to do, there won't be any PII
6 disclosed; correct?

7 A. There would still be
8 confidential information.

9 So, the first step, the
10 redaction is to remove the PI information,
11 names, the Social Security numbers.

12 All the information is
13 confidential and so the DCPF's goal would be
14 to reduce the amount not only of the PI data,
15 but of all the claimant data.

16 It's all confidential and we
17 have a duty to protect it all. In all of
18 that, we would want to impose limitations on
19 its use and disclosure.

20 Q. And this paragraph talks about
21 how the DCPF client trusts addressed a mass
22 subpoena.

23 What's the basis for your
24 knowledge on how the individual member trusts

1 address mass subpoenas?

2 A. I'm not involved in that part of
3 the process, but just, you know, in general
4 over receiving the subpoenas that the -- that
5 that is the process, that is the goal of the
6 trusts and the DCPF to try to limit the
7 amount of information that needs to be
8 disclosed.

9 Q. Have the DCPF client trust
10 crafted sampling protocols for trust
11 discovery in other assessed bankruptcy cases?

12 A. I'm not aware of what they
13 crafted in other.

14 Q. This last part, limiting
15 disclosure of data and documents that will
16 not be used by the requesting party for the
17 purpose for which disclosure is sought.

18 Do you know what the purpose for
19 which disclosure is sought is in this case?

20 A. I do not know the specific
21 requirements.

22 Q. And so you wouldn't presume to
23 opine on all of the ways in which the debtors
24 would seek to use the data requested from the

1 DCPF?

2 A. I'm not aware of all the reasons
3 the debtor have requested or what their uses
4 would be.

5 Q. Do you recall any productions
6 made by the DCPF in any other asbestos
7 bankruptcy cases other than in DBMP?

8 A. There was a production in
9 BestWall within the past year as well.

10 Q. Any others that you're familiar
11 with?

12 A. There have been ones over the
13 years. I'm not familiar with all of them.

14 Q. Do you remember any of them?

15 A. I don't recall. I know there
16 was other ones. I think it was -- I'm not
17 sure what level or whether they ultimately
18 resulted in a production, but there was some,
19 I think General Motors, I think there was
20 some other ones, Porter Hagan, but I don't
21 recall the exact results of those.

22 Q. In any of those requests, do you
23 know if the response was ever limited to a
24 sample?

1 A. I don't recall.

2 Q. And would you happen to know the
3 number of claimants whose trust information
4 was requested in any of those prior
5 productions?

6 A. I do not.

7 Q. When the DCPF responded to the
8 prior data requests in the other cases, did
9 the DCPF's staff perform the work necessary
10 to respond?

11 A. What do you --

12 Q. Was it only DCPF staff that
13 worked on getting the data together for
14 production or did you hire any outside
15 entities to perform it?

16 A. No. We've not hired outside.
17 When we do these requests for -- responses to
18 subpoena, we do all of that in-house.

19 Q. Why do you do that in-house?

20 A. Because of the sensitivity of
21 the information, the confidentiality of the
22 information. We don't want to bring in now
23 another third party who would have access to
24 this information.

1 So, we keep it in-house with our
2 employees.

3 Q. Could you -- could the DCPF hire
4 outside people to work on the subpoena
5 compliance or the subpoena production and
6 just subject them to the same levels of
7 security and access that the DCPF employees
8 are subject to?

9 MR. GUERKE: Objection. Calls
10 for speculation.

11 THE WITNESS: The DCPF has
12 always handled these in-house and I don't see
13 a change to that process.

14 BY MS. MAISANO:

15 Q. In those other cases where the
16 DCPF made a data production in these mass
17 subpoenas, was the DCPF able to meet the
18 DCPF's other contractual obligations while
19 responding to these data requests?

20 MR. GUERKE: Objection.

21 THE WITNESS: I don't recall. I
22 mean any time we respond in the subpoena, it
23 does take time from our employees and time
24 away from our main focus of reviewing and

1 processing claims. So it does take us away
2 from that, all of these productions.

3 There's been several of these
4 within the past year.

5 BY MS. MAISANO:

6 Q. How many have been in the past
7 year?

8 A. Well, we had the BestWall, the
9 DBMP and now we have this subpoena as well.

10 Q. Did the work responding to the
11 subpoenas in DBMP and BestWall cause any
12 delays in claim processing at DCPF?

13 A. Yes, there were delays.

14 We had reviewers and various
15 other departments working those thousand
16 hours that were required or almost 1,100 did
17 pull employees off of not only processing the
18 existing trusts that we had, but that was
19 coming around the same time as we were
20 bringing two new trusts up and running.

21 So, there were delays and claims
22 that were not reviewed because of the amount
23 of time that were spent on these productions.

24 Q. In addition to the time that was

1 necessary to ramp up by bringing on two new
2 trusts?

3 A. Yes. The -- reviewers, for half
4 of the people who worked on redacting this
5 where the reviewer in QA and during that time
6 that they spent, they were not able to
7 process asbestos claims.

8 Q. And do you know how long those
9 delays were?

10 A. The DCPF spent, it was hours,
11 the 1,100 hours.

12 That amount of work, I don't
13 have an exact how many exact number of claims
14 that would be, but it was a substantial
15 amount of hours over a very short period of
16 time.

17 I think it was over the second
18 production was 45 days and so taking that
19 amount of hours out of our productivity
20 certainly had an impact on the amount of
21 claims that were processed and each month we
22 set up goals based on the backlogs of all the
23 trusts and our productivity and, you know, I
24 know that we did not meet those goals that

1 month because of the resources that were
2 taken off to work on the subpoena.

3 But I don't know an exact count
4 on claims or anything of that nature.

5 Q. So, there was a backlog prior to
6 the work that started to happen in response
7 to the request made by DBMP?

8 A. I don't know -- each trust has a
9 certain number of claims.

10 So, there is -- we have claims
11 that are in the review queue awaiting review
12 and claims waiting in the rereview queue.

13 So, there's a certain number in
14 each of those trusts and so the DCPF applies
15 our resources based on the number of claims
16 that are in those queues in each of the
17 trusts. Each trust gets their proportional
18 share based on the claims that are in those
19 queues.

20 Q. Do you know how the debtors got
21 to the 12,000 number of claimants that they
22 requested the data for from the DCPF?

23 A. No, I do not.

24 Q. So, you don't know what that

1 subset represents in terms of the debtors'
2 claims?

3 MR. GUERKE: Objection.

4 THE WITNESS: No, I do not know.

5 BY MS. MAISANO:

6 Q. And do you know how many
7 mesothelioma claims the debtors have resolved
8 with payment since 2005?

9 A. No, I do not know.

10 Q. In Paragraph 25 of your
11 declaration, you talk about the potential for
12 identity theft or exploitation of senior
13 claimants.

14 Do you know how many of the
15 claimants among the 12,000 requested by the
16 debtors are senior claimants?

17 A. No, I do not. I just know from
18 the exposure information and things that when
19 a lot of this exposure occurred, that a
20 number of the claimants are older. But the
21 exact percentages, I do not know.

22 Q. And so you also say in Paragraph
23 25 that just mere compliance with the
24 subpoena will create a security risk.

1 How does complying with this
2 data request create a security risk?

3 A. Well, there's risks to the
4 individual claimants. As I talked to you
5 before about their information and as much
6 information that is out there, even if it's
7 not SBI, there is still a risk that the more
8 someone was to know about a claimant, the
9 more they could take advantage.

10 The data being out there in a
11 number of different locations is a risk.

12 There may be productions of that
13 data, but it's still a risk.

14 Every time the data -- every
15 other location that the data is, there's
16 risks for that data to be hacked; either by
17 human error or there's other things -- other
18 risks out there.

19 So, there is that additional
20 risk to all these claimants and then for the
21 DCPF, we have a requirement to protect this
22 data. We have to do everything we can to
23 protect it.

24 And if we're not protecting this

1 data, you know, the law firms and trusts
2 would lose confidence in the DCPF and also
3 potential future trust, when they are
4 deciding who to process their claims.

5 It's a risk to both the
6 claimants and to the DCPF.

7 Q. So, is it just by virtue of the
8 information being transferred to you that
9 creates risk?

10 A. There's risks out there.

11 And having -- there's all sorts
12 of risks out there.

13 So, even if a company that we
14 send this data to, they have the data, they
15 have, you know, the matching key that
16 potentially could compile it back and they
17 could do everything and have, you know, best
18 security measures, but there's still always
19 other issues.

20 There's other vulnerabilities.
21 There's things like, there was, you know,
22 what's called a supply chain hack where
23 you're doing everything you should be doing.
24 You're patching all your systems. But the

1 patch you're using on your software, someone
2 has infiltrated that other company. That
3 happened relatively recently with Solar
4 Winds. So a company then is patching,
5 thinking they are doing everything they are
6 supposed to and following their guidelines
7 but they still then get a vulnerability.

8 There's other vulnerabilities,
9 sort of the zero day attacks where a
10 vulnerability is found in a piece of software
11 and a piece of hardware and there's no
12 patching for it.

13 So, this is, you know, these bad
14 actors out there are only getting worse.
15 There's more and more people trying to get
16 data and so it is a risk any time you have
17 the data out there and the more places you
18 have the data, the higher the risk.

19 Q. So, the more places the data is,
20 the higher the risk? That's the basis?

21 MR. GUERKE: Objection.

22 THE WITNESS: There is the risk
23 for, like I said, for the individual
24 claimants and then that risk, the more places

1 the data is, then there is an additional
2 risk. That's why we want to protect the data
3 as much as possible.

4 BY MS. MAISANO:

5 Q. But so the -- but all of these
6 bad outcomes would only happen if one of the
7 end users was hacked; correct?

8 A. I mean there could be
9 inadvertent human error, there could be --
10 once we let -- once the data leaves us, the
11 DCPF, we lose control of it. There's all
12 sorts of potential things that could happen
13 to that data.

14 And once it gets out of our
15 control, that's a risk out there.

16 Q. And so that's why prior to
17 production, both the DCPF and the debtor's
18 experts are going to engage in this highly
19 specialized and highly intensive redaction
20 process; correct?

21 A. That is why the DCPF is going
22 through the redaction process, is to remove
23 as much of that information as possible.

24 But again, even if remaining

1 information is still confidential and we
2 would like to reduce that as much as
3 possible. And that's why we talk about
4 sampling and things like that to reduce as
5 much as possible the risk to the -- that this
6 data could present.

7 Q. And so you did, speaking of the
8 sample, production of sensitive, private and
9 confidential data should be limited to the
10 production of only a random sample of claims
11 to significantly limit the scope of
12 disclosure and the review burden on the DCPF.

13 What kind of a random sample are
14 you envisioning here?

15 A. That is not my area. There
16 would have to be other people who would be
17 involved who had more of the expertise to
18 determine what type of random sample.

19 Q. When you're talking about
20 sensitive data, would you consider data that
21 is disclosed by a claimant in a public court
22 filing to be sensitive?

23 MR. GUERKE: Objection.

24 THE WITNESS: What I'm referring

1 to is the data that we have in our
2 responsibility to protect it, regardless of
3 what happens in other filings or anywhere
4 else.

5 We have a duty, we have a
6 responsibility to protect the data and that's
7 what we strive to do.

8 BY MS. MAISANO:

9 Q. So, would you consider data
10 that's disclosed by a claimant in a public
11 court filing to be confidential, even if --
12 just by virtue of it being in possession of
13 the DCPF, that in your eyes makes it
14 confidential?

15 MR. GUERKE: Objection.

16 THE WITNESS: All the data that
17 the DCPF has, we're required to keep it
18 confidential. We have a duty per the TDPs in
19 our contract with the trust. So, yes, it is
20 all confidential.

21 BY MS. MAISANO:

22 Q. In Paragraph 26, you talk about
23 a randomized sample of claimants, such that
24 was ordered in the BestWall case.

1 What's your understanding of
2 what you called the randomized sampling of
3 claimants that was ordered in BestWall?

4 A. I just know that at some point,
5 that the BestWall, that they had determined
6 or ruled to do a sampling. The specifics of
7 that, I don't know how that was -- or how
8 that exactly was set up or how the sampling
9 was done. Just that, you know, it was a
10 sample and by taking a sample of the claims,
11 it helps mitigate the risk and the burden on
12 the DCPF.

13 Q. So, it's your understanding that
14 the DCPF's production in the BestWall case
15 was constrained to a sample?

16 A. No, I don't believe it was -- I
17 think at one point it was, but I think then
18 that later changed.

19 I'm not involved in that whole
20 process, and all that back and forth.

21 But I'm not sure at the end of
22 the day whether it was a sample that was
23 actually produced.

24 Q. How many claimants did the

1 BestWall production involve?

2 A. Claimants? I'm not sure of the
3 exact number. I think it was somewhere
4 around 14,000.

5 Q. So more than were requested by
6 Aldrich and Murray in this case?

7 A. I think there's 12,000 in this
8 for Aldrich, yes.

9 Q. You also say in Paragraph 26 the
10 debtor's purported purpose described in the
11 subpoena can be established through a
12 representative sample.

13 What is the debtor's purported
14 purpose as described in the subpoena?

15 A. I mean the information that -- I
16 don't know the specifics on exactly what the
17 debtor is using the information for. I see
18 the fields that they are requesting.

19 So, the po -- our position would
20 be that a sampling would help mitigate this
21 risk but the exact requirements of what the
22 debtor is looking for, I do not know.

23 Q. What is a representative sample,
24 in your view?

1 A. The different way -- the sample
2 can be set up to look for certain
3 characteristics.

4 I mean it could be a truly
5 random sample. It could be then is a sample
6 that would take into account other factors,
7 you know, disease level or certain other
8 attributes to provide not a completely true,
9 just random sample, but a random sample
10 that's more representative of the claimant
11 population.

12 What that -- what that would be
13 in this case, I do not know.

14 But it's just distinguishing
15 between just a general random sample and
16 those that take into account certain
17 characteristics of the population in the
18 determination of the sample.

19 Q. Do you have any training in
20 sample design?

21 A. I do not.

22 Q. Do you have any training in
23 sample evaluation?

24 A. I do not.

1 Q. Get to Paragraph 27 of your
2 declaration.

3 And this is where we -- this
4 goes back to what we were talking about
5 before in that, you believe that there is the
6 potential in the exposure fields for there to
7 be sensitive PII; correct?

8 A. Correct.

9 Q. And this sensitive information
10 could potentially be disclosed unless that
11 information is reviewed and redacted;
12 correct?

13 A. Correct.

14 Q. And so the narrative fields at
15 issue are the occupational exposure field
16 where the claimants describe how they were
17 exposed to asbestos; the debtor's exposure
18 field where claimants describe how they were
19 exposed to the debtor's product; the
20 secondary exposure field where the claimants
21 describe secondary exposure from other
22 persons and the product exposure field where
23 the claimants describe the debtor's products
24 to which they were exposed.

1 For the secondary exposure
2 field, how many claimants at -- at issue in
3 this case, meaning among the 12,000 that the
4 debtors have requested allege secondary
5 exposure?

6 A. I do not know that percentage.

7 Q. If you had to give an estimate
8 based on your experience in DCPF on or excuse
9 me, in DBMP, sorry about that, how many of
10 the claimant's alleged secondary exposure
11 such that that field would have been
12 populated?

13 A. I do not know.

14 Q. And when you're referring to the
15 narrative response fields that the claimants
16 complete that contain Social Security
17 numbers, are you referring to the claimants'
18 Social Security numbers or somebody else's
19 Social Security number?

20 A. The Social Security number could
21 be -- I mean these are narrative fields where
22 the -- the narrative. They could enter in
23 anybody's social.

24 It could be for the secondary

1 exposure, the person who had the secondary
2 exposure. It could also be for the
3 occupationally exposed person.

4 The claimants have the ability
5 to add on whatever information they wanted in
6 those fields.

7 So, potentially could they be
8 giving it for a co-worker, things like that,
9 it is possible.

10 But certainly for the claimant,
11 for the occupationally exposed person, there
12 could be Social Security numbers.

13 Q. In most cases would those be
14 limited to the claimant or the person through
15 whom household or secondary exposure is
16 alleged?

17 A. I can't say. I mean in general,
18 a lot of the exposure is household exposure.

19 So it would be, you know,
20 someone coming home with the asbestos.

21 But as far as the knowing, you
22 know, if that's always the case or a
23 percentage of those cases, I don't know.

24 Q. Does it happen often that a

1 claimant puts a co-worker's Social Security
2 number in one of these exposure fields?

3 A. I'm not aware of how often that
4 would happen.

5 Q. Has it ever happened?

6 A. Do not know.

7 Q. Because as we know, the debtors
8 already have the claimants' Social Security
9 numbers; right?

10 A. They provide us a Social
11 Security number that we're using for
12 matching.

13 Q. And you noted also that the
14 narrative response fields can contain other
15 highly sensitive information.

16 What is an example of some
17 highly sensitive information, putting aside
18 what we've already talked about, that could
19 end up in one of these narrative fields
20 related to product exposure?

21 A. We -- the fields that we were
22 redacting were the Social Security, like we
23 said, the names, the addresses, the date of
24 births. Information like that that

1 identifies a specific individual.

2 Q. And is that regardless of
3 whether that individual is the claimant who
4 filed the claim?

5 A. Correct. We're removing all of
6 names, all socials and date of births.

7 Q. And that's what -- I'm sorry. I
8 thought you were done.

9 That's what the DCPF redacted in
10 the DBMP production; correct?

11 A. Yes, correct.

12 Q. And moving down, you talk about
13 that excluding production of the data from
14 the narrative fields related to exposure will
15 eliminate the DCPF's need to manually review
16 each exposure record submitted in each claim.

17 When you say exposure record
18 submitted in each claim, what does that mean?

19 A. So, when a claim is filed, the
20 individual can list their various exposures.

21 So, they will list the start
22 date of exposure, the end date, the site that
23 they were exposed and explain their exposure.
24 And then they can have multiple exposure

1 records within a claim. You know, a claim
2 may have one exposure record, a claim could
3 have several hundred exposure records.

4 So, each claim has, you know,
5 one or more exposure records and each of
6 those records then would have these narrative
7 fields that would need to be reviewed.

8 Q. So, for -- if a claimant files a
9 claim against the -- a particular trust and
10 the claimant is alleging exposure to two
11 different products that are associated with
12 that trust, does that mean that there are two
13 exposure records?

14 A. The exposure records, the claim
15 form asks for the claimant to provide their
16 exposure related to the trust that they are
17 submitting and there are certain
18 requirements.

19 So, what they'll typically do is
20 give, you know, an exposure record for each
21 of the various sites they were at where they
22 were exposed to asbestos; either to the
23 company's product or to general asbestos
24 exposure.

1 Q. In the DBMP production, do you
2 know how many exposure records in total were
3 reviewed?

4 A. It was over 200,000 records.

5 Q. So, more than would be at issue
6 in this case; correct?

7 A. No. I mean for DBMP there were
8 9,000 or so claims. There was about 100,000
9 then I think claims and then those claims
10 then had multiple exposure records. So the
11 actual number of exposure records that had to
12 be reviewed were, you know, somewhere over
13 200,000.

14 Q. And was it a multi-stage process
15 for this review or is it something that kind
16 of started at one, in -- was there more than
17 one batch of records that were reviewed?

18 A. For DBMP?

19 Q. Yes.

20 A. There were two productions.
21 There was first an initial what they were
22 calling the stub production and then there
23 was the second larger production.

24 Q. And in going through the

1 redaction process, was there a -- was there a
2 decision that needed to be made to determine
3 if something should be redacted based on the
4 content or was the exercise more if there's a
5 name or a number in one of these fields it
6 should be deleted?

7 A. No. The process -- the part of
8 that process was that all of these -- the
9 information in all of these fields had to be
10 reviewed and you had to look at the
11 information that was provided and determine
12 whether or not the information should be
13 redacted.

14 There were information, for
15 example, company names that weren't really an
16 individual, but John Williams' company. So,
17 you know, there were also ships that are
18 named after individuals.

19 So, there were, when the
20 reviewer went through it, they were looking
21 to see if it was an actual person and
22 individual or it was more of a, you know,
23 like I said, those other two examples.

24 There's also numbers in there

1 that may not have been a Social Security
2 number. There were, you know, the trust have
3 approved site list and some of those have
4 site code numbers. They would be on there.

5 There were documents that were
6 also uploaded with the claim that may have
7 had a number. And they would say see
8 document number and they would list the
9 document number.

10 So, the reviewers spent time
11 going through and looking at the information
12 within the content of the narrative to see
13 whether or not it was a name or whether or
14 not it was, you know, another piece of this
15 information that we're talking about related
16 to an individual.

17 For example, there might be an
18 address, but the address was not related to
19 the injured party's address or things like
20 that.

21 So, that information had to be
22 reviewed within the context of the claim to
23 determine what needed to be redacted.

24 Q. So, there was some discretion

1 taken so, for example, a ship that also
2 matched to a name of a proper name, that
3 wouldn't have been redacted because that was
4 determined to not be PII?

5 A. That was the approach we took.
6 And, you know, we had a two stage, there was
7 an initial reviewer who went through and
8 applied those and then we had then a second
9 level QA to ensure, you know, within the time
10 we were provided to provide as accurate as
11 response as we were able to.

12 Q. So out of those 200,000 records,
13 and I just want to make sure we're talking
14 about, that I'm -- that we're talking about
15 the same thing.

16 So, we're talking about 200,000,
17 I think you called them exposure records?

18 A. Uh-huh.

19 Q. That needed to be reviewed in
20 DBMP.

21 Out of the upwards of 200,000, I
22 think you said it was a little more than
23 200,000 --

24 A. Uh-huh.

1 Q. -- records, how many of those
2 records needed redaction because they
3 contained PII?

4 A. I'm not sure of the exact number
5 that needed redaction, but there are
6 thousands and thousands of these that --
7 fields that had to be redacted.

8 Q. And what was redacted from those
9 fields?

10 A. The information we've discussed,
11 that -- I'm not -- I'm not aware of every,
12 but in general it is, like we said, it was
13 the names of, you know, the injured party,
14 potential family members, co-workers, Social
15 Security numbers, date of births, addresses.
16 All of that information I believe was within
17 what was redacted in this case and with the
18 DBMP case.

19 Q. So in DBMP, how many names were
20 redacted from the exposure records?

21 A. I don't know the count on
22 exactly how many.

23 Q. How many Social Security numbers
24 were redacted from the DBMP production?

1 A. I'm not sure of the number of
2 Social Security numbers that were redacted.

3 Q. But it was -- was it more than
4 one?

5 A. I believe there was probably
6 more than one and there were more names than
7 Social Security numbers.

8 Q. Is it fair to say that the
9 majority of the information redacted from the
10 DBMP production were names of people who were
11 not the claimant who had filed the trust
12 claim?

13 A. Most of the names that I think
14 were redacted were probably the co-worker
15 names.

16 Q. And do you know how many
17 addresses were redacted?

18 A. I do not know the number, but
19 that was -- that did happen occasionally, but
20 I don't know the numbers.

21 Q. Do you know about how many of
22 those redacted records were thought to
23 contain PII of an individual? When I say
24 PII, I don't mean just their names. I mean

1 just some sort of confidential or sensitive
2 information.

3 A. No, I cannot.

4 Q. But we're talking -- strike
5 that.

6 So out of 200,000, I know you
7 said there were thousands of records that
8 needed to be redacted.

9 Could you put a finer point on
10 the number?

11 MR. GUERKE: Objection.

12 MS. MAISANO: If you can.

13 THE WITNESS: I can't at this
14 point. I know there was several thousand
15 that ended up being redacted, but I do not
16 know.

17 BY MS. MAISANO:

18 Q. And that included for names,
19 addresses and other information in addition
20 to potentially Social Security numbers?

21 A. That was, yes, that was for all
22 the different reasons that a redaction could
23 have occurred.

24 Q. I'll show you what was marked as

1 Exhibit 3 and 4. I have them right here, the
2 two invoices that we were just talking about.

3 - - -

4 (Whereupon, Deposition Exhibit
5 Winner-3, Delaware Claims Processing Facility
6 Invoice No. 12 dated November 2, 2022, was
7 marked for identification.)

8 - - -

9 (Whereupon, Deposition Exhibit
10 Winner-4, Delaware Claims Processing Facility
11 Invoice No. 13 dated January 18, 2023, was
12 marked for identification.)

13 - - -

14 BY MS. MAISANO:

15 Q. Are these the invoices that the
16 DCPF submitted to DBMP in connection with
17 compliance with the trust discovery
18 subpoenas?

19 A. Yes, they appear to be.

20 Q. And for Exhibit 3, I think you
21 said there was an initial, I think you called
22 it the stub production.

23 What does this invoice cover?

24 A. Which one is Exhibit 3? Is it

1 the first one?

2 Q. Yeah. October, 22 and then the
3 next one is January of 2023. I think that's
4 3 and 4.

5 If we take a look at Exhibit
6 3 --

7 A. Uh-huh.

8 Q. -- what were the services
9 covered by this invoice?

10 A. That would have covered all the
11 hours that were involved in this production
12 up until that point.

13 So, that was up through the
14 point of the first stub production.

15 Q. And so sticking with Exhibit 3,
16 all of this work was performed by DCPF
17 employees; correct?

18 A. Correct.

19 Q. How many DCPF employees worked
20 on the project that's covered by this
21 invoice?

22 A. I'm not sure of the number. I
23 know there was a little over 40 employees
24 that were involved across both. I'm not sure

1 of the exact number just for this invoice.

2 Q. Do you know what the positions
3 were of people who performed the work in
4 connection with the invoice that's Exhibit 3?

5 A. There would have been myself,
6 there would have been the people in the data
7 analysis department. There would have been
8 people in our web support department. There
9 would have been other people in our support
10 department. There would have been viewers,
11 QA people and individuals from our claimant
12 relations department.

13 Q. So, when this charge for work
14 came in or when this assignment came in, how
15 did you decide how you were going to staff
16 it?

17 A. There were certain parts of
18 that, the nature of what was required,
19 matching the claimant data and things like
20 that would be, you know, the data analyst.

21 In this production we also
22 provided what was called a data dictionary
23 which was a description of the fields that
24 were being produced and our web service group

1 is the one who put that together.

2 Our other support people were
3 involved in the actual mail-in notice to the
4 firms.

5 And then for the redaction and
6 the review, it was matter of looking at, you
7 know, all the work that was going on at the
8 facility and who we could assign to these
9 projects.

10 Q. Did everyone who performed work
11 in connection with the invoice that's Exhibit
12 3 normally have access to claimant data as
13 part of their job duties?

14 A. These individuals that I spoke
15 about would typically have access to claim
16 and claim data.

17 Q. Specifically talking about their
18 redaction process, how many of the 40
19 employees who worked on this project overall
20 worked on the redaction piece of it?

21 A. The majority -- I don't know the
22 exact.

23 I know over half where we would
24 review in QA.

1 So, those were only involved in
2 this redaction process and there was probably
3 some additional individuals from some of
4 these other departments whose only
5 involvement was in the redaction part.

6 Q. So, when we get to the redaction
7 process, we've got say 20 or so people who
8 are working on the redaction process and half
9 were doing something else?

10 A. There was over -- it's probably
11 more than that. 20, 25. I don't know
12 exactly how many more than that.

13 But there was definitely more on
14 the redaction portion of it.

15 Q. And for the folks who were doing
16 the redaction work, how was the data provided
17 to them that they needed to review and what
18 instructions were they given?

19 A. When we had to redact these
20 fields, having never done this before and so
21 we worked with a data analyst and they
22 developed an in-house application that would
23 assist the people doing the redaction.

24 There was no way you could do

1 this in Excel spread sheets or things like
2 that so we developed this application that
3 the reviewer would go in and be able to see
4 the information on a particular claim, read
5 that information, highlight the information
6 that was to be redacted and save that record
7 and it would be served up as the next record
8 in the process.

9 That's a tool we created in
10 order to handle redacting the volume of
11 records we had to redact in the period of
12 time that we had.

13 Q. So the application essentially
14 teed up whatever the reviewer needed to look
15 at for him or her and assisted in the
16 efficiency of the process? I'm just trying
17 to figure out what the application did.

18 Because I understand your point
19 that you didn't give everybody an Excel
20 spread sheet and tell them to have at it.

21 A. We create batches. We would
22 create a batch of a certain number of
23 records.

24 Each then person working the

1 project was assigned a specific batch. That
2 way we could -- they were responsible, they
3 would process all the records within that
4 batch before they would be assigned another
5 batch.

6 Q. The application that was
7 developed more handled the assigning of the
8 batches?

9 A. The application is where all the
10 redaction occurred.

11 We would then create the batches
12 and we would create a list and we would say,
13 you know, employee one, you're to do batch
14 20. So, they would go into the application,
15 log in, they would pull up that batch and
16 within the application, they would process
17 it, you know, exposure record by exposure
18 record, redacting the information that needed
19 to be redacted and work their way through all
20 the exposure records within a batch.

21 Q. So, the application also
22 assisted with the redaction process?

23 A. The way the application worked,
24 the individual would highlight the section

1 and click a button to redact and the
2 application then would replace that
3 information with X's.

4 Q. And did the application have any
5 capability to identify particular
6 information? So for example, numbers that
7 would be in a certain sequence perhaps with
8 three numbers?

9 A. No. The application just served
10 up the records and then it was up to the
11 reviewer to look at the information that was
12 in there.

13 Q. And who assisted in the
14 design -- strike that.

15 Who designed this application?

16 A. This was done in-house by our
17 data analyst.

18 Q. And who advised the data analyst
19 on what functionality this application should
20 have?

21 A. I was involved, it was a group
22 effort for the people, a few of us who were
23 involved in this production to determine, you
24 know, what this application needed to do,

1 what was the best way to set it up.

2 So, yeah, I was involved, the
3 data analyst was involved. There were
4 probably a couple of other people who we
5 brought in to talk about who would be working
6 this process or overseeing and managing this
7 process to assist with the development of the
8 application.

9 Q. And have you explored with the
10 people who developed the application whether
11 it could potentially be enhanced to write
12 code that can identify numbers that fit a
13 Social Security number format, for example?

14 A. No, we did not enhance it. I
15 mean there was some time between this first
16 production and the second production. So, we
17 did make some minor tweaks for people who
18 were using it. Move a button here, do this
19 or that.

20 Some minor sort of tweaks, but
21 given the nature of the information, given
22 how you have to review that information in
23 the context of the narrative, you know, we
24 did not try to automate any more of that

1 process.

2 Q. You said you made some tweaks to
3 the application. I know you mentioned moving
4 some numbers around, or moving some buttons
5 around. Were those more interface-type
6 changes or were there changes in
7 functionality that were different between the
8 first batch and the second batch?

9 A. I believe they were mostly just
10 the people actually using it who provided
11 feedback on, you know, improvements they
12 could make to make it a little bit easier to
13 navigate the system.

14 I think those were mostly the
15 enhancements that were made in the
16 application.

17 Q. In terms of the steps that were
18 taken to redact the potential PII that would
19 have been on the exposure field, I think we
20 talked about the first pass was a reviewer
21 was assigned through the application a batch
22 of records to review and should something
23 come up that was suspect, the reviewer had
24 the option to redact using the application,

1 that particular record.

2 Then what is the next step in
3 the process?

4 A. Once the reviewer completed the
5 batch, then we would, then there was a second
6 level process.

7 The way we set that up was that
8 any claim that had exposure records that had
9 a redaction were grouped and then any claims
10 that there were no redactions within the
11 exposure records were into a separate group
12 and then we had different sets of teams, one
13 team would focus on those that had a
14 redaction, another team focused on those
15 where there were no redactions and we went
16 through the process again and reviewed the
17 work that the previous reviewer did.

18 And if they thought that, hey,
19 they redacted something that was a ship and
20 shouldn't have been, they could be, you know,
21 return the original data so they could update
22 it, they could both redact information that
23 potentially was missed or unredact
24 information that the first reviewer had

1 redacted.

2 Q. So, all of the records got a
3 second level review, whether they needed a
4 redaction or not?

5 A. Correct.

6 Q. How many sort of false positives
7 did you get in terms of things that on the
8 first pass they thought needed redaction, but
9 then once they got escalated it was known
10 that they did not require redaction?

11 A. I'm not sure of the exact
12 number.

13 I think there may have been some
14 cases with some names that was really a
15 company name versus an individual, but I
16 don't know how often that happened.

17 Q. And sticking with the work just
18 done on that first pass, Exhibit 3, when you
19 staffed this, were the folks tasked with
20 doing this work put on the project sort of
21 full time or were they told to get this done
22 in addition to getting their other work done?

23 A. Given the time constraints on
24 this, there were some people who were --

1 people were put on this as we could make the
2 resources available.

3 Some people were working on this
4 full time. Some people were only able maybe
5 to work part time.

6 We'd like to try to find people
7 who could focus on this and, you know, we
8 didn't want -- it would be much better for us
9 to have ten people working, for example, on a
10 full time than 40 people working part time.

11 Our goal was to try to get as
12 many of these people working on this project
13 for as many hours as they could to get this
14 done.

15 Q. For some of the folks, it was
16 this was your life's work until it gets done
17 and for many others this was you need to do
18 your other work in addition to working on
19 this project?

20 A. I mean if they worked on this
21 project, it was pulling them off their
22 existing.

23 But it was -- we had to identify
24 how many resources we needed to get done in a

1 time period and from there, go through to all
2 of our various departments and work with all
3 of the managers and supervisors to say, you
4 know, who do you have available? Who can you
5 spare? Who has the skill set to sit there
6 and look through exposure records?

7 You know, you need a certain
8 attention to detail and focus to be able to
9 look at these records, you know, over and
10 over again.

11 So, we were looking for those
12 individuals.

13 Q. And so after the first pass was
14 made and then there was sort of the second
15 level keyway check for both the records that
16 potentially needed redaction and those that
17 were not identified as ones potentially
18 needing redaction in this first stub
19 production, then what was the next step?

20 A. Once we got through and redacted
21 all of them, then had the second QA, when
22 that part was done then the data for these
23 fields that we looked at were then
24 incorporated back into the production for

1 each. So files were created for each of the
2 trusts.

3 So, based on the other
4 information that was required in the
5 subpoena, the information was compiled back
6 together and then so then you had a file for
7 AWI, for example, that would have all of
8 their requested information and the redacted
9 fields and then we had another group who then
10 went through the actual spread sheets to look
11 through to see again, they looked to make
12 sure all the fields were there, all the
13 information was there, that the information
14 contained matched, you know, for that
15 claimant.

16 They also went through some of
17 the other fields that were in there and to
18 identify, you know, the focus in the
19 application was for the four fields that we
20 talked about.

21 But they did find some
22 additional fields that also had SBI data
23 during that review.

24 One of the fields, for example,

1 was relationship to the
2 occupationally-exposed person. So that's on
3 the secondary.

4 And for the most part, you know,
5 people would put spouse or husband but some
6 people would put spouse dash and then the
7 person's name. And so there was the ability
8 in those fields to add that information.

9 So, they were, you know, on
10 those, they were able to in that sort of
11 other QA step identify some of those pieces
12 of information that also needed to be
13 redacted.

14 Q. And so after that process was
15 completed for this first stub production,
16 then what was the next step?

17 A. Well, once the files, where
18 we've gone through and redacted, compiled the
19 files by trust, done that QA, then that
20 redaction, then that data along with what we
21 talked about the data dictionary, then there
22 was the process, I believe in this case --
23 let's see there was another step in this -- I
24 think there was some other information then

1 that was requested.

2 I mean I think in the original
3 data there may have been a state, VA,
4 abbreviation and they did request that we
5 provide what all those abbreviations meant,
6 not only the 50 states, but some other
7 countries and things like that.

8 I think there was some
9 additional information provided for that.
10 But I think that's the pieces of data.

11 And then each one of those were
12 created then for each of the 15 trusts.

13 Q. So the, I guess files, for lack
14 of a better term, but you'll correct me if
15 there's a better term, that were made for
16 each of the trusts or the compilations,
17 however you want to say it, that's all done
18 electronically; right?

19 A. The data analyst would combine
20 those and then those were then combined into
21 Excel spread sheets with the final version of
22 the data and those Excel spread sheets were
23 what then were QAs again in that last step.

24 Q. And was that the last thing that

1 happened prior to production?

2 A. I believe that was the last step
3 in producing this data.

4 Q. And before we leave that first
5 stub production Exhibit 3, do you know how
6 many records needed to be reviewed for
7 potential need for redaction in connection
8 with this first stub production of the 1,500
9 claimants?

10 A. I don't know the breakdown
11 between the first and second.

12 Q. And so you couldn't tell me how
13 many of that initial stub production of those
14 records may have contained information that
15 needed to be redacted?

16 A. I don't know the number. I
17 don't. I mean overall I know there were
18 thousands and thousands, between the two, but
19 I don't know the distinction between the
20 first and the second.

21 Q. And moving to Exhibit 4, which
22 is, as I understand it, the second larger
23 production of the data after that initial
24 stub production?

1 A. Correct.

2 Q. How many people were tasked with
3 doing the redaction work associated with this
4 invoice?

5 A. Again, I know there was a little
6 over 40 between the two. I don't know the
7 exact breakdown, but the majority of them
8 would have been working on this part, given
9 the volume of records that were in this
10 second production.

11 Q. So, was it the same team I guess
12 as between the first and the second
13 productions?

14 A. There was some people the same.
15 But again, every time, you know,
16 when we have this, at that second period,
17 then we had to go back out and look at the
18 availability of the individuals and some of
19 the individuals, you know, were the same and
20 some who worked on the project before were
21 not able to and then there were many
22 additional people who had to be assigned to
23 the project.

24 Q. So, when you staffed the second

1 project, did you try to get folks from the
2 first project if possible so that there would
3 be some efficiency gains there?

4 A. We tried to -- we looked at all
5 of that and tried to, you know, if people
6 were experienced at the project and they did
7 a good job on the project, we would like to
8 use them, but it depended on what other work
9 they had going on at the time.

10 Q. How many hours of your time was
11 put into the work that is captured by the
12 second invoice that's Exhibit 4?

13 A. I'm not sure of my exact hours.
14 I mean I think -- I think
15 between the two, I mean it was over -- over
16 40 hours of direct billed time. I mean that
17 doesn't count, all the other time working on
18 the project, trying to get it set up or
19 things like that, but I think, you know,
20 direct bill time was somewhere in that range.

21 Q. And I know you mentioned there
22 were some tweaks between not just to the
23 application, but I thought also to the
24 process between the stub production and the

1 second larger production.

2 Was that -- did I understand
3 that correctly or were the tweaks made just
4 at the app?

5 A. I was referring to the
6 application.

7 Q. Okay.

8 A. Whether or not -- mostly it was
9 to the application and how the application
10 worked and served up the information and how
11 that whole process -- I'm trying to think if
12 there were any other procedural type.

13 I think most of it was the
14 design and then tweaking of the application.

15 Q. So but interface -- more of the
16 interface of the application as opposed to
17 the functionality of the application?

18 A. I mean there's sort of -- I'm
19 not sure of all the -- I know, I mean some of
20 it was the locations of where things were and
21 the ease of going through.

22 Some were, I think, the ease of
23 you're on one record and you go to the next
24 but then you want to go back to the previous

1 record.

2 So it was sort of given that
3 functionality and the application to be able
4 to, you know, when the actual people were
5 using this for the first time, there were
6 suggestions made to say, you know, hey, can
7 we make this change? I'd like to be able to
8 go back.

9 And then I think that they made
10 the ability to go back and see the last five.

11 So, if I'm working it, there was
12 a section at the top so I can see the last
13 five that I worked. So if I wanted to go
14 back or if I may have missed something, you
15 know, I could go back.

16 I think it's sort of those type
17 of tweaks that were done.

18 Q. So, things perhaps geared to
19 make the second go-round a little more
20 efficient based on what you learned from the
21 first stub production?

22 A. Some things were done as we were
23 going in that first direction.

24 You know, it was -- this was

1 sort of a build it as you go, you know, given
2 the time constraints.

3 But yeah, then, you know, with
4 the second, when we did the second, that
5 application then, you know, was at a good,
6 you know, it was set up, it was ready to go
7 and that then we used for processing it and
8 that would be, if we were to do this type of
9 work again, that would be the application
10 that would be used to do the redaction.

11 Q. And so as you worked through the
12 DBMP production, you made enhancements to the
13 application to improve it and improve the
14 process?

15 A. There were some, I mean there
16 was some enhancements to it. I mean the
17 amount -- most of what was involved was the
18 manual review of each of these exposure
19 fields.

20 We did make some minor
21 enhancements of the application to assist
22 those people doing the job to make at least
23 that part of it, if there were some
24 enhancements that would help them get through

1 the process. And suggestions, yes, we did
2 implement those enhancements into the
3 application.

4 Q. Are there any potential
5 enhancements that you all have considered
6 adding to the application in the event of
7 productions in future cases?

8 A. No. I think the application
9 that we designed I think worked well and
10 helped us, you know, within that 45 days over
11 the Christmas holiday redact and spend, in
12 this case, 809 hours to redact all those
13 records.

14 So I imagine we would use that
15 same application as it is.

16 Q. Did the second production go
17 more smoothly than the first when it came to
18 the review of the records because of the
19 improvements made to the app?

20 A. I mean the application, yeah,
21 there was parts of it with the application
22 that we had worked out some of the issues and
23 the application was working. The bigger
24 challenge on the second part was not so much

1 the application, but was just getting the
2 number of individuals available.

3 Like I said, it would be also
4 just brought on to a new trust and so we were
5 being, you know, stretched thin with
6 everything and having, you know, over 800
7 hours of additional work that needed to be
8 done.

9 So, that was the challenge was
10 identifying these people and resources and
11 working with them to get this all done within
12 the time frame we were given.

13 Q. How many records or excuse me,
14 how many claimants were involved in that
15 second production?

16 A. Again, I don't know the
17 difference between the first and second.

18 I think in total, there's over
19 100,000, 105,000 claims and then the exposure
20 records would have been over 200,000. I
21 don't know.

22 Q. I didn't mean to talk over you.
23 I thought you were done.

24 . As 105,000 claims, that's

1 claims among all of the member trusts?

2 That's not individual claimants?

3 A. That's -- that's claims. We
4 have claimants and that transfers to the 105
5 claims and then within the 105 or so claims
6 there's the 200 some thousand exposure
7 records.

8 Q. So, was there any material
9 difference between the process that was
10 taken, that was undertaken for the first
11 production and the second?

12 A. I don't believe so. We did the
13 same things with the application. I think it
14 was the same process.

15 Q. And are -- is DCPF bringing on
16 any additional asbestos trusts for claims
17 processing in the next six months that you
18 can disclose?

19 A. I'm not aware at this point.

20 Q. And so moving off of the
21 invoices, I mean I think we've discussed your
22 concerns that a data breach could reveal some
23 sensitive claimant information that may
24 inadvertently be included in some of the

1 fields that are produced to the debtors. Is
2 that a fair statement?

3 A. I'm concerned with both the
4 sensitive information and just all of the
5 confidential information. All the
6 information the claimants provides is
7 considered is confidential. It's not just
8 the SBI data related to the fields, but it's
9 all of the data.

10 Q. But sticking with just for the
11 purposes of these few questions, the whole
12 redaction process, so, in order for some SBI
13 or sensitive or personal PII to be
14 inadvertently disclosed, we would have to
15 have in the first instance the data sort of
16 getting by that, somehow not getting redacted
17 on the first pass taken by DCPF,
18 understanding that DCPF undertook a very
19 robust and time-consuming process to redact
20 that data.

21 And then that data would then
22 not have to be properly redacted by the
23 debtor's experts who are required to
24 undertake such an exercise. And then there

1 would have to be a breach.

2 Are those -- isn't that the only
3 way that this data could be inadvertently
4 disclosed?

5 MR. GUERKE: Objection.

6 THE WITNESS: I mean this data,
7 we've got, through the process, going through
8 and redacting the information, but then the
9 information that was produced, there still is
10 then, you know, a matching key that
11 potentially could be used to, you know,
12 recompile this data with other pieces of
13 information.

14 What happens to the data after
15 it leaves us, you know, I can't speak to.

16 There is a risk, there is a data
17 out there but, you know, we do everything we
18 can to redact this information out of these
19 exposure fields within the time frame that
20 we're given.

21 Like we've said, there's quite a
22 number of exposure records and the data can
23 be in even some locations you necessarily
24 wouldn't think someone would put some of this

1 data.

2 So, it is quite an effort and we
3 do our best to get out as much information,
4 hopefully all of this information that we
5 can.

6 Q. So as we talked about, the DCPF
7 has provided similar trust data as requested
8 by the debtors in this case to DBMP and that
9 data was redacted before it was sent; right?

10 A. Correct.

11 Q. And DCPF did its best to ensure
12 that anything that was not supposed to be
13 included in that transmission was redacted;
14 right?

15 A. We did, yes, to remove those
16 pieces of information, correct.

17 Q. And so what is the process after
18 the transmission, such that do you know how
19 many records DCPF may have failed to properly
20 redact before the info went to Bates White?

21 MR. GUERKE: Objection.

22 You can answer.

23 THE WITNESS: No, I do not.

24 BY MS. MAISANO:

1 Q. So, was there a process by which
2 after the data was transmitted somebody came
3 back to DCPF and said hey, I think we might
4 have, some of these might have been missed,
5 we should talk about it or how does that
6 work?

7 A. Well, when we produce the data
8 for DBNP, they did come -- DBNP did come back
9 with a couple of questions.

10 There was -- when we created the
11 spread sheet, there was a spread sheet on one
12 of the trust's DII, which was to Hal Harbison
13 Walker and I think it was the secondary
14 exposure that the, one of the other Harbison
15 Walker data was on both of those spread
16 sheets and when the data had been pulled in
17 by the data analyst, they pulled in the
18 Harbison -- one trust instead of the other.

19 And so then we were able then to
20 pull and produce the, that tab, there was
21 three tabs in it, that one tab for that one
22 trust.

23 Then they also had some
24 questions about information I believe that

1 was in certain fields and the way it was
2 described and then we explained to them that
3 that's the information as it was provided by
4 the trust, by the claimant.

5 So, we only give you back the
6 information, I think some of it was the
7 information provided didn't look like it was
8 for a different question. And we confirmed
9 that that, you know, that is the information
10 that was provided by the claimant.

11 Q. So, does DCPF have any knowledge
12 of how many records associated with the DBNP
13 production may have gone out that could have
14 included sensitive information or personal
15 information in those exposure-related
16 narrative fields?

17 A. No, I do not know.

18 Q. And has DCPF produced this type
19 of redacted claimant data to anyone other
20 than DBNP?

21 A. In this format, I do not believe
22 so. There were others in more of the
23 individual subpoenas where information would
24 be redacted, but I think this exercise that

1 we did with DBNP was the first time we've
2 done that.

3 Q. And so for the -- any Aldrich
4 Murray claimant who was also included in the
5 DBNP discovery data, you'd be able to skip
6 the redaction process, right, because you
7 already redacted for that claimant?

8 MR. GUERKE: Objection.

9 THE WITNESS: Not necessarily.

10 I mean this subpoena here, I
11 don't know, you know, if that occurred or how
12 many it occurred.

13 The subpoena here is, you know,
14 doesn't talk about using information from a
15 previous production and we typically just, we
16 deal with, you know, each of these subpoenas
17 separately as they are received and not rely
18 on information that was previously produced
19 in another matter.

20 BY MS. MAISANO:

21 Q. Do you know what the overlap is
22 between the claimants requested by DBMP for
23 which you produced the redacted data and the
24 claimants requested by Aldrich and Murray?

1 A. No, I do not.

2 Q. But assuming that there is some
3 overlap, is it your expectation that DCPF
4 would undertake that redaction process all
5 over again and not use the work on the
6 redaction that was done previously for the
7 same claimants' claims?

8 A. I mean we haven't -- I haven't
9 thought through exactly what we would do in
10 that case.

11 I mean I'm certainly hoping we
12 still produce the sample in this case. But
13 the data changes, too.

14 I mean there's information,
15 there's new information, exposure records get
16 updated. So, I don't know how or the
17 usefulness of reusing some of the data from
18 the DBMP production into this.

19 I know -- yeah, so I'm not sure.
20 We'd have to -- it would be something we'd
21 have to look at if we were instructed to do
22 so.

23 Q. But assuming that there was
24 potentially overlap, and you were able to use

1 the records that have already been reviewed
2 and redacted for the DBMP production, would
3 then the burden of producing the data
4 requested by the Aldrich Murray debtors in
5 this case just be limited to review of a
6 limited number of -- those limited number of
7 fields for those limited claimants who did
8 not overlap?

9 MR. GUERKE: Objection.

10 THE WITNESS: I mean in this --
11 there's more claimants in this request. And
12 I think in here, there's 12,000. So, I think
13 there's 30 percent more claimants and I think
14 on claims, I think we're up to close to
15 150,000 versus I think it was 105.

16 So, I think there's quite a
17 number of more claims and then each of those
18 claims that have a correlating increase in
19 the number of exposure records that would
20 need to be reviewed.

21 So, you have all of those that
22 would have to be reviewed. You have all of
23 the ones that would not overlap. You would
24 have all those ones that maybe do overlap,

1 but the information would then -- within the
2 claim has changed since the DBMP was
3 produced.

4 All of that -- and, you know, I
5 wouldn't want to get into trying then to
6 identify what piece of data changed and then
7 trying to take what was produced here and
8 sort of merge certain fields to the other.

9 I think if the data is changed,
10 we definitely would want to relook at those
11 claims.

12 So, I'm not sure what the
13 overlap is, but there is substantial number
14 of claims just given the 40 percent or so
15 increase in additional records that we would
16 need to review -- not records -- claims,
17 review and redact.

18 Q. Why would a record -- why would
19 a trust claimant's record change after that
20 claimant has been paid?

21 A. We're not just looking at
22 records that have been paid. We're matching
23 against all claims for that individual.

24 Q. So, if a claimant -- so I guess

1 there is the potential perhaps for a field or
2 for a claimant's record to change, and
3 understanding that we're doing this on a
4 claim basis, right, not a claimant basis?

5 A. Uh-huh.

6 Q. So, is that -- so is the
7 situation you're envisioning one in which a
8 claimant was paid by one trust, but perhaps
9 has submitted a claim to another trust?

10 A. We reproduce all this data.
11 It's trust by trust.

12 So, regardless of what happened
13 in one trust, for each of these trusts, the
14 data, we're to produce all the matching
15 claims. And so within each of these trusts,
16 claims can change.

17 We're required to, you know, if
18 it was paid, if it wasn't paid, give it's
19 current status. Statuses can change,
20 exposure records can change. That type of
21 information can change.

22 Q. In reviewing the information for
23 the DBMP production, did you -- did the DCPF
24 sort of cut it off to account for this

1 potential change? So what I'm trying to get
2 at is was there a date certain whereby even
3 if, for example, an exposure field may have
4 changed for some kind of a claimant or a
5 claim record may have changed, that may not
6 have been included because it was -- you had
7 already started work on the production?

8 Because I guess what I'm trying
9 to get to is from what you're saying, it
10 seems that this information is kind of
11 dynamic and subject to change all the time.

12 And so how did you handle it in
13 DBMP, understanding that as you said this
14 information can be subject to change
15 regarding the claims records?

16 MR. GUERKE: Objection.

17 THE WITNESS: When in this
18 process it's finally decided that, you know,
19 yes, we need to produce the data, then we
20 would go and develop the queries to pull all
21 of this data that's requested.

22 So, the first step would then,
23 at that point in time, we would pull all of
24 the information that's requested for all of

1 these fields.

2 Then that data set becomes the
3 basis then for what then gets redacted.

4 Q. And so assuming that there
5 are -- that there is claimant overlap between
6 the claimants requested in Aldrich Murray and
7 the claimants for which DCPF undertook this
8 redaction process for DBMP, if there were no
9 changes in the claim record data, could that
10 data be used in connection with responding to
11 the Aldrich Murray subpoenas?

12 MR. GUERKE: Objection.

13 THE WITNESS: Again, we would --
14 if we -- we could identify potentially that a
15 record has not changed. But, you know, we've
16 not been instructed to reuse that data. It
17 doesn't seem to be a part of this subpoena.

18 But given that, we would still
19 want to, you know, QA that information and
20 take another look at it before that data then
21 gets produced in another production.

22 BY MS. MAISANO:

23 Q. So you would QA it again from --
24 after -- I just want to make sure we're

1 talking about the same thing. The DBMP data
2 that was already redacted and produced, you
3 all would QA it and look at it again prior to
4 any potential production in another case?

5 A. There would be some QA that
6 would be done, yes, absolutely.

7 I mean we're pulling certain
8 fields out of what was produced previously
9 and adding it to additional new records.

10 I mean all of that, we would
11 have -- we'd want to QA and make sure that
12 everything is as accurate as possible. So,
13 yeah, there would be some QA that we would
14 want to do.

15 I haven't thought about it or
16 worked out all the details in sort of what
17 that would envision.

18 Q. But assuming that you were --
19 that the DCPF was able to use the data that
20 had been unchanged since the DBMP production
21 had already been redacted, that would reduce
22 the time needed on the DCPF then to make that
23 production; right?

24 MR. GUERKE: Objection.

1 THE WITNESS: Reduce the time, I
2 mean over all the production? I'm not sure.

3 On an individual record basis?
4 For those potential records that had the
5 overlap? You know, there may be scenarios
6 where that would save time.

7 But given the additional number
8 of records and, you know, the records that
9 would have changed or not overlapping, you
10 know, they certainly could be, you know, more
11 time consuming than what it was in the DBMP.

12 I mean I just have no way of
13 knowing at this time.

14 BY MS. MAISANO:

15 Q. Because we don't know because we
16 don't know what the overlap would be; right?

17 A. I don't know the overlap, but I
18 do know there are substantially more records.

19 Q. Did you tell me there were
20 89,000 claimants who were requested in DBMP?

21 A. Somewhere around 9,000.

22 Q. And we've got about 12,000 in
23 the case; right?

24 A. I think it was 12,002 for this

1 one.

2 Q. And so assuming that there is
3 overlap among the claimants and assuming that
4 you might be able to use some of the work
5 that you had done in DBMP, potentially there
6 could be some claims wherein you might not
7 have to undertake that redaction, possibly?

8 MR. GUERKE: Objection. Calls
9 for speculation and asked and answered.

10 THE WITNESS: This is assumption
11 on assumption. I mean we'd actually have to
12 see what it was to make those determinations.

13 I mean this is nothing we've
14 ever done before. It certainly wasn't
15 envisioned in this production.

16 So, it's something that we would
17 and I would need to look into.

18 BY MS. MAISANO:

19 Q. Moving on to Paragraph 29, you
20 talk about the burden of responding to this
21 request that was made by the debtors.

22 We talked about what happened in
23 DBMP. You say here first this production has
24 already taken up a significant amount of DCPF

1 employees' time.

2 How much time has DCPF taken so
3 far to respond to the Aldrich Murray
4 subpoena?

5 A. I'm not sure of the hours so
6 far, but there's many parts in the process
7 that the DCPF has already worked on, you
8 know, including here it talks about the
9 initial, the matching.

10 So, we worked on the initial
11 matching. It provided, we say 12,000 claims.
12 It actually provided somewhere over 13,000
13 records.

14 For some of the claims, they
15 gave multiple versions of the last name.

16 So then we matched up, so, we
17 would match up the social and then whether or
18 not it was an exact match.

19 So, we completed that, we
20 created then the initial meet and confer list
21 that had probably over 10,000 records that
22 matched on social but didn't match exactly on
23 last name. And we went through the process
24 of trying to identify the reason for it not

1 matching.

2 Some of these were because they
3 were the additional name variations, but they
4 provided that the claim that was being
5 matched was already on the list of an exact
6 match. It was a portion of those.

7 There was ones where we would
8 look through to see that it appeared to be a
9 typo in the last name field or they had the
10 first and last name reversed.

11 So, we went through all of those
12 records to develop the meet and confer and I
13 believe we've also been sent the initial
14 notice to the law firms who represent these
15 150,000 claims.

16 So, I think all of that work, I
17 don't believe the meet and confer process was
18 ever finalized. We started them and that was
19 all put on hold.

20 Q. So, just to make sure that I've
21 got it correctly, if I, Clare Maisano am one
22 of the 12,000 claimants who is among those
23 requested and I submit claims against all 15
24 of the trusts and the sub funds, would that

1 be, that would be 15 unique claims because
2 the sub funds are all separate or is that the
3 ten?

4 A. It would be 15.

5 So, individuals can have, in
6 each of the 15 and they can have multiple
7 claims within a given trust.

8 Q. And is there a way to do a
9 single query against all of the trust
10 databases for a name and Social Security
11 number?

12 A. I'm not sure --

13 Q. For example, for all of the
14 trusts that DCPF manages, is there a way to
15 be a Trust Online or some other mechanism
16 where you can do a query and put in a Social
17 Security number and last name and it will
18 deliver all of the hits for all of the member
19 trusts for those two data claims?

20 If you put in my name and Social
21 Security number, would you get a list of all
22 of the trust claims that I've made for -- to
23 the DCPF member trusts?

24 A. All of the data is in the

1 database. We keep all of the information.
2 We don't commingle the data between the
3 trusts.

4 So, the information, and again,
5 it's not just to make the point, it's not the
6 Social Security number but the --

7 Q. SSID?

8 A. -- the SSID that's in the
9 database. There's the ability, but it's a
10 matter of the procedures and the policies and
11 reductions, you know, we don't compare data
12 across trust.

13 Q. So, of the 12,000 claimants that
14 were requested by the debtors in this case,
15 how many of those matched to at least one of
16 the DCPF database or one of the DCPF member
17 trusts?

18 A. I do not know that number. I
19 don't know the number. It did not match to
20 anything.

21 Q. And I think you said in your
22 declaration that after completing a
23 preliminary database search over a series of
24 days for more than 12,000 claimants, almost

1 150,000 potential relevant claims came up.

2 How does a preliminary database
3 search take days?

4 A. Well, part of the process is the
5 information that's provided to us, again, was
6 the name, the Social Security number.

7 That Social Security number then
8 is a process, a tool that we have that we
9 then feed the Social Security numbers in
10 through software that then will let us know
11 what the surrogate key is or the SSNID is
12 that we could then use for matching. That is
13 a more time-consuming process.

14 So, we feed those through, the
15 data analysts will set up a query and submit
16 them one by one through the system. So, that
17 takes time to run through.

18 So, once then it goes through
19 and then pulls all of the SSN IDs, then it
20 would run and do the matching of each of --
21 for each of the trusts.

22 And then would create, when it
23 does the initial matching so then you would
24 create I think it was at least three tabs.

1 It's one tab would have, you know, here are
2 the claims that are the exact match. And
3 then there would be another tab that
4 identified claims that were just a Social
5 Security but did not match on last name.

6 There was also I believe another
7 tab then that would list those pro se
8 claimants and then there was another tab that
9 would I believe list those records that
10 didn't match to anything. So, I think those
11 were those four fields.

12 So, the data analyst has to pull
13 out all the socials, run the data for each
14 trust and then create each of these
15 individual spread sheets for each of the
16 different 15 entities.

17 Q. But he has -- he or she has
18 scripts to help with that, with doing the
19 queries?

20 A. I mean he does run programs, but
21 I'm not sure the level of -- I'm not sure how
22 much the creation of the actual Excel spread
23 sheets are automated. I know he goes through
24 and does the comparison and whether he

1 manually creates the spread sheets or whether
2 he has a more auto -- has them more
3 automated, I'm not sure.

4 Q. Do you remember -- strike that.

5 So, you undertook this same work
6 I presume in DBMP, this initial pass through
7 the database to see how many relevant claims
8 there were matching to the claimants?

9 A. Yes.

10 Q. Do you know how long that took
11 in the DBMP case?

12 A. I do not know.

13 Q. Do you know how many DCPF
14 employees did this work in the DBMP case?

15 A. The initial matching?

16 Q. Yes.

17 A. Well, the different -- the
18 actual running the queries and developing
19 those 15 spread sheets would have been done
20 by one individual.

21 I then got involved in at the
22 next step with the meet and confer and going
23 through those that were the partial matches
24 and trying then to categorize those, the

1 level of matching and provide that
2 information.

3 So, I was involved in more of
4 that manual review of the meet and confer
5 claims.

6 Q. How many DCPF employees
7 undertook this initial search and process
8 that we just talked about in the Aldrich and
9 Murray case?

10 A. It would have been I believe the
11 same people.

12 Q. And have you done the work yet
13 in Aldrich Murray to determine whether a
14 claim should be considered the -- a match
15 under the subpoena?

16 A. I do not believe that the meet
17 and confer process has been completed.

18 Q. Other than what we talked about,
19 has the DCPF performed any other work related
20 to complying with the subpoena served by
21 Aldrich and Murray in this case?

22 MR. GUERKE: Objection.

23 THE WITNESS: As far as what I'm
24 involved with, I mean like I mentioned the

1 matching, the notice to the law firms, there
2 may have been some work in creating the data
3 dictionaries of listing the, you know, by
4 trust, the fields that would be produced.
5 But I'm not aware of anything else at the
6 moment.

7 Q. And in terms of the motion to
8 quash, I mean you obviously executed a
9 declaration in support of the motion to quash
10 the subpoena; right?

11 A. I'm not quite following that
12 one.

13 Q. I'm just trying to figure out,
14 everything that DCPF has done in response to
15 the subpoena served by Aldrich and Murray in
16 this case, so we talked about the work that
17 DCPF undertook in terms of the matching and
18 the preliminary queries and we've got your
19 declaration here which also was drafted I
20 believe in connection with the subpoenas that
21 were served in this case.

22 So, I just wanted to make sure
23 we had talked about everything that DCPF has
24 done in connection with responding to the

1 subpoena served by the debtors in this case?

2 MR. GUERKE: Objection. Are you
3 asking him about everything including the
4 litigation over the last ten months or just
5 the nuts and bolts of responding to that?

6 MS. MAISANO: Anything that DCPF
7 has done in response to the subpoena. I feel
8 like the motion came in response to the
9 subpoena. That's what I'm trying to get at.

10 MR. GUERKE: I object to that.

11 THE WITNESS: There was other
12 work related to the actual notice to the law
13 firms and I think we've talked about it on
14 noticeable claimant.

15 So, there's certain law firms
16 that have lost contact with the facility and
17 despite our best efforts to notify the
18 counsel, weren't able to. So, there's some
19 work around that researching these firms,
20 making sure we have the correct contact
21 information in order to send the notice.

22 There's, you know, then research
23 if any of these were to bounce back or come
24 back, then I believe related to that, also,

1 was some of the law firms that would file a
2 motion to quash and I believe we also, there
3 were people who also would track those firms
4 that filed those motions.

5 Sitting here today, I can't
6 think of anything beyond what I just
7 discussed.

8 BY MS. MAISANO:

9 Q. We talked a little bit about the
10 meet and confer process.

11 You note in your declaration
12 that DCPF would have to meet and confer with
13 the debtors to receive additional information
14 on any hits that came up as inconclusive?

15 A. Uh-huh.

16 Q. What makes a hit inconclusive?
17 Is that if it doesn't match exactly on social
18 ID and name? How do you all define a hit as
19 inconclusive or potential hit, I should say?

20 A. Well, we look at, yes, we look
21 at the information that, if it doesn't
22 match on name -- we know it matches on -- if
23 it's in the SSNID. If it doesn't match on
24 Social, it's not considered a match at all.

1 Then it's a matter of going
2 through where the name, and if you look at
3 it, there's somewhere it may be a hyphenated
4 name. It may be due to formatting. There
5 may be cases where it really does appear that
6 it is for the same individual and there's
7 other cases where it does not appear to be
8 clearly for the individual. The name is not
9 a match.

10 So, those would go back during
11 in the meet and confer process and sometimes
12 they would then provide additional
13 information that potentially could help to
14 clear up the issue.

15 Q. And so you had a, I would
16 presume DCP had a meet and confer process
17 with DBMP in connection with the trust
18 discovery and they saw the same inconclusive
19 hits; right?

20 A. I was not involved in the actual
21 meet and confer meeting with DBMP, but yes,
22 that process did occur.

23 Q. Do you know how many claims you
24 out of the population requested, how many

1 came up as inconclusive hits?

2 A. I don't recall how many.

3 Q. And so do you know how many you
4 had to meet and confer on in connection with
5 that production?

6 A. No, I do not.

7 Q. Do you envision that the same
8 folks on the DCPF side who did the legwork on
9 the potential matches and the meet and confer
10 process in DBMP would be doing it in the
11 Aldrich Murray case?

12 A. Yeah, I would think it would be
13 the same individuals.

14 Q. You note, too, when we talked
15 about that DCPF is going to send notice to or
16 has sent notice to the legal counsel of any
17 claimants who are identified in the search
18 and come up as hits.

19 What does this notice involve
20 other than sending a letter to the claimant's
21 counsel?

22 A. I mean we send -- send notice to
23 the firm.

24 I'm not involved directly in

1 that part, but I think it includes a copy of
2 the subpoena, it includes, you know, the body
3 of the email that explains the subpoena and
4 any sort of requirements.

5 Then I think it's a list of
6 their claimants that match, that were
7 identified as matches.

8 Q. And so -- and then is -- is that
9 the extent of that work?

10 A. We send it out. There may be --
11 there's some questions that the law firm may
12 call in to ask about.

13 There may be some requests by
14 the law firms to get that. We send them out,
15 you know, as a PDF. There may be some that
16 they request to receive it in an Excel or
17 some other format.

18 It's just the responding to
19 those types of requests to the law firm and
20 then I believe as I said before, then the law
21 firm, whether or not they file a motion to
22 quash, I think then that also then, someone
23 at the DCPF will track, you know, those firms
24 that have filed the motion and those that

1 have not and answer, you know, any questions
2 related to that.

3 Q. We also talked previously about
4 those counsel who might not be able to be
5 identified, some of these claimants' counsel?

6 A. The non noticeable?

7 Q. Yeah.

8 A. Yeah.

9 Q. Do you know how many potentially
10 unnoticeable counsel there are in the Aldrich
11 Murray claimants that have been requested?

12 A. I do not know.

13 Q. Did you encounter this issue in
14 DBMP such that there were unnoticeable
15 counsel?

16 A. There were unnoticeable claims
17 in DBMP.

18 There was another individual who
19 was handling the tracking and the monitoring
20 of the unnoticeable claimants in breaching
21 out and trying -- in doing the research in
22 trying to identify a better way to contact
23 these -- this counsel.

24 So, there was firms that were

1 unnoticeable on DBMP.

2 Q. Do you know how many there were?

3 A. I do not know.

4 MS. MAISANO: Off the record.

5 - - -

6 (Whereupon, there was a recess
7 commencing at 12:29 p.m. and concluding at
8 12:32 p.m.)

9 - - -

10 BY MS. MAISANO:

11 Q. We're getting to the home
12 stretch here, Mr. Winner. Thank you for your
13 patience and time today.

14 Going back to the DBMP
15 production briefly, I think we talked about
16 that there were about 200,000 records that
17 needed to be reviewed for potential redaction
18 in that case. Is that right?

19 MR. GUERKE: Objection.
20 Misstates his testimony.

21 BY MS. MAISANO:

22 Q. What was the -- what was number?

23 A. DBMP, yeah, I think it was
24 somewhere over 200,000 exposure records.

1 Q. And sorry if I wasn't precise in
2 my terminology there.

3 So, it was 200,000 exposure
4 records that needed to be reviewed for
5 potential -- potential redaction I think you
6 said, that there were more than 1,000 records
7 that needed to be redacted in connection with
8 that initial 200,000 that were initially
9 reviewed?

10 MR. GUERKE: Objection.
11 Misstates his testimony.

12 THE WITNESS: I don't know the
13 exact number, but there were several thousand
14 records that had to be redacted.

15 BY MS. MAISANO:

16 Q. And several thousand that needed
17 to be redacted, I think you said that that
18 was the best estimate you could give us was
19 several thousand? Could you give me a more
20 precise number than that?

21 A. Again, several thousand.

22 Q. That's fine. I think we talked
23 about how that contained not only just
24 potentially Social Security numbers, but also

1 names, addresses, dates of birth with other
2 sensitive information that did not belong in
3 those exposure fields. Is that right?

4 A. Correct.

5 Q. Out of that small percentage of
6 the -- or that percentage of the 200,000
7 records that needed to be redacted and
8 contained information that shouldn't have
9 been there, can you tell me how many of those
10 records contained non-claimant PII, meaning
11 PII that was different than the person who
12 filed the claim?

13 A. I'm not sure. I know that
14 co-worker and co-workers names made up a
15 large percentage of those that were redacted.
16 I don't know the exact percentage.

17 Q. But it was mostly names of
18 co-workers?

19 A. I believe there were more names
20 than anything else for the co-worker.

21 MS. MAISANO: I think those are
22 all the questions that I have. Thank you
23 very much for your time today.

24 THE WITNESS: You're welcome.

1 MR. GUERKE: Thank you.

2 THE COURT REPORTER: Transcript
3 orders?

4 MS. KREPTO: Expedited.

5 MR. HOGAN: Regular ordinary
6 course.

7 MR. GUERKE: I'll take a regular
8 order that gets me a condensed version.

9 I would say if I could get it
10 within a week, that would be great.

11 MS. MOSKOW-SCHNOLL: Same with
12 me.

13 MS. MAISANO: That's the same.

14 THE COURT REPORTER: Jones Day
15 ordered it as a two day. I'm just confirming
16 that.

17 MS. MAISANO: Whatever they said
18 is fine. Just send it to them or send it to
19 me.

20

21

22


23

24

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

C E R T I F I C A T E

I hereby certify that the proceedings and evidence noted are contained fully and accurately in the notes taken by me on the deposition of the above matter, and that this is a correct transcript of the same.



Teresa M. Beaver

(The foregoing certification of this transcript does not apply to any reproduction of the same by any means, unless under the direct control and/or supervision of the certifying shorthand reporter.)

EXHIBIT H

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

UNITED STATES BANKRUPTCY COURT
DISTRICT OF DELAWARE

IN RE: . Chapter 11
. Case No. 20-10028 (LSS)
PADDOCK ENTERPRISES, LLC, .
. .
. Courtroom 2
. 824 Market Street
Debtor. . Wilmington, Delaware 19801
. .
. Friday, January 6, 2023
. 9:58 a.m.

TRANSCRIPT OF HEARING
BEFORE THE HONORABLE LAURIE SELBER SILVERSTEIN
CHIEF UNITED STATES BANKRUPTCY JUDGE

APPEARANCES:

For the Debtor: Amy C. Quartarolo, Esquire
LATHAM & WATKINS, LLP
355 South Grand Avenue
Suite 100
Los Angeles, California 90071

For the Owens-Illinois
Trust Advisory
Committee: Todd E. Phillips, Esquire
CAPLIN & DRYSDALE, CHARTERED
One Thomas Circle, N.W.
Suite 1100
Washington, DC 20005

(APPEARANCES CONTINUED)

Electronically
Recorded By: LaCrisha Harden, ECRO

Transcription Service: Reliable
1007 N. Orange Street
Wilmington, Delaware 19801
Telephone: (302) 654-8080
E-Mail: gmatthews@reliable-co.com

Proceedings recorded by electronic sound recording:
transcript produced by transcription service.

1 APPEARANCES (CONTINUED):

2 For Bestwall, LLC: Gregory M. Gordon, Esquire
3 JONES DAY
4 2727 North Harwood Street
5 Suite 500
6 Dallas, Texas 75201

7 Morgan R. Hirst, Esquire
8 110 North Wacker Drive
9 Suite 4800
10 Chicago, Illinois 60606

11 For Official Committee
12 of Asbestos Claimants
13 of Bestwall, LLC: Davis L. Wright, Esquire
14 ROBINSON & COLE, LLP
15 1201 North Market Street
16 Suite 1406
17 Wilmington, Delaware 19801
18
19
20
21
22
23
24
25

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

INDEX

MOTIONS:

PAGE

Agenda

Item 1: Supplemental Brief and Motion for Stay of Discovery of the Owens-Illinois Asbestos Personal Injury Trust, the Owens-Illinois Asbestos Trust Advisory Committee, and the Court-Appointed Future Claimants' Representative in Response to the Court's Letter Ruling [Docket No. 1657 - filed November 28, 2022]

Court's Ruling: 113

Transcriptionist's Certificate 118

1 years? I mean, some of the asbestos bankruptcies, as you are
2 well aware, lasted 15 years. I don't think it's appropriate
3 for this claimant data to be sitting in North Carolina
4 debtors' files for 15 years, that to me is inconsistent with
5 protecting and appreciation the security interests of that
6 data.

7 THE COURT: How is that different than it sitting
8 in Paddock's files for the next 20 years?

9 MR. PHILLIPS: I don't -- Paddock is in the
10 process of transferring it all to the trust.

11 THE COURT: Okay, or this trust's for the next 20
12 years?

13 MR. PHILLIPS: Well, the Trust has a different --
14 I mean, I don't want to malign the North Carolina debtors,
15 but the trusts have a very different incentive to protect
16 that data.

17 THE COURT: But I don't know that it does or it
18 doesn't. I mean, that's -- it seems to me that -- and maybe
19 a finite time is appropriate, but it seems to me that we deal
20 with this Court, the court across the street, many courts
21 deal with sensitive information -- it's not privileged, but
22 it's sensitive -- in discovery situations all the time.

23 MR. PHILLIPS: I appreciate that.

24 THE COURT: And I do think this information is
25 sensitive and that is -- it has to be protected, but we deal

1 with it all the time and we deal with it through protective
2 orders. We assume the good faith, quite frankly, of the
3 people who are -- who have access to that information and, if
4 we can't depend on the good faith of the people who have
5 access to the information, then that just throws the whole
6 scheme out.

7 MR. PHILLIPS: I appreciate that, Your Honor.
8 Having worked with the trusts for a number of years, I know
9 that they have very -- they have specific protocols and
10 security in place for their doc -- like, they actually -- I
11 know that they have protections in place, I'm just not
12 comfortable. I don't know what Bates White -- I just don't
13 know what they do to protect their data.

14 So it's hard for me to say that it's going to be
15 safe sitting in their files for a number of years, but I
16 appreciate what you're saying that relying on the good faith,
17 but I will say that the longer it sits, the more of a chance
18 there is for hacks and for data breaches and that kind of
19 thing.

20 THE COURT: It clearly is. The more it sits
21 anywhere, there is a chance that anybody can be hacked, but
22 just as your firm may get confidential information and
23 discovery in cases that you're working on and your employees
24 get to look at it and whoever gets to look at it, you know,
25 we trust that your firm is going to handle it appropriately

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

CERTIFICATION

We certify that the foregoing is a correct transcript from the electronic sound recording of the proceedings in the above-entitled matter to the best of our knowledge and ability.

/s/ William J. Garling

January 9, 2023

William J. Garling, CET-543
Certified Court Transcriptionist
For Reliable

/s/ Tracey J. Williams

January 9, 2023

Tracey J. Williams, CET-914
Certified Court Transcriptionist
For Reliable

/s/ Coleen Rand

January 9, 2023

Coleen Rand, CET-341
Certified Court Transcriptionist
For Reliable